

# **EORTC QLQ-C30 Reference Values**

---

**This manual presents reference data for the  
QLQ-C30 based upon data provided by EORTC  
Quality of Life Group Members and other users  
of the QLQ-C30**

**July 2008**

---

**Neil W Scott, Peter M Fayers, Neil K Aaronson, Andrew  
Bottomley, Alexander de Graeff, Mogens Groenvold, Chad  
Gundy, Michael Koller, Morten A Petersen, Mirjam AG  
Sprangers on behalf of the EORTC Quality of Life Group**

**EORTC Quality  
of Life Group**



AISBL International Non-Profit Association under Belgian law IVZW

All rights reserved. No part of this manual covered by copyrights hereon may be reproduced or transmitted in any form or by any means without prior permission of the copyright holder.

The EORTC QLQ-C30 (in all versions), and the modules which supplement it, are copyrighted and may not be used without prior written consent of the EORTC Headquarters.

Requests for permission to use the EORTC QLQ-C30 or to reproduce or quote materials contained in this manual should be addressed to:

Quality of Life Department,  
EORTC Headquarters,  
Avenue E Mounier 83 - B11,  
1200 Brussels  
BELGIUM.

Tel: +32 2 779 1678.

Fax: +32 2 779 4568.

This manual is based upon data contributed by members of the EORTC Groups, and by other users of the QLQ-C30.

It was prepared on behalf of the EORTC Quality of Life Group by:

Neil W Scott<sup>1</sup>, Peter M Fayers<sup>1,2</sup>, Neil K Aaronson<sup>3</sup>, Andrew Bottomley<sup>4</sup>, Alexander de Graeff<sup>5</sup>, Mogens Groenvold<sup>6,7</sup>, Chad Gundy<sup>3</sup>, Michael Koller<sup>8</sup>, Morten A Petersen<sup>6</sup>, Mirjam AG Sprangers<sup>9</sup>

<sup>1</sup> Department of Public Health, University of Aberdeen, UK

<sup>2</sup> Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway

<sup>3</sup> Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands

<sup>4</sup> Quality of Life Department, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium

<sup>5</sup> Division of Medical Oncology, Department of Internal Medicine, University Medical Centre, Utrecht, Netherlands

<sup>6</sup> Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark

<sup>7</sup> Institute of Public Health, University of Copenhagen, Denmark

<sup>8</sup> Centre for Clinical Studies, University Hospital Regensburg, Regensburg, Germany

<sup>9</sup> Department of Medical Psychology, Academic Medical Centre, University of Amsterdam, Netherlands

## **Members of the Quality of Life Cross-Cultural Meta-Analysis Group**

**Australia:** M King, S Leutenegger, N Spry; **Austria:** E Greimel, B Holzner; **Belgium:** C Coens, K West; **Brazil:** G de Castro, C de Souza; **Canada:** A Bezjak, M Whitehead; **Denmark:** M Klee; **France:** A Brédart, T Conroy, C Rodary; **Germany:** M Berend, B Bestmann, O Krauß, T Küchler, B Malchow, R Schwarz, S Singer; **Greece:** K Mystakidou; **Iran:** A Montazeri; **Italy:** C Brunelli, M Tamburini; **Japan:** T Matsuoka, H Zhao; **Netherlands:** R de Leeuw, M Muller; **Norway:** K Bjordal, E Brenne, M Hjermstad, M Jordhøy, S Kaasa, P Klepstad, S Sundstrøm, F Wisløff; **Singapore:** YB Cheung, SB Tan, J Thumboo, HB Wong; **South Korea:** YH Yun; **Spain:** J Arraras; **Sri Lanka:** H Jayasekara, L Rajapakse; **Sweden:** M Ahlner-Elmqvist; **Switzerland:** P Ballabeni, J Bernhard; **Taiwan:** W-C Chie; **Turkey:** U Abacioglu; **UK:** J Blazeby, J Bruce, A Davies, L Friend, Z Krukowski, T Massett, J Nicklin, J Ramage, A Smyth-Cull, T Young; **USA:** D Cella, D-L Esseltine, C Gotay, I Pagano.

## **Contributing Groups**

European Organisation for Research and Treatment of Cancer (EORTC) Brain Group, EORTC Breast Cancer Group, EORTC Chronotherapy Group, EORTC Gastro-Intestinal Group, EORTC Genito-Urinary Group, EORTC Gynaecological Group, EORTC Head and Neck Group, EORTC Leukaemia Group, EORTC Lung Group, EORTC Lymphoma Group, EORTC Melanoma Group, EORTC Quality of Life Group, EORTC Radiotherapy Group, EORTC Soft Tissue Group, National Cancer Institute Grant CA60068, National Cancer Institute of Canada (NCIC) Clinical Trials Group, Nordic Myeloma Study Group, Swiss Group for Clinical Cancer Research (SAKK)

# Contents

	<b>Page</b>
<b>Introduction and background</b>	<b>1</b>
<b>Why reference data are important</b>	<b>2</b>
<b>Description of the tables</b>	<b>4</b>
<b>Sample size</b>	<b>6</b>
<b>References</b>	<b>11</b>
<b>EORTC QLQ-C30 Tables of Reference Values</b>	<b>14</b>
All cancer patients: all stages	15
All cancer patients: males	19
All cancer patients: females	22
All cancer patients: <50	25
All cancer patients: 50-59	28
All cancer patients: 60-69	31
All cancer patients: $\geq 70$	34
All cancer patients: stage I-II	37
All cancer patients: stage III-IV	40
All cancer patients: recurrent/metastatic	43
Brain cancer: all stages	46
Breast cancer: all stages	49
Breast cancer: <50	52
Breast cancer: 50-59	55
Breast cancer: 60-69	58
Breast cancer: $\geq 70$	61
Breast cancer: stage I-II	64
Breast cancer: stage III-IV	67
Breast cancer: recurrent/metastatic	70
Colorectal cancer: all stages	73
Colorectal cancer: males	76
Colorectal cancer: females	79
Colorectal cancer: <50	82
Colorectal cancer: 50-59	85
Colorectal cancer: 60-69	88
Colorectal cancer: $\geq 70$	91
Colorectal cancer: stage I-II	94
Colorectal cancer: stage III-IV	97
Colorectal cancer: recurrent/metastatic	100
Genito-urinary cancer: all stages	103
Gynaecological cancer (cervical): all stages	106
Gynaecological cancer (ovarian): all stages	109

Gynaecological cancer (ovarian): stage I-II	112
Gynaecological cancer (ovarian): stage III-IV	115
Head and neck cancer: all stages	118
Head and neck cancer: males	121
Head and neck cancer: females	124
Head and neck cancer: <50	127
Head and neck cancer: 50-59	130
Head and neck cancer: 60-69	133
Head and neck cancer: $\geq 70$	136
Head and neck cancer: stage I-II	139
Head and neck cancer: stage III-IV	142
Head and neck cancer: hypopharynx/larynx	145
Head and neck cancer: oral cavity/oropharynx	148
Acute myelogenous leukaemia: all stages	151
Liver/bile/pancreas cancer: all stages	154
Lung cancer: all stages	157
Lung cancer: males	160
Lung cancer: females	163
Lung cancer: <50	166
Lung cancer: 50-59	169
Lung cancer: 60-69	172
Lung cancer: $\geq 70$	175
Lung cancer: stage I-II	178
Lung cancer: stage III-IV	181
Lung cancer: recurrent/metastatic	184
Small cell lung cancer: all stages	187
Small cell lung cancer: limited disease	190
Small cell lung cancer: extensive disease	193
Non-small cell lung cancer: all stages	196
Mesothelioma	199
Malignant lymphoma	202
Non-Hodgkin lymphoma	205
Malignant melanoma: all stages	208
Malignant melanoma: males	211
Malignant melanoma: females	214
Malignant melanoma: <50	217
Malignant melanoma: 50-59	220
Malignant melanoma: 60-69	223
Malignant melanoma: stage I-II	226
Malignant melanoma: stage III-IV	229
Malignant melanoma: recurrent/metastatic	231
Myeloma: all stages	232
Myeloma: stage I-II	238
Myeloma: stage III-IV	241
Oesophageal cancer: all stages	244
Oesophageal cancer: males	247
Oesophageal cancer: females	250
Oesophageal cancer: <50	253

Oesophageal cancer: 50-59	256
Oesophageal cancer: 60-69	259
Oesophageal cancer: $\geq 70$	262
Gastric cancer: all stages	265
Prostate cancer: all stages	268
Prostate cancer: 50-59	271
Prostate cancer: 60-69	274
Prostate cancer: $>70$	277
Prostate cancer: stage I-II	280
Prostate cancer: stage III-IV	283
Prostate cancer: recurrent/metastatic	286
Testicular cancer	289
General population	292

### **QLQ-C30 Module Data**

Breast module: all stages	295
Breast module: $<50$	299
Breast module: 50-59	301
Breast module: 60-69	304
Breast module: recurrent/metastatic	307
Head and neck module: all stages	310
Head and neck module: males	313
Head and neck module: females	316
Head and neck module: $<50$	319
Head and neck module: 50-59	322
Head and neck module: 60-69	325
Head and neck module: $>70$	328
Head and neck module: stage I-II	331
Head and neck module: stage III-IV	334
Head and neck module: hypopharynx/larynx	337
Head and neck module oral cavity/oropharynx	340
Lung module: all stages	343
Lung module: males	346
Lung module: females	349
Lung module: $<50$	352
Lung module: 50-59	355
Lung module: 60-69	358
Lung module: $>70$	361
Lung module: stage I-II	364
Lung module: stage III-IV	367
Lung module: recurrent/metastatic	370
Lung module: small cell lung cancer	373
Lung module: non-small cell lung cancer	376
Oesophageal module: all stages	379
Oesophageal module: males	382
Oesophageal module: females	385
Oesophageal module: 50-59	388
Oesophageal module: 60-69	391
Oesophageal module: $>70$	394

Ovarian module: all stages	397
Ovarian module: stage I-II	400
Ovarian module: stage III-IV	403
<b>EORTC QLQ-C30 Graphs</b>	406
<b>EORTC QLQ-C30 Correlation matrices</b>	415
General population	416
Stage I-II	417
Stage III-IV	418
Recurrent/metastatic	419

## *Acknowledgements*

We wish to thank all those who contributed data to this reference manual. Without their collaboration, this manual would not have been possible. We also wish to thank the thousands of patients who were willing to complete the EORTC QLQ-C30 in the varied studies embodied in this manual.



# **EORTC QLQ-C30**

## **REFERENCE VALUES**

### **Introduction**

The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) is an integrated system for assessing the quality of life (QoL) of cancer patients participating in clinical trials and other types of research in which patient-reported outcomes are collected. The EORTC QLQ-C30 is designed for use with a wide range of cancer patient populations, and is intended to be supplemented by tumour-specific questionnaire modules or supplements such as those for lung cancer (QLQ-LC13) (Bergman et al., 1994), breast cancer (QLQ-BR23) (Sprangers et al., 1996), head and neck cancer (QLQ-H&N35) (Bjordal et al., 2000), oesophageal cancer (QLQ-OES18) (Blazeby et al., 1996) and ovarian cancer (QLQ-OV28) (Greimel et al., 2003).

Reference data may be useful for various reasons:

- (1) comparisons of a group of patients with similar characteristics, perhaps to explain differences in clinical outcomes, such as death and progression
- (2) to increase familiarity with the distribution of scores for each scale
- (3) sample size calculation
- (4) comparison of an individual patient's score with patients with similar characteristics
- (5) quality control in translation procedures

This manual presents reference data for the EORTC QLQ-C30 when assessed in various cancer populations.

### **Background to the EORTC QLQ-C30**

In 1986, the EORTC initiated a research program to develop an integrated, modular approach for evaluating the QoL of patients participating in international cancer clinical trials. This research resulted in the development of a core questionnaire which is referred to as the EORTC QLQ-C30 (Aaronson et al., 1993). The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). The psychometric properties of the questionnaire were tested and in conclusion it was found to possess the required standards such as validity (measuring what it is intended to measure), reliability

(measuring with sufficient precision) and sensitivity (ability to detect changes) (Aaronson et al., 1993; Osoba et al., 1994; Kaasa et al., 1995). The questionnaire was initially tested in a population of lung cancer patients (Aaronson et al., 1993) and subsequently in a variety of cancer patient groups. A bibliography is contained in the *EORTC QLQ-C30 Scoring Manual* (Fayers et al., 2001).

There is a continuing programme of development for the EORTC QLQ-C30. There have been four versions of the questionnaire: the QLQ-C30 version 1.0, the interim version QLQ-C30 (+3), which introduced new questions for the Role Functioning and Global Health Status/QoL scales, the QLQ-C30 version 2.0, which was released after validation of the new questions, and the current version 3.0 of the QLQ-C30. Version 3.0 differs from version 2.0 only in that it has four-point scales for the first five items comprising the Physical Functioning scale. Data from all four versions are used in this manual, but only the current versions of the Global Health Status/QoL, Physical Functioning and Role Functioning scales are reported: this means that available sample sizes for these three scales will generally be lower. In previous publications the abbreviations QL2, RF2 and PF2 are often used to distinguish the revised versions of these scales from the original versions, but in this manual QL, RF and PF will instead be used to denote the current versions. The remaining 12 scales have remained unchanged throughout the history of the questionnaire.

## **Why reference data are important**

### **Comparisons of scores from groups of patients**

Reference data provide information about the distribution of QoL scores for given cancer populations with certain predefined characteristics, in particular stage and cancer site. They provide one potential reference point against which future populations may be compared. Also, if one has observed unexpected results with respect to clinical endpoints it may be useful to compare the baseline QoL scores of patients against those of a reference population to gain some insight with regard to some plausible explanations. For example, pre-randomisation scores in a randomised clinical trial might be compared against the reference values in an attempt to explain an unexpected response rate or median survival.

It has been shown that QoL at baseline may be of use as a prognostic factor for clinical outcomes. For example, it predicts survival (Coates et al., 1993; Gralla et al., 1995; Gotay et al., 2008; Tannock et al., 1996), response to treatment (Gralla et al., 1995) and nausea and vomiting (Osoba, Pater and Zee, 1994). In future cancer trials, it may be useful to include baseline QoL to further investigate its predictive value for the various endpoints under study, or as a stratifying factor for the treatment allocation process.

### **Familiarity with distribution of scores**

It is important in the design stage of clinical trials that the investigators involved in protocol development should have an idea of the distribution of QoL scores at baseline and the possible magnitude of changes over time in the particular group of patients under study. This enables development of realistic hypotheses. Information about the expected scores is also valuable when analysing and reporting the results of the trial. Knowledge about the distribution of the QLQ-C30 scores will develop as we become more familiar with it, and as more reference data become available. Possibly, a qualitative descriptive system could be developed for each of the scales (such as “good”, “moderate” and “poor”), to describe patients’ position relative to ‘normal’ values. This

will allow a clearer understanding of the results for non-QoL researchers while simplifying analyses and ensuring standardisation for other forms of analyses such as prognostic factor analyses.

## **Sample size calculation**

In a phase III clinical trial an adequate sample size is necessary to provide sufficient power to test the significance of treatment effects. Historically, in cancer clinical trials the main endpoint of the trial has been a biological outcome such as survival, disease free survival or response to therapy. Subsequently the sample size calculation was based on either a time to event analysis or a comparison of two proportions. However, in recent years several clinical trials have been initiated with a QoL outcome as the main endpoint. Even when QoL is a secondary endpoint it may be important to make power estimates to ensure that there is a reasonable likelihood of detecting realistic differences between the groups. A number of methods are available for sample size calculation in QoL studies, based on various assumptions about the distribution of the QoL measure: (1) Normal distribution, (2) binomial and (3) ordered categorical (Campbell, Julious and Altman, 1995; Julious and Campbell, 1996). Sample size calculations using these three alternative methods with a two sided significance level ( $\alpha=0.05$ ) and a power of 80% ( $\beta = 0.20$ ) are given below.

## **Comparison of an individual patient's score**

Reference data provide clinicians with a guide to the average scores for the single items, which can facilitate communication with the patient about likely side effects of disease or treatment. The tables enable clinicians to know whether an individual patient's responses are very much higher or lower than is usually expected. Reference data may also be used to obtain an indication of the most likely range of scale scores for patients. However, the interpretation of scores from individual patients requires additional research, and we do not at this stage recommend that the reference values be used for screening patients. It should be noted that individual-patient scale scores have large standard deviations and thus the confidence intervals are wide. This makes the scale scores unreliable for decision making.

## **Translation procedures**

The EORTC Quality of Life Study Group has developed procedures for translation of the EORTC QLQ-C30 and its cancer site specific modules (Cull et al., 2002; Koller et al., 2007). These procedures require repeated forward and backward translations of the questionnaire until a satisfactory translation is obtained, followed by field testing in a sample of patients. It may be useful to perform this field test on a sample population where reference data are available. Comparing the scores of the newly translated questionnaire with that of the original language could be used in the checking of the translation as it could highlight any obvious discrepancies.

# Description of the tables

## Patients and methods

All the data used in this report were originally supplied as part of a wider project (the EORTC Quality of Life Group's Cross-Cultural Analysis Project (Scott et al., 2006; Scott et al., 2007)). About a third of the respondents come from EORTC studies and these data were supplied with the permission of the relevant EORTC group. The other data were received from individuals and organisations from around the world. The main source of data was from cancer clinical trials and epidemiological studies, although some large studies of the general population were also received (Klee, Groenvold and Machin, 1997; Hjerstad et al., 1998; Schwarz and Hinz, 2001; Holzner et al., 2004). This manual is based on baseline (pre-treatment) QoL data only; data from patients currently receiving treatment or who are off treatment were excluded, although some data were included even when the treatment status of the patient was not known.

This manual first provides data for all cancer patients and then for specific disease sites. Finally, the data are presented for the general population sample. For each cancer site the data are first presented for all patients, if there are at least 100 patients available for that site. Provided there is sufficient sample size ( $\geq 100$  patients), the same data are then presented for the following subgroups: males, females, those aged  $<50$ ,  $50-59$ ,  $60-69$  and  $\geq 70$ , and for those in three stage categories. Since stage was classified in different ways in different data sets, and TNM staging was often not available, patients have been divided into three broad stage categories (I-II, III-IV and recurrent/metastatic). Unfortunately data were not always available for performance status, and previous treatment was often difficult to assess.

Each section comprises three separate pages of tables:

- 1) A description of the characteristics of the sample (e.g. the questionnaire version used, age band, gender, site and stage), followed by summary data (mean, standard deviation, median and inter-quartile range) for each of the 15 scale scores of the EORTC QLQ-C30 (version 3.0).
- 2) Frequency tables for each of the nine multi-item scale scores of the EORTC QLQ-C30.
- 3) Frequency tables for each of the 30 items of the EORTC QLQ-C30.

Similar tables of data are then provided for five of the EORTC QLQ-C30 modules: the breast, head and neck, lung, oesophageal and ovarian modules.

## Scoring procedures

Scale scores were calculated by averaging items within scales and transforming average scores linearly. All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems. For more details on the scoring procedures see the *EORTC QLQ-C30 Scoring Manual* (Fayers et al., 2001).

## Graphs

Graphs of the mean scale score by age are then provided for all 15 subscales of the EORTC QLQ-C30. Separate graphs are presented for four stage categories (general population, Stage I-II, Stage

III-IV and recurrent/metastatic) with separate lines representing males and females. The graphs have been produced using Lowess (locally weighted least squares) smoothing techniques in order to more clearly show the underlying pattern of the data (Cleveland, 1979, Cleveland and Devlin, 1988). Note that sample sizes for the youngest and oldest age groups tend to be lower (see tables) and that the distribution of sites across the four stage categories differs, for example, the recurrent/metastatic group contains a relatively higher proportion of breast, colorectal and oesophageal/stomach cancers compared with other groups.

## **Correlation matrices**

Matrices of correlation coefficients are also provided for these four subgroups: the general population sample, Stage I-II, Stage III-IV and recurrent/metastatic. The age and gender distributions of these four groups are described in the tables. Due to the coding of the scales, positive correlation coefficients are expected between two functional scales or between two symptom scales; negative correlations are expected between a functional and a symptom scale.

## **Problems with interpretation of reference data**

Most of the data presented here come from clinical trials or epidemiological studies. Clinical trials may have some recruitment bias as parameters such as patient choice, clinician choice, choice of institution (for example, large, experienced) and eligibility criteria may contribute to the non-random selection of patients into a clinical trial. Other factors which may influence the results are non-compliance due to data collection procedures and patient non-compliance. It has frequently been noted that patients in randomised clinical trials may have different outcomes from other patients (Stiller, 1994; Stiller and Draper, 1989), and that specialist centres may also obtain different results from other centres (Stiller, 1995; Harding et al., 1993). Thus the results presented here are not necessarily representative of other groups of cancer patients with similar diagnoses. It is important to bear in mind the source of these data when interpreting them.

The QLQ-C30 was designed as a self assessment questionnaire. Thus the results presented here are applicable only for patients who completed the questionnaire independently. Other modes of administration, such as interview, telephone or computer-assisted, may provide different results. Timing of the questionnaire is also important, and a patient's responses may be affected according to whether the assessment is made before or after the treatment has been allocated (that is, before or after randomisation), and before or after subsequent clinical consultations (Hurny et al., 1994; Fayers and Machin, 2007).

## Sample size

One of the important uses of reference data is the estimation of sample size requirements when planning a clinical trial. The following notes illustrate how this might be carried out using the reference data in this manual.

More detailed discussions of issues in sample size estimation are given in the book *Sample Size Tables for Clinical Studies*, by Machin, Campbell, Fayers & Pinol (Machin et al., 1997) which also provides extensive tables and software for performing the calculations.

One problem when estimating sample size for QoL scales is that there are often many outcome measures of interest. This presents problems of analysis, too, since multiple testing will distort the nominal p-values. In practice, most investigators define one or two outcome measures as being of primary interest, and then design their study so that they have reasonable power for detecting relevant changes in each of these chosen outcome measures.

In many respects sample size estimation should reflect the intended analysis at the end of the study. If it is planned to carry out t-tests, then sample size is based upon the properties of the t-statistic. If it is planned to use a rank-sum test (Wilcoxon or Mann-Whitney), then sample size estimation is based upon that; and if a global test statistic is to be used, to avoid the problems of multiple testing, the estimates should reflect that.

The calculations that follow assume that all data are available at the time of analysis. However, many studies involving QoL assessment have experienced compliance problems resulting in missing data. Also, for some cancer studies, there may also be a number of early deaths. Therefore the estimates of sample size requirements should be increased to allow for missing or incomplete forms, and for deaths or other forms of drop-out.

The examples of sample size calculations that are given below assume a two sided significance level of  $\alpha=0.05$  and a power of 80% ( $\beta = 0.20$ ). For many studies a higher power (say, 90%) may be desired. It is also necessary to specify the target difference that we hope to be able to detect. Thus, based upon experience with the QLQ-C30, we have arbitrarily selected a change of 8 units in Global Health Status/QoL as being reasonable for the first example below. Other differences will be applicable in other studies, and the reference data will help suggest the magnitude of plausible differences corresponding to various patient groups. Effect sizes and clinically significant differences for the QLQ-C30 have been discussed in papers by King and Osoba (King, 1996; Osoba et al.; 1998; Osoba and King, 2005).

### ***Normal distribution***

Suppose we have selected Global Health Status/QoL score at two months as our main endpoint in a lung cancer trial. This is one of the relatively few scales of the QLQ-C30 which is often approximately Normally distributed, and so analysis of the trial results may use the t-test. Therefore it is appropriate to estimate sample size requirements using the Normal approximation.

Consider a two group comparison comparing the mean of the new treatment group,  $\mu_1$ , against the mean value of the controls,  $\mu_0$ , with between subject standard deviation of  $s$ . We wish to test for a difference between the two means, which may be conveniently expressed in terms of an effect size which is defined as:

$$\delta = \frac{|\mu_t - \mu_c|}{s}$$

We represent the Normal deviate by  $Z$ , so that for a two-tailed test at the 5% level we have:  $\alpha = 0.05$  and  $Z_{1-\alpha/2} = 1.96$  and for 80% power  $1 - \beta = 0.80$ ,  $Z_{1-\beta} = 0.84$ .

Then the total sample size for a two-group comparison is given by:

$$N = \frac{4(Z_{1-\alpha/2} + Z_{1-\beta})^2}{\delta^2} + \frac{Z_{1-\alpha/2}^2}{2}$$

### *Example*

Suppose we assume that in the control group the mean score will be unchanged from baseline ( $\mu_c = 57$  for the Global Health Status/QoL from the lung cancer reference data) and we want to see an improvement of 8 points in the mean score in the treatment group ( $\mu_t = 65$ ). From the tables the standard deviation ( $s$ ) of this scale is 24.3. The effect size is given by:

$$\delta = \frac{(\mu_t - \mu_c)}{s} = \frac{65 - 57}{24.3} = 0.329$$

To detect a significant result at the 5% level, with 80% power, we would need:

$$N = \frac{4(1.96 + 0.84)^2}{(0.329)^2} + \frac{(1.96)^2}{2} \approx 293 \text{ patients in total (147 in each treatment arm).}$$

### **Binary data**

One simple method of analysing categorical data is to define a cut-point or threshold for each scale of interest. For example, one might decide to design a study to test whether there is a change in levels of the Pain Scale, where we are interested in a cut-point of 50. From the tables showing the percentages in each Pain category it can be calculated that 30% of patients are expected to score 50 or more. The data can then be tested for evidence of a difference between the two groups, using a chi-squared test.

Assuming that the data have a binomial distribution, the effect size is given as  $\delta = |\pi_t - \pi_c|$  where  $\pi_t$  and  $\pi_c$  represent the proportion of patients below a certain score in both groups. The total number of cases required for the two-group comparison is given by:

$$N = \frac{2(Z_{1-\alpha/2} + Z_{1-\beta})^2 [\pi_t(1 - \pi_t) + \pi_c(1 - \pi_c)]}{\delta^2} \quad (1)$$

### Example

Using the Physical Functioning score and taking a cut-point of  $\leq 50$ ,  $\pi_c$  is 30%. Assuming an improvement to only 20 % having a score  $\geq 50$  in the treatment group  $\delta = |0.2 - 0.3| = 0.1$ .

Thus

$$N = \frac{2(1.96 + 0.84)^2 [0.2(0.8) + 0.3(0.7)]}{(0.1)^2} \approx 580$$

Therefore 580 patients would be required (290 patients per treatment arm).

Published tables (Machin et al., 1998) provide more accurate methods of estimating the sample size.

### **Binary data - using odds ratio**

The difference between two proportions can also be expressed as an odds ratio, and this leads to another method of analysing binary data. The odds ratio is defined as:

$$OR = \frac{\pi_c(1 - \pi_t)}{\pi_t(1 - \pi_c)}$$

This leads to an alternative equation for the sample size, which does however give very similar results to equation (1). Writing  $\bar{\pi} = (\pi_t + \pi_c)/2$ , we have for the sample size:

$$N = \frac{2(Z_{1-\alpha/2} + Z_{1-B})^2 / (\log_e OR)^2}{\bar{\pi}(1 - \bar{\pi})} \quad (2)$$

### Example

Using the same example as for the binary method, the odds ratio is given by:

$$OR = \frac{\pi_c(1 - \pi_t)}{\pi_t(1 - \pi_c)} = \frac{0.3(0.8)}{0.2(0.7)} = 1.714$$

$$\bar{\pi} = (0.3 + 0.2)/2 = 0.25$$

$$N = \frac{4(1.96 + 0.84)^2 / \{\log_e(1.714)\}^2}{0.25(1 - 0.25)} \approx 576$$

... which is very similar to the previous solution.

### **Ordered categorical data**

The binary comparison, by selecting a single cut-point, ignores the detailed information in the data. An alternative approach is to use statistical tests which make full use of the ordered categorical data, such as the Wilcoxon or Mann-Whitney rank sum tests. The sample size requirements can be estimated by using a method based upon odds ratios, extending the method described in the previous section for binary data. We illustrate the approach below, but more comprehensive details are given in Campbell, Julious and Altman (1995) and Julious and Campbell (1996).



In this method we also make the additional assumption that the odds ratio,  $OR$ , remains constant throughout the scale (proportional odds). Writing  $Q_{ci}$  (controls) and  $Q_{ti}$  (new treatment group) for the cumulative proportions in category  $i$ , we assume that approximate values for  $Q_{ci}$  can be estimated from the tables of reference values. This enables the cumulative proportions in each category for the treatment group,  $Q_{ti}$ , to be estimated, using the formula:

$$Q_{ti} = \frac{Q_{ci}}{[Q_{ci} + OR(1 - Q_{ci})]}$$

The total sample size is then given as:

$$N = \frac{(Z_{1-\alpha/2} + Z_{1-\beta})^2 / (\text{Log}_e OR)^2}{(1 - \sum \bar{\pi}_i^3) / 6} \quad (3)$$

An appropriate significance test in this situation would be the Mann-Whitney test with allowance for ties.

*Example*

From above, we calculated the odds ratio as 1.71. Using the table of percentages of lung cancer patients in each pain category, the first observation of  $Q_{ti}$  is calculated as follows:

$$Q_{t1} = \frac{0.36}{[0.36 + 1.71(1 - 0.36)]} = 0.25$$

$P_{t1}$ , the proportion in category 1 for the treatment group, is therefore 0.25. The remaining  $Q_{ti}$  and  $P_{ti}$  are calculated similarly, resulting in Table 1.

*Table 1: Pain score*

Category	1	2	3	4	5	6	7
Score	0	16.7	33.3	50	66.7	83.3	100
Percent ( $P_{ci}$ %)	36	17	17	10	9	5	6
Cumulative Percent ( $Q_{ci}$ %)	36	53	70	80	89	94	100
Cumulative Percent ( $Q_{ti}$ %)	25	40	58	70	83	90	100
Percent ( $P_{ti}$ %)	25	15	18	12	13	7	10

The mean proportion of each category is then  $\bar{\pi}_i = \frac{(P_{ci} + P_{ti})}{2}$

Thus  $\bar{\pi}_1 = \frac{(P_{c1} + P_{t1})}{2} = \frac{(0.36 + 0.25)}{2} = 0.305$

Similarly  $\bar{\pi}_2=0.16$ ,  $\bar{\pi}_3=0.175$ ,  $\bar{\pi}_4=0.11$ ,  $\bar{\pi}_5=0.11$ ,  $\bar{\pi}_6=0.06$ ,  $\bar{\pi}_7=0.08$

Therefore  $1 - \sum \bar{\pi}_i^3 = 1 - 0.041 = 0.959$

From equation (3), the sample size is:

$$N = \frac{(1.96 + 0.84)^2 / (0.54)^2}{(0.959/6)} = 169$$

Note that this is substantially smaller than the estimate obtained for sample size when comparing percentages with a cut-point of 50 for the Pain subscale. A rank-sum test uses all seven levels of Pain, and is more powerful than testing for a difference in two proportions.

## References

- Aaronson NK, Ahmedzai S, Bergman B, *et al.* The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993; **85**: 365-76.
- Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. *Eur J Cancer*, 1994; **30A**: 635-642.
- Bjordal K, De Graeff A, Fayers PM, *et al.* A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. *Eur J Cancer*, 2000; **36**: 1796-1807.
- Blazeby JM, Alderson D, Winstone K, *et al.* Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. The EORTC Quality of Life Study Group. *Eur J Cancer*, 1996; **32A**: 1912-1917.
- Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. *Br Med J* 1995; **311**: 1145-7.
- Coates A, Thomson D, McLeod GR, *et al.* Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. *Eur J Cancer* 1993; **29A**: 1731-4.
- Cleveland WS. Robust locally weighted regression and smoothing scatterplots, *Journal of the American Statistical Association*, 1979; **74**: 829-836.
- Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. *Journal of the American Statistical Association*. 1988; **83**: 596-610.
- Cull A, Sprangers M, Bjordal K, Aaronson N, West K, Bottomley A. *EORTC Quality of Life Study Group Translation Procedure*. Brussels: EORTC, 2002.
- Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A on behalf of the EORTC Quality of Life Group. *EORTC QLQ-C30 Scoring Manual (3<sup>rd</sup> edition)*. Brussels: EORTC, 2001.
- Fayers PM, Machin D. *Quality of life. The assessment, analysis and interpretation of patient-reported outcomes (2<sup>nd</sup> ed)*. Chichester: John Wiley & Sons, 2007.
- Gotay C, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. *J Clin Oncol*, 2007. DOI:10.1200/JCO.2007.13.3439.
- Gralla RJ, Hollen PJ, Eberley S, Cox C. Quality of life score predicts both response and survival in patients receiving chemotherapy for non-small cancer. *Support Care Cancer* 1995; **3**: 378-9.

Greimel E, Bottomley A, Cull A, *et al.* An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. *Eur J Cancer*, 2003; **39**: 1402-1408.

Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter? *Lancet* 1993; **341**: 999-1002.

Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ-C30 (+ 3). *J Clin Oncol*, 1998; **16**, 1188-1196.

Holzner B, Kemmler G, Cella D, *et al.* Normative data for functional assessment of cancer therapy. *Acta Oncologica*, 2004; **43**: 2,153-160.

Hurny C, Bernhard J, Coates A, *et al.* Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group. *Ann Oncol* 1994; **5**: 65-74.

Julious SA, Campbell MJ. Sample sizes calculations for ordered categorical-data. *Stat Med* 1996; **15**: 1065-6.

Kaasa S, Bjordal K, Aaronson N, *et al.* The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. *Eur J Cancer* 1995; **31A**: 2260-3.

King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. *Qual Life Res* 1996; **5**: 555-67.

Klee M, Groenvold M, Machin D. Quality of life of Danish women: population-based norms of the EORTC QLQ-C30. *Qual Life Res*, 1997; **6**: 27-34.

Koller M, Aaronson NK, Blazeby J, *et al.* Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. *Eur J Cancer*, 2007; **43**: 1810-1820.

Machin D, Campbell MJ, Fayers PM, Pinol A. *Sample Size Tables for Clinical Studies*. (2nd ed.) Oxford: Blackwell Science, 1997.

Osoba D, King M. Meaningful differences. In: Fayers PM, Hays R (eds). *Assessing quality of life in clinical trials: methods and practice*. Oxford University Press: Oxford, 2005.

Osoba D, Pater JL, Zee B. Effective anti-emetic therapy improves quality of life (QoL) after moderately emetogenic chemotherapy (MEC). *Qual Life Res* 1994; **4**: 467-8.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality of life scores. *J Clin Oncol* 1998; **16**: 139-144.

Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. *Qual Life Res* 1994; **3**: 353-64.

Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. *Eur J Cancer*. 2001; **37**: 1345-1351.

Scott NW, Fayers PM, Aaronson NK, *et al*. The use of differential item functioning analyses to identify cultural differences in responses to the EORTC QLQ-C30. *Qual Life Res*, 2007; **16**, 115-129.

Scott NW, Fayers PM, Bottomley A, *et al*. Comparing translations of the EORTC QLQ-C30 using differential item functioning analysis. *Qual Life Res*, 2006; **15**: 1103-1115.

Sprangers MA, Groenvold M, Arraras JI, *et al*. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. *J Clin Oncol*, 1996; **14**: 2756-2768.

Stiller CA. Centralised treatment, entry to trials and survival. *Br J Cancer* 1994; **70**: 352-62.

Stiller CA. Non-specialist units, clinical trials and survival from testicular cancer. *Eur J Cancer* 1995; **31A**: 289-91.

Stiller CA, Draper GJ. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. *Arch Dis Child* 1989; **64**: 657-61.

Tannock IF, Osoba D, Stockler MR, *et al*. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol* 1996; **14**: 1756-64.

***EORTC QLQ-C30***

***Tables of Reference Values***

## All cancer patients: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	3,853	16
v +3	1,061	5
v 2.0	8,258	35
v 3.0	10,381	44
Total	23,553	

#### Age

	N	(%)
<40	1,825	8
40-49	3,382	14
50-59	5,707	24
60-69	6,709	29
70-79	4,650	20
80+	707	3
Not known	573	2
Total	23,553	

#### Gender

	N	(%)
Male	13,225	56
Female	9,028	38
Not known	1,300	6
Total	23,553	

#### Primary disease site

	N	(%)
Bladder	13	0
Bone	4	0
Brain	280	1
Breast	2,788	12
Colorectal	1,773	8
Genito-urinary (other)	45	0
Gynaecological (excluding ovarian)	270	1
Head & neck: hypopharynx/larynx	436	2
Head & neck: oral cavity/oropharynx	272	1
Kidney	188	1
Leukaemia	346	2
Liver/bile	452	2
Lung	3,332	14
Lymphoma	396	2
Malignant melanoma	1,200	5
Malignant myeloma	944	4
Oesophagus/stomach	1,893	8
Ovarian	918	4
Pancreas	298	1
Prostate	3,361	14
Sarcoma	55	0
Testicular	387	2
Other	2,796	12
Not known	1,106	5
Total	23,553	

#### Stage

	N	(%)
Stage I-II	4,720	20
Stage III-IV	8,066	34
Recurrent/metastatic	4,812	20
Not known	5,955	25
Total	23,553	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.3	(24.2)	66.7	[50-83.3]
Physical functioning	PF	76.7	(23.2)	80	[66.7-93.3]
Role Functioning	RF	70.5	(32.8)	83.3	[50-100]
Emotional functioning	EF	71.4	(24.2)	75	[58.3-91.7]
Cognitive functioning	CF	82.6	(21.9)	83.3	[66.7-100]
Social functioning	SF	75.0	(29.1)	83.3	[66.7-100]
Fatigue	FA	34.6	(27.8)	33.3	[11.1-55.6]
Nausea and vomiting	NV	9.1	(19)	0	[0-16.7]
Pain	PA	27.0	(29.9)	16.7	[0-50]
Dyspnoea	DY	21.0	(28.4)	0	[0-33.3]
Insomnia	SL	28.9	(31.9)	33.3	[0-33.3]
Appetite loss	AP	21.1	(31.3)	0	[0-33.3]
Constipation	CO	17.5	(28.4)	0	[0-33.3]
Diarrhoea	DI	9.0	(20.3)	0	[0-0]
Financial difficulties	FI	16.3	(28.1)	0	[0-33.3]

## All cancer patients: all stages

### Characteristics of the sample (continued)

#### Country

	N	(%)
Netherlands	3,253	14
Germany	3,201	14
Norway	2,477	11
United Kingdom	2,018	9
France	1,426	6
United States	1,235	5
Sweden	994	4
Belgium	969	4
Sri Lanka	939	4
Spain	917	4
Italy	656	3
Canada	650	3
Singapore	549	2
South Korea	501	2
Austria	475	2
Australia	401	2
Poland	373	2
Switzerland	290	1
Turkey	242	1
Taiwan	208	1
Denmark	187	1
Iran	167	1
China	143	1
Greece	124	1
Myanmar	103	0
Brazil	101	0
Hungary	99	0
Russia	98	0
Hong Kong	97	0
Egypt	95	0
Finland	80	0
New Zealand	72	0
Portugal	71	0
Czech Republic	62	0
Israel	54	0
South Africa	33	0
Argentina	30	0
Ireland	27	0
Serbia and Montenegro	27	0
Slovakia	27	0
Slovenia	25	0
Bulgaria	16	0
Croatia	13	0
Peru	9	0
Japan	8	0
Romania	6	0
Estonia	3	0
Latvia	1	0
Malta	1	0
Total	23,553	



**All cancer patients: all stages  
Constructed scales**

QL	N	(%)
0	464	2
8.3	173	1
16.7	686	4
25	493	3
33.3	1,527	8
41.7	1,130	6
50	3,123	16
58.3	1,456	8
66.7	3,335	17
75	1,460	8
83.3	2,967	15
91.7	756	4
100	1,667	9
Total	19,237	

PF	N	(%)
0	74	1
6.7	65	1
13.3	91	1
20	144	1
26.7	203	2
33.3	210	2
40	296	3
46.7	349	3
53.3	424	4
60	564	6
66.7	739	7
73.3	857	8
80	1,086	11
86.7	1,339	13
93.3	1,370	14
100	2,347	23
Total	10,158	

RF	N	(%)
0	1,599	8
16.7	734	4
33.3	1,902	10
50	1,405	7
66.7	3,209	17
83.3	2,382	12
100	7,924	41
Total	19,155	

EF	N	(%)
0	236	1
8.3	255	1
16.7	446	2
25	575	3
33.3	970	4
41.7	1,170	5
50	1,535	7
58.3	1,876	8
66.7	2,920	13
75	2,861	12
83.3	3,033	13
91.7	2,831	12
100	4,316	19
Total	23,024	

CF	N	(%)
0	224	1
16.7	350	2
33.3	854	4
50	1,645	7
66.7	3,478	15
83.3	5,677	25
100	10,866	47
Total	23,094	

SF	N	(%)
0	1,009	4
16.7	753	3
33.3	1,866	8
50	1,980	9
66.7	4,048	18
83.3	3,336	15
100	10,072	44
Total	23,064	

FA	N	(%)
0	4,396	19
11.1	2,535	11
22.2	3,226	14
33.3	4,378	19
44.4	2,171	10
55.6	1,867	8
66.7	1,833	8
77.8	894	4
88.9	789	3
100	856	4
Total	22,945	

NV	N	(%)
0	16,844	73
16.7	2,932	13
33.3	1,665	7
50	645	3
66.7	467	2
83.3	187	1
100	252	1
Total	22,992	

PA	N	(%)
0	9,006	39
16.7	4,167	18
33.3	3,745	16
50	1,988	9
66.7	1,902	8
83.3	1,026	5
100	1,155	5
Total	22,989	

**All cancer patients: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	3,367	33	3,291	32	2,120	21	1,521	15	10,299
2) Long walk	PF	4,013	39	2,936	29	1,858	18	1,508	15	10,315
3) Short walk	PF	7,410	72	1,832	18	674	7	401	4	10,317
4) Bed or chair	PF	5,850	57	2,591	25	1,328	13	539	5	10,308
5) Self care	PF	9,331	90	646	6	220	2	143	1	10,340
6) Limited in work	RF	8,888	46	5,067	26	3,128	16	2,224	12	19,307
7) Limited in leisure	RF	10,117	53	4,320	22	2,635	14	2,194	11	19,266
8) Dyspnoea	DY	13,247	57	6,399	28	2,526	11	1,058	5	23,230
9) Pain	PA	9,956	43	7,414	32	3,954	17	1,893	8	23,217
10) Need to rest	FA	6,862	30	9,069	39	5,099	22	2,198	10	23,228
11) Insomnia	SL	10,614	46	6,911	30	3,917	17	1,799	8	23,241
12) Felt weak	FA	9,336	40	7,991	34	3,936	17	1,974	9	23,237
13) Appetite loss	AP	14,436	62	4,594	20	2,580	11	1,652	7	23,262
14) Nausea	NV	17,488	75	3,838	17	1,322	6	621	3	23,269
15) Vomiting	NV	20,095	87	1,953	9	654	3	352	2	23,054
16) Constipation	CO	15,415	67	4,538	20	2,086	9	1,150	5	23,189
17) Diarrhoea	DI	18,569	80	3,343	14	876	4	385	2	23,173
18) Felt tired	FA	6,879	30	9,838	43	4,517	20	1,916	8	23,150
19) Pain interference	PA	13,074	57	5,309	23	2,903	13	1,833	8	23,119
20) Concentration	CF	15,286	66	5,043	22	2,091	9	796	3	23,216
21) Tension	EF	9,464	41	8,900	38	3,704	16	1,264	5	23,332
22) Worry	EF	7,015	30	8,909	38	4,870	21	2,563	11	23,357
23) Irritability	EF	12,062	52	7,803	33	2,623	11	842	4	23,330
24) Depression	EF	10,793	46	7,997	34	3,249	14	1,256	5	23,295
25) Memory trouble	CF	13,887	60	6,911	30	1,961	8	585	3	23,344
26) Family life	SF	13,241	57	5,681	25	2,821	12	1,471	6	23,214
27) Social activities	SF	11,777	51	5,850	25	3,375	15	2,215	10	23,217
28) Financial difficulties	FI	16,005	69	4,034	17	1,959	9	1,126	5	23,124
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	792	1,043	2,401	4,594	4,766	3,856	2,023		19,475
		4	5	12	24	25	20	10		
30) Overall quality of life	QL	877	1,285	2,823	4,795	5,280	4,941	3,043		23,044
		4	6	12	21	23	21	13		

## All cancer patients: males

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	1,974	15
v +3	568	4
v 2.0	5,215	39
v 3.0	5,468	41
Total	13,225	

#### Age

	N	(%)
<40	926	7
40-49	1,421	11
50-59	2,993	23
60-69	4,230	32
70-79	3,194	24
80+	449	3
Not known	12	0
Total	13,225	

#### Primary disease site

	N	(%)
Bladder	13	0
Bone	3	0
Brain	164	1
Breast	4	0
Colorectal	1,023	8
Genito-urinary (other)	37	0
Gynaecological (excluding ovarian)	0	0
Head & neck: hypopharynx/larynx	387	3
Head & neck: oral cavity/oropharynx	182	1
Kidney	125	1
Leukaemia	103	1
Liver/bile	333	3
Lung	1,925	15
Lymphoma	220	2
Malignant melanoma	671	5
Malignant myeloma	561	4
Oesophagus/stomach	1,330	10
Ovarian	0	0
Pancreas	130	1
Prostate	3,361	25
Sarcoma	29	0
Testicular	384	3
Other	2,030	15
Not known	210	2
Total	13,225	

#### Stage

	N	(%)
Stage I-II	2,705	21
Stage III-IV	4,910	37
Recurrent/metastatic	2,524	19
Not known	3,086	23
Total	13,225	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	62.9	(23.8)	66.7	[50-83.3]
Physical functioning	PF	78.5	(23)	86.7	[66.7-100]
Role Functioning	RF	73.4	(32.4)	83.3	[50-100]
Emotional functioning	EF	73.9	(23.6)	75	[58.3-91.7]
Cognitive functioning	CF	83.7	(21.1)	83.3	[66.7-100]
Social functioning	SF	76.3	(28.4)	83.3	[66.7-100]
Fatigue	FA	32.4	(27.4)	33.3	[11.1-44.4]
Nausea and vomiting	NV	7.7	(17.2)	0	[0-0]
Pain	PA	25.4	(29.6)	16.7	[0-33.3]
Dyspnoea	DY	21.1	(28.4)	0	[0-33.3]
Insomnia	SL	26.7	(31.3)	33.3	[0-33.3]
Appetite loss	AP	19.2	(30.2)	0	[0-33.3]
Constipation	CO	16.2	(27.7)	0	[0-33.3]
Diarrhoea	DI	8.7	(20)	0	[0-0]
Financial difficulties	FI	15.6	(27.9)	0	[0-33.3]

**All cancer patients: males  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	212	2
8.3	86	1
16.7	340	3
25	256	2
33.3	799	7
41.7	611	6
50	1,721	16
58.3	824	8
66.7	1,932	18
75	810	7
83.3	1,859	17
91.7	441	4
100	1,024	9
<b>Total</b>	<b>10,915</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	34	1
6.7	33	1
13.3	44	1
20	75	1
26.7	95	2
33.3	99	2
40	137	3
46.7	160	3
53.3	201	4
60	301	6
66.7	363	7
73.3	403	8
80	502	9
86.7	673	13
93.3	745	14
100	1,487	28
<b>Total</b>	<b>5,352</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	832	8
16.7	369	3
33.3	975	9
50	695	6
66.7	1,631	15
83.3	1,298	12
100	5,099	47
<b>Total</b>	<b>10,899</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	101	1
8.3	120	1
16.7	213	2
25	281	2
33.3	476	4
41.7	567	4
50	770	6
58.3	980	8
66.7	1,513	12
75	1,586	12
83.3	1,759	14
91.7	1,728	13
100	2,865	22
<b>Total</b>	<b>12,959</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	105	1
16.7	154	1
33.3	426	3
50	910	7
66.7	1,834	14
83.3	3,139	24
100	6,351	49
<b>Total</b>	<b>12,919</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	506	4
16.7	396	3
33.3	953	7
50	1,091	8
66.7	2,226	17
83.3	1,920	15
100	5,904	45
<b>Total</b>	<b>12,996</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	2,849	22
11.1	1,471	12
22.2	1,781	14
33.3	2,378	19
44.4	1,184	9
55.6	981	8
66.7	974	8
77.8	417	3
88.9	405	3
100	400	3
<b>Total</b>	<b>12,840</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	9,814	76
16.7	1,555	12
33.3	827	6
50	288	2
66.7	216	2
83.3	90	1
100	93	1
<b>Total</b>	<b>12,883</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	5,504	43
16.7	2,182	17
33.3	1,970	15
50	1,059	8
66.7	1,041	8
83.3	521	4
100	593	5
<b>Total</b>	<b>12,870</b>	

**All cancer patients: males  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	2,120	39	1,574	29	1,073	20	668	12	5,435
2) Long walk	PF	2,287	42	1,442	27	942	17	766	14	5,437
3) Short walk	PF	4,004	74	906	17	325	6	195	4	5,430
4) Bed or chair	PF	3,322	61	1,220	23	615	11	263	5	5,420
5) Self care	PF	4,940	91	307	6	126	2	77	1	5,450
6) Limited in work	RF	5,658	52	2,606	24	1,552	14	1,150	11	10,966
7) Limited in leisure	RF	6,238	57	2,214	20	1,378	13	1,124	10	10,954
8) Dyspnoea	DY	7,411	57	3,509	27	1,495	12	569	4	12,984
9) Pain	PA	6,078	47	3,815	29	2,108	16	985	8	12,986
10) Need to rest	FA	4,298	33	4,940	38	2,680	21	1,071	8	12,989
11) Insomnia	SL	6,353	49	3,744	29	1,997	15	895	7	12,989
12) Felt weak	FA	5,536	43	4,299	33	2,176	17	981	8	12,992
13) Appetite loss	AP	8,471	65	2,374	18	1,344	10	805	6	12,994
14) Nausea	NV	10,186	78	1,956	15	614	5	253	2	13,009
15) Vomiting	NV	11,474	89	974	8	313	2	152	1	12,913
16) Constipation	CO	8,943	69	2,329	18	1,122	9	580	5	12,974
17) Diarrhoea	DI	10,452	81	1,836	14	492	4	195	2	12,975
18) Felt tired	FA	4,316	33	5,396	42	2,339	18	885	7	12,936
19) Pain interference	PA	7,597	59	2,801	22	1,589	12	942	7	12,929
20) Concentration	CF	8,896	69	2,651	20	1,065	8	364	3	12,976
21) Tension	EF	5,989	46	4,755	36	1,799	14	571	4	13,114
22) Worry	EF	4,514	34	4,938	38	2,496	19	1,186	9	13,134
23) Irritability	EF	6,921	53	4,370	33	1,411	11	414	3	13,116
24) Depression	EF	6,705	51	4,199	32	1,627	12	575	4	13,106
25) Memory trouble	CF	7,952	61	3,808	29	1,086	8	280	2	13,126
26) Family life	SF	7,624	58	3,159	24	1,530	12	754	6	13,067
27) Social activities	SF	6,931	53	3,261	25	1,773	14	1,109	9	13,074
28) Financial difficulties	FI	9,259	71	2,101	16	1,071	8	620	5	13,051
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	425	551	1,266	2,543	2,725	2,379	1,235		11,124
		4	5	11	23	25	21	11		
30) Overall quality of life	QL	427	666	1,495	2,675	3,054	2,842	1,713		12,872
		3	5	12	21	24	22	13		

## All cancer patients: females

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	1,422	16
v +3	394	4
v 2.0	2,563	28
v 3.0	4,649	52
Total	9,028	

#### Age

	N	(%)
<40	819	9
40-49	1,784	20
50-59	2,411	27
60-69	2,197	24
70-79	1,291	14
80+	235	3
Not known	291	3
Total	9,028	

#### Primary disease site

	N	(%)
Bladder	0	0
Bone	1	0
Brain	112	1
Breast	2,782	31
Colorectal	687	8
Genito-urinary (other)	8	0
Gynaecological (excluding ovarian)	270	3
Head & neck: hypopharynx/larynx	49	1
Head & neck: oral cavity/oropharynx	90	1
Kidney	60	1
Leukaemia	243	3
Liver/bile	118	1
Lung	830	9
Lymphoma	176	2
Malignant melanoma	529	6
Malignant myeloma	381	4
Oesophagus/stomach	549	6
Ovarian	917	10
Pancreas	110	1
Prostate	0	0
Sarcoma	26	0
Testicular	0	0
Other	729	8
Not known	361	4
Total	9,028	

#### Stage

	N	(%)
Stage I-II	1,669	19
Stage III-IV	2,483	28
Recurrent/metastatic	2,131	24
Not known	2,745	30
Total	9,028	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	59.3	(24.9)	58.3	[41.7-83.3]
Physical functioning	PF	74.7	(23.3)	80	[60-93.3]
Role Functioning	RF	67.1	(32.9)	66.7	[50-100]
Emotional functioning	EF	67.8	(24.7)	75	[50-83.3]
Cognitive functioning	CF	80.9	(23.1)	83.3	[66.7-100]
Social functioning	SF	72.9	(30.1)	83.3	[50-100]
Fatigue	FA	37.7	(28.2)	33.3	[11.1-55.6]
Nausea and vomiting	NV	11.1	(21.3)	0	[0-16.7]
Pain	PA	29.3	(30.3)	16.7	[0-50]
Dyspnoea	DY	20.3	(28.1)	0	[0-33.3]
Insomnia	SL	31.8	(32.6)	33.3	[0-66.7]
Appetite loss	AP	23.8	(32.6)	0	[0-33.3]
Constipation	CO	19.9	(29.8)	0	[0-33.3]
Diarrhoea	DI	9.3	(20.8)	0	[0-0]
Financial difficulties	FI	17.5	(28.5)	0	[0-33.3]

**All cancer patients: females  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	233	3
8.3	79	1
16.7	319	4
25	219	3
33.3	647	9
41.7	469	6
50	1,251	17
58.3	560	8
66.7	1,247	17
75	575	8
83.3	1,012	14
91.7	274	4
100	605	8
<b>Total</b>	<b>7,490</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	40	1
6.7	32	1
13.3	45	1
20	67	2
26.7	102	2
33.3	99	2
40	150	3
46.7	180	4
53.3	209	5
60	243	5
66.7	356	8
73.3	432	10
80	556	12
86.7	631	14
93.3	595	13
100	811	18
<b>Total</b>	<b>4,548</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	681	9
16.7	326	4
33.3	799	11
50	639	9
66.7	1,417	19
83.3	1,000	14
100	2,565	35
<b>Total</b>	<b>7,427</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	122	1
8.3	123	1
16.7	210	2
25	263	3
33.3	451	5
41.7	536	6
50	673	8
58.3	792	9
66.7	1,219	14
75	1,117	13
83.3	1,116	13
91.7	938	11
100	1,239	14
<b>Total</b>	<b>8,799</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	114	1
16.7	183	2
33.3	384	4
50	658	7
66.7	1,466	17
83.3	2,141	24
100	3,948	44
<b>Total</b>	<b>8,894</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	450	5
16.7	323	4
33.3	818	9
50	762	9
66.7	1,595	18
83.3	1,220	14
100	3,624	41
<b>Total</b>	<b>8,792</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	1,348	15
11.1	931	11
22.2	1,224	14
33.3	1,737	20
44.4	861	10
55.6	781	9
66.7	762	9
77.8	436	5
88.9	333	4
100	414	5
<b>Total</b>	<b>8,827</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	6,109	69
16.7	1,195	14
33.3	734	8
50	311	4
66.7	234	3
83.3	94	1
100	149	2
<b>Total</b>	<b>8,826</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	3,051	35
16.7	1,710	19
33.3	1,574	18
50	805	9
66.7	744	8
83.3	460	5
100	495	6
<b>Total</b>	<b>8,839</b>	

**All cancer patients: females**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	1,171	25	1,639	36	990	22	802	17	4,602
2) Long walk	PF	1,637	36	1,425	31	859	19	696	15	4,617
3) Short walk	PF	3,223	70	879	19	319	7	202	4	4,623
4) Bed or chair	PF	2,390	52	1,300	28	667	14	268	6	4,625
5) Self care	PF	4,148	90	323	7	90	2	66	1	4,627
6) Limited in work	RF	2,931	39	2,235	30	1,389	19	952	13	7,507
7) Limited in leisure	RF	3,551	48	1,877	25	1,097	15	956	13	7,481
8) Dyspnoea	DY	5,205	58	2,468	28	864	10	416	5	8,953
9) Pain	PA	3,398	38	3,136	35	1,613	18	797	9	8,944
10) Need to rest	FA	2,242	25	3,556	40	2,132	24	1,016	11	8,946
11) Insomnia	SL	3,706	41	2,769	31	1,695	19	795	9	8,965
12) Felt weak	FA	3,277	37	3,225	36	1,540	17	910	10	8,952
13) Appetite loss	AP	5,183	58	1,942	22	1,087	12	766	9	8,978
14) Nausea	NV	6,354	71	1,641	18	634	7	338	4	8,967
15) Vomiting	NV	7,494	85	854	10	318	4	189	2	8,855
16) Constipation	CO	5,548	62	1,960	22	893	10	530	6	8,931
17) Diarrhoea	DI	7,103	80	1,303	15	336	4	170	2	8,912
18) Felt tired	FA	2,252	25	3,828	43	1,944	22	906	10	8,930
19) Pain interference	PA	4,743	53	2,205	25	1,153	13	800	9	8,901
20) Concentration	CF	5,550	62	2,095	23	909	10	397	4	8,951
21) Tension	EF	2,992	34	3,629	41	1,680	19	626	7	8,927
22) Worry	EF	2,165	24	3,449	39	2,074	23	1,248	14	8,936
23) Irritability	EF	4,498	50	2,972	33	1,078	12	389	4	8,937
24) Depression	EF	3,504	39	3,314	37	1,458	16	629	7	8,905
25) Memory trouble	CF	5,163	58	2,696	30	786	9	289	3	8,934
26) Family life	SF	4,869	55	2,194	25	1,150	13	653	7	8,866
27) Social activities	SF	4,224	48	2,261	26	1,381	16	993	11	8,859
28) Financial difficulties	FI	5,846	67	1,705	19	796	9	442	5	8,789
		1	2	3	4	5	6	7	Total	
		<b>(very poor)</b>							<b>(excellent)</b>	
29) Overall health	QL	338	447	1,025	1,829	1,813	1,331	733	7,516	
		5	6	14	24	24	18	10		
30) Overall quality of life	QL	425	566	1,182	1,881	1,927	1,796	1,109	8,886	
		5	6	13	21	22	20	13		



## All cancer patients: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	707	14
v +3	190	4
v 2.0	1,971	38
v 3.0	2,339	45
Total	5,207	

#### Age

	N	(%)
<40	1,825	35
40-49	3,382	65
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	5,207	

#### Gender

	N	(%)
Male	2,347	45
Female	2,603	50
Not known	257	5
Total	5,207	

#### Primary disease site

	N	(%)
Bladder	1	0
Bone	1	0
Brain	150	3
Breast	936	18
Colorectal	271	5
Genito-urinary (other)	4	0
Gynaecological (excluding ovarian)	105	2
Head & neck: hypopharynx/larynx	52	1
Head & neck: oral cavity/oropharynx	50	1
Kidney	51	1
Leukaemia	185	4
Liver/bile	83	2
Lung	501	10
Lymphoma	201	4
Malignant melanoma	606	12
Malignant myeloma	121	2
Oesophagus/stomach	212	4
Ovarian	180	4
Pancreas	63	1
Prostate	40	1
Sarcoma	28	1
Testicular	375	7
Other	637	12
Not known	354	7
Total	5,207	

#### Stage

	N	(%)
Stage I-II	859	17
Stage III-IV	1,454	28
Recurrent/metastatic	1,187	23
Not known	1,707	33
Total	5,207	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.4	(23.4)	66.7	[50-83.3]
Physical functioning	PF	80.2	(20.8)	86.7	[66.7-100]
Role Functioning	RF	68.6	(31.7)	66.7	[50-100]
Emotional functioning	EF	69.2	(24.4)	75	[58.3-91.7]
Cognitive functioning	CF	82.9	(21.6)	83.3	[66.7-100]
Social functioning	SF	72.1	(29.5)	83.3	[50-100]
Fatigue	FA	33.9	(26.1)	33.3	[11.1-55.6]
Nausea and vomiting	NV	9.4	(19.1)	0	[0-16.7]
Pain	PA	27.2	(28.8)	16.7	[0-50]
Dyspnoea	DY	17.1	(25.8)	0	[0-33.3]
Insomnia	SL	30.2	(32.2)	33.3	[0-66.7]
Appetite loss	AP	19.7	(29.1)	0	[0-33.3]
Constipation	CO	15.3	(26.5)	0	[0-33.3]
Diarrhoea	DI	9.0	(19.9)	0	[0-0]
Financial difficulties	FI	23.6	(32)	0	[0-33.3]

**All cancer patients: <50  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	85	2
8.3	26	1
16.7	143	3
25	106	3
33.3	360	8
41.7	274	6
50	670	16
58.3	356	8
66.7	749	17
75	373	9
83.3	663	15
91.7	185	4
100	314	7
<b>Total</b>	<b>4,304</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	12	1
6.7	9	0
13.3	14	1
20	13	1
26.7	23	1
33.3	37	2
40	45	2
46.7	61	3
53.3	88	4
60	131	6
66.7	143	6
73.3	199	9
80	263	12
86.7	328	14
93.3	299	13
100	630	28
<b>Total</b>	<b>2,295</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	329	8
16.7	164	4
33.3	459	11
50	374	9
66.7	866	20
83.3	578	14
100	1,511	35
<b>Total</b>	<b>4,281</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	63	1
8.3	64	1
16.7	126	3
25	136	3
33.3	238	5
41.7	266	5
50	366	7
58.3	428	8
66.7	763	15
75	670	13
83.3	639	13
91.7	536	11
100	827	16
<b>Total</b>	<b>5,122</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	40	1
16.7	78	2
33.3	170	3
50	361	7
66.7	770	15
83.3	1,188	24
100	2,391	48
<b>Total</b>	<b>4,998</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	251	5
16.7	181	4
33.3	479	9
50	456	9
66.7	1,062	21
83.3	748	15
100	1,945	38
<b>Total</b>	<b>5,122</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	872	18
11.1	552	11
22.2	731	15
33.3	1,089	22
44.4	491	10
55.6	411	8
66.7	385	8
77.8	173	4
88.9	159	3
100	124	3
<b>Total</b>	<b>4,987</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	3,577	72
16.7	655	13
33.3	418	8
50	116	2
66.7	116	2
83.3	34	1
100	57	1
<b>Total</b>	<b>4,973</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	1,790	36
16.7	976	20
33.3	941	19
50	464	9
66.7	384	8
83.3	204	4
100	222	5
<b>Total</b>	<b>4,981</b>	

**All cancer patients: <50  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	864	37	800	34	436	19	224	10	2,324
2) Long walk	PF	1,047	45	715	31	373	16	196	8	2,331
3) Short walk	PF	1,796	77	375	16	111	5	48	2	2,330
4) Bed or chair	PF	1,292	56	636	28	278	12	105	5	2,311
5) Self care	PF	2,149	92	130	6	32	1	21	1	2,332
6) Limited in work	RF	1,764	41	1,333	31	723	17	484	11	4,304
7) Limited in leisure	RF	2,015	47	1,152	27	660	15	467	11	4,294
8) Dyspnoea	DY	3,168	63	1,287	26	415	8	152	3	5,022
9) Pain	PA	1,985	40	1,839	37	813	16	380	8	5,017
10) Need to rest	FA	1,398	28	2,106	42	1,087	22	429	9	5,020
11) Insomnia	SL	2,183	44	1,556	31	855	17	426	9	5,020
12) Felt weak	FA	2,001	40	1,902	38	805	16	316	6	5,024
13) Appetite loss	AP	3,108	62	1,114	22	554	11	249	5	5,025
14) Nausea	NV	3,702	74	927	18	265	5	136	3	5,030
15) Vomiting	NV	4,284	86	477	10	148	3	70	1	4,979
16) Constipation	CO	3,477	69	984	20	358	7	200	4	5,019
17) Diarrhoea	DI	3,983	80	783	16	172	3	75	2	5,013
18) Felt tired	FA	1,394	28	2,292	46	993	20	335	7	5,014
19) Pain interference	PA	2,721	54	1,326	27	613	12	344	7	5,004
20) Concentration	CF	3,100	62	1,248	25	492	10	176	4	5,016
21) Tension	EF	1,832	35	2,169	42	860	17	317	6	5,178
22) Worry	EF	1,328	26	2,110	41	1,118	22	628	12	5,184
23) Irritability	EF	2,386	46	1,904	37	646	13	231	5	5,167
24) Depression	EF	2,241	43	1,940	38	714	14	273	5	5,168
25) Memory trouble	CF	3,360	65	1,354	26	354	7	108	2	5,176
26) Family life	SF	2,571	50	1,531	30	676	13	378	7	5,156
27) Social activities	SF	2,358	46	1,474	29	806	16	505	10	5,143
28) Financial difficulties	FI	2,908	57	1,192	23	604	12	405	8	5,109
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	220	256	564	1,009	1,105	906	410		4,470
		5	6	13	23	25	20	9		
30) Overall quality of life	QL	145	255	628	992	1,199	1,147	641		5,007
		3	5	13	20	24	23	13		

## All cancer patients: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	874	15
v +3	287	5
v 2.0	1,777	31
v 3.0	2,769	49
Total	5,707	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	5,707	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	5,707	

#### Gender

	N	(%)
Male	2,993	52
Female	2,411	42
Not known	303	5
Total	5,707	

#### Primary disease site

	N	(%)
Bladder	1	0
Bone	1	0
Brain	86	2
Breast	788	14
Colorectal	456	8
Genito-urinary (other)	6	0
Gynaecological (excluding ovarian)	66	1
Head & neck: hypopharynx/larynx	113	2
Head & neck: oral cavity/oropharynx	95	2
Kidney	68	1
Leukaemia	97	2
Liver/bile	93	2
Lung	971	17
Lymphoma	90	2
Malignant melanoma	294	5
Malignant myeloma	314	6
Oesophagus/stomach	420	7
Ovarian	255	5
Pancreas	82	1
Prostate	336	6
Sarcoma	16	0
Testicular	9	0
Other	820	14
Not known	230	4
Total	5,707	

#### Stage

	N	(%)
Stage I-II	1,097	19
Stage III-IV	2,030	36
Recurrent/metastatic	961	17
Not known	1,619	28
Total	5,707	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.2	(24.1)	66.7	[50-83.3]
Physical functioning	PF	78.0	(22.5)	86.7	[66.7-93.3]
Role Functioning	RF	69.4	(32.7)	83.3	[50-100]
Emotional functioning	EF	69.0	(24.2)	75	[50-91.7]
Cognitive functioning	CF	83.2	(21.9)	83.3	[66.7-100]
Social functioning	SF	73.5	(29.4)	83.3	[50-100]
Fatigue	FA	34.4	(27.7)	33.3	[11.1-55.6]
Nausea and vomiting	NV	8.9	(18.5)	0	[0-16.7]
Pain	PA	28.2	(30.1)	16.7	[0-50]
Dyspnoea	DY	20.4	(28)	0	[0-33.3]
Insomnia	SL	30.1	(32.1)	33.3	[0-66.7]
Appetite loss	AP	20.8	(30.4)	0	[0-33.3]
Constipation	CO	15.1	(26.3)	0	[0-33.3]
Diarrhoea	DI	8.9	(20.2)	0	[0-0]
Financial difficulties	FI	20.1	(30.1)	0	[0-33.3]

**All cancer patients: 50-59  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	111	2
8.3	43	1
16.7	173	4
25	116	2
33.3	384	8
41.7	268	6
50	791	17
58.3	373	8
66.7	838	18
75	361	8
83.3	699	15
91.7	199	4
100	404	9
<b>Total</b>	<b>4,760</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	12	0
6.7	13	1
13.3	19	1
20	40	2
26.7	51	2
33.3	55	2
40	74	3
46.7	84	3
53.3	120	4
60	140	5
66.7	176	7
73.3	210	8
80	308	11
86.7	369	14
93.3	391	14
100	661	24
<b>Total</b>	<b>2,723</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	395	8
16.7	182	4
33.3	514	11
50	370	8
66.7	838	18
83.3	584	12
100	1,859	39
<b>Total</b>	<b>4,742</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	65	1
8.3	70	1
16.7	113	2
25	158	3
33.3	263	5
41.7	314	6
50	420	8
58.3	509	9
66.7	751	14
75	713	13
83.3	745	13
91.7	628	11
100	832	15
<b>Total</b>	<b>5,581</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	55	1
16.7	88	2
33.3	199	4
50	395	7
66.7	819	15
83.3	1,290	23
100	2,783	49
<b>Total</b>	<b>5,629</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	258	5
16.7	174	3
33.3	517	9
50	532	10
66.7	1,013	18
83.3	803	14
100	2,303	41
<b>Total</b>	<b>5,600</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	1,094	20
11.1	607	11
22.2	740	13
33.3	1,157	21
44.4	541	10
55.6	405	7
66.7	430	8
77.8	232	4
88.9	204	4
100	199	4
<b>Total</b>	<b>5,609</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	4,120	73
16.7	752	13
33.3	391	7
50	172	3
66.7	101	2
83.3	46	1
100	53	1
<b>Total</b>	<b>5,635</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	2,056	37
16.7	1,056	19
33.3	973	17
50	485	9
66.7	503	9
83.3	243	4
100	305	5
<b>Total</b>	<b>5,621</b>	

**All cancer patients: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	924	34	857	31	566	21	402	15	2,749
2) Long walk	PF	1,151	42	794	29	474	17	335	12	2,754
3) Short walk	PF	2,052	74	434	16	182	7	92	3	2,760
4) Bed or chair	PF	1,599	58	699	25	350	13	108	4	2,756
5) Self care	PF	2,535	92	149	5	51	2	29	1	2,764
6) Limited in work	RF	2,100	44	1,258	26	865	18	551	12	4,774
7) Limited in leisure	RF	2,416	51	1,115	23	701	15	535	11	4,767
8) Dyspnoea	DY	3,273	58	1,571	28	570	10	254	5	5,668
9) Pain	PA	2,304	41	1,899	34	983	17	488	9	5,674
10) Need to rest	FA	1,701	30	2,265	40	1,180	21	522	9	5,668
11) Insomnia	SL	2,468	44	1,759	31	979	17	466	8	5,672
12) Felt weak	FA	2,197	39	2,057	36	933	16	491	9	5,678
13) Appetite loss	AP	3,475	61	1,213	21	626	11	357	6	5,671
14) Nausea	NV	4,256	75	958	17	319	6	142	3	5,675
15) Vomiting	NV	4,953	88	469	8	159	3	74	1	5,655
16) Constipation	CO	3,936	70	1,094	19	404	7	220	4	5,654
17) Diarrhoea	DI	4,533	80	811	14	220	4	87	2	5,651
18) Felt tired	FA	1,684	30	2,442	43	1,062	19	465	8	5,653
19) Pain interference	PA	3,052	54	1,395	25	734	13	461	8	5,642
20) Concentration	CF	3,632	64	1,293	23	546	10	189	3	5,660
21) Tension	EF	2,008	36	2,287	40	1,012	18	352	6	5,659
22) Worry	EF	1,375	24	2,269	40	1,308	23	703	12	5,655
23) Irritability	EF	2,785	49	1,984	35	681	12	205	4	5,655
24) Depression	EF	2,433	43	2,055	36	818	15	347	6	5,653
25) Memory trouble	CF	3,579	63	1,546	27	388	7	143	3	5,656
26) Family life	SF	3,033	54	1,472	26	752	13	371	7	5,628
27) Social activities	SF	2,709	48	1,472	26	927	17	527	9	5,635
28) Financial difficulties	FI	3,486	62	1,173	21	580	10	345	6	5,584
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	172	258	610	1,099	1,201	937	506		4,783
		4	5	13	23	25	20	11		
30) Overall quality of life	QL	195	320	716	1,140	1,333	1,175	741		5,620
		4	6	13	20	24	21	13		

## All cancer patients: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	1,003	15
v +3	255	4
v 2.0	2,553	38
v 3.0	2,898	43
Total	6,709	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	6,709	100
70-79	0	0
80+	0	0
Not known	0	0
Total	6,709	

#### Gender

	N	(%)
Male	4,230	63
Female	2,197	33
Not known	282	4
Total	6,709	

#### Primary disease site

	N	(%)
Bladder	2	0
Bone	0	0
Brain	44	1
Breast	525	8
Colorectal	633	9
Genito-urinary (other)	6	0
Gynaecological (excluding ovarian)	64	1
Head & neck: hypopharynx/larynx	149	2
Head & neck: oral cavity/oropharynx	46	1
Kidney	55	1
Leukaemia	43	1
Liver/bile	159	2
Lung	1,108	17
Lymphoma	55	1
Malignant melanoma	233	4
Malignant myeloma	264	4
Oesophagus/stomach	604	9
Ovarian	318	5
Pancreas	88	1
Prostate	1,327	20
Sarcoma	6	0
Testicular	2	0
Other	784	12
Not known	194	3
Total	6,709	

#### Stage

	N	(%)
Stage I-II	1,498	22
Stage III-IV	2,423	36
Recurrent/metastatic	1,233	18
Not known	1,555	23
Total	6,709	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.8	(24.4)	66.7	[50-83.3]
Physical functioning	PF	76.3	(23.5)	80	[66.7-93.3]
Role Functioning	RF	72.6	(32.7)	83.3	[50-100]
Emotional functioning	EF	71.8	(24.3)	75	[58.3-91.7]
Cognitive functioning	CF	83.1	(21.6)	83.3	[66.7-100]
Social functioning	SF	76.4	(28.8)	83.3	[66.7-100]
Fatigue	FA	34.1	(28.2)	33.3	[11.1-55.6]
Nausea and vomiting	NV	8.7	(19)	0	[0-16.7]
Pain	PA	26.4	(30.2)	16.7	[0-50]
Dyspnoea	DY	22.1	(29.1)	0	[0-33.3]
Insomnia	SL	28.6	(32)	33.3	[0-33.3]
Appetite loss	AP	21.0	(31.9)	0	[0-33.3]
Constipation	CO	17.7	(28.8)	0	[0-33.3]
Diarrhoea	DI	9.2	(20.7)	0	[0-0]
Financial difficulties	FI	13.8	(26.4)	0	[0-33.3]

**All cancer patients: 60-69  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	133	2
8.3	54	1
16.7	186	3
25	144	3
33.3	437	8
41.7	328	6
50	921	16
58.3	409	7
66.7	954	17
75	398	7
83.3	905	16
91.7	203	4
100	539	10
<b>Total</b>	<b>5,611</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	21	1
6.7	15	1
13.3	24	1
20	43	2
26.7	68	2
33.3	63	2
40	85	3
46.7	108	4
53.3	110	4
60	148	5
66.7	233	8
73.3	238	8
80	284	10
86.7	345	12
93.3	373	13
100	667	24
<b>Total</b>	<b>2,825</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	443	8
16.7	215	4
33.3	501	9
50	353	6
66.7	852	15
83.3	687	12
100	2,541	45
<b>Total</b>	<b>5,592</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	65	1
8.3	76	1
16.7	122	2
25	163	3
33.3	274	4
41.7	343	5
50	428	7
58.3	528	8
66.7	770	12
75	813	12
83.3	854	13
91.7	866	13
100	1,250	19
<b>Total</b>	<b>6,552</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	62	1
16.7	92	1
33.3	251	4
50	433	7
66.7	974	15
83.3	1,625	25
100	3,191	48
<b>Total</b>	<b>6,628</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	273	4
16.7	198	3
33.3	494	8
50	536	8
66.7	1,070	16
83.3	939	14
100	3,059	47
<b>Total</b>	<b>6,569</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	1,364	21
11.1	729	11
22.2	915	14
33.3	1,144	17
44.4	612	9
55.6	562	9
66.7	521	8
77.8	260	4
88.9	217	3
100	252	4
<b>Total</b>	<b>6,576</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	4,949	75
16.7	780	12
33.3	443	7
50	177	3
66.7	123	2
83.3	60	1
100	77	1
<b>Total</b>	<b>6,609</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	2,717	41
16.7	1,161	18
33.3	1,020	16
50	548	8
66.7	507	8
83.3	300	5
100	346	5
<b>Total</b>	<b>6,599</b>	



**All cancer patients: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	933	33	850	30	636	22	449	16	2,868
2) Long walk	PF	1,100	38	765	27	539	19	467	16	2,871
3) Short walk	PF	2,052	72	503	18	201	7	115	4	2,871
4) Bed or chair	PF	1,689	59	693	24	339	12	160	6	2,881
5) Self care	PF	2,610	90	175	6	62	2	39	1	2,886
6) Limited in work	RF	2,791	50	1,415	25	817	15	614	11	5,637
7) Limited in leisure	RF	3,170	56	1,150	20	688	12	619	11	5,627
8) Dyspnoea	DY	3,684	55	1,859	28	768	12	341	5	6,652
9) Pain	PA	2,988	45	2,033	31	1,106	17	544	8	6,671
10) Need to rest	FA	2,093	31	2,487	37	1,480	22	607	9	6,667
11) Insomnia	SL	3,094	46	1,938	29	1,129	17	511	8	6,672
12) Felt weak	FA	2,764	41	2,139	32	1,174	18	593	9	6,670
13) Appetite loss	AP	4,242	64	1,202	18	715	11	523	8	6,682
14) Nausea	NV	5,126	77	1,001	15	379	6	178	3	6,684
15) Vomiting	NV	5,833	88	504	8	175	3	111	2	6,623
16) Constipation	CO	4,429	67	1,252	19	619	9	346	5	6,646
17) Diarrhoea	DI	5,313	80	956	14	254	4	122	2	6,645
18) Felt tired	FA	2,104	32	2,695	41	1,288	19	547	8	6,634
19) Pain interference	PA	3,857	58	1,414	21	803	12	555	8	6,629
20) Concentration	CF	4,527	68	1,352	20	558	8	224	3	6,661
21) Tension	EF	2,806	42	2,443	37	1,055	16	337	5	6,641
22) Worry	EF	2,054	31	2,494	38	1,365	21	741	11	6,654
23) Irritability	EF	3,500	53	2,152	32	745	11	246	4	6,643
24) Depression	EF	3,121	47	2,181	33	964	15	364	6	6,630
25) Memory trouble	CF	3,927	59	2,000	30	567	9	157	2	6,651
26) Family life	SF	3,977	60	1,473	22	759	12	400	6	6,609
27) Social activities	SF	3,531	53	1,591	24	889	13	604	9	6,615
28) Financial difficulties	FI	4,877	74	962	15	509	8	252	4	6,600
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	197	278	671	1,367	1,362	1,124	637		5,636
		4	5	12	24	24	20	11		
30) Overall quality of life	QL	259	368	782	1,429	1,445	1,430	888		6,601
		4	6	12	22	22	22	14		

## All cancer patients: ≥70

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	902	17
v +3	229	4
v 2.0	1,947	36
v 3.0	2,279	43
Total	5,357	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	4,650	87
80+	707	13
Not known	0	0
Total	5,357	

#### Gender

	N	(%)
Male	3,643	68
Female	1,526	29
Not known	188	4
Total	5,357	

#### Primary disease site

	N	(%)
Bladder	9	0
Bone	2	0
Brain	0	0
Breast	253	5
Colorectal	413	8
Genito-urinary (other)	29	1
Gynaecological (excluding ovarian)	34	1
Head & neck: hypopharynx/larynx	122	2
Head & neck: oral cavity/oropharynx	80	2
Kidney	14	0
Leukaemia	21	0
Liver/bile	114	2
Lung	656	12
Lymphoma	50	1
Malignant melanoma	67	1
Malignant myeloma	243	5
Oesophagus/stomach	654	12
Ovarian	164	3
Pancreas	65	1
Prostate	1,657	31
Sarcoma	5	0
Testicular	1	0
Other	552	10
Not known	152	3
Total	5,357	

#### Stage

	N	(%)
Stage I-II	1,257	24
Stage III-IV	1,967	37
Recurrent/metastatic	1,142	21
Not known	991	19
Total	5,357	

#### Constructed scales

	QL	Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	60.6	(25.1)	66.7	[50-83.3]
Physical functioning	PF	72.1	(25.4)	80	[60-93.3]
Role Functioning	RF	70.7	(34.1)	83.3	[50-100]
Emotional functioning	EF	76.1	(23.2)	83.3	[66.7-100]
Cognitive functioning	CF	81.0	(22.4)	83.3	[66.7-100]
Social functioning	SF	78.2	(28.2)	83.3	[66.7-100]
Fatigue	FA	35.7	(29)	33.3	[11.1-55.6]
Nausea and vomiting	NV	9.1	(19.2)	0	[0-16.7]
Pain	PA	25.9	(30.5)	16.7	[0-50]
Dyspnoea	DY	23.1	(29.6)	0	[0-33.3]
Insomnia	SL	26.4	(31.3)	33.3	[0-33.3]
Appetite loss	AP	22.4	(33.2)	0	[0-33.3]
Constipation	CO	21.7	(31.2)	0	[0-33.3]
Diarrhoea	DI	8.9	(20.7)	0	[0-0]
Financial difficulties	FI	8.5	(20.6)	0	[0-0]

**All cancer patients: ≥70  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	132	3
8.3	47	1
16.7	180	4
25	123	3
33.3	333	8
41.7	245	6
50	704	16
58.3	303	7
66.7	759	17
75	308	7
83.3	669	15
91.7	156	4
100	398	9
<b>Total</b>	<b>4,357</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	29	1
6.7	28	1
13.3	34	2
20	47	2
26.7	58	3
33.3	54	2
40	89	4
46.7	92	4
53.3	101	5
60	136	6
66.7	178	8
73.3	199	9
80	225	10
86.7	282	13
93.3	295	13
100	376	17
<b>Total</b>	<b>2,223</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	421	10
16.7	168	4
33.3	412	10
50	295	7
66.7	612	14
83.3	511	12
100	1,918	44
<b>Total</b>	<b>4,337</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	32	1
8.3	40	1
16.7	74	1
25	106	2
33.3	173	3
41.7	213	4
50	274	5
58.3	358	7
66.7	534	10
75	593	11
83.3	723	14
91.7	741	14
100	1,346	26
<b>Total</b>	<b>5,207</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	64	1
16.7	85	2
33.3	211	4
50	418	8
66.7	831	16
83.3	1,435	27
100	2,230	42
<b>Total</b>	<b>5,274</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	197	4
16.7	174	3
33.3	304	6
50	406	8
66.7	783	15
83.3	763	15
100	2,581	50
<b>Total</b>	<b>5,208</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	997	19
11.1	599	12
22.2	742	14
33.3	863	17
44.4	472	9
55.6	436	8
66.7	445	9
77.8	200	4
88.9	195	4
100	262	5
<b>Total</b>	<b>5,211</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	3,841	74
16.7	638	12
33.3	355	7
50	163	3
66.7	111	2
83.3	44	1
100	58	1
<b>Total</b>	<b>5,210</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	2,282	44
16.7	854	16
33.3	712	14
50	427	8
66.7	444	9
83.3	248	5
100	259	5
<b>Total</b>	<b>5,226</b>	

**All cancer patients: ≥70**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	620	27	752	33	462	20	431	19	2,265	
2) Long walk	PF	691	31	631	28	448	20	496	22	2,266	
3) Short walk	PF	1,444	64	501	22	171	8	144	6	2,260	
4) Bed or chair	PF	1,225	54	530	23	345	15	164	7	2,264	
5) Self care	PF	1,949	86	185	8	74	3	54	2	2,262	
6) Limited in work	RF	2,124	48	1,008	23	695	16	560	13	4,387	
7) Limited in leisure	RF	2,405	55	851	20	559	13	559	13	4,374	
8) Dyspnoea	DY	2,886	54	1,455	27	699	13	276	5	5,316	
9) Pain	PA	2,513	48	1,427	27	909	17	437	8	5,286	
10) Need to rest	FA	1,560	29	1,948	37	1,212	23	581	11	5,301	
11) Insomnia	SL	2,651	50	1,456	27	843	16	355	7	5,305	
12) Felt weak	FA	2,155	41	1,672	32	930	18	538	10	5,295	
13) Appetite loss	AP	3,319	62	908	17	608	11	482	9	5,317	
14) Nausea	NV	4,035	76	812	15	316	6	150	3	5,313	
15) Vomiting	NV	4,552	87	437	8	153	3	90	2	5,232	
16) Constipation	CO	3,212	61	1,089	21	648	12	355	7	5,304	
17) Diarrhoea	DI	4,284	81	703	13	213	4	97	2	5,297	
18) Felt tired	FA	1,591	30	2,126	40	1,053	20	515	10	5,285	
19) Pain interference	PA	3,142	60	1,038	20	669	13	429	8	5,278	
20) Concentration	CF	3,682	69	999	19	444	8	187	4	5,312	
21) Tension	EF	2,652	50	1,743	33	672	13	220	4	5,287	
22) Worry	EF	2,149	41	1,775	34	947	18	428	8	5,299	
23) Irritability	EF	3,138	59	1,534	29	490	9	137	3	5,299	
24) Depression	EF	2,790	53	1,578	30	671	13	241	5	5,280	
25) Memory trouble	CF	2,659	50	1,853	35	615	12	169	3	5,296	
26) Family life	SF	3,403	65	1,026	20	544	10	282	5	5,255	
27) Social activities	SF	2,961	56	1,144	22	641	12	512	10	5,258	
28) Financial difficulties	FI	4,337	82	603	12	236	5	90	2	5,266	
<hr/>											
		1	2	3	4	5	6	7	Total		
		(very poor)								(excellent)	
29) Overall health	QL	197	245	533	1,063	1,050	842	450	4,380		
		5	6	12	24	24	19	10			
<hr/>											
30) Overall quality of life	QL	254	304	607	1,101	1,190	1,070	718	5,244		
		5	6	12	21	23	20	14			

## All cancer patients: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	1,096	23
v +3	386	8
v 2.0	1,437	30
v 3.0	1,801	38
Total	4,720	

#### Age

	N	(%)
<40	277	6
40-49	582	12
50-59	1,097	23
60-69	1,498	32
70-79	1,113	24
80+	144	3
Not known	9	0
Total	4,720	

#### Gender

	N	(%)
Male	2,705	57
Female	1,669	35
Not known	346	7
Total	4,720	

#### Primary disease site

	N	(%)
Bladder	13	0
Bone	3	0
Brain	0	0
Breast	465	10
Colorectal	230	5
Genito-urinary (other)	6	0
Gynaecological (excluding ovarian)	132	3
Head & neck: hypopharynx/larynx	222	5
Head & neck: oral cavity/oropharynx	45	1
Kidney	2	0
Leukaemia	48	1
Liver/bile	41	1
Lung	538	11
Lymphoma	33	1
Malignant melanoma	223	5
Malignant myeloma	295	6
Oesophagus/stomach	157	3
Ovarian	214	5
Pancreas	0	0
Prostate	959	20
Sarcoma	8	0
Testicular	27	1
Other	714	15
Not known	345	7
Total	4,720	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	65.8	(23.4)	66.7	[50-83.3]
Physical functioning	PF	84.5	(18.7)	93.3	[73.3-100]
Role Functioning	RF	81.2	(27.5)	100	[66.7-100]
Emotional functioning	EF	73.5	(23.9)	75	[58.3-91.7]
Cognitive functioning	CF	84.7	(20.3)	100	[83.3-100]
Social functioning	SF	81.1	(25.8)	100	[66.7-100]
Fatigue	FA	26.9	(25.5)	22.2	[0-44.4]
Nausea and vomiting	NV	5.5	(14.7)	0	[0-0]
Pain	PA	20.8	(26.6)	16.7	[0-33.3]
Dyspnoea	DY	18.0	(27)	0	[0-33.3]
Insomnia	SL	25.4	(30.7)	0	[0-33.3]
Appetite loss	AP	13.2	(25.8)	0	[0-33.3]
Constipation	CO	13.2	(24.5)	0	[0-33.3]
Diarrhoea	DI	8.1	(19.5)	0	[0-0]
Financial difficulties	FI	14.1	(25.7)	0	[0-33.3]

**All cancer patients: stage I-II  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	50	1
8.3	20	1
16.7	98	3
25	59	2
33.3	243	7
41.7	166	5
50	508	14
58.3	245	7
66.7	627	18
75	294	8
83.3	657	19
91.7	173	5
100	417	12
<b>Total</b>	<b>3,557</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	5	0
6.7	7	0
13.3	2	0
20	9	1
26.7	14	1
33.3	12	1
40	15	1
46.7	39	2
53.3	59	3
60	65	4
66.7	102	6
73.3	132	7
80	193	11
86.7	208	12
93.3	255	14
100	658	37
<b>Total</b>	<b>1,775</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	139	4
16.7	75	2
33.3	204	6
50	174	5
66.7	505	14
83.3	458	13
100	2,003	56
<b>Total</b>	<b>3,558</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	45	1
8.3	41	1
16.7	88	2
25	107	2
33.3	155	3
41.7	209	5
50	280	6
58.3	363	8
66.7	531	12
75	570	12
83.3	623	14
91.7	614	13
100	1,003	22
<b>Total</b>	<b>4,629</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	36	1
16.7	41	1
33.3	141	3
50	279	6
66.7	655	14
83.3	1,162	25
100	2,356	50
<b>Total</b>	<b>4,670</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	119	3
16.7	103	2
33.3	232	5
50	323	7
66.7	737	16
83.3	670	14
100	2,466	53
<b>Total</b>	<b>4,650</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	1,291	28
11.1	634	14
22.2	687	15
33.3	818	18
44.4	377	8
55.6	299	6
66.7	235	5
77.8	112	2
88.9	109	2
100	81	2
<b>Total</b>	<b>4,643</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	3,845	82
16.7	462	10
33.3	215	5
50	72	2
66.7	47	1
83.3	21	0
100	25	1
<b>Total</b>	<b>4,687</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	2,220	48
16.7	833	18
33.3	705	15
50	349	8
66.7	279	6
83.3	115	3
100	136	3
<b>Total</b>	<b>4,637</b>	

**All cancer patients: stage I-II**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	820	46	541	30	295	16	140	8	1,796
2) Long walk	PF	927	52	501	28	250	14	118	7	1,796
3) Short walk	PF	1,472	82	240	13	54	3	23	1	1,789
4) Bed or chair	PF	1,256	70	369	21	135	8	35	2	1,795
5) Self care	PF	1,715	96	50	3	19	1	10	1	1,794
6) Limited in work	RF	2,163	60	771	22	418	12	231	6	3,583
7) Limited in leisure	RF	2,492	70	604	17	288	8	194	5	3,578
8) Dyspnoea	DY	2,937	63	1,155	25	433	9	174	4	4,699
9) Pain	PA	2,436	52	1,398	30	621	13	231	5	4,686
10) Need to rest	FA	1,909	41	1,757	37	787	17	248	5	4,701
11) Insomnia	SL	2,397	51	1,310	28	708	15	284	6	4,699
12) Felt weak	FA	2,405	51	1,455	31	577	12	253	5	4,690
13) Appetite loss	AP	3,507	75	698	15	324	7	174	4	4,703
14) Nausea	NV	3,910	83	563	12	155	3	71	2	4,699
15) Vomiting	NV	4,351	93	248	5	65	1	32	1	4,696
16) Constipation	CO	3,409	73	832	18	319	7	129	3	4,689
17) Diarrhoea	DI	3,838	82	621	13	157	3	70	2	4,686
18) Felt tired	FA	1,861	40	1,895	41	698	15	220	5	4,674
19) Pain interference	PA	3,027	65	971	21	447	10	220	5	4,665
20) Concentration	CF	3,328	71	950	20	321	7	97	2	4,696
21) Tension	EF	2,087	45	1,683	36	678	15	228	5	4,676
22) Worry	EF	1,587	34	1,722	37	903	19	463	10	4,675
23) Irritability	EF	2,571	55	1,482	32	469	10	161	3	4,683
24) Depression	EF	2,341	50	1,496	32	597	13	238	5	4,672
25) Memory trouble	CF	2,794	60	1,437	31	351	8	96	2	4,678
26) Family life	SF	2,963	64	1,084	23	410	9	204	4	4,661
27) Social activities	SF	2,873	61	1,075	23	464	10	264	6	4,676
28) Financial difficulties	FI	3,368	72	795	17	363	8	151	3	4,677
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	87	138	372	762	863	842	509		3,573
		2	4	10	21	24	24	14		
30) Overall quality of life	QL	111	182	453	847	988	1,197	867		4,645
		2	4	10	18	21	26	19		

## All cancer patients: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	981	12
v +3	555	7
v 2.0	3,557	44
v 3.0	2,973	37
Total	8,066	

#### Age

	N	(%)
<40	379	5
40-49	1,075	13
50-59	2,030	25
60-69	2,423	30
70-79	1,748	22
80+	219	3
Not known	192	2
Total	8,066	

#### Gender

	N	(%)
Male	4,910	61
Female	2,483	31
Not known	673	8
Total	8,066	

#### Primary disease site

	N	(%)
Bladder	0	0
Bone	0	0
Brain	0	0
Breast	377	5
Colorectal	281	4
Genito-urinary (other)	2	0
Gynaecological (excluding ovarian)	30	0
Head & neck: hypopharynx/larynx	210	3
Head & neck: oral cavity/oropharynx	224	3
Kidney	157	2
Leukaemia	66	1
Liver/bile	197	2
Lung	1,313	16
Lymphoma	0	0
Malignant melanoma	585	7
Malignant myeloma	647	8
Oesophagus/stomach	234	3
Ovarian	662	8
Pancreas	28	0
Prostate	1,511	19
Sarcoma	1	0
Testicular	0	0
Other	1,404	17
Not known	137	2
Total	8,066	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.5	(23.6)	66.7	[50-83.3]
Physical functioning	PF	71.2	(25.8)	80	[53.3-93.3]
Role Functioning	RF	70.6	(32.8)	83.3	[50-100]
Emotional functioning	EF	71.5	(23.8)	75	[58.3-91.7]
Cognitive functioning	CF	83.2	(21.3)	83.3	[66.7-100]
Social functioning	SF	75.1	(28.9)	83.3	[66.7-100]
Fatigue	FA	34.7	(27.9)	33.3	[11.1-55.6]
Nausea and vomiting	NV	7.8	(17.3)	0	[0-0]
Pain	PA	29.2	(30.8)	16.7	[0-50]
Dyspnoea	DY	21.7	(28.7)	0	[0-33.3]
Insomnia	SL	28.5	(31.7)	33.3	[0-33.3]
Appetite loss	AP	20.8	(31)	0	[0-33.3]
Constipation	CO	17.0	(28.4)	0	[0-33.3]
Diarrhoea	DI	8.3	(19.5)	0	[0-0]
Financial difficulties	FI	15.4	(27.7)	0	[0-33.3]



**All cancer patients: stage III-IV  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	138	2
8.3	53	1
16.7	239	3
25	157	2
33.3	566	8
41.7	407	6
50	1,156	17
58.3	566	8
66.7	1,252	18
75	518	7
83.3	1,051	15
91.7	263	4
100	588	9
<b>Total</b>	<b>6,954</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	28	1
6.7	37	1
13.3	41	1
20	74	3
26.7	85	3
33.3	102	4
40	124	4
46.7	133	5
53.3	161	6
60	182	6
66.7	226	8
73.3	237	8
80	265	9
86.7	343	12
93.3	340	12
100	541	19
<b>Total</b>	<b>2,919</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	587	8
16.7	263	4
33.3	671	10
50	532	8
66.7	1,153	17
83.3	882	13
100	2,883	41
<b>Total</b>	<b>6,971</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	53	1
8.3	98	1
16.7	140	2
25	187	2
33.3	331	4
41.7	415	5
50	574	7
58.3	653	8
66.7	964	12
75	983	13
83.3	1,032	13
91.7	1,003	13
100	1,445	18
<b>Total</b>	<b>7,878</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	59	1
16.7	109	1
33.3	285	4
50	557	7
66.7	1,196	15
83.3	1,924	24
100	3,825	48
<b>Total</b>	<b>7,955</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	323	4
16.7	244	3
33.3	655	8
50	719	9
66.7	1,388	18
83.3	1,094	14
100	3,473	44
<b>Total</b>	<b>7,896</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	1,585	20
11.1	832	11
22.2	1,060	13
33.3	1,447	18
44.4	783	10
55.6	651	8
66.7	702	9
77.8	315	4
88.9	241	3
100	295	4
<b>Total</b>	<b>7,911</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	6,054	76
16.7	985	12
33.3	532	7
50	195	2
66.7	121	2
83.3	52	1
100	62	1
<b>Total</b>	<b>8,001</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	2,885	36
16.7	1,443	18
33.3	1,289	16
50	705	9
66.7	734	9
83.3	444	6
100	430	5
<b>Total</b>	<b>7,930</b>	

**All cancer patients: stage III-IV  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	813	28	810	27	726	25	605	21	2,954
2) Long walk	PF	963	33	714	24	612	21	663	23	2,952
3) Short walk	PF	1,877	64	610	21	283	10	187	6	2,957
4) Bed or chair	PF	1,481	50	725	25	515	17	233	8	2,954
5) Self care	PF	2,576	87	230	8	105	4	52	2	2,963
6) Limited in work	RF	3,218	46	1,819	26	1,160	17	821	12	7,018
7) Limited in leisure	RF	3,706	53	1,571	22	956	14	774	11	7,007
8) Dyspnoea	DY	4,484	56	2,207	28	952	12	370	5	8,013
9) Pain	PA	3,229	40	2,544	32	1,514	19	721	9	8,008
10) Need to rest	FA	2,297	29	3,070	38	1,891	24	753	9	8,011
11) Insomnia	SL	3,710	46	2,345	29	1,371	17	585	7	8,011
12) Felt weak	FA	3,218	40	2,705	34	1,441	18	657	8	8,021
13) Appetite loss	AP	5,012	62	1,579	20	895	11	545	7	8,031
14) Nausea	NV	6,200	77	1,253	16	408	5	171	2	8,032
15) Vomiting	NV	7,163	89	602	8	168	2	85	1	8,018
16) Constipation	CO	5,417	68	1,476	19	699	9	399	5	7,991
17) Diarrhoea	DI	6,515	82	1,078	14	291	4	109	1	7,993
18) Felt tired	FA	2,531	32	3,233	41	1,574	20	642	8	7,980
19) Pain interference	PA	4,277	54	1,864	23	1,130	14	710	9	7,981
20) Concentration	CF	5,233	65	1,776	22	743	9	250	3	8,002
21) Tension	EF	3,182	40	3,038	38	1,362	17	417	5	7,999
22) Worry	EF	2,350	29	3,061	38	1,736	22	851	11	7,998
23) Irritability	EF	4,239	53	2,603	33	887	11	252	3	7,981
24) Depression	EF	3,736	47	2,718	34	1,134	14	390	5	7,978
25) Memory trouble	CF	4,919	62	2,238	28	668	8	162	2	7,987
26) Family life	SF	4,593	58	1,887	24	981	12	476	6	7,937
27) Social activities	SF	4,009	50	1,984	25	1,237	16	728	9	7,958
28) Financial difficulties	FI	5,649	71	1,322	17	591	7	391	5	7,953
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	216	341	852	1,716	1,784	1,370	702		6,981
		3	5	12	25	26	20	10		
30) Overall quality of life	QL	284	445	1,007	1,674	1,944	1,612	959		7,925
		4	6	13	21	25	20	12		

## All cancer patients: recurrent/metastatic

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	692	14
v +3	22	1
v 2.0	2,088	43
v 3.0	2,010	42
Total	4,812	

#### Age

	N	(%)
<40	563	12
40-49	624	13
50-59	961	20
60-69	1,233	26
70-79	946	20
80+	196	4
Not known	289	6
Total	4,812	

#### Gender

	N	(%)
Male	2,524	53
Female	2,131	44
Not known	157	3
Total	4,812	

#### Primary disease site

	N	(%)
Bladder	0	0
Bone	1	0
Brain	2	0
Breast	1,147	24
Colorectal	653	14
Genito-urinary (other)	22	1
Gynaecological (excluding ovarian)	30	1
Head & neck: hypopharynx/larynx	0	0
Head & neck: oral cavity/oropharynx	3	0
Kidney	29	1
Leukaemia	16	0
Liver/bile	148	3
Lung	307	6
Lymphoma	11	0
Malignant melanoma	387	8
Malignant myeloma	2	0
Oesophagus/stomach	642	13
Ovarian	19	0
Pancreas	188	4
Prostate	640	13
Sarcoma	45	1
Testicular	359	8
Other	131	3
Not known	30	1
Total	4,812	

#### Stage

	N	(%)
Stage I-II	0	0
Stage III-IV	0	0
Recurrent/metastatic	4,812	100
Not known	0	0
Total	4,812	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	56.3	(25.6)	58.3	[41.7-75]
Physical functioning	PF	75.8	(23.1)	80	[66.7-93.3]
Role Functioning	RF	60.7	(35.1)	66.7	[33.3-100]
Emotional functioning	EF	68.7	(24.8)	75	[50-91.7]
Cognitive functioning	CF	80.5	(23.2)	83.3	[66.7-100]
Social functioning	SF	70.5	(30.7)	83.3	[50-100]
Fatigue	FA	41.8	(29.4)	33.3	[22.2-66.7]
Nausea and vomiting	NV	13.1	(22.5)	0	[0-16.7]
Pain	PA	33.7	(32.4)	33.3	[0-50]
Dyspnoea	DY	23.4	(30.1)	0	[0-33.3]
Insomnia	SL	33.6	(33.4)	33.3	[0-66.7]
Appetite loss	AP	28.2	(34.9)	0	[0-66.7]
Constipation	CO	23.2	(32.3)	0	[0-33.3]
Diarrhoea	DI	10.7	(22.4)	0	[0-0]
Financial difficulties	FI	16.2	(27.7)	0	[0-33.3]

**All cancer patients: recurrent/metastatic  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	171	4
8.3	55	1
16.7	194	5
25	145	4
33.3	372	10
41.7	265	7
50	641	17
58.3	271	7
66.7	615	16
75	275	7
83.3	525	14
91.7	137	4
100	227	6
<b>Total</b>	<b>3,893</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	12	1
6.7	6	0
13.3	28	1
20	25	1
26.7	50	3
33.3	38	2
40	71	4
46.7	65	3
53.3	69	4
60	99	5
66.7	150	8
73.3	174	9
80	216	11
86.7	297	15
93.3	266	14
100	372	19
<b>Total</b>	<b>1,938</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	509	13
16.7	213	6
33.3	546	14
50	343	9
66.7	668	17
83.3	437	11
100	1,149	30
<b>Total</b>	<b>3,865</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	65	1
8.3	51	1
16.7	104	2
25	152	3
33.3	235	5
41.7	283	6
50	334	7
58.3	405	9
66.7	600	13
75	612	13
83.3	593	13
91.7	488	10
100	753	16
<b>Total</b>	<b>4,675</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	51	1
16.7	101	2
33.3	206	5
50	383	8
66.7	742	16
83.3	1,083	24
100	2,007	44
<b>Total</b>	<b>4,573</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	270	6
16.7	202	4
33.3	474	10
50	446	10
66.7	871	19
83.3	680	15
100	1,739	37
<b>Total</b>	<b>4,682</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	576	13
11.1	429	9
22.2	571	13
33.3	861	19
44.4	459	10
55.6	406	9
66.7	457	10
77.8	230	5
88.9	257	6
100	298	7
<b>Total</b>	<b>4,544</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	2,950	64
16.7	705	15
33.3	442	10
50	195	4
66.7	154	3
83.3	69	2
100	77	2
<b>Total</b>	<b>4,592</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	1,445	32
16.7	727	16
33.3	801	18
50	461	10
66.7	481	11
83.3	275	6
100	366	8
<b>Total</b>	<b>4,556</b>	

**All cancer patients: recurrent/metastatic  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	570	29	743	37	389	20	292	15	1,994
2) Long walk	PF	727	37	684	34	295	15	284	14	1,990
3) Short walk	PF	1,374	69	394	20	138	7	87	4	1,993
4) Bed or chair	PF	1,066	54	543	28	266	14	101	5	1,976
5) Self care	PF	1,722	86	201	10	41	2	31	2	1,995
6) Limited in work	RF	1,320	34	1,107	28	804	21	673	17	3,904
7) Limited in leisure	RF	1,547	40	944	24	702	18	694	18	3,887
8) Dyspnoea	DY	2,498	54	1,273	28	559	12	281	6	4,611
9) Pain	PA	1,586	34	1,485	32	974	21	563	12	4,608
10) Need to rest	FA	1,003	22	1,741	38	1,182	26	682	15	4,608
11) Insomnia	SL	1,811	39	1,432	31	888	19	482	10	4,613
12) Felt weak	FA	1,465	32	1,604	35	922	20	622	14	4,613
13) Appetite loss	AP	2,412	52	1,010	22	662	14	523	11	4,607
14) Nausea	NV	3,069	67	945	21	393	9	207	5	4,614
15) Vomiting	NV	3,762	82	528	12	203	4	114	3	4,607
16) Constipation	CO	2,703	59	964	21	565	12	367	8	4,599
17) Diarrhoea	DI	3,542	77	728	16	205	5	110	2	4,585
18) Felt tired	FA	969	21	1,955	43	1,075	23	591	13	4,590
19) Pain interference	PA	2,204	48	1,136	25	699	15	544	12	4,583
20) Concentration	CF	2,810	61	1,041	23	517	11	234	5	4,602
21) Tension	EF	1,717	36	1,902	40	816	17	317	7	4,752
22) Worry	EF	1,240	26	1,821	38	1,084	23	626	13	4,771
23) Irritability	EF	2,349	49	1,636	34	591	12	182	4	4,758
24) Depression	EF	1,947	41	1,723	36	758	16	317	7	4,745
25) Memory trouble	CF	2,833	60	1,373	29	428	9	127	3	4,761
26) Family life	SF	2,432	51	1,232	26	698	15	372	8	4,734
27) Social activities	SF	2,084	44	1,234	26	795	17	601	13	4,714
28) Financial difficulties	FI	3,216	69	815	18	408	9	207	5	4,646
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	333	342	599	931	898	678	295		4,076
		8	8	15	23	22	17	7		
30) Overall quality of life	QL	267	337	688	1,012	1,005	841	427		4,577
		6	7	15	22	22	18	9		

## Brain cancer

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	0	0
v 2.0	269	96
v 3.0	11	4
Total	280	

#### Age

	N	(%)
<40	76	27
40-49	74	26
50-59	86	31
60-69	44	16
70-79	0	0
80+	0	0
Not known	0	0
Total	280	

#### Gender

	N	(%)
Male	164	59
Female	112	40
Not known	4	1
Total	280	

#### Stage

	N	(%)
Stage I-II	0	0
Stage III-IV	0	0
Recurrent/metastatic	2	1
Not known	278	99
Total	280	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.6	(22.2)	58.3	[50-75]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	58.1	(32.9)	66.7	[33.3-83.3]
Emotional functioning	EF	70.9	(23.4)	75	[58.3-91.7]
Cognitive functioning	CF	72.8	(26.1)	83.3	[50-100]
Social functioning	SF	66.8	(31)	66.7	[50-100]
Fatigue	FA	37.5	(26.2)	33.3	[22.2-55.6]
Nausea and vomiting	NV	3.9	(12.9)	0	[0-0]
Pain	PA	16.5	(23.9)	0	[0-33.3]
Dyspnoea	DY	12.1	(21.3)	0	[0-33.3]
Insomnia	SL	21.7	(29.2)	0	[0-33.3]
Appetite loss	AP	7.0	(17.3)	0	[0-0]
Constipation	CO	17.8	(29.6)	0	[0-33.3]
Diarrhoea	DI	3.8	(14.2)	0	[0-0]
Financial difficulties	FI	20.3	(28.9)	0	[0-33.3]

**Brain cancer  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	1	0
8.3	3	1
16.7	8	3
25	7	3
33.3	25	9
41.7	16	6
50	40	15
58.3	40	15
66.7	44	16
75	25	9
83.3	29	11
91.7	14	5
100	22	8
Total	274	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	5	2
16.7	13	5
33.3	18	7
50	37	14
66.7	55	20
83.3	61	22
100	86	31
Total	275	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	18	7
16.7	8	3
33.3	38	14
50	34	13
66.7	41	15
83.3	46	17
100	81	31
Total	266	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	36	13
11.1	25	9
22.2	38	14
33.3	67	25
44.4	26	10
55.6	27	10
66.7	26	10
77.8	10	4
88.9	8	3
100	10	4
Total	273	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	33	13
16.7	13	5
33.3	35	14
50	27	11
66.7	60	24
83.3	34	13
100	52	21
Total	254	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	240	87
16.7	24	9
33.3	7	3
50	1	0
66.7	3	1
83.3	0	0
100	2	1
Total	277	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	4	2
8.3	1	0
16.7	4	2
25	5	2
33.3	12	4
41.7	16	6
50	18	7
58.3	21	8
66.7	47	17
75	30	11
83.3	35	13
91.7	32	12
100	46	17
Total	271	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	153	56
16.7	46	17
33.3	31	11
50	19	7
66.7	15	6
83.3	4	2
100	4	2
Total	272	

**Brain cancer  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	<i>Previous version of this scale used</i>									
2) Long walk	PF	<i>Previous version of this scale used</i>									
3) Short walk	PF	<i>Previous version of this scale used</i>									
4) Bed or chair	PF	<i>Previous version of this scale used</i>									
5) Self care	PF	<i>Previous version of this scale used</i>									
6) Limited in work	RF	68	26	104	40	49	19	41	16	262	
7) Limited in leisure	RF	79	30	85	33	51	20	46	18	261	
8) Dyspnoea	DY	197	71	61	22	15	5	3	1	276	
9) Pain	PA	172	63	74	27	23	8	6	2	275	
10) Need to rest	FA	54	20	126	46	66	24	31	11	277	
11) Insomnia	SL	160	57	68	24	39	14	12	4	279	
12) Felt weak	FA	95	34	117	42	46	17	19	7	277	
13) Appetite loss	AP	233	84	34	12	11	4	1	0	279	
14) Nausea	NV	243	88	24	9	8	3	2	1	277	
15) Vomiting	NV	268	96	7	3	3	1	2	1	280	
16) Constipation	CO	189	68	47	17	27	10	16	6	279	
17) Diarrhoea	DI	255	91	19	7	2	1	3	1	279	
18) Felt tired	FA	63	23	133	48	62	22	20	7	278	
19) Pain interference	PA	188	68	52	19	25	9	10	4	275	
20) Concentration	CF	130	47	89	32	38	14	21	8	278	
21) Tension	EF	115	42	104	38	41	15	15	6	275	
22) Worry	EF	68	25	109	39	70	25	31	11	278	
23) Irritability	EF	137	50	101	37	27	10	12	4	277	
24) Depression	EF	139	50	90	33	32	12	16	6	277	
25) Memory trouble	CF	119	43	103	37	39	14	15	5	276	
26) Family life	SF	125	46	80	29	45	17	22	8	272	
27) Social activities	SF	104	39	65	24	59	22	40	15	268	
28) Financial difficulties	FI	166	61	59	22	37	14	11	4	273	
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>	
		<b>(very poor)</b>							<b>(excellent)</b>		
29) Overall health	QL	5	9	36	69	77	50	30		276	
		2	3	13	25	28	18	11			
30) Overall quality of life	QL	7	15	32	68	75	48	31		276	
		3	5	12	25	27	17	11			



## Breast cancer: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	559	20
v +3	95	3
v 2.0	583	21
v 3.0	1,545	56
Total	2,782	

#### Age

	N	(%)
<40	246	9
40-49	690	25
50-59	786	28
60-69	523	19
70-79	223	8
80+	28	1
Not known	286	10
Total	2,782	

#### Gender

	N	(%)
Male	0	0
Female	2,782	100
Not known	0	0
Total	2,782	

#### Stage

	N	(%)
Stage I-II	464	17
Stage III-IV	376	14
Recurrent/metastatic	1,147	41
Not known	795	29
Total	2,782	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.8	(24.6)	66.7	[50-83.3]
Physical functioning	PF	78.4	(21.3)	86.7	[66.7-93.3]
Role Functioning	RF	70.9	(29.9)	83.3	[50-100]
Emotional functioning	EF	68.6	(23.8)	75	[50-83.3]
Cognitive functioning	CF	81.5	(21.8)	83.3	[66.7-100]
Social functioning	SF	77.0	(27.1)	83.3	[66.7-100]
Fatigue	FA	33.3	(26.2)	33.3	[11.1-44.4]
Nausea and vomiting	NV	7.7	(17.3)	0	[0-0]
Pain	PA	28.7	(28.7)	16.7	[0-50]
Dyspnoea	DY	18.1	(26.8)	0	[0-33.3]
Insomnia	SL	29.8	(31.6)	33.3	[0-33.3]
Appetite loss	AP	18.5	(28.9)	0	[0-33.3]
Constipation	CO	17.4	(27.2)	0	[0-33.3]
Diarrhoea	DI	5.9	(15.4)	0	[0-0]
Financial difficulties	FI	18.3	(27.8)	0	[0-33.3]

**Breast cancer: all stages  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	65	3
8.3	18	1
16.7	70	3
25	49	2
33.3	172	8
41.7	137	6
50	338	15
58.3	142	7
66.7	406	19
75	178	8
83.3	326	15
91.7	88	4
100	211	10
<b>Total</b>	<b>2,200</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	4	0
6.7	7	1
13.3	12	1
20	18	1
26.7	19	1
33.3	31	2
40	46	3
46.7	44	3
53.3	46	3
60	66	4
66.7	100	7
73.3	149	10
80	197	13
86.7	211	14
93.3	256	17
100	304	20
<b>Total</b>	<b>1,510</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	127	6
16.7	73	3
33.3	209	10
50	203	9
66.7	451	21
83.3	349	16
100	781	36
<b>Total</b>	<b>2,193</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	32	1
8.3	31	1
16.7	51	2
25	75	3
33.3	120	4
41.7	171	6
50	220	8
58.3	253	9
66.7	370	14
75	377	14
83.3	342	13
91.7	291	11
100	385	14
<b>Total</b>	<b>2,718</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	17	1
16.7	46	2
33.3	123	5
50	196	7
66.7	467	17
83.3	692	25
100	1,198	44
<b>Total</b>	<b>2,739</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	76	3
16.7	68	3
33.3	226	8
50	195	7
66.7	534	20
83.3	394	15
100	1,228	45
<b>Total</b>	<b>2,721</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	471	17
11.1	331	12
22.2	440	16
33.3	576	21
44.4	247	9
55.6	237	9
66.7	176	6
77.8	90	3
88.9	80	3
100	81	3
<b>Total</b>	<b>2,729</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	2,100	76
16.7	331	12
33.3	176	6
50	65	2
66.7	45	2
83.3	20	1
100	20	1
<b>Total</b>	<b>2,757</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	871	32
16.7	589	22
33.3	552	20
50	255	9
66.7	221	8
83.3	118	4
100	129	5
<b>Total</b>	<b>2,735</b>	

**Breast cancer: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	406	27	571	37	333	22	217	14	1,527
2) Long walk	PF	693	45	462	30	207	14	172	11	1,534
3) Short walk	PF	1,191	77	222	14	81	5	45	3	1,539
4) Bed or chair	PF	864	56	410	27	196	13	68	4	1,538
5) Self care	PF	1,419	92	89	6	24	2	7	1	1,539
6) Limited in work	RF	917	42	694	31	399	18	201	9	2,211
7) Limited in leisure	RF	1,117	51	614	28	278	13	190	9	2,199
8) Dyspnoea	DY	1,707	62	729	26	223	8	110	4	2,769
9) Pain	PA	972	35	1,085	39	503	18	205	7	2,765
10) Need to rest	FA	759	28	1,167	42	589	21	248	9	2,763
11) Insomnia	SL	1,188	43	903	33	457	17	218	8	2,766
12) Felt weak	FA	1,185	43	1,069	39	349	13	160	6	2,763
13) Appetite loss	AP	1,791	65	564	20	274	10	142	5	2,771
14) Nausea	NV	2,132	77	440	16	135	5	59	2	2,766
15) Vomiting	NV	2,482	90	187	7	68	3	27	1	2,764
16) Constipation	CO	1,779	65	628	23	244	9	109	4	2,760
17) Diarrhoea	DI	2,348	85	344	13	48	2	15	1	2,755
18) Felt tired	FA	772	28	1,259	46	510	19	214	8	2,755
19) Pain interference	PA	1,453	53	759	28	335	12	201	7	2,748
20) Concentration	CF	1,715	62	672	24	271	10	100	4	2,758
21) Tension	EF	870	32	1,175	43	545	20	162	6	2,752
22) Worry	EF	690	25	1,104	40	654	24	312	11	2,760
23) Irritability	EF	1,386	50	944	34	323	12	104	4	2,757
24) Depression	EF	1,051	38	1,132	41	420	15	141	5	2,744
25) Memory trouble	CF	1,575	57	877	32	227	8	69	3	2,748
26) Family life	SF	1,605	59	705	26	315	12	117	4	2,742
27) Social activities	SF	1,409	52	736	27	400	15	188	7	2,733
28) Financial difficulties	FI	1,708	63	615	23	263	10	114	4	2,700
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	87	98	271	519	576	407	247		2,205
		4	4	12	24	26	19	11		
30) Overall quality of life	QL	111	135	341	564	607	614	382		2,754
		4	5	12	21	22	22	14		

## Breast cancer: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	89	10
v +3	41	4
v 2.0	261	28
v 3.0	545	58
Total	936	

#### Age

	N	(%)
<40	246	26
40-49	690	74
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	936	

#### Gender

	N	(%)
Male	0	0
Female	936	100
Not known	0	0
Total	936	

#### Stage

	N	(%)
Stage I-II	217	23
Stage III-IV	135	14
Recurrent/metastatic	289	31
Not known	295	32
Total	936	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.3	(24.5)	66.7	[50-83.3]
Physical functioning	PF	81.8	(19)	86.7	[73.3-100]
Role Functioning	RF	72.2	(28.1)	83.3	[50-100]
Emotional functioning	EF	65.5	(24.5)	66.7	[50-83.3]
Cognitive functioning	CF	80.4	(22.1)	83.3	[66.7-100]
Social functioning	SF	76.0	(27.5)	83.3	[66.7-100]
Fatigue	FA	30.7	(24.6)	33.3	[11.1-44.4]
Nausea and vomiting	NV	6.1	(14.6)	0	[0-0]
Pain	PA	24.8	(27)	16.7	[0-33.3]
Dyspnoea	DY	14.3	(23.9)	0	[0-33.3]
Insomnia	SL	30.0	(31.7)	33.3	[0-66.7]
Appetite loss	AP	16.0	(26.3)	0	[0-33.3]
Constipation	CO	15.4	(24.7)	0	[0-33.3]
Diarrhoea	DI	5.7	(14.2)	0	[0-0]
Financial difficulties	FI	22.9	(30)	0	[0-33.3]

**Breast cancer: <50**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	25	3
8.3	5	1
16.7	37	4
25	15	2
33.3	64	8
41.7	50	6
50	127	15
58.3	49	6
66.7	171	20
75	72	9
83.3	122	15
91.7	29	3
100	75	9
Total	841	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	0
6.7	1	0
13.3	4	1
20	2	0
26.7	1	0
33.3	11	2
40	13	2
46.7	13	2
53.3	10	2
60	21	4
66.7	22	4
73.3	58	11
80	72	14
86.7	87	16
93.3	83	16
100	136	25
Total	535	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	33	4
16.7	25	3
33.3	81	10
50	80	10
66.7	185	22
83.3	141	17
100	294	35
Total	839	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	10	1
8.3	17	2
16.7	33	4
25	24	3
33.3	49	5
41.7	62	7
50	77	8
58.3	89	10
66.7	134	15
75	133	14
83.3	101	11
91.7	88	10
100	104	11
Total	921	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	7	1
16.7	16	2
33.3	43	5
50	71	8
66.7	178	19
83.3	230	25
100	383	41
Total	928	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	33	4
16.7	22	2
33.3	77	8
50	59	6
66.7	196	21
83.3	146	16
100	391	42
Total	924	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	174	19
11.1	123	13
22.2	144	16
33.3	210	23
44.4	87	9
55.6	76	8
66.7	46	5
77.8	29	3
88.9	20	2
100	17	2
Total	926	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	742	80
16.7	95	10
33.3	54	6
50	22	2
66.7	11	1
83.3	3	0
100	2	0
Total	929	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	331	36
16.7	225	24
33.3	166	18
50	81	9
66.7	59	6
83.3	27	3
100	34	4
Total	923	

**Breast cancer: <50**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	172	32	199	37	113	21	55	10	539
2) Long walk	PF	278	51	164	30	66	12	34	6	542
3) Short walk	PF	442	82	68	13	25	5	7	1	542
4) Bed or chair	PF	327	61	138	26	54	10	21	4	540
5) Self care	PF	512	94	28	5	3	1	1	0	544
6) Limited in work	RF	359	43	279	33	141	17	64	8	843
7) Limited in leisure	RF	412	49	262	31	113	14	53	6	840
8) Dyspnoea	DY	639	68	211	23	65	7	20	2	935
9) Pain	PA	365	39	374	40	146	16	47	5	932
10) Need to rest	FA	278	30	403	43	177	19	71	8	929
11) Insomnia	SL	400	43	292	31	167	18	70	8	929
12) Felt weak	FA	424	46	364	39	108	12	35	4	931
13) Appetite loss	AP	632	68	181	19	93	10	27	3	933
14) Nausea	NV	751	81	133	14	39	4	10	1	933
15) Vomiting	NV	856	92	50	5	21	2	3	0	930
16) Constipation	CO	617	66	222	24	70	8	23	3	932
17) Diarrhoea	DI	788	85	126	14	13	1	2	0	929
18) Felt tired	FA	290	31	417	45	174	19	51	6	932
19) Pain interference	PA	545	59	242	26	84	9	55	6	926
20) Concentration	CF	532	57	237	25	124	13	38	4	931
21) Tension	EF	258	28	412	44	196	21	65	7	931
22) Worry	EF	208	22	353	38	225	24	146	16	932
23) Irritability	EF	413	44	335	36	136	15	46	5	930
24) Depression	EF	321	35	400	43	150	16	56	6	927
25) Memory trouble	CF	548	59	285	31	82	9	16	2	931
26) Family life	SF	508	55	262	28	111	12	49	5	930
27) Social activities	SF	473	51	264	29	118	13	71	8	926
28) Financial difficulties	FI	506	56	233	26	123	14	49	5	911
<hr/>										
		1	2	3	4	5	6	7	Total	
		(very poor)						(excellent)		
29) Overall health	QL	33	46	101	184	237	155	85	841	
		4	6	12	22	28	18	10		
30) Overall quality of life	QL	37	51	98	181	221	218	124	930	
		4	6	11	20	24	23	13		

## Breast cancer: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	96	12
v +3	25	3
v 2.0	145	18
v 3.0	520	66
Total	786	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	786	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	786	

#### Gender

	N	(%)
Male	0	0
Female	786	100
Not known	0	0
Total	786	

#### Stage

	N	(%)
Stage I-II	140	18
Stage III-IV	109	14
Recurrent/metastatic	267	34
Not known	270	34
Total	786	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	63.3	(24.4)	66.7	[50-83.3]
Physical functioning	PF	78.5	(21.5)	86.7	[66.7-93.3]
Role Functioning	RF	70.3	(30.5)	66.7	[50-100]
Emotional functioning	EF	70.5	(22.3)	75	[58.3-91.7]
Cognitive functioning	CF	82.4	(21.2)	83.3	[66.7-100]
Social functioning	SF	78.2	(26.5)	83.3	[66.7-100]
Fatigue	FA	32.6	(27)	33.3	[11.1-44.4]
Nausea and vomiting	NV	7.3	(16.8)	0	[0-0]
Pain	PA	28.8	(28.8)	16.7	[0-33.3]
Dyspnoea	DY	17.8	(26.7)	0	[0-33.3]
Insomnia	SL	30.1	(31.9)	33.3	[0-33.3]
Appetite loss	AP	16.5	(27.9)	0	[0-33.3]
Constipation	CO	15.4	(26.2)	0	[0-33.3]
Diarrhoea	DI	5.5	(14.3)	0	[0-0]
Financial difficulties	FI	18.8	(27.4)	0	[0-33.3]

**Breast cancer: 50-59**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	14	2
8.3	9	1
16.7	17	3
25	20	3
33.3	48	7
41.7	39	6
50	101	15
58.3	47	7
66.7	126	18
75	49	7
83.3	105	15
91.7	39	6
100	70	10
<b>Total</b>	<b>684</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	4	1
13.3	4	1
20	8	2
26.7	12	2
33.3	9	2
40	9	2
46.7	10	2
53.3	17	3
60	27	5
66.7	28	6
73.3	49	10
80	70	14
86.7	70	14
93.3	91	18
100	102	20
<b>Total</b>	<b>510</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	47	7
16.7	17	3
33.3	67	10
50	65	10
66.7	149	22
83.3	91	13
100	249	36
<b>Total</b>	<b>685</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	6	1
8.3	4	1
16.7	7	1
25	24	3
33.3	29	4
41.7	44	6
50	56	7
58.3	75	10
66.7	108	14
75	106	14
83.3	111	15
91.7	90	12
100	108	14
<b>Total</b>	<b>768</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	2	0
16.7	14	2
33.3	32	4
50	53	7
66.7	121	16
83.3	202	26
100	346	45
<b>Total</b>	<b>770</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	18	2
16.7	18	2
33.3	59	8
50	61	8
66.7	140	18
83.3	108	14
100	363	47
<b>Total</b>	<b>767</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	147	19
11.1	106	14
22.2	106	14
33.3	166	22
44.4	61	8
55.6	57	7
66.7	48	6
77.8	27	4
88.9	27	4
100	24	3
<b>Total</b>	<b>769</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	606	77
16.7	86	11
33.3	52	7
50	18	2
66.7	10	1
83.3	6	1
100	5	1
<b>Total</b>	<b>783</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	245	32
16.7	155	20
33.3	184	24
50	65	8
66.7	52	7
83.3	34	4
100	41	5
<b>Total</b>	<b>776</b>	



**Breast cancer: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	135	26	188	37	108	21	82	16	513
2) Long walk	PF	242	47	151	29	69	13	56	11	518
3) Short walk	PF	414	80	59	11	25	5	20	4	518
4) Bed or chair	PF	287	55	150	29	63	12	19	4	519
5) Self care	PF	475	91	31	6	12	2	2	0	520
6) Limited in work	RF	284	41	211	31	124	18	70	10	689
7) Limited in leisure	RF	348	51	186	27	87	13	64	9	685
8) Dyspnoea	DY	487	62	201	26	63	8	30	4	781
9) Pain	PA	276	35	327	42	115	15	66	8	784
10) Need to rest	FA	238	30	316	40	158	20	70	9	782
11) Insomnia	SL	333	43	259	33	124	16	66	8	782
12) Felt weak	FA	322	41	310	40	100	13	50	6	782
13) Appetite loss	AP	536	68	147	19	65	8	37	5	785
14) Nausea	NV	616	79	116	15	35	5	18	2	785
15) Vomiting	NV	704	90	60	8	12	2	8	1	784
16) Constipation	CO	532	68	165	21	51	7	31	4	779
17) Diarrhoea	DI	664	86	99	13	12	2	2	0	777
18) Felt tired	FA	246	32	344	44	128	17	58	8	776
19) Pain interference	PA	390	50	239	31	89	11	60	8	778
20) Concentration	CF	500	64	192	25	62	8	24	3	778
21) Tension	EF	249	32	341	44	153	20	32	4	775
22) Worry	EF	206	26	327	42	188	24	58	7	779
23) Irritability	EF	420	54	258	33	79	10	22	3	779
24) Depression	EF	307	40	328	42	108	14	35	5	778
25) Memory trouble	CF	443	57	253	33	54	7	23	3	773
26) Family life	SF	479	62	184	24	78	10	31	4	772
27) Social activities	SF	400	52	204	26	121	16	47	6	772
28) Financial difficulties	FI	460	61	200	26	66	9	32	4	758
<hr/>										
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
29) Overall health	QL	22	31	78	161	170	134	89		685
		3	5	11	24	25	20	13		
30) Overall quality of life	QL	20	35	95	147	175	173	129		774
		3	5	12	19	23	22	17		

## Breast cancer: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	70	13
v +3	24	5
v 2.0	124	24
v 3.0	305	58
Total	523	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	523	100
70-79	0	0
80+	0	0
Not known	0	0
Total	523	

#### Gender

	N	(%)
Male	0	0
Female	523	100
Not known	0	0
Total	523	

#### Stage

	N	(%)
Stage I-II	77	15
Stage III-IV	73	14
Recurrent/metastatic	193	37
Not known	180	34
Total	523	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	62.2	(24.4)	66.7	[50-83.3]
Physical functioning	PF	76.9	(21.6)	80	[66.7-93.3]
Role Functioning	RF	71.0	(31.1)	83.3	[50-100]
Emotional functioning	EF	71.0	(23.4)	75	[50-91.7]
Cognitive functioning	CF	82.6	(21.1)	83.3	[66.7-100]
Social functioning	SF	81.5	(25)	100	[66.7-100]
Fatigue	FA	33.4	(26.1)	33.3	[11.1-44.4]
Nausea and vomiting	NV	7.6	(18.3)	0	[0-0]
Pain	PA	28.7	(29.5)	16.7	[0-50]
Dyspnoea	DY	19.0	(28.5)	0	[0-33.3]
Insomnia	SL	28.1	(32.3)	33.3	[0-33.3]
Appetite loss	AP	17.6	(28.5)	0	[0-33.3]
Constipation	CO	17.4	(27.4)	0	[0-33.3]
Diarrhoea	DI	6.2	(17.5)	0	[0-0]
Financial difficulties	FI	14.3	(25.5)	0	[0-33.3]

**Breast cancer: 60-69**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	15	3
8.3	4	1
16.7	7	2
25	10	2
33.3	34	8
41.7	34	8
50	64	14
58.3	35	8
66.7	73	16
75	37	8
83.3	74	17
91.7	16	4
100	42	9
<b>Total</b>	<b>445</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	2	1
6.7	0	0
13.3	2	1
20	4	1
26.7	3	1
33.3	7	2
40	10	3
46.7	13	4
53.3	11	4
60	12	4
66.7	28	9
73.3	25	8
80	36	12
86.7	40	13
93.3	54	18
100	51	17
<b>Total</b>	<b>298</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	27	6
16.7	24	5
33.3	36	8
50	40	9
66.7	79	18
83.3	71	16
100	169	38
<b>Total</b>	<b>446</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	2	0
8.3	5	1
16.7	5	1
25	14	3
33.3	21	4
41.7	37	7
50	49	10
58.3	40	8
66.7	48	9
75	70	14
83.3	66	13
91.7	62	12
100	90	18
<b>Total</b>	<b>509</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	3	1
16.7	5	1
33.3	23	5
50	34	7
66.7	88	17
83.3	126	24
100	237	46
<b>Total</b>	<b>516</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	6	1
16.7	11	2
33.3	34	7
50	37	7
66.7	83	16
83.3	58	11
100	278	55
<b>Total</b>	<b>507</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	84	16
11.1	63	12
22.2	95	18
33.3	95	18
44.4	51	10
55.6	49	10
66.7	32	6
77.8	13	3
88.9	18	4
100	15	3
<b>Total</b>	<b>515</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	402	78
16.7	60	12
33.3	27	5
50	9	2
66.7	8	2
83.3	4	1
100	7	1
<b>Total</b>	<b>517</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	173	34
16.7	101	20
33.3	97	19
50	50	10
66.7	40	8
83.3	24	5
100	26	5
<b>Total</b>	<b>511</b>	

**Breast cancer: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	68	23	119	40	69	23	45	15	301
2) Long walk	PF	127	42	94	31	38	13	43	14	302
3) Short walk	PF	232	76	46	15	20	7	7	2	305
4) Bed or chair	PF	168	55	77	25	44	15	15	5	304
5) Self care	PF	281	92	18	6	4	1	2	1	305
6) Limited in work	RF	192	43	131	29	85	19	43	10	451
7) Limited in leisure	RF	239	53	114	25	49	11	46	10	448
8) Dyspnoea	DY	316	61	139	27	32	6	31	6	518
9) Pain	PA	190	37	190	37	98	19	39	8	517
10) Need to rest	FA	137	26	226	44	115	22	42	8	520
11) Insomnia	SL	241	46	170	33	59	11	50	10	520
12) Felt weak	FA	232	45	196	38	57	11	35	7	520
13) Appetite loss	AP	345	66	108	21	42	8	28	5	523
14) Nausea	NV	407	78	75	15	24	5	13	3	519
15) Vomiting	NV	471	90	30	6	11	2	9	2	521
16) Constipation	CO	338	65	114	22	47	9	21	4	520
17) Diarrhoea	DI	448	86	51	10	14	3	6	1	519
18) Felt tired	FA	139	27	241	46	95	18	45	9	520
19) Pain interference	PA	276	54	133	26	65	13	41	8	515
20) Concentration	CF	348	67	121	23	39	8	12	2	520
21) Tension	EF	181	35	200	39	109	21	28	5	518
22) Worry	EF	153	29	198	38	121	23	48	9	520
23) Irritability	EF	279	54	166	32	61	12	13	3	519
24) Depression	EF	224	44	194	38	80	16	16	3	514
25) Memory trouble	CF	287	55	168	32	50	10	13	3	518
26) Family life	SF	337	66	112	22	53	10	10	2	512
27) Social activities	SF	308	60	110	22	70	14	23	5	511
28) Financial difficulties	FI	362	72	84	17	47	9	13	3	506
<hr/>										
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
29) Overall health	QL	20	13	56	107	114	90	48		448
		5	3	13	24	25	20	11		
30) Overall quality of life	QL	23	17	61	109	106	126	74		516
		5	3	12	21	21	24	14		

## Breast cancer: ≥70

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	18	7
v +3	5	2
v 2.0	53	21
v 3.0	175	70
Total	251	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	223	89
80+	28	11
Not known	0	0
Total	251	

#### Gender

	N	(%)
Male	0	0
Female	251	100
Not known	0	0
Total	251	

#### Stage

	N	(%)
Stage I-II	30	12
Stage III-IV	59	24
Recurrent/metastatic	112	45
Not known	50	20
Total	251	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	58.2	(25.6)	58.3	[41.7-75]
Physical functioning	PF	69.5	(23.9)	73.3	[53.3-93.3]
Role Functioning	RF	67.8	(32.1)	83.3	[50-100]
Emotional functioning	EF	73.5	(24.8)	75	[58.3-91.7]
Cognitive functioning	CF	81.0	(23.5)	83.3	[66.7-100]
Social functioning	SF	81.7	(22.9)	83.3	[66.7-100]
Fatigue	FA	36.4	(28.7)	33.3	[11.1-55.6]
Nausea and vomiting	NV	7.0	(17.9)	0	[0-0]
Pain	PA	31.9	(29.7)	33.3	[0-50]
Dyspnoea	DY	18.1	(27.4)	0	[0-33.3]
Insomnia	SL	27.3	(31.4)	33.3	[0-66.7]
Appetite loss	AP	22.5	(33.5)	0	[0-33.3]
Constipation	CO	23.3	(31.1)	0	[0-33.3]
Diarrhoea	DI	6.8	(18)	0	[0-0]
Financial difficulties	FI	9.8	(19.6)	0	[0-0]

**Breast cancer: ≥70  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	11	5
8.3	0	0
16.7	9	4
25	4	2
33.3	26	11
41.7	14	6
50	46	20
58.3	11	5
66.7	36	16
75	20	9
83.3	25	11
91.7	4	2
100	24	10
Total	230	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	1
6.7	2	1
13.3	2	1
20	4	2
26.7	3	2
33.3	4	2
40	14	8
46.7	8	5
53.3	8	5
60	6	4
66.7	22	13
73.3	17	10
80	19	11
86.7	14	8
93.3	28	17
100	15	9
Total	167	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	20	9
16.7	7	3
33.3	25	11
50	18	8
66.7	38	17
83.3	46	21
100	69	31
Total	223	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	5	2
8.3	1	0
16.7	1	0
25	9	4
33.3	8	3
41.7	12	5
50	15	6
58.3	21	9
66.7	23	10
75	29	12
83.3	30	12
91.7	30	12
100	59	24
Total	243	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	4	2
16.7	5	2
33.3	13	5
50	15	6
66.7	31	13
83.3	73	30
100	106	43
Total	247	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	3	1
16.7	2	1
33.3	13	5
50	17	7
66.7	48	20
83.3	40	17
100	120	49
Total	243	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	44	18
11.1	20	8
22.2	38	16
33.3	50	21
44.4	19	8
55.6	23	10
66.7	22	9
77.8	5	2
88.9	6	3
100	16	7
Total	243	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	198	80
16.7	28	11
33.3	9	4
50	5	2
66.7	3	1
83.3	4	2
100	2	1
Total	249	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	70	28
16.7	51	21
33.3	46	19
50	28	11
66.7	27	11
83.3	12	5
100	13	5
Total	247	

**Breast cancer: ≥70**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	31	18	65	37	43	25	35	20	174	
2) Long walk	PF	46	27	53	31	34	20	39	23	172	
3) Short walk	PF	103	59	49	28	11	6	11	6	174	
4) Bed or chair	PF	82	47	45	26	35	20	13	7	175	
5) Self care	PF	151	89	12	7	5	3	2	1	170	
6) Limited in work	RF	82	36	73	32	49	22	24	11	228	
7) Limited in leisure	RF	118	52	52	23	29	13	27	12	226	
8) Dyspnoea	DY	158	64	56	23	26	10	9	4	249	
9) Pain	PA	86	35	81	33	58	23	23	9	248	
10) Need to rest	FA	64	26	93	38	63	26	27	11	247	
11) Insomnia	SL	123	49	63	25	50	20	14	6	250	
12) Felt weak	FA	95	39	89	36	39	16	24	10	247	
13) Appetite loss	AP	155	62	45	18	26	10	24	10	250	
14) Nausea	NV	202	81	33	13	6	2	8	3	249	
15) Vomiting	NV	227	91	13	5	7	3	3	1	250	
16) Constipation	CO	142	57	55	22	37	15	15	6	249	
17) Diarrhoea	DI	211	84	31	12	4	2	4	2	250	
18) Felt tired	FA	66	27	112	45	42	17	29	12	249	
19) Pain interference	PA	120	48	68	27	44	18	17	7	249	
20) Concentration	CF	175	70	46	18	17	7	11	4	249	
21) Tension	EF	113	46	87	35	35	14	13	5	248	
22) Worry	EF	82	33	86	34	55	22	27	11	250	
23) Irritability	EF	156	63	67	27	17	7	9	4	249	
24) Depression	EF	118	48	75	30	40	16	14	6	247	
25) Memory trouble	CF	129	52	84	34	21	9	14	6	248	
26) Family life	SF	167	67	54	22	20	8	7	3	248	
27) Social activities	SF	136	56	69	28	28	12	11	5	244	
28) Financial difficulties	FI	190	77	41	17	14	6	1	0	246	
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>		
		<b>(very poor)</b>							<b>(excellent)</b>		
29) Overall health	QL	12	8	36	67	55	28	25		231	
		5	4	16	29	24	12	11			
30) Overall quality of life	QL	14	10	35	59	47	46	37		248	
		6	4	14	24	19	19	15			

## Breast cancer: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	66	14
v +3	58	13
v 2.0	81	18
v 3.0	259	56
Total	464	

#### Age

	N	(%)
<40	50	11
40-49	167	36
50-59	140	30
60-69	77	17
70-79	28	6
80+	2	0
Not known	0	0
Total	464	

#### Gender

	N	(%)
Male	0	0
Female	464	100
Not known	0	0
Total	464	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	64.6	(22.7)	66.7	[50-83.3]
Physical functioning	PF	83.2	(14.7)	83.3	[73.3-93.3]
Role Functioning	RF	78.9	(22.8)	83.3	[66.7-100]
Emotional functioning	EF	72.5	(21.6)	75	[58.3-91.7]
Cognitive functioning	CF	84.1	(18.7)	83.3	[66.7-100]
Social functioning	SF	83.7	(21.1)	100	[66.7-100]
Fatigue	FA	25.8	(21.8)	22.2	[0-33.3]
Nausea and vomiting	NV	3.6	(11.8)	0	[0-0]
Pain	PA	19.4	(20.9)	16.7	[0-33.3]
Dyspnoea	DY	11.6	(20)	0	[0-33.3]
Insomnia	SL	24.8	(28.9)	33.3	[0-33.3]
Appetite loss	AP	10.7	(21.2)	0	[0-0]
Constipation	CO	12.8	(21.1)	0	[0-33.3]
Diarrhoea	DI	6.2	(14.7)	0	[0-0]
Financial difficulties	FI	16.0	(24.4)	0	[0-33.3]



**Breast cancer: stage I-II  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	5	1
8.3	1	0
16.7	13	3
25	7	2
33.3	27	7
41.7	25	6
50	51	13
58.3	27	7
66.7	70	18
75	48	12
83.3	66	17
91.7	18	5
100	35	9
<b>Total</b>	<b>393</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	0	0
13.3	0	0
20	0	0
26.7	0	0
33.3	4	2
40	1	0
46.7	4	2
53.3	4	2
60	10	4
66.7	14	6
73.3	36	14
80	55	22
86.7	32	13
93.3	34	13
100	62	24
<b>Total</b>	<b>256</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	6	2
16.7	3	1
33.3	21	5
50	24	6
66.7	118	30
83.3	57	14
100	166	42
<b>Total</b>	<b>395</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	1	0
8.3	4	1
16.7	4	1
25	10	2
33.3	12	3
41.7	27	6
50	29	6
58.3	42	9
66.7	65	14
75	69	15
83.3	69	15
91.7	43	10
100	80	18
<b>Total</b>	<b>455</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	1	0
16.7	3	1
33.3	12	3
50	28	6
66.7	78	17
83.3	129	28
100	207	45
<b>Total</b>	<b>458</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	5	1
16.7	3	1
33.3	15	3
50	18	4
66.7	113	25
83.3	64	14
100	240	52
<b>Total</b>	<b>458</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	115	25
11.1	64	14
22.2	62	14
33.3	113	25
44.4	40	9
55.6	33	7
66.7	19	4
77.8	7	2
88.9	5	1
100	1	0
<b>Total</b>	<b>459</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	404	88
16.7	34	7
33.3	11	2
50	6	1
66.7	2	0
83.3	2	0
100	1	0
<b>Total</b>	<b>460</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	186	40
16.7	106	23
33.3	112	24
50	33	7
66.7	16	4
83.3	4	1
100	4	1
<b>Total</b>	<b>461</b>	

**Breast cancer: stage I-II**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	81	31	115	45	50	19	12	5	258
2) Long walk	PF	116	45	107	42	27	11	7	3	257
3) Short walk	PF	219	85	34	13	6	2	0	0	259
4) Bed or chair	PF	129	50	98	38	27	10	5	2	259
5) Self care	PF	253	98	6	2	0	0	0	0	259
6) Limited in work	RF	192	49	125	32	67	17	12	3	396
7) Limited in leisure	RF	240	61	114	29	32	8	9	2	395
8) Dyspnoea	DY	330	71	111	24	19	4	4	1	464
9) Pain	PA	206	45	199	43	49	11	9	2	463
10) Need to rest	FA	165	36	210	46	76	17	10	2	461
11) Insomnia	SL	226	49	152	33	63	14	22	5	463
12) Felt weak	FA	209	45	208	45	39	8	7	2	463
13) Appetite loss	AP	354	77	74	16	31	7	4	1	463
14) Nausea	NV	409	88	39	8	10	2	5	1	463
15) Vomiting	NV	443	96	12	3	4	1	2	0	461
16) Constipation	CO	316	68	120	26	20	4	6	1	462
17) Diarrhoea	DI	384	83	72	16	4	1	2	0	462
18) Felt tired	FA	182	39	205	44	61	13	14	3	462
19) Pain interference	PA	283	61	148	32	27	6	4	1	462
20) Concentration	CF	317	69	112	24	29	6	5	1	463
21) Tension	EF	158	34	194	42	90	20	18	4	460
22) Worry	EF	130	28	202	44	101	22	27	6	460
23) Irritability	EF	267	58	150	33	33	7	9	2	459
24) Depression	EF	184	40	201	44	60	13	16	4	461
25) Memory trouble	CF	251	55	168	37	31	7	8	2	458
26) Family life	SF	282	62	141	31	29	6	6	1	458
27) Social activities	SF	275	60	143	31	33	7	9	2	460
28) Financial difficulties	FI	297	64	116	25	39	9	9	2	461
<hr/>										
		1	2	3	4	5	6	7		Total
		(very poor)						(excellent)		
<hr/>										
29) Overall health	QL	11	11	43	103	107	81	38		394
		3	3	11	26	27	21	10		
<hr/>										
30) Overall quality of life	QL	9	16	45	79	80	137	93		459
		2	4	10	17	17	30	20		

## Breast cancer: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	0	0
v 2.0	90	24
v 3.0	286	76
Total	376	

#### Age

	N	(%)
<40	47	13
40-49	88	23
50-59	109	29
60-69	73	19
70-79	54	14
80+	5	1
Not known	0	0
Total	376	

#### Gender

	N	(%)
Male	0	0
Female	376	100
Not known	0	0
Total	376	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	55.0	(24.5)	50	[41.7-75]
Physical functioning	PF	59.8	(26.2)	60	[40-80]
Role Functioning	RF	57.9	(32.6)	66.7	[33.3-83.3]
Emotional functioning	EF	68.4	(23.1)	75	[50-91.7]
Cognitive functioning	CF	80.2	(22.2)	83.3	[66.7-100]
Social functioning	SF	70.3	(28.5)	66.7	[50-100]
Fatigue	FA	38.1	(27.9)	33.3	[22.2-55.6]
Nausea and vomiting	NV	8.5	(18.2)	0	[0-16.7]
Pain	PA	39.0	(32)	33.3	[16.7-66.7]
Dyspnoea	DY	18.1	(26.9)	0	[0-33.3]
Insomnia	SL	25.3	(30.8)	0	[0-33.3]
Appetite loss	AP	23.8	(32.2)	0	[0-33.3]
Constipation	CO	20.3	(29.4)	0	[0-33.3]
Diarrhoea	DI	5.1	(15.9)	0	[0-0]
Financial difficulties	FI	22.2	(29.5)	0	[0-33.3]

**Breast cancer: stage III-IV  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	12	3
8.3	5	1
16.7	22	6
25	11	3
33.3	39	11
41.7	32	9
50	72	20
58.3	21	6
66.7	60	16
75	25	7
83.3	40	11
91.7	8	2
100	22	6
<b>Total</b>	<b>369</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	2	1
6.7	7	3
13.3	8	3
20	12	4
26.7	13	5
33.3	23	8
40	20	7
46.7	17	6
53.3	19	7
60	22	8
66.7	23	8
73.3	29	10
80	20	7
86.7	23	8
93.3	27	10
100	16	6
<b>Total</b>	<b>281</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	52	14
16.7	14	4
33.3	46	12
50	47	13
66.7	87	23
83.3	58	16
100	68	18
<b>Total</b>	<b>372</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	4	1
8.3	3	1
16.7	4	1
25	9	2
33.3	13	4
41.7	31	8
50	44	12
58.3	39	10
66.7	33	9
75	58	16
83.3	41	11
91.7	47	13
100	48	13
<b>Total</b>	<b>374</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	0	0
16.7	9	2
33.3	28	8
50	16	4
66.7	63	17
83.3	110	30
100	146	39
<b>Total</b>	<b>372</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	11	3
16.7	11	3
33.3	48	13
50	56	15
66.7	69	19
83.3	42	11
100	134	36
<b>Total</b>	<b>371</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	51	14
11.1	41	11
22.2	48	13
33.3	80	22
44.4	34	9
55.6	44	12
66.7	27	7
77.8	13	4
88.9	11	3
100	22	6
<b>Total</b>	<b>371</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	279	75
16.7	47	13
33.3	24	6
50	10	3
66.7	6	2
83.3	7	2
100	1	0
<b>Total</b>	<b>374</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	76	20
16.7	79	21
33.3	67	18
50	43	12
66.7	46	12
83.3	29	8
100	34	9
<b>Total</b>	<b>374</b>	

**Breast cancer: stage III-IV**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	34	12	75	27	85	30	88	31	282
2) Long walk	PF	63	22	59	21	57	20	104	37	283
3) Short walk	PF	134	47	76	27	47	17	28	10	285
4) Bed or chair	PF	57	20	101	36	85	30	41	14	284
5) Self care	PF	238	83	28	10	16	6	4	1	286
6) Limited in work	RF	84	23	129	35	81	22	79	21	373
7) Limited in leisure	RF	137	37	120	32	58	16	59	16	374
8) Dyspnoea	DY	231	62	98	26	30	8	15	4	374
9) Pain	PA	95	25	142	38	89	24	50	13	376
10) Need to rest	FA	75	20	144	39	108	29	45	12	372
11) Insomnia	SL	194	52	102	27	57	15	23	6	376
12) Felt weak	FA	124	33	158	42	60	16	34	9	376
13) Appetite loss	AP	215	57	84	22	47	13	30	8	376
14) Nausea	NV	282	75	63	17	19	5	11	3	375
15) Vomiting	NV	330	88	32	9	11	3	2	1	375
16) Constipation	CO	224	60	90	24	37	10	21	6	372
17) Diarrhoea	DI	330	89	33	9	6	2	4	1	373
18) Felt tired	FA	114	31	150	40	67	18	43	12	374
19) Pain interference	PA	144	39	104	28	72	19	54	14	374
20) Concentration	CF	215	58	107	29	37	10	15	4	374
21) Tension	EF	110	29	164	44	88	24	12	3	374
22) Worry	EF	105	28	124	33	110	29	36	10	375
23) Irritability	EF	204	54	109	29	46	12	16	4	375
24) Depression	EF	132	35	158	42	70	19	15	4	375
25) Memory trouble	CF	215	58	110	30	36	10	11	3	372
26) Family life	SF	195	53	87	24	73	20	16	4	371
27) Social activities	SF	150	40	103	28	80	21	40	11	373
28) Financial difficulties	FI	204	55	112	30	32	9	24	7	372
<hr/>										
		1 (very poor)		3	4	5	6	7 (excellent)		Total
29) Overall health	QL	16	33	67	93	91	47	23		370
		4	9	18	25	25	13	6		
30) Overall quality of life	QL	20	29	54	86	79	66	36		370
		5	8	15	23	21	18	10		

## Breast cancer: recurrent/metastatic

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	291	25
v +3	0	0
v 2.0	202	18
v 3.0	654	57
Total	1,147	

#### Age

	N	(%)
<40	85	7
40-49	204	18
50-59	267	23
60-69	193	17
70-79	98	9
80+	14	1
Not known	286	25
Total	1,147	

#### Gender

	N	(%)
Male	0	0
Female	1,147	100
Not known	0	0
Total	1,147	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	60.2	(25.5)	66.7	[50-83.3]
Physical functioning	PF	81.6	(18.7)	86.7	[73.3-93.3]
Role Functioning	RF	67.4	(31.1)	66.7	[50-100]
Emotional functioning	EF	65.9	(24.6)	66.7	[50-83.3]
Cognitive functioning	CF	80.5	(23.2)	83.3	[66.7-100]
Social functioning	SF	74.2	(28.4)	83.3	[66.7-100]
Fatigue	FA	36.3	(27)	33.3	[11.1-55.6]
Nausea and vomiting	NV	10.3	(19.7)	0	[0-16.7]
Pain	PA	30.9	(29.6)	33.3	[0-50]
Dyspnoea	DY	20.4	(28.2)	0	[0-33.3]
Insomnia	SL	33.1	(32.6)	33.3	[0-66.7]
Appetite loss	AP	21.7	(31)	0	[0-33.3]
Constipation	CO	19.2	(28.8)	0	[0-33.3]
Diarrhoea	DI	5.8	(15.2)	0	[0-0]
Financial difficulties	FI	18.6	(28.6)	0	[0-33.3]

**Breast cancer: recurrent/metastatic  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	38	5
8.3	8	1
16.7	26	3
25	21	3
33.3	73	9
41.7	44	5
50	127	15
58.3	55	7
66.7	170	20
75	61	7
83.3	114	14
91.7	37	4
100	73	9
<b>Total</b>	<b>847</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	0
6.7	0	0
13.3	4	1
20	5	1
26.7	5	1
33.3	2	0
40	20	3
46.7	20	3
53.3	14	2
60	19	3
66.7	41	6
73.3	58	9
80	79	12
86.7	104	16
93.3	130	20
100	137	21
<b>Total</b>	<b>639</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	55	7
16.7	41	5
33.3	99	12
50	88	11
66.7	154	18
83.3	144	17
100	260	31
<b>Total</b>	<b>841</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	20	2
8.3	12	1
16.7	30	3
25	39	4
33.3	59	5
41.7	74	7
50	83	7
58.3	116	10
66.7	162	15
75	153	14
83.3	138	12
91.7	95	9
100	135	12
<b>Total</b>	<b>1,116</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	9	1
16.7	25	2
33.3	53	5
50	102	9
66.7	188	17
83.3	244	22
100	505	45
<b>Total</b>	<b>1,126</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	42	4
16.7	34	3
33.3	110	10
50	81	7
66.7	226	20
83.3	179	16
100	449	40
<b>Total</b>	<b>1,121</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	152	14
11.1	131	12
22.2	189	17
33.3	231	21
44.4	107	10
55.6	100	9
66.7	75	7
77.8	47	4
88.9	44	4
100	44	4
<b>Total</b>	<b>1,120</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	786	69
16.7	162	14
33.3	99	9
50	36	3
66.7	28	3
83.3	10	1
100	12	1
<b>Total</b>	<b>1,133</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	337	30
16.7	213	19
33.3	240	21
50	113	10
66.7	105	9
83.3	53	5
100	61	5
<b>Total</b>	<b>1,122</b>	

**Breast cancer: recurrent/metastatic  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	186	29	267	41	131	20	67	10	651
2) Long walk	PF	317	49	216	33	72	11	45	7	650
3) Short walk	PF	533	82	85	13	19	3	15	2	652
4) Bed or chair	PF	416	64	149	23	68	11	17	3	650
5) Self care	PF	593	91	49	8	6	1	2	0	650
6) Limited in work	RF	304	36	290	34	172	20	87	10	853
7) Limited in leisure	RF	393	47	229	27	134	16	87	10	843
8) Dyspnoea	DY	663	58	318	28	108	9	55	5	1,144
9) Pain	PA	359	32	440	39	241	21	97	9	1,137
10) Need to rest	FA	276	24	480	42	257	23	129	11	1,142
11) Insomnia	SL	436	38	387	34	203	18	113	10	1,139
12) Felt weak	FA	465	41	430	38	154	14	86	8	1,135
13) Appetite loss	AP	684	60	248	22	131	12	77	7	1,140
14) Nausea	NV	799	70	226	20	80	7	32	3	1,137
15) Vomiting	NV	982	86	98	9	40	4	16	1	1,136
16) Constipation	CO	711	63	253	22	118	10	56	5	1,138
17) Diarrhoea	DI	964	85	142	13	18	2	6	1	1,130
18) Felt tired	FA	253	22	535	47	237	21	107	10	1,132
19) Pain interference	PA	576	51	313	28	149	13	92	8	1,130
20) Concentration	CF	666	59	270	24	141	12	58	5	1,135
21) Tension	EF	312	28	510	45	226	20	85	8	1,133
22) Worry	EF	230	20	459	40	283	25	163	14	1,135
23) Irritability	EF	533	47	402	35	148	13	51	5	1,134
24) Depression	EF	412	37	453	40	189	17	73	7	1,127
25) Memory trouble	CF	679	60	329	29	94	8	28	3	1,130
26) Family life	SF	615	54	318	28	136	12	64	6	1,133
27) Social activities	SF	534	48	306	27	186	17	97	9	1,123
28) Financial difficulties	FI	693	64	231	21	112	10	51	5	1,087
<hr/>										
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>							<b>(excellent)</b>	
29) Overall health	QL	46	36	108	192	229	145	93		849
		5	4	13	23	27	17	11		
30) Overall quality of life	QL	63	66	151	234	277	219	128		1,138
		6	6	13	21	24	19	11		



## Colorectal cancer: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	45	3
v 2.0	1,158	65
v 3.0	570	32
Total	1,773	

#### Age

	N	(%)
<40	62	4
40-49	209	12
50-59	456	26
60-69	633	36
70-79	374	21
80+	39	2
Not known	0	0
Total	1,773	

#### Gender

	N	(%)
Male	1,023	58
Female	687	39
Not known	63	4
Total	1,773	

#### Stage

	N	(%)
Stage I-II	230	13
Stage III-IV	281	16
Recurrent/metastatic	653	37
Not known	609	34
Total	1,773	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	60.7	(23.4)	66.7	[50-83.3]
Physical functioning	PF	79.2	(21.1)	86.7	[66.7-100]
Role Functioning	RF	70.4	(32.8)	83.3	[50-100]
Emotional functioning	EF	68.9	(24.5)	75	[50-91.7]
Cognitive functioning	CF	85.2	(20.4)	100	[83.3-100]
Social functioning	SF	76.0	(28.6)	83.3	[66.7-100]
Fatigue	FA	34.7	(28.4)	33.3	[11.1-55.6]
Nausea and vomiting	NV	7.3	(17.2)	0	[0-0]
Pain	PA	24.0	(29.6)	16.7	[0-33.3]
Dyspnoea	DY	17.4	(26.3)	0	[0-33.3]
Insomnia	SL	30.5	(32.6)	33.3	[0-66.7]
Appetite loss	AP	19.1	(30.2)	0	[0-33.3]
Constipation	CO	15.8	(27.9)	0	[0-33.3]
Diarrhoea	DI	16.6	(27.6)	0	[0-33.3]
Financial difficulties	FI	13.6	(26.3)	0	[0-33.3]

**Colorectal cancer: all stages  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	44	3
8.3	14	1
16.7	48	3
25	35	2
33.3	142	8
41.7	104	6
50	318	18
58.3	123	7
66.7	335	19
75	125	7
83.3	256	15
91.7	50	3
100	133	8
<b>Total</b>	<b>1,727</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	1	0
13.3	2	0
20	3	1
26.7	12	2
33.3	16	3
40	12	2
46.7	22	4
53.3	24	4
60	26	5
66.7	34	6
73.3	46	8
80	59	11
86.7	79	14
93.3	81	15
100	142	25
<b>Total</b>	<b>559</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	139	8
16.7	61	4
33.3	189	11
50	126	7
66.7	257	15
83.3	230	14
100	695	41
<b>Total</b>	<b>1,697</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	16	1
8.3	25	2
16.7	42	2
25	53	3
33.3	91	5
41.7	89	5
50	120	7
58.3	150	9
66.7	230	13
75	221	13
83.3	231	13
91.7	198	12
100	256	15
<b>Total</b>	<b>1,722</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	11	1
16.7	22	1
33.3	44	3
50	112	6
66.7	244	14
83.3	383	22
100	936	53
<b>Total</b>	<b>1,752</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	65	4
16.7	58	3
33.3	125	7
50	155	9
66.7	297	17
83.3	235	14
100	785	46
<b>Total</b>	<b>1,720</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	349	20
11.1	183	11
22.2	223	13
33.3	328	19
44.4	154	9
55.6	133	8
66.7	131	8
77.8	86	5
88.9	57	3
100	68	4
<b>Total</b>	<b>1,712</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	1,355	78
16.7	201	12
33.3	99	6
50	34	2
66.7	26	2
83.3	16	1
100	13	1
<b>Total</b>	<b>1,744</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	789	46
16.7	272	16
33.3	284	17
50	108	6
66.7	124	7
83.3	56	3
100	90	5
<b>Total</b>	<b>1,723</b>	

**Colorectal cancer: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	197	35	173	31	112	20	85	15	567
2) Long walk	PF	243	43	150	27	96	17	77	14	566
3) Short walk	PF	423	75	97	17	35	6	11	2	566
4) Bed or chair	PF	355	63	129	23	66	12	16	3	566
5) Self care	PF	539	95	22	4	7	1	0	0	568
6) Limited in work	RF	771	45	475	28	296	17	183	11	1,725
7) Limited in leisure	RF	911	53	356	21	251	15	194	11	1,712
8) Dyspnoea	DY	1,109	63	417	24	170	10	52	3	1,748
9) Pain	PA	853	49	521	30	237	14	133	8	1,744
10) Need to rest	FA	552	32	652	37	374	21	169	10	1,747
11) Insomnia	SL	772	44	499	29	336	19	144	8	1,751
12) Felt weak	FA	676	39	588	34	333	19	153	9	1,750
13) Appetite loss	AP	1,142	65	329	19	174	10	110	6	1,755
14) Nausea	NV	1,383	79	233	13	93	5	46	3	1,755
15) Vomiting	NV	1,608	92	90	5	32	2	23	1	1,753
16) Constipation	CO	1,221	70	304	17	132	8	87	5	1,744
17) Diarrhoea	DI	1,174	67	366	21	127	7	85	5	1,752
18) Felt tired	FA	532	31	727	42	341	20	145	8	1,745
19) Pain interference	PA	1,062	61	372	21	183	11	128	7	1,745
20) Concentration	CF	1,230	70	341	19	144	8	46	3	1,761
21) Tension	EF	702	40	676	39	267	15	108	6	1,753
22) Worry	EF	404	23	634	36	405	23	303	17	1,746
23) Irritability	EF	919	53	600	34	182	10	49	3	1,750
24) Depression	EF	761	44	561	32	295	17	134	8	1,751
25) Memory trouble	CF	1,146	65	453	26	126	7	33	2	1,758
26) Family life	SF	997	58	434	25	207	12	97	6	1,735
27) Social activities	SF	919	53	425	24	235	14	163	9	1,742
28) Financial difficulties	FI	1,278	74	253	15	121	7	69	4	1,721
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	57	61	210	452	471	320	164		1,735
		3	4	12	26	27	18	10		
30) Overall quality of life	QL	65	82	213	399	443	345	186		1,733
		4	5	12	23	26	20	11		

## Colorectal cancer: males

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	30	3
v 2.0	668	65
v 3.0	325	32
Total	1,023	

#### Age

	N	(%)
<40	35	3
40-49	98	10
50-59	264	26
60-69	402	39
70-79	208	20
80+	16	2
Not known	0	0
Total	1,023	

#### Stage

	N	(%)
Stage I-II	112	11
Stage III-IV	169	17
Recurrent/metastatic	352	34
Not known	390	38
Total	1,023	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	62.1	(23)	66.7	[50-83.3]
Physical functioning	PF	83.0	(18.4)	86.7	[73.3-100]
Role Functioning	RF	72.3	(32.2)	83.3	[50-100]
Emotional functioning	EF	70.8	(24.1)	75	[58.3-91.7]
Cognitive functioning	CF	86.7	(19.4)	100	[83.3-100]
Social functioning	SF	76.7	(28.2)	83.3	[66.7-100]
Fatigue	FA	30.9	(26.7)	33.3	[11.1-44.4]
Nausea and vomiting	NV	5.4	(15)	0	[0-0]
Pain	PA	22.3	(28.4)	16.7	[0-33.3]
Dyspnoea	DY	16.1	(25.2)	0	[0-33.3]
Insomnia	SL	27.9	(31.7)	33.3	[0-33.3]
Appetite loss	AP	16.4	(28.2)	0	[0-33.3]
Constipation	CO	14.3	(26.4)	0	[0-33.3]
Diarrhoea	DI	15.8	(27)	0	[0-33.3]
Financial difficulties	FI	14.4	(26.8)	0	[0-33.3]

**Colorectal cancer: males**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	23	2
8.3	8	1
16.7	25	3
25	20	2
33.3	69	7
41.7	55	6
50	175	18
58.3	73	7
66.7	210	21
75	74	7
83.3	160	16
91.7	24	2
100	84	8
Total	1,000	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	1	0
13.3	0	0
20	0	0
26.7	4	1
33.3	5	2
40	5	2
46.7	9	3
53.3	9	3
60	12	4
66.7	21	7
73.3	26	8
80	30	9
86.7	48	15
93.3	60	19
100	89	28
Total	319	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	74	8
16.7	31	3
33.3	101	10
50	68	7
66.7	143	15
83.3	142	14
100	425	43
Total	984	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	7	1
8.3	11	1
16.7	23	2
25	27	3
33.3	50	5
41.7	49	5
50	64	6
58.3	81	8
66.7	131	13
75	125	13
83.3	135	14
91.7	123	12
100	172	17
Total	998	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	5	1
16.7	9	1
33.3	20	2
50	67	7
66.7	116	12
83.3	219	22
100	574	57
Total	1,010	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	36	4
16.7	28	3
33.3	75	8
50	85	9
66.7	172	17
83.3	131	13
100	466	47
Total	993	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	230	23
11.1	118	12
22.2	135	14
33.3	199	20
44.4	92	9
55.6	71	7
66.7	57	6
77.8	33	3
88.9	33	3
100	24	2
Total	992	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	836	83
16.7	101	10
33.3	37	4
50	14	1
66.7	13	1
83.3	5	1
100	6	1
Total	1,012	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	476	48
16.7	158	16
33.3	165	17
50	57	6
66.7	71	7
83.3	26	3
100	43	4
Total	996	

**Colorectal cancer: males**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	128	39	101	31	63	19	33	10	325
2) Long walk	PF	153	47	94	29	49	15	27	8	323
3) Short walk	PF	266	82	45	14	11	3	3	1	325
4) Bed or chair	PF	219	68	70	22	27	8	5	2	321
5) Self care	PF	313	97	7	2	4	1	0	0	324
6) Limited in work	RF	481	48	268	27	154	16	92	9	995
7) Limited in leisure	RF	544	55	203	21	141	14	103	10	991
8) Dyspnoea	DY	660	65	238	24	88	9	25	3	1,011
9) Pain	PA	520	52	293	29	127	13	68	7	1,008
10) Need to rest	FA	366	36	381	38	186	18	76	8	1,009
11) Insomnia	SL	482	48	288	28	172	17	73	7	1,015
12) Felt weak	FA	425	42	350	35	171	17	69	7	1,015
13) Appetite loss	AP	701	69	174	17	88	9	49	5	1,012
14) Nausea	NV	850	84	112	11	35	3	19	2	1,016
15) Vomiting	NV	952	94	41	4	15	2	9	1	1,017
16) Constipation	CO	728	72	172	17	67	7	42	4	1,009
17) Diarrhoea	DI	695	69	202	20	74	7	44	4	1,015
18) Felt tired	FA	350	35	437	43	160	16	61	6	1,008
19) Pain interference	PA	632	63	215	21	100	10	62	6	1,009
20) Concentration	CF	732	72	189	19	73	7	23	2	1,017
21) Tension	EF	447	44	371	37	142	14	53	5	1,013
22) Worry	EF	255	25	377	37	227	23	151	15	1,010
23) Irritability	EF	530	52	356	35	104	10	24	2	1,014
24) Depression	EF	487	48	301	30	165	16	61	6	1,014
25) Memory trouble	CF	699	69	237	23	60	6	17	2	1,013
26) Family life	SF	566	57	265	27	118	12	51	5	1,000
27) Social activities	SF	553	55	233	23	137	14	84	8	1,007
28) Financial difficulties	FI	723	73	153	15	77	8	41	4	994
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	27	33	109	247	293	196	98		1,003
		3	3	11	25	29	20	10		
30) Overall quality of life	QL	35	44	108	226	270	206	114		1,003
		4	4	11	23	27	21	11		

## Colorectal cancer: females

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	15	2
v 2.0	490	71
v 3.0	182	27
Total	687	

#### Age

	N	(%)
<40	23	3
40-49	99	14
50-59	169	25
60-69	216	31
70-79	157	23
80+	23	3
Not known	0	0
Total	687	

#### Stage

	N	(%)
Stage I-II	118	17
Stage III-IV	112	16
Recurrent/metastatic	238	35
Not known	219	32
Total	687	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	58.8	(23.6)	58.3	[41.7-75]
Physical functioning	PF	75.2	(23.1)	80	[60-93.3]
Role Functioning	RF	68.4	(33.2)	83.3	[50-100]
Emotional functioning	EF	65.7	(24.5)	66.7	[50-83.3]
Cognitive functioning	CF	83.7	(21.4)	100	[66.7-100]
Social functioning	SF	75.8	(29)	83.3	[66.7-100]
Fatigue	FA	39.1	(29.5)	33.3	[11.1-66.7]
Nausea and vomiting	NV	9.6	(19.6)	0	[0-16.7]
Pain	PA	25.8	(30.5)	16.7	[0-33.3]
Dyspnoea	DY	18.5	(27.3)	0	[0-33.3]
Insomnia	SL	34.5	(33.1)	33.3	[0-66.7]
Appetite loss	AP	23.2	(32.6)	0	[0-33.3]
Constipation	CO	18.8	(30.4)	0	[0-33.3]
Diarrhoea	DI	16.7	(27.8)	0	[0-33.3]
Financial difficulties	FI	12.2	(25.4)	0	[0-0]

**Colorectal cancer: females  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	20	3
8.3	5	1
16.7	18	3
25	15	2
33.3	66	10
41.7	46	7
50	133	20
58.3	48	7
66.7	113	17
75	43	7
83.3	90	14
91.7	24	4
100	43	7
<b>Total</b>	<b>664</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	0	0
13.3	2	1
20	2	1
26.7	6	3
33.3	6	3
40	6	3
46.7	9	5
53.3	8	5
60	10	6
66.7	10	6
73.3	16	9
80	21	12
86.7	25	14
93.3	17	10
100	40	23
<b>Total</b>	<b>178</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	56	9
16.7	27	4
33.3	79	12
50	54	8
66.7	99	15
83.3	88	14
100	248	38
<b>Total</b>	<b>651</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	7	1
8.3	12	2
16.7	18	3
25	26	4
33.3	40	6
41.7	36	5
50	54	8
58.3	65	10
66.7	88	13
75	91	14
83.3	90	14
91.7	67	10
100	67	10
<b>Total</b>	<b>661</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	6	1
16.7	11	2
33.3	21	3
50	36	5
66.7	117	17
83.3	146	22
100	342	50
<b>Total</b>	<b>679</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	26	4
16.7	27	4
33.3	47	7
50	57	9
66.7	112	17
83.3	92	14
100	303	46
<b>Total</b>	<b>664</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	109	17
11.1	64	10
22.2	81	12
33.3	118	18
44.4	60	9
55.6	57	9
66.7	67	10
77.8	46	7
88.9	15	2
100	41	6
<b>Total</b>	<b>658</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	483	72
16.7	86	13
33.3	57	9
50	16	2
66.7	10	2
83.3	11	2
100	7	1
<b>Total</b>	<b>670</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	290	44
16.7	101	15
33.3	112	17
50	48	7
66.7	46	7
83.3	29	4
100	38	6
<b>Total</b>	<b>664</b>	



**Colorectal cancer: females**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	54	30	55	31	35	20	35	20	179
2) Long walk	PF	69	38	45	25	34	19	32	18	180
3) Short walk	PF	119	67	37	21	15	8	7	4	178
4) Bed or chair	PF	102	56	47	26	25	14	8	4	182
5) Self care	PF	168	92	11	6	3	2	0	0	182
6) Limited in work	RF	268	40	191	29	129	19	79	12	667
7) Limited in leisure	RF	344	52	134	20	101	15	80	12	659
8) Dyspnoea	DY	417	62	164	24	68	10	25	4	674
9) Pain	PA	310	46	207	31	101	15	55	8	673
10) Need to rest	FA	173	26	252	37	170	25	80	12	675
11) Insomnia	SL	257	38	200	30	152	23	64	10	673
12) Felt weak	FA	232	35	221	33	142	21	77	12	672
13) Appetite loss	AP	400	59	144	21	78	12	58	9	680
14) Nausea	NV	497	74	105	16	51	8	23	3	676
15) Vomiting	NV	599	89	47	7	14	2	14	2	674
16) Constipation	CO	444	66	122	18	61	9	45	7	672
17) Diarrhoea	DI	450	67	147	22	41	6	36	5	674
18) Felt tired	FA	171	25	273	40	164	24	67	10	675
19) Pain interference	PA	394	59	147	22	76	11	56	8	673
20) Concentration	CF	459	67	137	20	64	9	21	3	681
21) Tension	EF	226	33	281	42	118	17	52	8	677
22) Worry	EF	122	18	235	35	170	25	146	22	673
23) Irritability	EF	358	53	222	33	72	11	21	3	673
24) Depression	EF	247	37	236	35	124	18	67	10	674
25) Memory trouble	CF	424	62	189	28	54	8	15	2	682
26) Family life	SF	403	60	150	22	76	11	43	6	672
27) Social activities	SF	345	51	169	25	86	13	72	11	672
28) Financial difficulties	FI	511	77	89	13	38	6	26	4	664
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	28	22	90	196	156	117	60		669
		4	3	14	29	23	18	9		
30) Overall quality of life	QL	29	32	95	167	156	125	63		667
		4	5	14	25	23	19	9		

## Colorectal cancer: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	7	3
v 2.0	146	54
v 3.0	118	44
Total	271	

#### Age

	N	(%)
<40	62	23
40-49	209	77
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	271	

#### Gender

	N	(%)
Male	133	49
Female	122	45
Not known	16	6
Total	271	

#### Stage

	N	(%)
Stage I-II	18	7
Stage III-IV	40	15
Recurrent/metastatic	110	41
Not known	103	38
Total	271	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	59.8	(23.7)	58.3	[50-83.3]
Physical functioning	PF	80.2	(20.1)	86.7	[66.7-100]
Role Functioning	RF	68.1	(32.6)	83.3	[33.3-100]
Emotional functioning	EF	65.6	(26.3)	66.7	[50-83.3]
Cognitive functioning	CF	85.0	(20.5)	100	[66.7-100]
Social functioning	SF	68.9	(31.4)	66.7	[50-100]
Fatigue	FA	37.3	(28.1)	33.3	[22.2-55.6]
Nausea and vomiting	NV	9.5	(19.3)	0	[0-16.7]
Pain	PA	30.2	(33.3)	16.7	[0-50]
Dyspnoea	DY	20.7	(29)	0	[0-33.3]
Insomnia	SL	33.8	(34.4)	33.3	[0-66.7]
Appetite loss	AP	21.9	(30.4)	0	[0-33.3]
Constipation	CO	17.7	(30)	0	[0-33.3]
Diarrhoea	DI	18.5	(28.1)	0	[0-33.3]
Financial difficulties	FI	23.8	(32.7)	0	[0-33.3]

**Colorectal cancer: <50**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	9	3
8.3	1	0
16.7	6	2
25	6	2
33.3	25	9
41.7	19	7
50	50	19
58.3	20	8
66.7	43	16
75	19	7
83.3	43	16
91.7	8	3
100	18	7
<b>Total</b>	<b>267</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	0	0
13.3	1	1
20	0	0
26.7	1	1
33.3	3	3
40	4	3
46.7	4	3
53.3	3	3
60	4	3
66.7	11	9
73.3	8	7
80	15	13
86.7	20	17
93.3	9	8
100	34	29
<b>Total</b>	<b>117</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	19	7
16.7	10	4
33.3	42	16
50	21	8
66.7	35	13
83.3	42	16
100	96	36
<b>Total</b>	<b>265</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	5	2
8.3	7	3
16.7	8	3
25	11	4
33.3	16	6
41.7	12	5
50	19	7
58.3	25	9
66.7	41	15
75	32	12
83.3	32	12
91.7	21	8
100	40	15
<b>Total</b>	<b>269</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	1	0
16.7	5	2
33.3	5	2
50	19	7
66.7	38	14
83.3	58	22
100	142	53
<b>Total</b>	<b>268</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	16	6
16.7	13	5
33.3	27	10
50	31	12
66.7	51	20
83.3	25	10
100	99	38
<b>Total</b>	<b>262</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	46	18
11.1	19	7
22.2	38	14
33.3	53	20
44.4	34	13
55.6	15	6
66.7	20	8
77.8	18	7
88.9	9	3
100	11	4
<b>Total</b>	<b>263</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	191	72
16.7	35	13
33.3	22	8
50	7	3
66.7	7	3
83.3	0	0
100	4	2
<b>Total</b>	<b>266</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	103	39
16.7	36	14
33.3	51	19
50	19	7
66.7	17	6
83.3	12	5
100	26	10
<b>Total</b>	<b>264</b>	

**Colorectal cancer: <50  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	39	33	43	36	23	20	13	11	118
2) Long walk	PF	54	46	35	30	17	14	12	10	118
3) Short walk	PF	87	74	23	20	7	6	1	1	118
4) Bed or chair	PF	67	57	34	29	13	11	4	3	118
5) Self care	PF	109	93	6	5	2	2	0	0	117
6) Limited in work	RF	109	41	81	30	51	19	27	10	268
7) Limited in leisure	RF	130	49	53	20	54	20	30	11	267
8) Dyspnoea	DY	161	60	61	23	37	14	11	4	270
9) Pain	PA	108	40	90	34	33	12	37	14	268
10) Need to rest	FA	74	28	104	39	64	24	26	10	268
11) Insomnia	SL	110	41	77	29	52	19	31	12	270
12) Felt weak	FA	95	36	97	37	51	19	22	8	265
13) Appetite loss	AP	157	59	62	23	33	12	16	6	268
14) Nausea	NV	194	72	44	16	19	7	11	4	268
15) Vomiting	NV	241	90	16	6	7	3	4	2	268
16) Constipation	CO	185	69	44	16	24	9	17	6	270
17) Diarrhoea	DI	169	63	64	24	23	9	13	5	269
18) Felt tired	FA	61	23	121	45	61	23	25	9	268
19) Pain interference	PA	140	53	69	26	24	9	33	12	266
20) Concentration	CF	176	65	64	24	21	8	9	3	270
21) Tension	EF	81	30	119	44	44	16	27	10	271
22) Worry	EF	61	23	105	39	64	24	41	15	271
23) Irritability	EF	117	44	105	39	33	12	14	5	269
24) Depression	EF	102	38	95	35	48	18	25	9	270
25) Memory trouble	CF	180	67	69	26	16	6	4	2	269
26) Family life	SF	116	44	77	29	50	19	23	9	266
27) Social activities	SF	122	46	68	26	45	17	32	12	267
28) Financial difficulties	FI	154	58	56	21	34	13	22	8	266
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	10	7	41	65	66	59	19		267
		4	3	15	24	25	22	7		
30) Overall quality of life	QL	12	11	37	66	57	57	27		267
		5	4	14	25	21	21	10		

## Colorectal cancer: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	14	3
v 2.0	278	61
v 3.0	164	36
Total	456	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	456	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	456	

#### Gender

	N	(%)
Male	264	58
Female	169	37
Not known	23	5
Total	456	

#### Stage

	N	(%)
Stage I-II	35	8
Stage III-IV	70	15
Recurrent/metastatic	172	38
Not known	179	39
Total	456	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.6	(24.3)	66.7	[50-83.3]
Physical functioning	PF	78.1	(23)	86.7	[60-100]
Role Functioning	RF	68.7	(33.4)	83.3	[50-100]
Emotional functioning	EF	68.4	(24.6)	75	[50-91.7]
Cognitive functioning	CF	85.8	(19.3)	100	[83.3-100]
Social functioning	SF	73.7	(29.6)	83.3	[50-100]
Fatigue	FA	33.5	(29)	33.3	[11.1-55.6]
Nausea and vomiting	NV	7.3	(16.9)	0	[0-0]
Pain	PA	24.8	(29.6)	16.7	[0-33.3]
Dyspnoea	DY	16.2	(25.6)	0	[0-33.3]
Insomnia	SL	30.6	(33.2)	33.3	[0-66.7]
Appetite loss	AP	17.5	(28.9)	0	[0-33.3]
Constipation	CO	12.3	(24.6)	0	[0-0]
Diarrhoea	DI	16.1	(27)	0	[0-33.3]
Financial difficulties	FI	16.2	(28)	0	[0-33.3]

**Colorectal cancer: 50-59  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	13	3
8.3	3	1
16.7	16	4
25	10	2
33.3	31	7
41.7	26	6
50	76	17
58.3	33	7
66.7	78	17
75	35	8
83.3	73	16
91.7	15	3
100	40	9
<b>Total</b>	<b>449</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	1	1
13.3	1	1
20	1	1
26.7	3	2
33.3	6	4
40	2	1
46.7	10	6
53.3	12	7
60	5	3
66.7	8	5
73.3	12	7
80	14	9
86.7	18	11
93.3	21	13
100	48	30
<b>Total</b>	<b>162</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	44	10
16.7	13	3
33.3	46	10
50	39	9
66.7	74	17
83.3	55	12
100	173	39
<b>Total</b>	<b>444</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	4	1
8.3	8	2
16.7	11	3
25	12	3
33.3	24	5
41.7	27	6
50	33	7
58.3	39	9
66.7	58	13
75	48	11
83.3	69	15
91.7	56	13
100	59	13
<b>Total</b>	<b>448</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	1	0
16.7	5	1
33.3	11	2
50	25	6
66.7	70	15
83.3	96	21
100	246	54
<b>Total</b>	<b>454</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	21	5
16.7	16	4
33.3	36	8
50	45	10
66.7	80	18
83.3	60	13
100	189	42
<b>Total</b>	<b>447</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	111	25
11.1	42	9
22.2	53	12
33.3	81	18
44.4	43	10
55.6	34	8
66.7	32	7
77.8	21	5
88.9	17	4
100	17	4
<b>Total</b>	<b>451</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	347	76
16.7	60	13
33.3	25	6
50	9	2
66.7	5	1
83.3	5	1
100	3	1
<b>Total</b>	<b>454</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	203	45
16.7	59	13
33.3	85	19
50	30	7
66.7	35	8
83.3	14	3
100	23	5
<b>Total</b>	<b>449</b>	

**Colorectal cancer: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	58	35	43	26	29	18	34	21	164
2) Long walk	PF	74	45	35	22	30	18	24	15	163
3) Short walk	PF	121	74	29	18	8	5	6	4	164
4) Bed or chair	PF	105	64	29	18	24	15	5	3	163
5) Self care	PF	158	96	5	3	1	1	0	0	164
6) Limited in work	RF	195	43	125	28	72	16	57	13	449
7) Limited in leisure	RF	221	50	101	23	68	15	55	12	445
8) Dyspnoea	DY	298	66	101	22	41	9	12	3	452
9) Pain	PA	219	49	132	29	71	16	30	7	452
10) Need to rest	FA	155	34	163	36	98	22	40	9	456
11) Insomnia	SL	201	44	133	29	76	17	44	10	454
12) Felt weak	FA	179	39	155	34	81	18	39	9	454
13) Appetite loss	AP	304	67	86	19	39	9	25	6	454
14) Nausea	NV	355	78	65	14	22	5	13	3	455
15) Vomiting	NV	418	92	24	5	9	2	4	1	455
16) Constipation	CO	338	75	74	16	22	5	16	4	450
17) Diarrhoea	DI	306	68	94	21	32	7	20	4	452
18) Felt tired	FA	152	34	182	40	79	17	40	9	453
19) Pain interference	PA	262	58	105	23	52	12	33	7	452
20) Concentration	CF	307	68	97	21	43	10	7	2	454
21) Tension	EF	181	40	169	37	78	17	25	6	453
22) Worry	EF	96	21	179	40	91	20	86	19	452
23) Irritability	EF	232	51	163	36	48	11	11	2	454
24) Depression	EF	201	44	142	31	72	16	39	9	454
25) Memory trouble	CF	313	69	106	23	32	7	4	1	455
26) Family life	SF	241	54	119	26	58	13	32	7	450
27) Social activities	SF	221	49	120	27	67	15	42	9	450
28) Financial difficulties	FI	305	70	76	17	37	8	21	5	439
<hr/>										
		1	2	3	4	5	6	7	Total	
		(very poor)					(excellent)			
29) Overall health	QL	15	19	49	115	113	87	52	450	
		3	4	11	26	25	19	12		
30) Overall quality of life	QL	16	26	54	91	110	100	53	450	
		4	6	12	20	24	22	12		

## Colorectal cancer: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	14	2
v 2.0	427	68
v 3.0	192	30
Total	633	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	633	100
70-79	0	0
80+	0	0
Not known	0	0
Total	633	

#### Gender

	N	(%)
Male	402	64
Female	216	34
Not known	15	2
Total	633	

#### Stage

	N	(%)
Stage I-II	83	13
Stage III-IV	82	13
Recurrent/metastatic	245	39
Not known	223	35
Total	633	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	61.7	(22)	66.7	[50-75]
Physical functioning	PF	79.3	(21)	86.7	[66.7-93.3]
Role Functioning	RF	72.3	(33.1)	83.3	[50-100]
Emotional functioning	EF	69.5	(23.4)	75	[58.3-91.7]
Cognitive functioning	CF	85.8	(20.3)	100	[83.3-100]
Social functioning	SF	77.6	(27.9)	83.3	[66.7-100]
Fatigue	FA	33.4	(27.2)	33.3	[11.1-55.6]
Nausea and vomiting	NV	6.9	(17.1)	0	[0-0]
Pain	PA	22.4	(28.2)	16.7	[0-33.3]
Dyspnoea	DY	17.1	(25.7)	0	[0-33.3]
Insomnia	SL	29.8	(31.6)	33.3	[0-66.7]
Appetite loss	AP	18.3	(30.5)	0	[0-33.3]
Constipation	CO	15.8	(27.1)	0	[0-33.3]
Diarrhoea	DI	15.6	(27.2)	0	[0-33.3]
Financial difficulties	FI	11.8	(25.2)	0	[0-0]



**Colorectal cancer: 60-69**  
**Constructed scales**

QL	N	(%)
0	8	1
8.3	5	1
16.7	16	3
25	9	2
33.3	48	8
41.7	37	6
50	123	20
58.3	44	7
66.7	132	21
75	50	8
83.3	79	13
91.7	17	3
100	52	8
Total	620	

PF	N	(%)
0	0	0
6.7	0	0
13.3	0	0
20	1	1
26.7	6	3
33.3	7	4
40	3	2
46.7	6	3
53.3	5	3
60	10	5
66.7	10	5
73.3	18	10
80	18	10
86.7	27	15
93.3	30	16
100	45	24
Total	186	

RF	N	(%)
0	48	8
16.7	22	4
33.3	66	11
50	30	5
66.7	91	15
83.3	67	11
100	278	46
Total	602	

EF	N	(%)
0	4	1
8.3	6	1
16.7	13	2
25	20	3
33.3	27	4
41.7	33	5
50	44	7
58.3	56	9
66.7	78	13
75	88	14
83.3	86	14
91.7	74	12
100	83	14
Total	612	

CF	N	(%)
0	6	1
16.7	5	1
33.3	15	2
50	40	6
66.7	74	12
83.3	143	23
100	343	55
Total	626	

SF	N	(%)
0	21	3
16.7	18	3
33.3	41	7
50	53	9
66.7	101	16
83.3	85	14
100	295	48
Total	614	

FA	N	(%)
0	121	20
11.1	77	13
22.2	76	13
33.3	123	20
44.4	49	8
55.6	56	9
66.7	43	7
77.8	30	5
88.9	17	3
100	17	3
Total	609	

NV	N	(%)
0	496	79
16.7	68	11
33.3	28	5
50	13	2
66.7	7	1
83.3	10	2
100	3	1
Total	625	

PA	N	(%)
0	290	47
16.7	103	17
33.3	99	16
50	40	7
66.7	43	7
83.3	19	3
100	24	4
Total	618	

**Colorectal cancer: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	70	37	51	27	41	22	27	14	189
2) Long walk	PF	82	43	48	25	33	18	26	14	189
3) Short walk	PF	144	76	28	15	14	7	3	2	189
4) Bed or chair	PF	119	63	43	23	22	12	6	3	190
5) Self care	PF	181	95	8	4	2	1	0	0	191
6) Limited in work	RF	300	49	158	26	96	16	60	10	614
7) Limited in leisure	RF	343	57	115	19	78	13	71	12	607
8) Dyspnoea	DY	392	63	158	25	53	9	18	3	621
9) Pain	PA	315	50	188	30	81	13	41	7	625
10) Need to rest	FA	199	32	239	38	125	20	59	10	622
11) Insomnia	SL	277	44	178	29	130	21	40	6	625
12) Felt weak	FA	249	40	210	34	122	20	45	7	626
13) Appetite loss	AP	426	68	98	16	62	10	41	7	627
14) Nausea	NV	507	81	76	12	34	5	12	2	629
15) Vomiting	NV	578	92	28	5	11	2	10	2	627
16) Constipation	CO	427	69	124	20	44	7	28	5	623
17) Diarrhoea	DI	432	69	123	20	40	6	30	5	625
18) Felt tired	FA	203	33	257	41	122	20	39	6	621
19) Pain interference	PA	392	63	129	21	66	11	38	6	625
20) Concentration	CF	457	73	108	17	46	7	19	3	630
21) Tension	EF	255	41	253	41	82	13	34	5	624
22) Worry	EF	135	22	225	36	160	26	105	17	625
23) Irritability	EF	344	55	201	32	62	10	17	3	624
24) Depression	EF	275	44	199	32	111	18	38	6	623
25) Memory trouble	CF	411	66	169	27	32	5	15	2	627
26) Family life	SF	375	61	147	24	66	11	32	5	620
27) Social activities	SF	344	55	146	24	74	12	58	9	622
28) Financial difficulties	FI	486	78	74	12	40	6	22	4	622
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	13	20	65	171	187	102	64		622
		2	3	11	28	30	16	10		
30) Overall quality of life	QL	17	26	73	151	174	110	73		624
		3	4	12	24	28	18	12		

## Colorectal cancer: ≥70

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	10	2
v 2.0	307	74
v 3.0	96	23
Total	413	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	374	91
80+	39	9
Not known	0	0
Total	413	

#### Gender

	N	(%)
Male	224	54
Female	180	44
Not known	9	2
Total	413	

#### Stage

	N	(%)
Stage I-II	94	23
Stage III-IV	89	22
Recurrent/metastatic	126	31
Not known	104	25
Total	413	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	58.7	(24)	66.7	[41.7-75]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	70.8	(31.8)	83.3	[50-100]
Emotional functioning	EF	70.7	(24.6)	75	[58.3-91.7]
Cognitive functioning	CF	83.5	(21.7)	100	[66.7-100]
Social functioning	SF	80.9	(25.2)	100	[66.7-100]
Fatigue	FA	36.4	(29.6)	33.3	[11.1-55.6]
Nausea and vomiting	NV	6.3	(16)	0	[0-0]
Pain	PA	21.3	(28.6)	16.7	[0-33.3]
Dyspnoea	DY	17.1	(26)	0	[0-33.3]
Insomnia	SL	29.4	(32.1)	33.3	[0-66.7]
Appetite loss	AP	20.3	(30.8)	0	[0-33.3]
Constipation	CO	18.6	(30.7)	0	[0-33.3]
Diarrhoea	DI	17.7	(28.6)	0	[0-33.3]
Financial difficulties	FI	6.7	(17.4)	0	[0-0]

**Colorectal cancer:  $\geq 70$   
Constructed scales**

QL	N	(%)
0	14	4
8.3	5	1
16.7	10	3
25	10	3
33.3	38	10
41.7	22	6
50	69	18
58.3	26	7
66.7	82	21
75	21	5
83.3	61	16
91.7	10	3
100	23	6
Total	391	

**PF**

Previous version of this scale used

CF	N	(%)
0	3	1
16.7	7	2
33.3	13	3
50	28	7
66.7	62	15
83.3	86	21
100	205	51
Total	404	

SF	N	(%)
0	7	2
16.7	11	3
33.3	21	5
50	26	7
66.7	65	16
83.3	65	16
100	202	51
Total	397	

FA	N	(%)
0	71	18
11.1	45	12
22.2	56	14
33.3	71	18
44.4	28	7
55.6	28	7
66.7	36	9
77.8	17	4
88.9	14	4
100	23	6
Total	389	

RF	N	(%)
0	28	7
16.7	16	4
33.3	35	9
50	36	9
66.7	57	15
83.3	66	17
100	148	38
Total	386	

NV	N	(%)
0	321	81
16.7	38	10
33.3	24	6
50	5	1
66.7	7	2
83.3	1	0
100	3	1
Total	399	

EF	N	(%)
0	3	1
8.3	4	1
16.7	10	3
25	10	3
33.3	24	6
41.7	17	4
50	24	6
58.3	30	8
66.7	53	14
75	53	14
83.3	44	11
91.7	47	12
100	74	19
Total	393	

PA	N	(%)
0	193	49
16.7	74	19
33.3	49	13
50	19	5
66.7	29	7
83.3	11	3
100	17	4
Total	392	

**Colorectal cancer: ≥70**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	167	42	111	28	77	20	39	10	394
7) Limited in leisure	RF	217	55	87	22	51	13	38	10	393
8) Dyspnoea	DY	258	64	97	24	39	10	11	3	405
9) Pain	PA	211	53	111	28	52	13	25	6	399
10) Need to rest	FA	124	31	146	36	87	22	44	11	401
11) Insomnia	SL	184	46	111	28	78	19	29	7	402
12) Felt weak	FA	153	38	126	31	79	20	47	12	405
13) Appetite loss	AP	255	63	83	20	40	10	28	7	406
14) Nausea	NV	327	81	48	12	18	5	10	3	403
15) Vomiting	NV	371	92	22	6	5	1	5	1	403
16) Constipation	CO	271	68	62	16	42	11	26	7	401
17) Diarrhoea	DI	267	66	85	21	32	8	22	5	406
18) Felt tired	FA	116	29	167	41	79	20	41	10	403
19) Pain interference	PA	268	67	69	17	41	10	24	6	402
20) Concentration	CF	290	71	72	18	34	8	11	3	407
21) Tension	EF	185	46	135	33	63	16	22	5	405
22) Worry	EF	112	28	125	31	90	23	71	18	398
23) Irritability	EF	226	56	131	33	39	10	7	2	403
24) Depression	EF	183	45	125	31	64	16	32	8	404
25) Memory trouble	CF	242	60	109	27	46	11	10	3	407
26) Family life	SF	265	66	91	23	33	8	10	3	399
27) Social activities	SF	232	58	91	23	49	12	31	8	403
28) Financial difficulties	FI	333	85	47	12	10	3	4	1	394
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	19	15	55	101	105	72	29		396
		5	4	14	26	27	18	7		
30) Overall quality of life	QL	20	19	49	91	102	78	33		392
		5	5	13	23	26	20	8		

## Colorectal cancer: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	0	0
v 2.0	212	92
v 3.0	18	8
Total	230	

#### Age

	N	(%)
<40	3	1
40-49	15	7
50-59	35	15
60-69	83	36
70-79	77	34
80+	17	7
Not known	0	0
Total	230	

#### Gender

	N	(%)
Male	112	49
Female	118	51
Not known	0	0
Total	230	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	59.8	(26.3)	66.7	[41.7-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	81.7	(30.4)	100	[83.3-100]
Emotional functioning	EF	65.8	(25.6)	66.7	[50-83.3]
Cognitive functioning	CF	84.3	(22.1)	100	[75-100]
Social functioning	SF	81.4	(26.7)	100	[66.7-100]
Fatigue	FA	27.7	(28.6)	22.2	[0-44.4]
Nausea and vomiting	NV	6.4	(17.4)	0	[0-0]
Pain	PA	17.5	(27.6)	0	[0-33.3]
Dyspnoea	DY	16.7	(25.4)	0	[0-33.3]
Insomnia	SL	27.9	(32.9)	16.7	[0-66.7]
Appetite loss	AP	13.4	(27)	0	[0-0]
Constipation	CO	18.4	(31)	0	[0-33.3]
Diarrhoea	DI	22.6	(31.4)	0	[0-33.3]
Financial difficulties	FI	7.6	(18.8)	0	[0-0]

**Colorectal cancer: stage I-II  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	7	3
8.3	5	2
16.7	8	4
25	5	2
33.3	26	12
41.7	9	4
50	34	16
58.3	12	6
66.7	35	16
75	11	5
83.3	38	17
91.7	8	4
100	21	10
<b>Total</b>	<b>219</b>	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	3	1
16.7	3	1
33.3	7	3
50	16	7
66.7	28	12
83.3	50	22
100	121	53
<b>Total</b>	<b>228</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	5	2
16.7	6	3
33.3	17	8
50	11	5
66.7	27	12
83.3	32	15
100	123	56
<b>Total</b>	<b>221</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	67	31
11.1	34	16
22.2	29	13
33.3	30	14
44.4	12	6
55.6	10	5
66.7	14	6
77.8	8	4
88.9	10	5
100	5	2
<b>Total</b>	<b>219</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	14	7
16.7	7	3
33.3	7	3
50	11	5
66.7	12	6
83.3	31	15
100	132	62
<b>Total</b>	<b>214</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	186	83
16.7	16	7
33.3	12	5
50	4	2
66.7	2	1
83.3	3	1
100	2	1
<b>Total</b>	<b>225</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	3	1
8.3	2	1
16.7	7	3
25	13	6
33.3	13	6
41.7	11	5
50	17	8
58.3	17	8
66.7	29	13
75	26	12
83.3	28	13
91.7	23	11
100	27	13
<b>Total</b>	<b>216</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	133	61
16.7	29	13
33.3	20	9
50	11	5
66.7	14	6
83.3	5	2
100	8	4
<b>Total</b>	<b>220</b>	

**Colorectal cancer: stage I-II  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	139	64	33	15	25	11	22	10	219
7) Limited in leisure	RF	172	79	17	8	15	7	15	7	219
8) Dyspnoea	DY	145	64	54	24	22	10	5	2	226
9) Pain	PA	143	64	41	18	29	13	12	5	225
10) Need to rest	FA	102	45	76	34	34	15	15	7	227
11) Insomnia	SL	113	50	55	24	40	18	18	8	226
12) Felt weak	FA	122	54	43	19	42	19	18	8	225
13) Appetite loss	AP	172	76	30	13	14	6	11	5	227
14) Nausea	NV	187	83	22	10	11	5	6	3	226
15) Vomiting	NV	210	93	8	4	3	1	4	2	225
16) Constipation	CO	154	68	34	15	21	9	16	7	225
17) Diarrhoea	DI	132	58	57	25	22	10	18	8	229
18) Felt tired	FA	96	43	74	33	39	17	15	7	224
19) Pain interference	PA	164	73	26	12	24	11	10	5	224
20) Concentration	CF	163	71	37	16	23	10	6	3	229
21) Tension	EF	90	40	72	32	40	18	23	10	225
22) Worry	EF	47	21	54	25	66	30	53	24	220
23) Irritability	EF	118	53	73	33	27	12	6	3	224
24) Depression	EF	100	44	63	28	38	17	24	11	225
25) Memory trouble	CF	145	63	58	25	20	9	6	3	229
26) Family life	SF	139	62	52	23	21	9	11	5	223
27) Social activities	SF	148	66	39	17	25	11	14	6	226
28) Financial difficulties	FI	187	83	28	12	7	3	3	1	225
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	12	9	30	50	44	49	27		221
		5	4	14	23	20	22	12		
30) Overall quality of life	QL	13	18	27	48	43	45	28		222
		6	8	12	22	19	20	13		



## Colorectal cancer: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	0	0
v 2.0	225	80
v 3.0	56	20
Total	281	

#### Age

	N	(%)
<40	8	3
40-49	32	11
50-59	70	25
60-69	82	29
70-79	74	26
80+	15	5
Not known	0	0
Total	281	

#### Gender

	N	(%)
Male	169	60
Female	112	40
Not known	0	0
Total	281	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	60.7	(21.9)	66.7	[50-75]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	80.0	(28.2)	100	[66.7-100]
Emotional functioning	EF	67.1	(25.3)	66.7	[50-91.7]
Cognitive functioning	CF	86.5	(18.8)	100	[83.3-100]
Social functioning	SF	76.7	(27.5)	83.3	[66.7-100]
Fatigue	FA	30.7	(28.5)	22.2	[0-55.6]
Nausea and vomiting	NV	4.7	(14.1)	0	[0-0]
Pain	PA	22.3	(30)	8.3	[0-33.3]
Dyspnoea	DY	15.8	(26)	0	[0-33.3]
Insomnia	SL	29.8	(32)	33.3	[0-66.7]
Appetite loss	AP	14.3	(26.3)	0	[0-33.3]
Constipation	CO	16.2	(29.3)	0	[0-33.3]
Diarrhoea	DI	23.8	(32.9)	0	[0-33.3]
Financial difficulties	FI	10.8	(24.9)	0	[0-0]

**Colorectal cancer: stage III-IV  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	5	2
8.3	2	1
16.7	5	2
25	3	1
33.3	28	10
41.7	19	7
50	39	15
58.3	23	9
66.7	69	26
75	19	7
83.3	29	11
91.7	8	3
100	19	7
<b>Total</b>	<b>268</b>	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	0	0
16.7	4	2
33.3	3	1
50	20	7
66.7	35	13
83.3	60	22
100	153	56
<b>Total</b>	<b>275</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	10	4
16.7	8	3
33.3	12	4
50	29	11
66.7	53	20
83.3	36	13
100	122	45
<b>Total</b>	<b>270</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	71	26
11.1	38	14
22.2	33	12
33.3	40	15
44.4	20	7
55.6	21	8
66.7	19	7
77.8	14	5
88.9	7	3
100	8	3
<b>Total</b>	<b>271</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	12	5
16.7	6	2
33.3	17	6
50	13	5
66.7	29	11
83.3	52	20
100	137	52
<b>Total</b>	<b>266</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	233	85
16.7	22	8
33.3	12	4
50	2	1
66.7	2	1
83.3	1	0
100	2	1
<b>Total</b>	<b>274</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	0	0
8.3	7	3
16.7	7	3
25	9	3
33.3	15	6
41.7	22	8
50	23	9
58.3	28	10
66.7	28	10
75	33	12
83.3	26	10
91.7	30	11
100	44	16
<b>Total</b>	<b>272</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	134	50
16.7	46	17
33.3	34	13
50	10	4
66.7	20	8
83.3	10	4
100	14	5
<b>Total</b>	<b>268</b>	

**Colorectal cancer: stage III-IV  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	148	55	66	24	40	15	17	6	271
7) Limited in leisure	RF	195	73	35	13	23	9	15	6	268
8) Dyspnoea	DY	187	68	53	19	28	10	7	3	275
9) Pain	PA	144	53	66	24	37	14	23	9	270
10) Need to rest	FA	122	45	79	29	52	19	20	7	273
11) Insomnia	SL	124	45	74	27	59	22	18	7	275
12) Felt weak	FA	126	46	78	28	49	18	23	8	276
13) Appetite loss	AP	200	72	45	16	22	8	10	4	277
14) Nausea	NV	237	86	26	9	8	3	5	2	276
15) Vomiting	NV	261	95	9	3	2	1	4	1	276
16) Constipation	CO	195	71	39	14	23	8	16	6	273
17) Diarrhoea	DI	159	57	64	23	28	10	26	9	277
18) Felt tired	FA	104	37	101	36	51	18	22	8	278
19) Pain interference	PA	186	67	45	16	26	9	19	7	276
20) Concentration	CF	200	72	51	18	17	6	10	4	278
21) Tension	EF	119	43	95	34	49	18	16	6	279
22) Worry	EF	62	23	74	27	72	26	66	24	274
23) Irritability	EF	151	54	88	32	35	13	4	1	278
24) Depression	EF	116	42	78	28	56	20	25	9	275
25) Memory trouble	CF	185	67	75	27	15	5	1	0	276
26) Family life	SF	154	57	74	27	26	10	17	6	271
27) Social activities	SF	147	54	69	25	40	15	19	7	275
28) Financial difficulties	FI	218	80	32	12	10	4	12	4	272
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	7	7	38	65	87	41	24		269
		3	3	14	24	32	15	9		
30) Overall quality of life	QL	8	9	41	51	86	48	26		269
		3	3	15	19	32	18	10		

## Colorectal cancer: recurrent/metastatic

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	17	3
v 2.0	534	82
v 3.0	102	16
Total	653	

#### Age

	N	(%)
<40	29	4
40-49	81	12
50-59	172	26
60-69	245	38
70-79	122	19
80+	4	1
Not known	0	0
Total	653	

#### Gender

	N	(%)
Male	352	54
Female	238	36
Not known	63	10
Total	653	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	60.7	(22.9)	66.7	[50-75]
Physical functioning	PF	73.3	(23.3)	80	[53.3-93.3]
Role Functioning	RF	64.8	(33.4)	66.7	[33.3-100]
Emotional functioning	EF	70.7	(23.7)	75	[58.3-91.7]
Cognitive functioning	CF	83.4	(20.9)	83.3	[66.7-100]
Social functioning	SF	74.3	(28.6)	83.3	[50-100]
Fatigue	FA	38.9	(28)	33.3	[22.2-55.6]
Nausea and vomiting	NV	9.8	(19.2)	0	[0-16.7]
Pain	PA	25.2	(28.9)	16.7	[0-33.3]
Dyspnoea	DY	18.6	(27.3)	0	[0-33.3]
Insomnia	SL	30.5	(31.8)	33.3	[0-66.7]
Appetite loss	AP	22.6	(31.6)	0	[0-33.3]
Constipation	CO	16.3	(27.1)	0	[0-33.3]
Diarrhoea	DI	15.4	(25.6)	0	[0-33.3]
Financial difficulties	FI	13.8	(26.4)	0	[0-33.3]

**Colorectal cancer: recurrent/metastatic  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	15	2
8.3	3	1
16.7	21	3
25	12	2
33.3	48	8
41.7	48	8
50	120	19
58.3	40	6
66.7	117	18
75	61	10
83.3	96	15
91.7	22	3
100	40	6
<b>Total</b>	<b>643</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	0	0
13.3	0	0
20	1	1
26.7	4	4
33.3	5	5
40	1	1
46.7	9	9
53.3	8	8
60	7	7
66.7	5	5
73.3	7	7
80	11	11
86.7	10	10
93.3	10	10
100	22	22
<b>Total</b>	<b>100</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	61	10
16.7	27	4
33.3	93	15
50	51	8
66.7	121	19
83.3	70	11
100	210	33
<b>Total</b>	<b>633</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	10	2
8.3	5	1
16.7	11	2
25	16	3
33.3	27	4
41.7	33	5
50	38	6
58.3	44	7
66.7	95	15
75	92	14
83.3	92	14
91.7	83	13
100	92	14
<b>Total</b>	<b>638</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	5	1
16.7	8	1
33.3	18	3
50	48	7
66.7	100	16
83.3	156	24
100	311	48
<b>Total</b>	<b>646</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	22	4
16.7	24	4
33.3	54	9
50	65	10
66.7	109	17
83.3	96	15
100	264	42
<b>Total</b>	<b>634</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	92	15
11.1	52	8
22.2	82	13
33.3	147	23
44.4	67	11
55.6	49	8
66.7	62	10
77.8	27	4
88.9	24	4
100	34	5
<b>Total</b>	<b>636</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	450	70
16.7	107	17
33.3	39	6
50	21	3
66.7	16	3
83.3	9	1
100	4	1
<b>Total</b>	<b>646</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	262	41
16.7	113	18
33.3	127	20
50	42	7
66.7	46	7
83.3	19	3
100	33	5
<b>Total</b>	<b>642</b>	

**Colorectal cancer: recurrent/metastatic  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	27	27	28	28	22	22	25	25	102
2) Long walk	PF	38	38	16	16	20	20	27	27	101
3) Short walk	PF	68	67	21	21	10	10	3	3	102
4) Bed or chair	PF	54	53	28	28	17	17	3	3	102
5) Self care	PF	96	95	5	5	0	0	0	0	101
6) Limited in work	RF	234	37	204	32	123	19	80	13	641
7) Limited in leisure	RF	268	42	168	26	113	18	88	14	637
8) Dyspnoea	DY	399	62	159	25	65	10	24	4	647
9) Pain	PA	277	43	244	38	77	12	49	8	647
10) Need to rest	FA	148	23	271	42	153	24	73	11	645
11) Insomnia	SL	274	42	207	32	117	18	51	8	649
12) Felt weak	FA	198	30	261	40	131	20	61	9	651
13) Appetite loss	AP	382	59	140	22	79	12	47	7	648
14) Nausea	NV	464	71	118	18	45	7	24	4	651
15) Vomiting	NV	576	89	46	7	18	3	8	1	648
16) Constipation	CO	436	68	132	20	51	8	27	4	646
17) Diarrhoea	DI	438	68	138	21	50	8	20	3	646
18) Felt tired	FA	148	23	295	46	135	21	67	10	645
19) Pain interference	PA	374	58	157	24	70	11	46	7	647
20) Concentration	CF	435	67	139	21	58	9	18	3	650
21) Tension	EF	233	36	285	44	92	14	37	6	647
22) Worry	EF	153	24	305	47	126	19	66	10	650
23) Irritability	EF	331	51	233	36	62	10	19	3	645
24) Depression	EF	284	44	232	36	93	14	39	6	648
25) Memory trouble	CF	391	60	191	30	52	8	14	2	648
26) Family life	SF	356	56	174	27	84	13	27	4	641
27) Social activities	SF	309	48	165	26	91	14	76	12	641
28) Financial difficulties	FI	458	74	98	16	39	6	27	4	622
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	17	25	83	167	184	117	52		645
		3	4	13	26	29	18	8		
30) Overall quality of life	QL	21	30	80	150	157	137	68		643
		3	5	12	23	24	21	11		

## Genito-urinary cancer

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	18	7
v +3	1	0
v 2.0	178	72
v 3.0	49	20
Total	246	

#### Primary disease site

	N	(%)
Bladder	13	5
Genito-urinary (other)	45	18
Kidney	188	76
Total	246	

#### Age

	N	(%)
<40	19	8
40-49	37	15
50-59	75	31
60-69	63	26
70-79	44	18
80+	8	3
Not known	0	0
Total	246	

#### Gender

	N	(%)
Male	175	71
Female	68	28
Not known	3	1
Total	246	

#### Stage

	N	(%)
Stage I-II	21	9
Stage III-IV	159	65
Recurrent/metastatic	51	21
Not known	15	6
Total	246	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	62.6	(22.2)	66.7	[50-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	56.8	(33.5)	66.7	[33.3-83.3]
Emotional functioning	EF	74.7	(22.9)	83.3	[66.7-91.7]
Cognitive functioning	CF	86.6	(18.2)	100	[83.3-100]
Social functioning	SF	71.7	(28.2)	83.3	[50-100]
Fatigue	FA	35.7	(28.6)	33.3	[11.1-55.6]
Nausea and vomiting	NV	6.0	(13.5)	0	[0-0]
Pain	PA	27.0	(29.7)	16.7	[0-50]
Dyspnoea	DY	16.5	(25)	0	[0-33.3]
Insomnia	SL	26.3	(29.2)	33.3	[0-33.3]
Appetite loss	AP	16.5	(27.6)	0	[0-33.3]
Constipation	CO	18.9	(30)	0	[0-33.3]
Diarrhoea	DI	8.3	(19.8)	0	[0-0]
Financial difficulties	FI	15.1	(26.1)	0	[0-33.3]

**Genito-urinary cancer  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	2	1
8.3	2	1
16.7	4	2
25	3	1
33.3	21	9
41.7	16	7
50	39	17
58.3	25	11
66.7	28	12
75	23	10
83.3	34	15
91.7	9	4
100	19	8
Total	225	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	0	0
16.7	2	1
33.3	7	3
50	9	4
66.7	37	15
83.3	57	24
100	131	54
Total	243	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	8	3
16.7	3	1
33.3	34	14
50	27	11
66.7	45	19
83.3	34	14
100	87	37
Total	238	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	44	18
11.1	26	11
22.2	33	14
33.3	46	19
44.4	25	10
55.6	22	9
66.7	17	7
77.8	8	3
88.9	4	2
100	16	7
Total	241	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	25	11
16.7	19	9
33.3	38	17
50	21	10
66.7	44	20
83.3	25	11
100	49	22
Total	221	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	190	78
16.7	34	14
33.3	10	4
50	6	3
66.7	4	2
83.3	0	0
100	0	0
Total	244	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	3	1
8.3	1	0
16.7	4	2
25	6	3
33.3	6	3
41.7	8	3
50	9	4
58.3	21	9
66.7	34	14
75	26	11
83.3	37	15
91.7	37	15
100	48	20
Total	240	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	94	39
16.7	38	16
33.3	46	19
50	25	10
66.7	14	6
83.3	10	4
100	13	5
Total	240	



**Genito-urinary cancer  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	<i>Previous version of this scale used</i>									
2) Long walk	PF	<i>Previous version of this scale used</i>									
3) Short walk	PF	<i>Previous version of this scale used</i>									
4) Bed or chair	PF	<i>Previous version of this scale used</i>									
5) Self care	PF	<i>Previous version of this scale used</i>									
6) Limited in work	RF	61	27	69	31	60	27	33	15	223	
7) Limited in leisure	RF	69	31	62	28	53	24	41	18	225	
8) Dyspnoea	DY	155	63	66	27	17	7	7	3	245	
9) Pain	PA	102	42	88	36	33	14	22	9	245	
10) Need to rest	FA	66	27	101	41	53	22	25	10	245	
11) Insomnia	SL	113	46	83	34	37	15	12	5	245	
12) Felt weak	FA	93	38	89	36	39	16	24	10	245	
13) Appetite loss	AP	165	68	48	20	20	8	11	5	244	
14) Nausea	NV	193	79	41	17	10	4	2	1	246	
15) Vomiting	NV	227	93	12	5	5	2	0	0	244	
16) Constipation	CO	160	65	46	19	24	10	15	6	245	
17) Diarrhoea	DI	200	82	30	12	11	5	3	1	244	
18) Felt tired	FA	71	29	104	43	44	18	24	10	243	
19) Pain interference	PA	129	54	65	27	27	11	20	8	241	
20) Concentration	CF	176	72	44	18	18	7	6	2	244	
21) Tension	EF	106	43	95	39	32	13	11	5	244	
22) Worry	EF	79	32	112	46	37	15	17	7	245	
23) Irritability	EF	140	58	75	31	23	10	5	2	243	
24) Depression	EF	119	49	88	36	21	9	15	6	243	
25) Memory trouble	CF	165	68	61	25	17	7	1	0	244	
26) Family life	SF	124	51	66	27	41	17	11	5	242	
27) Social activities	SF	103	43	60	25	62	26	16	7	241	
28) Financial difficulties	FI	169	70	42	17	23	10	7	3	241	
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>	
		<b>(very poor)</b>							<b>(excellent)</b>		
29) Overall health	QL	5	4	31	62	55	48	22		227	
		2	2	14	27	24	21	10			
30) Overall quality of life	QL	5	7	33	53	50	57	37		242	
		2	3	14	22	21	24	15			

## Gynaecological cancer (cervical)

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	27	24
v +3	0	0
v 2.0	72	63
v 3.0	15	13
Total	114	

#### Age

	N	(%)
<40	31	27
40-49	26	23
50-59	23	20
60-69	20	18
70-79	10	9
80+	3	3
Not known	1	1
Total	114	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	<i>Previous version of this scale used</i>			
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	<i>Previous version of this scale used</i>			
Emotional functioning	EF	64.2	(26)	66.7	[50-83.3]
Cognitive functioning	CF	86.0	(20.5)	100	[66.7-100]
Social functioning	SF	77.1	(25.6)	83.3	[66.7-100]
Fatigue	FA	33.8	(33.4)	22.2	[0-55.6]
Nausea and vomiting	NV	8.7	(22.8)	0	[0-0]
Pain	PA	29.4	(37.1)	16.7	[0-66.7]
Dyspnoea	DY	16.2	(25.2)	0	[0-33.3]
Insomnia	SL	36.6	(35.6)	33.3	[0-66.7]
Appetite loss	AP	15.9	(30.2)	0	[0-33.3]
Constipation	CO	20.2	(33.6)	0	[0-33.3]
Diarrhoea	DI	7.1	(18.6)	0	[0-0]
Financial difficulties	FI	9.9	(20.9)	0	[0-0]

**Gynaecological cancer (cervical)  
Constructed scales**

**QL**

Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	0	0
16.7	3	3
33.3	1	1
50	7	6
66.7	20	18
83.3	15	13
100	67	59
Total	113	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	1	1
16.7	1	1
33.3	13	12
50	12	11
66.7	21	19
83.3	13	12
100	51	46
Total	112	

**PF**

Previous version of this scale used

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	31	27
11.1	19	17
22.2	7	6
33.3	17	15
44.4	7	6
55.6	6	5
66.7	5	4
77.8	4	4
88.9	9	8
100	8	7
Total	113	

**RF**

Previous version of this scale used

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	93	82
16.7	6	5
33.3	5	4
50	1	1
66.7	3	3
83.3	2	2
100	3	3
Total	113	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	1	1
8.3	4	4
16.7	4	4
25	2	2
33.3	8	7
41.7	7	6
50	11	10
58.3	12	11
66.7	16	14
75	10	9
83.3	11	10
91.7	12	11
100	14	13
Total	112	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	56	50
16.7	13	12
33.3	11	10
50	4	4
66.7	5	4
83.3	12	11
100	12	11
Total	113	

**Gynaecological cancer (cervical)  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	<i>Previous version of this scale used</i>									
2) Long walk	PF	<i>Previous version of this scale used</i>									
3) Short walk	PF	<i>Previous version of this scale used</i>									
4) Bed or chair	PF	<i>Previous version of this scale used</i>									
5) Self care	PF	<i>Previous version of this scale used</i>									
6) Limited in work	RF	<i>Previous version of this scale used</i>									
7) Limited in leisure	RF	<i>Previous version of this scale used</i>									
8) Dyspnoea	DY	73	65	28	25	9	8	3	3	113	
9) Pain	PA	59	52	18	16	14	12	22	20	113	
10) Need to rest	FA	49	43	34	30	11	10	19	17	113	
11) Insomnia	SL	43	38	32	28	22	20	16	14	113	
12) Felt weak	FA	53	47	29	26	12	11	19	17	113	
13) Appetite loss	AP	82	73	17	15	5	4	9	8	113	
14) Nausea	NV	95	84	6	5	6	5	6	5	113	
15) Vomiting	NV	101	89	5	4	3	3	4	4	113	
16) Constipation	CO	75	67	18	16	7	6	12	11	112	
17) Diarrhoea	DI	96	85	11	10	5	4	1	1	113	
18) Felt tired	FA	45	40	34	30	15	13	19	17	113	
19) Pain interference	PA	71	63	13	12	13	12	16	14	113	
20) Concentration	CF	76	67	22	19	10	9	5	4	113	
21) Tension	EF	40	35	43	38	23	20	7	6	113	
22) Worry	EF	27	24	40	35	13	12	33	29	113	
23) Irritability	EF	56	50	32	29	15	13	9	8	112	
24) Depression	EF	39	35	42	37	18	16	14	12	113	
25) Memory trouble	CF	83	74	24	21	4	4	2	2	113	
26) Family life	SF	61	55	25	22	19	17	7	6	112	
27) Social activities	SF	68	61	23	21	16	14	5	5	112	
28) Financial difficulties	FI	88	79	13	12	10	9	0	0	111	
				1	2	3	4	5	6	7	Total
				<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	<i>Previous version of this scale used</i>									
30) Overall quality of life	QL	4	6	11	29	21	16	25		112	
		4	5	10	26	19	14	22			

## Gynaecological cancer (ovarian): all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	10	1
v +3	64	7
v 2.0	109	12
v 3.0	734	80
Total	917	

#### Age

	N	(%)
<40	44	5
40-49	136	15
50-59	255	28
60-69	317	35
70-79	156	17
80+	8	1
Not known	1	0
Total	917	

#### Stage

	N	(%)
Stage I-II	214	23
Stage III-IV	662	72
Recurrent/metastatic	18	2
Not known	23	3
Total	917	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	60.0	(25.2)	62.5	[50-83.3]
Physical functioning	PF	77.5	(21.8)	80	[66.7-93.3]
Role Functioning	RF	66.0	(33.5)	66.7	[33.3-100]
Emotional functioning	EF	67.9	(25.3)	75	[50-91.7]
Cognitive functioning	CF	81.6	(22.4)	83.3	[66.7-100]
Social functioning	SF	72.1	(31.2)	83.3	[50-100]
Fatigue	FA	37.6	(28.8)	33.3	[11.1-55.6]
Nausea and vomiting	NV	11.2	(21.5)	0	[0-16.7]
Pain	PA	26.7	(28.7)	16.7	[0-50]
Dyspnoea	DY	19.4	(27.6)	0	[0-33.3]
Insomnia	SL	34.5	(33.7)	33.3	[0-66.7]
Appetite loss	AP	25.7	(34.2)	0	[0-33.3]
Constipation	CO	22.0	(30.6)	0	[0-33.3]
Diarrhoea	DI	10.8	(22.6)	0	[0-0]
Financial difficulties	FI	13.2	(26.1)	0	[0-33.3]

**Gynaecological cancer (ovarian): all stages**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	19	2
8.3	14	2
16.7	45	5
25	36	4
33.3	64	7
41.7	42	5
50	158	18
58.3	68	8
66.7	138	16
75	70	8
83.3	119	13
91.7	36	4
100	83	9
<b>Total</b>	<b>892</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	6	1
13.3	2	0
20	5	1
26.7	16	2
33.3	14	2
40	26	4
46.7	25	4
53.3	38	5
60	30	4
66.7	58	8
73.3	67	9
80	76	11
86.7	84	12
93.3	108	15
100	165	23
<b>Total</b>	<b>720</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	84	9
16.7	46	5
33.3	104	12
50	73	8
66.7	174	20
83.3	100	11
100	310	35
<b>Total</b>	<b>891</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	15	2
8.3	11	1
16.7	22	2
25	25	3
33.3	50	6
41.7	66	7
50	66	7
58.3	71	8
66.7	106	12
75	120	13
83.3	110	12
91.7	105	12
100	134	15
<b>Total</b>	<b>901</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	11	1
16.7	16	2
33.3	37	4
50	52	6
66.7	159	18
83.3	223	25
100	402	45
<b>Total</b>	<b>900</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	57	6
16.7	30	3
33.3	91	10
50	75	8
66.7	147	16
83.3	122	14
100	373	42
<b>Total</b>	<b>895</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	149	17
11.1	92	10
22.2	127	14
33.3	168	19
44.4	78	9
55.6	73	8
66.7	83	9
77.8	53	6
88.9	34	4
100	42	5
<b>Total</b>	<b>899</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	624	68
16.7	134	15
33.3	78	9
50	30	3
66.7	20	2
83.3	7	1
100	20	2
<b>Total</b>	<b>913</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	335	37
16.7	176	20
33.3	161	18
50	73	8
66.7	81	9
83.3	41	5
100	33	4
<b>Total</b>	<b>900</b>	

**Gynaecological cancer (ovarian): all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	233	32	218	30	159	22	121	17	731
2) Long walk	PF	274	38	197	27	153	21	106	15	730
3) Short walk	PF	528	72	130	18	57	8	17	2	732
4) Bed or chair	PF	461	63	170	23	78	11	22	3	731
5) Self care	PF	675	93	41	6	10	1	4	1	730
6) Limited in work	RF	349	39	257	29	173	19	120	13	899
7) Limited in leisure	RF	408	46	223	25	144	16	121	14	896
8) Dyspnoea	DY	549	60	231	25	97	11	35	4	912
9) Pain	PA	376	41	323	35	156	17	58	6	913
10) Need to rest	FA	250	27	347	38	210	23	106	12	913
11) Insomnia	SL	356	39	270	29	195	21	96	11	917
12) Felt weak	FA	339	37	305	33	184	20	86	9	914
13) Appetite loss	AP	516	56	187	20	119	13	94	10	916
14) Nausea	NV	637	70	174	19	70	8	33	4	914
15) Vomiting	NV	789	86	75	8	29	3	23	3	916
16) Constipation	CO	522	58	225	25	92	10	62	7	901
17) Diarrhoea	DI	701	78	135	15	49	5	20	2	905
18) Felt tired	FA	233	26	375	41	198	22	99	11	905
19) Pain interference	PA	510	56	206	23	120	13	68	8	904
20) Concentration	CF	545	60	229	25	99	11	37	4	910
21) Tension	EF	301	33	358	39	176	19	74	8	909
22) Worry	EF	220	24	335	37	215	24	140	15	910
23) Irritability	EF	497	55	273	30	104	11	35	4	909
24) Depression	EF	403	45	280	31	155	17	68	8	906
25) Memory trouble	CF	554	62	262	29	58	6	27	3	901
26) Family life	SF	487	54	215	24	118	13	84	9	904
27) Social activities	SF	438	49	214	24	145	16	100	11	897
28) Financial difficulties	FI	672	75	131	15	57	6	37	4	897
<hr/>										
		1	2	3	4	5	6	7	Total	
		(very poor)						(excellent)		
29) Overall health	QL	29	68	110	215	210	157	104	893	
		3	8	12	24	24	18	12		
30) Overall quality of life	QL	32	79	104	181	194	194	119	903	
		4	9	12	20	22	22	13		

## Gynaecological cancer (ovarian): stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	9	4
v +3	3	1
v 2.0	23	11
v 3.0	179	84
Total	214	

#### Age

	N	(%)
<40	25	12
40-49	37	17
50-59	64	30
60-69	57	27
70-79	29	14
80+	1	1
Not known	1	1
Total	214	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	72.6	(22.7)	75	[58.3-91.7]
Physical functioning	PF	86.4	(17.5)	93.3	[80-100]
Role Functioning	RF	84.1	(25.3)	100	[66.7-100]
Emotional functioning	EF	71.5	(26.1)	75	[58.3-91.7]
Cognitive functioning	CF	83.8	(23.5)	100	[83.3-100]
Social functioning	SF	84.2	(25.2)	100	[83.3-100]
Fatigue	FA	24.4	(25.4)	22.2	[0-33.3]
Nausea and vomiting	NV	7.2	(17.7)	0	[0-0]
Pain	PA	17.6	(24.2)	0	[0-33.3]
Dyspnoea	DY	10.7	(20.5)	0	[0-33.3]
Insomnia	SL	34.7	(35)	33.3	[0-66.7]
Appetite loss	AP	10.0	(22.2)	0	[0-0]
Constipation	CO	18.5	(27.5)	0	[0-33.3]
Diarrhoea	DI	6.6	(19)	0	[0-0]
Financial difficulties	FI	11.7	(25.4)	0	[0-0]



**Gynaecological cancer (ovarian): stage I-II  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	2	1
8.3	3	2
16.7	3	2
25	2	1
33.3	8	4
41.7	1	1
50	25	12
58.3	8	4
66.7	32	16
75	22	11
83.3	44	22
91.7	16	8
100	36	18
<b>Total</b>	<b>202</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	1	1
13.3	0	0
20	1	1
26.7	2	1
33.3	0	0
40	3	2
46.7	1	1
53.3	4	2
60	4	2
66.7	10	6
73.3	11	6
80	20	11
86.7	18	10
93.3	33	19
100	68	39
<b>Total</b>	<b>176</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	7	3
16.7	4	2
33.3	7	3
50	3	2
66.7	34	17
83.3	28	14
100	122	60
<b>Total</b>	<b>205</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	7	3
8.3	1	1
16.7	7	3
25	4	2
33.3	6	3
41.7	9	4
50	8	4
58.3	12	6
66.7	28	14
75	32	16
83.3	24	12
91.7	31	15
100	38	18
<b>Total</b>	<b>207</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	4	2
16.7	6	3
33.3	6	3
50	8	4
66.7	24	11
83.3	54	26
100	108	51
<b>Total</b>	<b>210</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	6	3
16.7	5	2
33.3	7	3
50	9	4
66.7	25	12
83.3	33	16
100	125	60
<b>Total</b>	<b>210</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	63	30
11.1	32	16
22.2	35	17
33.3	33	16
44.4	13	6
55.6	13	6
66.7	5	2
77.8	4	2
88.9	2	1
100	7	3
<b>Total</b>	<b>207</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	169	79
16.7	21	10
33.3	15	7
50	2	1
66.7	3	1
83.3	1	1
100	3	1
<b>Total</b>	<b>214</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	110	52
16.7	38	18
33.3	31	15
50	13	6
66.7	12	6
83.3	1	1
100	5	2
<b>Total</b>	<b>210</b>	

**Gynaecological cancer (ovarian): stage I-II**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	77	43	60	34	19	11	23	13	179
2) Long walk	PF	101	57	42	24	23	13	12	7	178
3) Short walk	PF	153	86	18	10	6	3	2	1	179
4) Bed or chair	PF	153	86	17	10	6	3	3	2	179
5) Self care	PF	173	98	2	1	2	1	0	0	177
6) Limited in work	RF	131	64	49	24	17	8	8	4	205
7) Limited in leisure	RF	147	72	40	20	6	3	12	6	205
8) Dyspnoea	DY	160	75	41	19	11	5	2	1	214
9) Pain	PA	121	57	57	27	29	14	7	3	214
10) Need to rest	FA	98	46	77	36	26	12	12	6	213
11) Insomnia	SL	89	42	51	24	50	23	24	11	214
12) Felt weak	FA	123	58	61	29	19	9	9	4	212
13) Appetite loss	AP	170	79	29	14	10	5	5	2	214
14) Nausea	NV	171	80	26	12	13	6	4	2	214
15) Vomiting	NV	196	92	11	5	4	2	3	1	214
16) Constipation	CO	130	62	50	24	21	10	8	4	209
17) Diarrhoea	DI	180	87	19	9	5	2	4	2	208
18) Felt tired	FA	81	39	94	45	21	10	13	6	209
19) Pain interference	PA	149	71	42	20	11	5	8	4	210
20) Concentration	CF	149	71	40	19	16	8	6	3	211
21) Tension	EF	86	41	83	39	27	13	15	7	211
22) Worry	EF	65	31	85	40	33	16	28	13	211
23) Irritability	EF	103	49	71	34	24	11	12	6	210
24) Depression	EF	112	54	58	28	22	11	16	8	208
25) Memory trouble	CF	126	60	66	31	6	3	12	6	210
26) Family life	SF	145	69	44	21	8	4	13	6	210
27) Social activities	SF	145	69	41	19	14	7	11	5	211
28) Financial difficulties	FI	164	78	30	14	7	3	10	5	211
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			(very poor)					(excellent)		
29) Overall health	QL	3	7	10	32	49	56	45		202
		2	4	5	16	24	28	22		
30) Overall quality of life	QL	4	6	11	27	43	68	52		211
		2	3	5	13	20	32	25		

## Gynaecological cancer (ovarian): stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	61	9
v 2.0	79	12
v 3.0	522	79
Total	662	

#### Age

	N	(%)
<40	19	3
40-49	92	14
50-59	181	27
60-69	249	38
70-79	114	17
80+	7	1
Not known	0	0
Total	662	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	56.3	(24.5)	58.3	[41.7-75]
Physical functioning	PF	74.9	(21.9)	80	[60-93.3]
Role Functioning	RF	60.8	(33.6)	66.7	[33.3-100]
Emotional functioning	EF	66.7	(25.1)	66.7	[50-83.3]
Cognitive functioning	CF	81.3	(21.7)	83.3	[66.7-100]
Social functioning	SF	68.3	(32.2)	66.7	[50-100]
Fatigue	FA	41.2	(28.1)	33.3	[22.2-66.7]
Nausea and vomiting	NV	12.2	(21.8)	0	[0-16.7]
Pain	PA	29.0	(29)	16.7	[0-50]
Dyspnoea	DY	21.9	(28.8)	0	[0-33.3]
Insomnia	SL	34.6	(33.2)	33.3	[0-66.7]
Appetite loss	AP	30.8	(35.5)	33.3	[0-66.7]
Constipation	CO	22.6	(31.1)	0	[0-33.3]
Diarrhoea	DI	12.0	(23.4)	0	[0-33.3]
Financial difficulties	FI	13.5	(26.3)	0	[0-33.3]

**Gynaecological cancer (ovarian): stage III-IV  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	15	2
8.3	11	2
16.7	36	6
25	34	5
33.3	52	8
41.7	41	6
50	129	20
58.3	56	9
66.7	98	15
75	43	7
83.3	72	11
91.7	19	3
100	44	7
<b>Total</b>	<b>650</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	5	1
13.3	1	0
20	4	1
26.7	10	2
33.3	14	3
40	20	4
46.7	24	5
53.3	32	6
60	26	5
66.7	43	8
73.3	54	11
80	55	11
86.7	63	12
93.3	70	14
100	90	18
<b>Total</b>	<b>511</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	72	11
16.7	40	6
33.3	86	13
50	68	11
66.7	134	21
83.3	70	11
100	176	27
<b>Total</b>	<b>646</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	8	1
8.3	10	2
16.7	14	2
25	20	3
33.3	42	6
41.7	55	8
50	51	8
58.3	56	9
66.7	74	11
75	84	13
83.3	80	12
91.7	67	10
100	92	14
<b>Total</b>	<b>653</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	5	1
16.7	9	1
33.3	30	5
50	42	7
66.7	123	19
83.3	161	25
100	280	43
<b>Total</b>	<b>650</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	50	8
16.7	24	4
33.3	77	12
50	61	10
66.7	116	18
83.3	83	13
100	233	36
<b>Total</b>	<b>644</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	80	12
11.1	58	9
22.2	86	13
33.3	128	20
44.4	62	10
55.6	60	9
66.7	75	12
77.8	46	7
88.9	26	4
100	30	5
<b>Total</b>	<b>651</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	428	65
16.7	108	16
33.3	60	9
50	27	4
66.7	16	2
83.3	5	1
100	14	2
<b>Total</b>	<b>658</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	213	33
16.7	131	20
33.3	125	19
50	56	9
66.7	64	10
83.3	35	5
100	25	4
<b>Total</b>	<b>649</b>	

**Gynaecological cancer (ovarian): stage III-IV**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	147	28	149	29	133	26	90	17	519
2) Long walk	PF	160	31	149	29	122	24	88	17	519
3) Short walk	PF	355	68	107	21	46	9	12	2	520
4) Bed or chair	PF	290	56	146	28	65	13	18	4	519
5) Self care	PF	476	92	34	7	7	1	3	1	520
6) Limited in work	RF	206	32	199	30	146	22	103	16	654
7) Limited in leisure	RF	247	38	173	27	128	20	103	16	651
8) Dyspnoea	DY	366	56	182	28	78	12	31	5	657
9) Pain	PA	242	37	255	39	117	18	44	7	658
10) Need to rest	FA	141	21	259	39	177	27	82	12	659
11) Insomnia	SL	249	38	205	31	142	22	66	10	662
12) Felt weak	FA	206	31	230	35	159	24	66	10	661
13) Appetite loss	AP	321	49	151	23	108	16	81	12	661
14) Nausea	NV	438	67	142	22	54	8	25	4	659
15) Vomiting	NV	561	85	60	9	23	4	17	3	661
16) Constipation	CO	374	58	161	25	68	10	48	7	651
17) Diarrhoea	DI	490	75	110	17	41	6	15	2	656
18) Felt tired	FA	144	22	265	41	169	26	77	12	655
19) Pain interference	PA	339	52	161	25	98	15	55	8	653
20) Concentration	CF	375	57	176	27	79	12	28	4	658
21) Tension	EF	199	30	262	40	139	21	57	9	657
22) Worry	EF	142	22	236	36	171	26	109	17	658
23) Irritability	EF	374	57	187	28	75	11	22	3	658
24) Depression	EF	276	42	206	31	128	20	47	7	657
25) Memory trouble	CF	407	63	186	29	46	7	12	2	651
26) Family life	SF	323	50	161	25	103	16	66	10	653
27) Social activities	SF	273	42	161	25	125	19	86	13	645
28) Financial difficulties	FI	480	74	94	15	45	7	26	4	645
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
29) Overall health	QL	23	55	96	174	151	97	55		651
		4	8	15	27	23	15	8		
30) Overall quality of life	QL	26	67	90	150	140	114	64		651
		4	10	14	23	22	18	10		

## Head and neck cancer: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	23	1
v +3	688	24
v 2.0	489	17
v 3.0	1,729	59
Total	2,929	

#### Age

	N	(%)
<40	110	4
40-49	480	16
50-59	919	31
60-69	832	28
70-79	489	17
80+	97	3
Not known	2	0
Total	2,929	

#### Gender

	N	(%)
Male	2,318	79
Female	589	20
Not known	22	1
Total	2,929	

#### Stage

	N	(%)
Stage I-II	946	32
Stage III-IV	1,722	59
Recurrent/metastatic	37	1
Not known	224	8
Total	2,929	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	64.1	(22.7)	66.7	[50-83.3]
Physical functioning	PF	81.2	(20.4)	86.7	[66.7-100]
Role Functioning	RF	78.9	(28.1)	100	[66.7-100]
Emotional functioning	EF	72.5	(24.1)	75	[58.3-91.7]
Cognitive functioning	CF	85.9	(19.7)	100	[83.3-100]
Social functioning	SF	82.6	(24.7)	100	[66.7-100]
Fatigue	FA	26.9	(24.9)	22.2	[0-44.4]
Nausea and vomiting	NV	5.3	(13.7)	0	[0-0]
Pain	PA	23.2	(26.1)	16.7	[0-33.3]
Dyspnoea	DY	18.2	(26.9)	0	[0-33.3]
Insomnia	SL	27.3	(31.8)	33.3	[0-33.3]
Appetite loss	AP	17.7	(28.2)	0	[0-33.3]
Constipation	CO	11.1	(22.6)	0	[0-0]
Diarrhoea	DI	6.1	(16.9)	0	[0-0]
Financial difficulties	FI	18.2	(29.6)	0	[0-33.3]

#### Primary disease site

	N	(%)
Head and neck: oral cavity	189	6
Head and neck: oropharynx	80	3
Head and neck: hypopharynx	74	3
Head and neck: larynx	362	12
Head and neck: oral cavity/larynx	1	0
Head and neck: oral cavity/oropharynx	2	0
Ophthalmic	2	0
Thyroid	5	0
Maxilla	1	0
Head and neck: not known	2,213	76
Total	2,929	

**Head and neck cancer: all stages  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	31	1
8.3	10	0
16.7	89	3
25	53	2
33.3	202	7
41.7	166	6
50	433	15
58.3	241	8
66.7	529	19
75	239	8
83.3	454	16
91.7	118	4
100	291	10
<b>Total</b>	<b>2,856</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	5	0
6.7	6	0
13.3	4	0
20	17	1
26.7	18	1
33.3	21	1
40	29	2
46.7	44	3
53.3	73	4
60	89	5
66.7	124	7
73.3	124	7
80	180	11
86.7	208	12
93.3	254	15
100	505	30
<b>Total</b>	<b>1,701</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	111	4
16.7	68	2
33.3	203	7
50	178	6
66.7	467	16
83.3	350	12
100	1,500	52
<b>Total</b>	<b>2,877</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	26	1
8.3	43	2
16.7	58	2
25	52	2
33.3	98	3
41.7	143	5
50	180	6
58.3	232	8
66.7	368	13
75	338	12
83.3	403	14
91.7	368	13
100	579	20
<b>Total</b>	<b>2,888</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	17	1
16.7	22	1
33.3	66	2
50	193	7
66.7	375	13
83.3	643	22
100	1,579	55
<b>Total</b>	<b>2,895</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	57	2
16.7	55	2
33.3	139	5
50	187	7
66.7	449	16
83.3	402	14
100	1,610	56
<b>Total</b>	<b>2,899</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	779	27
11.1	381	13
22.2	451	16
33.3	520	18
44.4	249	9
55.6	193	7
66.7	150	5
77.8	52	2
88.9	54	2
100	53	2
<b>Total</b>	<b>2,882</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	2,394	82
16.7	284	10
33.3	147	5
50	52	2
66.7	25	1
83.3	9	0
100	8	0
<b>Total</b>	<b>2,919</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	1,144	40
16.7	660	23
33.3	487	17
50	259	9
66.7	182	6
83.3	99	3
100	66	2
<b>Total</b>	<b>2,897</b>	

**Head and neck cancer: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	685	40	466	27	370	22	200	12	1,721	
2) Long walk	PF	804	47	427	25	313	18	178	10	1,722	
3) Short walk	PF	1,365	80	242	14	72	4	37	2	1,716	
4) Bed or chair	PF	1,160	67	374	22	142	8	45	3	1,721	
5) Self care	PF	1,611	93	65	4	29	2	19	1	1,724	
6) Limited in work	RF	1,657	57	679	24	372	13	183	6	2,891	
7) Limited in leisure	RF	1,823	63	607	21	299	10	158	6	2,887	
8) Dyspnoea	DY	1,808	62	744	26	262	9	109	4	2,923	
9) Pain	PA	1,293	44	981	34	488	17	155	5	2,917	
10) Need to rest	FA	1,120	38	1,154	40	492	17	151	5	2,917	
11) Insomnia	SL	1,438	49	775	27	507	17	200	7	2,920	
12) Felt weak	FA	1,489	51	919	32	381	13	130	5	2,919	
13) Appetite loss	AP	1,927	66	564	19	300	10	128	4	2,919	
14) Nausea	NV	2,453	84	346	12	99	3	27	1	2,925	
15) Vomiting	NV	2,687	92	181	6	41	1	14	1	2,923	
16) Constipation	CO	2,224	76	462	16	169	6	58	2	2,913	
17) Diarrhoea	DI	2,514	86	295	10	82	3	25	1	2,916	
18) Felt tired	FA	1,153	40	1,222	42	408	14	119	4	2,902	
19) Pain interference	PA	1,803	62	691	24	300	10	113	4	2,907	
20) Concentration	CF	2,049	70	603	21	207	7	51	2	2,910	
21) Tension	EF	1,175	40	1,124	39	460	16	153	5	2,912	
22) Worry	EF	916	31	1,151	39	575	20	276	10	2,918	
23) Irritability	EF	1,514	52	958	33	324	11	117	4	2,913	
24) Depression	EF	1,482	51	956	33	358	12	116	4	2,912	
25) Memory trouble	CF	1,928	66	720	25	214	7	47	2	2,909	
26) Family life	SF	1,970	68	605	21	234	8	95	3	2,904	
27) Social activities	SF	1,800	62	673	23	293	10	143	5	2,909	
28) Financial difficulties	FI	1,938	67	522	18	274	9	171	6	2,905	
<hr/>											
		1	2	3	4	5	6	7	Total		
		(very poor)			(excellent)						
29) Overall health	QL	51	136	327	676	744	580	353	2,867		
		2	5	11	24	26	20	12			
<hr/>											
30) Overall quality of life	QL	59	115	322	549	715	689	429	2,878		
		2	4	11	19	25	24	15			



## Head and neck cancer: males

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	20	1
v +3	491	21
v 2.0	396	17
v 3.0	1,411	61
Total	2,318	

#### Age

	N	(%)
<40	71	3
40-49	391	17
50-59	736	32
60-69	682	29
70-79	379	16
80+	57	3
Not known	2	0
Total	2,318	

#### Stage

	N	(%)
Stage I-II	751	32
Stage III-IV	1,401	60
Recurrent/metastatic	20	1
Not known	146	6
Total	2,318	

#### Primary disease site

	N	(%)
Head and neck: oral cavity	119	5
Head and neck: oropharynx	60	3
Head and neck: hypopharynx	63	3
Head and neck: larynx	324	14
Head and neck: oral cavity/larynx	1	0
Head and neck: oral cavity/oropharynx	2	0
Ophthalmic	1	0
Thyroid	3	0
Maxilla	1	0
Head and neck: not known	1,744	75
Total	2,318	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	64.2	(22.6)	66.7	[50-83.3]
Physical functioning	PF	81.7	(19.8)	86.7	[73.3-100]
Role Functioning	RF	79.0	(28)	100	[66.7-100]
Emotional functioning	EF	73.4	(24)	75	[58.3-91.7]
Cognitive functioning	CF	86.0	(19.7)	100	[83.3-100]
Social functioning	SF	82.9	(24)	100	[66.7-100]
Fatigue	FA	26.5	(24.8)	22.2	[0-44.4]
Nausea and vomiting	NV	5.0	(13.1)	0	[0-0]
Pain	PA	22.4	(25.6)	16.7	[0-33.3]
Dyspnoea	DY	18.9	(27.5)	0	[0-33.3]
Insomnia	SL	26.5	(31.2)	33.3	[0-33.3]
Appetite loss	AP	17.1	(27.7)	0	[0-33.3]
Constipation	CO	10.7	(22.1)	0	[0-0]
Diarrhoea	DI	6.0	(16.6)	0	[0-0]
Financial difficulties	FI	18.3	(29.6)	0	[0-33.3]

**Head and neck cancer: males**  
**Constructed scales**

QL	N	(%)
0	22	1
8.3	9	0
16.7	68	3
25	42	2
33.3	156	7
41.7	131	6
50	358	16
58.3	190	8
66.7	404	18
75	186	8
83.3	362	16
91.7	95	4
100	230	10
Total	2,253	

PF	N	(%)
0	2	0
6.7	4	0
13.3	3	0
20	15	1
26.7	13	1
33.3	13	1
40	24	2
46.7	35	3
53.3	54	4
60	79	6
66.7	98	7
73.3	104	8
80	142	10
86.7	168	12
93.3	215	16
100	422	30
Total	1,391	

RF	N	(%)
0	80	4
16.7	56	3
33.3	173	8
50	140	6
66.7	363	16
83.3	264	12
100	1,200	53
Total	2,276	

EF	N	(%)
0	20	1
8.3	36	2
16.7	45	2
25	38	2
33.3	72	3
41.7	100	4
50	138	6
58.3	173	8
66.7	276	12
75	274	12
83.3	330	14
91.7	301	13
100	482	21
Total	2,285	

CF	N	(%)
0	15	1
16.7	16	1
33.3	50	2
50	152	7
66.7	302	13
83.3	501	22
100	1,259	55
Total	2,295	

SF	N	(%)
0	37	2
16.7	42	2
33.3	101	4
50	152	7
66.7	366	16
83.3	328	14
100	1,267	55
Total	2,293	

FA	N	(%)
0	635	28
11.1	308	14
22.2	343	15
33.3	406	18
44.4	200	9
55.6	160	7
66.7	116	5
77.8	37	2
88.9	40	2
100	40	2
Total	2,285	

NV	N	(%)
0	1,913	83
16.7	214	9
33.3	115	5
50	39	2
66.7	15	1
83.3	7	0
100	5	0
Total	2,308	

PA	N	(%)
0	921	40
16.7	541	24
33.3	373	16
50	205	9
66.7	138	6
83.3	70	3
100	48	2
Total	2,296	

**Head and neck cancer: males**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	578	41	369	26	304	22	155	11	1,406
2) Long walk	PF	676	48	330	24	261	19	138	10	1,405
3) Short walk	PF	1,118	80	197	14	59	4	26	2	1,400
4) Bed or chair	PF	968	69	299	21	107	8	30	2	1,404
5) Self care	PF	1,315	93	53	4	24	2	16	1	1,408
6) Limited in work	RF	1,322	58	519	23	304	13	141	6	2,286
7) Limited in leisure	RF	1,445	63	472	21	252	11	115	5	2,284
8) Dyspnoea	DY	1,409	61	587	25	224	10	93	4	2,313
9) Pain	PA	1,043	45	790	34	367	16	111	5	2,311
10) Need to rest	FA	902	39	909	39	386	17	115	5	2,312
11) Insomnia	SL	1,150	50	634	27	381	17	147	6	2,312
12) Felt weak	FA	1,176	51	729	32	308	13	99	4	2,312
13) Appetite loss	AP	1,543	67	446	19	234	10	91	4	2,314
14) Nausea	NV	1,956	85	265	12	77	3	16	1	2,314
15) Vomiting	NV	2,139	93	135	6	27	1	11	1	2,312
16) Constipation	CO	1,776	77	356	16	131	6	41	2	2,304
17) Diarrhoea	DI	1,987	86	239	10	64	3	17	1	2,307
18) Felt tired	FA	944	41	952	41	317	14	84	4	2,297
19) Pain interference	PA	1,440	63	554	24	227	10	81	4	2,302
20) Concentration	CF	1,633	71	477	21	159	7	37	2	2,306
21) Tension	EF	967	42	878	38	344	15	114	5	2,303
22) Worry	EF	766	33	912	40	433	19	197	9	2,308
23) Irritability	EF	1,210	53	747	32	254	11	94	4	2,305
24) Depression	EF	1,211	53	744	32	266	12	85	4	2,306
25) Memory trouble	CF	1,523	66	567	25	175	8	38	2	2,303
26) Family life	SF	1,558	68	493	22	183	8	64	3	2,298
27) Social activities	SF	1,419	62	556	24	221	10	105	5	2,301
28) Financial difficulties	FI	1,526	66	420	18	221	10	133	6	2,300
		1	2	3	4	5	6	7	Total	
		(very poor)						(excellent)		
29) Overall health	QL	37	104	266	542	574	461	279	2,263	
		2	5	12	24	25	20	12		
30) Overall quality of life	QL	44	84	247	466	552	541	339	2,273	
		2	4	11	21	24	24	15		

## Head and neck cancer: females

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	3	1
v +3	197	33
v 2.0	82	14
v 3.0	307	52
Total	589	

#### Age

	N	(%)
<40	38	7
40-49	85	14
50-59	176	30
60-69	143	24
70-79	107	18
80+	40	7
Not known	0	0
Total	589	

#### Stage

	N	(%)
Stage I-II	195	33
Stage III-IV	316	54
Recurrent/metastatic	17	3
Not known	61	10
Total	589	

#### Primary disease site

	N	(%)
Head and neck: oral cavity	70	12
Head and neck: oropharynx	20	3
Head and neck: hypopharynx	11	2
Head and neck: larynx	38	6
Ophthalmic	1	0
Thyroid	2	0
Head and neck: not known	447	76
Total	589	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	63.9	(23.2)	66.7	[50-83.3]
Physical functioning	PF	78.1	(22.6)	86.7	[66.7-100]
Role Functioning	RF	78.6	(28.5)	100	[66.7-100]
Emotional functioning	EF	68.7	(24.3)	66.7	[50-91.7]
Cognitive functioning	CF	85.4	(19.9)	100	[83.3-100]
Social functioning	SF	81.3	(27.3)	100	[66.7-100]
Fatigue	FA	28.6	(25.6)	22.2	[11.1-44.4]
Nausea and vomiting	NV	6.6	(15.8)	0	[0-0]
Pain	PA	26.0	(27.9)	16.7	[0-33.3]
Dyspnoea	DY	15.5	(24.5)	0	[0-33.3]
Insomnia	SL	30.5	(34)	33.3	[0-66.7]
Appetite loss	AP	20.0	(30.5)	0	[0-33.3]
Constipation	CO	12.7	(24.2)	0	[0-33.3]
Diarrhoea	DI	6.3	(18.1)	0	[0-0]
Financial difficulties	FI	17.8	(29.9)	0	[0-33.3]

**Head and neck cancer: females  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	9	2
8.3	1	0
16.7	21	4
25	10	2
33.3	45	8
41.7	34	6
50	70	12
58.3	49	8
66.7	121	21
75	51	9
83.3	88	15
91.7	23	4
100	60	10
<b>Total</b>	<b>582</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	3	1
6.7	2	1
13.3	1	0
20	2	1
26.7	5	2
33.3	8	3
40	5	2
46.7	9	3
53.3	19	6
60	10	3
66.7	25	8
73.3	20	7
80	36	12
86.7	40	13
93.3	36	12
100	78	26
<b>Total</b>	<b>299</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	31	5
16.7	10	2
33.3	30	5
50	36	6
66.7	98	17
83.3	84	15
100	290	50
<b>Total</b>	<b>579</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	6	1
8.3	7	1
16.7	13	2
25	14	2
33.3	26	5
41.7	42	7
50	41	7
58.3	58	10
66.7	89	15
75	61	11
83.3	69	12
91.7	61	11
100	94	16
<b>Total</b>	<b>581</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	2	0
16.7	6	1
33.3	16	3
50	41	7
66.7	71	12
83.3	135	23
100	307	53
<b>Total</b>	<b>578</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	20	3
16.7	12	2
33.3	38	7
50	33	6
66.7	76	13
83.3	71	12
100	334	57
<b>Total</b>	<b>584</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	139	24
11.1	71	12
22.2	103	18
33.3	107	19
44.4	49	9
55.6	32	6
66.7	33	6
77.8	15	3
88.9	13	2
100	13	2
<b>Total</b>	<b>575</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	464	79
16.7	66	11
33.3	32	5
50	12	2
66.7	10	2
83.3	2	0
100	3	1
<b>Total</b>	<b>589</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	216	37
16.7	115	20
33.3	109	19
50	51	9
66.7	42	7
83.3	28	5
100	18	3
<b>Total</b>	<b>579</b>	

**Head and neck cancer: females**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	100	33	95	31	65	21	44	15	304
2) Long walk	PF	121	40	94	31	51	17	40	13	306
3) Short walk	PF	236	77	45	15	13	4	11	4	305
4) Bed or chair	PF	183	60	73	24	35	11	15	5	306
5) Self care	PF	285	93	12	4	5	2	3	1	305
6) Limited in work	RF	325	56	151	26	67	12	40	7	583
7) Limited in leisure	RF	366	63	128	22	44	8	43	7	581
8) Dyspnoea	DY	384	65	150	26	38	7	16	3	588
9) Pain	PA	241	41	184	32	117	20	42	7	584
10) Need to rest	FA	213	37	230	40	105	18	35	6	583
11) Insomnia	SL	278	47	133	23	122	21	53	9	586
12) Felt weak	FA	301	52	183	31	70	12	31	5	585
13) Appetite loss	AP	370	64	112	19	65	11	36	6	583
14) Nausea	NV	478	81	78	13	22	4	11	2	589
15) Vomiting	NV	529	90	44	8	13	2	3	1	589
16) Constipation	CO	433	74	101	17	37	6	16	3	587
17) Diarrhoea	DI	509	87	53	9	17	3	8	1	587
18) Felt tired	FA	202	35	258	44	89	15	34	6	583
19) Pain interference	PA	354	61	126	22	71	12	32	6	583
20) Concentration	CF	397	68	123	21	48	8	14	2	582
21) Tension	EF	195	33	239	41	114	19	39	7	587
22) Worry	EF	145	25	227	39	137	23	79	13	588
23) Irritability	EF	292	50	203	35	68	12	23	4	586
24) Depression	EF	256	44	206	35	91	16	31	5	584
25) Memory trouble	CF	391	67	145	25	39	7	9	2	584
26) Family life	SF	399	68	106	18	48	8	31	5	584
27) Social activities	SF	371	63	108	18	70	12	37	6	586
28) Financial difficulties	FI	396	68	99	17	51	9	37	6	583
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	14	31	59	129	163	114	73		583
		2	5	10	22	28	20	13		
30) Overall quality of life	QL	15	31	71	79	156	143	89		584
		3	5	12	14	27	25	15		

## Head and neck cancer: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	8	1
v +3	113	19
v 2.0	116	20
v 3.0	353	60
Total	590	

#### Age

	N	(%)
<40	110	19
40-49	480	81
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	590	

#### Gender

	N	(%)
Male	462	78
Female	123	21
Not known	5	1
Total	590	

#### Stage

	N	(%)
Stage I-II	122	21
Stage III-IV	391	66
Recurrent/metastatic	4	1
Not known	73	12
Total	590	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	64.5	(20.8)	66.7	[50-83.3]
Physical functioning	PF	86.6	(16.3)	93.3	[80-100]
Role Functioning	RF	79.4	(26.3)	100	[66.7-100]
Emotional functioning	EF	69.6	(22.6)	75	[58.3-83.3]
Cognitive functioning	CF	85.1	(19.4)	100	[83.3-100]
Social functioning	SF	80.7	(23.7)	83.3	[66.7-100]
Fatigue	FA	27.7	(23.6)	22.2	[11.1-38.9]
Nausea and vomiting	NV	5.8	(14.1)	0	[0-0]
Pain	PA	25.7	(25.2)	16.7	[0-33.3]
Dyspnoea	DY	14.2	(23)	0	[0-33.3]
Insomnia	SL	29.6	(30.9)	33.3	[0-33.3]
Appetite loss	AP	17.1	(26.8)	0	[0-33.3]
Constipation	CO	10.0	(21.6)	0	[0-0]
Diarrhoea	DI	6.6	(15.9)	0	[0-0]
Financial difficulties	FI	25.5	(33.2)	0	[0-33.3]

#### Primary disease site

	N	(%)
Head and neck: oral cavity	31	5
Head and neck: oropharynx	17	3
Head and neck: hypopharynx	19	3
Head and neck: larynx	33	6
Head and neck: oral cavity/oropharynx	2	0
Thyroid	1	0
Head and neck: not known	487	83
Total	590	

**Head and neck cancer: <50  
Constructed scales**

QL	N	(%)
0	3	1
8.3	0	0
16.7	12	2
25	8	1
33.3	39	7
41.7	44	8
50	94	16
58.3	47	8
66.7	107	19
75	57	10
83.3	101	17
91.7	21	4
100	46	8
Total	579	

PF	N	(%)
0	0	0
6.7	0	0
13.3	0	0
20	1	0
26.7	3	1
33.3	1	0
40	5	1
46.7	3	1
53.3	7	2
60	21	6
66.7	17	5
73.3	16	5
80	31	9
86.7	56	16
93.3	59	17
100	133	38
Total	353	

RF	N	(%)
0	14	2
16.7	15	3
33.3	38	7
50	28	5
66.7	131	23
83.3	59	10
100	294	51
Total	579	

EF	N	(%)
0	2	0
8.3	6	1
16.7	17	3
25	10	2
33.3	25	4
41.7	31	5
50	38	7
58.3	55	9
66.7	95	16
75	84	14
83.3	89	15
91.7	51	9
100	82	14
Total	585	

CF	N	(%)
0	2	0
16.7	5	1
33.3	12	2
50	46	8
66.7	80	14
83.3	142	24
100	299	51
Total	586	

SF	N	(%)
0	7	1
16.7	6	1
33.3	38	7
50	43	7
66.7	124	21
83.3	80	14
100	290	49
Total	588	

FA	N	(%)
0	139	24
11.1	69	12
22.2	99	17
33.3	134	23
44.4	48	8
55.6	35	6
66.7	40	7
77.8	8	1
88.9	8	1
100	8	1
Total	588	

NV	N	(%)
0	477	81
16.7	55	9
33.3	36	6
50	9	2
66.7	10	2
83.3	2	0
100	0	0
Total	589	

PA	N	(%)
0	185	32
16.7	147	25
33.3	121	21
50	66	11
66.7	34	6
83.3	26	4
100	9	2
Total	588	



**Head and neck cancer: <50  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	172	49	103	29	56	16	22	6	353
2) Long walk	PF	197	56	93	26	47	13	16	5	353
3) Short walk	PF	311	88	31	9	10	3	1	0	353
4) Bed or chair	PF	257	73	70	20	25	7	1	0	353
5) Self care	PF	338	96	12	3	2	1	1	0	353
6) Limited in work	RF	327	56	147	25	77	13	29	5	580
7) Limited in leisure	RF	353	61	153	26	47	8	27	5	580
8) Dyspnoea	DY	394	67	151	26	32	5	12	2	589
9) Pain	PA	204	35	245	42	111	19	28	5	588
10) Need to rest	FA	206	35	259	44	99	17	25	4	589
11) Insomnia	SL	249	42	193	33	106	18	39	7	587
12) Felt weak	FA	268	45	220	37	87	15	15	3	590
13) Appetite loss	AP	383	65	128	22	59	10	19	3	589
14) Nausea	NV	493	84	68	12	24	4	5	1	590
15) Vomiting	NV	530	90	46	8	12	2	1	0	589
16) Constipation	CO	460	78	91	16	25	4	12	2	588
17) Diarrhoea	DI	489	83	83	14	14	2	2	0	588
18) Felt tired	FA	203	35	285	49	85	15	15	3	588
19) Pain interference	PA	343	58	158	27	69	12	20	3	590
20) Concentration	CF	379	65	142	24	57	10	10	2	588
21) Tension	EF	186	32	266	45	101	17	36	6	589
22) Worry	EF	132	22	268	45	137	23	53	9	590
23) Irritability	EF	251	43	243	41	72	12	22	4	588
24) Depression	EF	273	47	230	39	68	12	16	3	587
25) Memory trouble	CF	397	68	149	25	35	6	7	1	588
26) Family life	SF	356	61	169	29	45	8	18	3	588
27) Social activities	SF	329	56	175	30	64	11	22	4	590
28) Financial difficulties	FI	324	55	130	22	82	14	52	9	588
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	5	17	71	144	152	127	63		579
		1	3	12	25	26	22	11		
30) Overall quality of life	QL	6	16	71	123	155	149	66		586
		1	3	12	21	27	25	11		

## Head and neck cancer: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	8	1
v +3	219	24
v 2.0	185	20
v 3.0	507	55
Total	919	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	919	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	919	

#### Gender

	N	(%)
Male	736	80
Female	176	19
Not known	7	1
Total	919	

#### Stage

	N	(%)
Stage I-II	247	27
Stage III-IV	599	65
Recurrent/metastatic	9	1
Not known	64	7
Total	919	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	63.6	(22.9)	66.7	[50-83.3]
Physical functioning	PF	83.3	(19.1)	93.3	[73.3-100]
Role Functioning	RF	79.5	(28.4)	100	[66.7-100]
Emotional functioning	EF	70.5	(25.1)	75	[58.3-91.7]
Cognitive functioning	CF	86.4	(20.3)	100	[83.3-100]
Social functioning	SF	81.7	(25.4)	100	[66.7-100]
Fatigue	FA	25.5	(25.3)	22.2	[0-33.3]
Nausea and vomiting	NV	5.8	(14.7)	0	[0-0]
Pain	PA	23.5	(26.5)	16.7	[0-33.3]
Dyspnoea	DY	17.3	(26.4)	0	[0-33.3]
Insomnia	SL	29.4	(32.5)	33.3	[0-66.7]
Appetite loss	AP	18.9	(28.3)	0	[0-33.3]
Constipation	CO	9.2	(20)	0	[0-0]
Diarrhoea	DI	6.2	(17.3)	0	[0-0]
Financial difficulties	FI	20.4	(31.2)	0	[0-33.3]

#### Primary disease site

	N	(%)
Head and neck: oral cavity	58	6
Head and neck: oropharynx	37	4
Head and neck: hypopharynx	30	3
Head and neck: larynx	83	9
Ophthalmic	1	0
Thyroid	2	0
Head and neck: not known	708	77
Total	919	

**Head and neck cancer: 50-59  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	17	2
8.3	3	0
16.7	27	3
25	13	2
33.3	64	7
41.7	38	4
50	149	17
58.3	81	9
66.7	171	19
75	71	8
83.3	138	15
91.7	41	5
100	83	9
Total	896	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	0	0
13.3	1	0
20	4	1
26.7	7	1
33.3	5	1
40	6	1
46.7	11	2
53.3	20	4
60	26	5
66.7	31	6
73.3	31	6
80	55	11
86.7	53	11
93.3	80	16
100	171	34
Total	501	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	39	4
16.7	20	2
33.3	61	7
50	48	5
66.7	140	16
83.3	109	12
100	486	54
Total	903	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	12	1
8.3	21	2
16.7	24	3
25	14	2
33.3	32	4
41.7	44	5
50	62	7
58.3	80	9
66.7	112	12
75	110	12
83.3	131	14
91.7	105	12
100	162	18
Total	909	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	7	1
16.7	9	1
33.3	19	2
50	63	7
66.7	107	12
83.3	175	19
100	531	58
Total	911	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	18	2
16.7	19	2
33.3	51	6
50	71	8
66.7	129	14
83.3	126	14
100	499	55
Total	913	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	284	31
11.1	108	12
22.2	131	15
33.3	170	19
44.4	67	7
55.6	47	5
66.7	43	5
77.8	19	2
88.9	16	2
100	19	2
Total	904	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	746	82
16.7	85	9
33.3	43	5
50	23	3
66.7	11	1
83.3	3	0
100	3	0
Total	914	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	357	39
16.7	209	23
33.3	152	17
50	75	8
66.7	68	8
83.3	25	3
100	25	3
Total	911	

**Head and neck cancer: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	219	43	129	26	103	20	55	11	506
2) Long walk	PF	263	52	124	25	79	16	39	8	505
3) Short walk	PF	415	82	62	12	22	4	7	1	506
4) Bed or chair	PF	355	71	106	21	29	6	13	3	503
5) Self care	PF	474	94	22	4	8	2	1	0	505
6) Limited in work	RF	539	59	199	22	111	12	59	7	908
7) Limited in leisure	RF	587	65	174	19	94	10	51	6	906
8) Dyspnoea	DY	580	63	234	26	71	8	34	4	919
9) Pain	PA	399	44	312	34	150	16	55	6	916
10) Need to rest	FA	376	41	350	38	137	15	49	5	912
11) Insomnia	SL	422	46	255	28	167	18	74	8	918
12) Felt weak	FA	492	54	288	31	91	10	47	5	918
13) Appetite loss	AP	575	63	197	22	104	11	38	4	914
14) Nausea	NV	760	83	111	12	36	4	9	1	916
15) Vomiting	NV	838	91	55	6	17	2	7	1	917
16) Constipation	CO	717	79	148	16	31	3	14	2	910
17) Diarrhoea	DI	790	86	89	10	29	3	8	1	916
18) Felt tired	FA	395	43	360	40	117	13	40	4	912
19) Pain interference	PA	559	61	229	25	93	10	33	4	914
20) Concentration	CF	641	70	184	20	66	7	22	2	913
21) Tension	EF	325	35	383	42	145	16	64	7	917
22) Worry	EF	246	27	379	41	183	20	108	12	916
23) Irritability	EF	458	50	304	33	107	12	44	5	913
24) Depression	EF	461	50	302	33	104	11	50	6	917
25) Memory trouble	CF	652	71	187	20	58	6	19	2	916
26) Family life	SF	600	66	200	22	85	9	30	3	915
27) Social activities	SF	567	62	195	21	105	12	47	5	914
28) Financial difficulties	FI	577	64	176	19	89	10	67	7	909
<hr/>										
		1		3		5		7		Total
		(very poor)						(excellent)		
29) Overall health	QL	23	45	97	209	235	189	104		902
		3	5	11	23	26	21	12		
30) Overall quality of life	QL	26	32	92	187	231	204	133		905
		3	4	10	21	26	23	15		

## Head and neck cancer: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	3	0
v +3	161	19
v 2.0	138	17
v 3.0	530	64
Total	832	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	832	100
70-79	0	0
80+	0	0
Not known	0	0
Total	832	

#### Gender

	N	(%)
Male	682	82
Female	143	17
Not known	7	1
Total	832	

#### Stage

	N	(%)
Stage I-II	327	39
Stage III-IV	437	53
Recurrent/metastatic	12	1
Not known	56	7
Total	832	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	64.9	(23.6)	66.7	[50-83.3]
Physical functioning	PF	79.5	(21)	86.7	[66.7-100]
Role Functioning	RF	78.9	(28.1)	100	[66.7-100]
Emotional functioning	EF	72.8	(24.4)	75	[58.3-91.7]
Cognitive functioning	CF	86.3	(19.5)	100	[83.3-100]
Social functioning	SF	83.5	(25.1)	100	[66.7-100]
Fatigue	FA	27.2	(25.6)	22.2	[0-44.4]
Nausea and vomiting	NV	4.9	(13.5)	0	[0-0]
Pain	PA	22.8	(26.7)	16.7	[0-33.3]
Dyspnoea	DY	20.1	(28.4)	0	[0-33.3]
Insomnia	SL	24.9	(31.1)	0	[0-33.3]
Appetite loss	AP	17.8	(29.4)	0	[0-33.3]
Constipation	CO	11.8	(23.4)	0	[0-0]
Diarrhoea	DI	6.3	(17.6)	0	[0-0]
Financial difficulties	FI	15.7	(27.7)	0	[0-33.3]

#### Primary disease site

	N	(%)
Head and neck: oral cavity	35	4
Head and neck: oropharynx	10	1
Head and neck: hypopharynx	16	2
Head and neck: larynx	133	16
Head and neck: oral cavity/larynx	1	0
Ophthalmic	1	0
Maxilla	1	0
Head and neck: not known	635	76
Total	832	

**Head and neck cancer: 60-69**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	9	1
8.3	3	0
16.7	26	3
25	14	2
33.3	62	8
41.7	55	7
50	110	14
58.3	59	7
66.7	143	18
75	59	7
83.3	133	16
91.7	38	5
100	100	12
Total	811	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	2	0
6.7	3	1
13.3	2	0
20	7	1
26.7	4	1
33.3	9	2
40	10	2
46.7	12	2
53.3	21	4
60	19	4
66.7	55	11
73.3	44	9
80	58	11
86.7	59	12
93.3	81	16
100	129	25
Total	515	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	34	4
16.7	18	2
33.3	52	6
50	58	7
66.7	122	15
83.3	117	14
100	418	51
Total	819	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	12	2
8.3	11	1
16.7	10	1
25	16	2
33.3	24	3
41.7	46	6
50	57	7
58.3	65	8
66.7	99	12
75	90	11
83.3	91	11
91.7	137	17
100	163	20
Total	821	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	5	1
16.7	6	1
33.3	21	3
50	44	5
66.7	108	13
83.3	186	23
100	453	55
Total	823	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	21	3
16.7	20	2
33.3	30	4
50	36	4
66.7	123	15
83.3	112	14
100	480	58
Total	822	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	226	28
11.1	106	13
22.2	129	16
33.3	135	17
44.4	69	8
55.6	66	8
66.7	41	5
77.8	15	2
88.9	12	2
100	21	3
Total	820	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	690	83
16.7	78	9
33.3	44	5
50	9	1
66.7	3	0
83.3	2	0
100	5	1
Total	831	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	342	42
16.7	179	22
33.3	136	17
50	69	8
66.7	47	6
83.3	28	3
100	24	3
Total	825	

**Head and neck cancer: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	184	35	151	29	129	25	61	12	525
2) Long walk	PF	233	44	132	25	99	19	62	12	526
3) Short walk	PF	411	79	73	14	20	4	18	3	522
4) Bed or chair	PF	331	63	132	25	44	8	19	4	526
5) Self care	PF	495	94	12	2	13	3	8	2	528
6) Limited in work	RF	461	56	217	26	89	11	56	7	823
7) Limited in leisure	RF	517	63	175	21	89	11	42	5	823
8) Dyspnoea	DY	495	60	204	25	94	11	36	4	829
9) Pain	PA	390	47	264	32	129	16	46	6	829
10) Need to rest	FA	326	39	320	39	141	17	43	5	830
11) Insomnia	SL	446	54	195	24	142	17	47	6	830
12) Felt weak	FA	422	51	237	29	124	15	46	6	829
13) Appetite loss	AP	558	67	144	17	80	10	46	6	828
14) Nausea	NV	707	85	92	11	26	3	7	1	832
15) Vomiting	NV	771	93	46	6	8	1	6	1	831
16) Constipation	CO	628	76	127	15	56	7	18	2	829
17) Diarrhoea	DI	715	86	80	10	27	3	8	1	830
18) Felt tired	FA	337	41	333	40	114	14	41	5	825
19) Pain interference	PA	516	62	186	23	86	10	40	5	828
20) Concentration	CF	600	72	165	20	51	6	13	2	829
21) Tension	EF	364	44	292	35	138	17	32	4	826
22) Worry	EF	284	34	299	36	165	20	82	10	830
23) Irritability	EF	434	52	270	33	86	10	39	5	829
24) Depression	EF	410	49	271	33	114	14	35	4	830
25) Memory trouble	CF	540	65	212	26	57	7	17	2	826
26) Family life	SF	588	71	145	18	58	7	32	4	823
27) Social activities	SF	527	64	186	23	67	8	46	6	826
28) Financial difficulties	FI	583	71	136	16	71	9	37	5	827
<hr/>										
		<b>1</b>		<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
<hr/>										
29) Overall health	QL	15	40	98	181	197	165	118		814
		2	5	12	22	24	20	15		
<hr/>										
30) Overall quality of life	QL	15	34	98	145	178	203	141		814
		2	4	12	18	22	25	17		

## Head and neck cancer: ≥70

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	4	1
v +3	194	33
v 2.0	50	9
v 3.0	338	58
Total	586	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	489	83
80+	97	17
Not known	0	0
Total	586	

#### Gender

	N	(%)
Male	436	74
Female	147	25
Not known	3	1
Total	586	

#### Stage

	N	(%)
Stage I-II	250	43
Stage III-IV	294	50
Recurrent/metastatic	12	2
Not known	30	5
Total	586	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	63.6	(23)	66.7	[50-83.3]
Physical functioning	PF	74.8	(23)	80	[60-93.3]
Role Functioning	RF	77.7	(29.4)	100	[66.7-100]
Emotional functioning	EF	78.4	(22.3)	83.3	[66.7-100]
Cognitive functioning	CF	85.4	(19.2)	100	[83.3-100]
Social functioning	SF	84.5	(23.8)	100	[66.7-100]
Fatigue	FA	27.7	(24.6)	22.2	[11.1-44.4]
Nausea and vomiting	NV	4.6	(11.6)	0	[0-0]
Pain	PA	20.6	(25.3)	16.7	[0-33.3]
Dyspnoea	DY	20.7	(28.5)	0	[0-33.3]
Insomnia	SL	24.9	(31.9)	0	[0-33.3]
Appetite loss	AP	16.2	(27.9)	0	[0-33.3]
Constipation	CO	14.4	(25.5)	0	[0-33.3]
Diarrhoea	DI	5.1	(16.4)	0	[0-0]
Financial difficulties	FI	10.9	(23.3)	0	[0-0]

#### Primary disease site

	N	(%)
Head and neck: oral cavity	65	11
Head and neck: oropharynx	15	3
Head and neck: hypopharynx	9	2
Head and neck: larynx	113	19
Thyroid	2	0
Head and neck: not known	382	65
Total	586	



**Head and neck cancer: ≥70  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	2	0
8.3	4	1
16.7	24	4
25	18	3
33.3	37	7
41.7	29	5
50	79	14
58.3	54	10
66.7	107	19
75	52	9
83.3	82	14
91.7	18	3
100	62	11
Total	568	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	3	1
6.7	3	1
13.3	1	0
20	5	2
26.7	4	1
33.3	6	2
40	8	2
46.7	18	5
53.3	25	8
60	23	7
66.7	21	6
73.3	33	10
80	36	11
86.7	39	12
93.3	34	10
100	72	22
Total	331	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	24	4
16.7	15	3
33.3	51	9
50	44	8
66.7	74	13
83.3	65	11
100	301	52
Total	574	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	0	0
8.3	5	1
16.7	7	1
25	12	2
33.3	17	3
41.7	21	4
50	23	4
58.3	32	6
66.7	62	11
75	54	10
83.3	91	16
91.7	75	13
100	172	30
Total	571	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	3	1
16.7	2	0
33.3	14	2
50	40	7
66.7	80	14
83.3	138	24
100	296	52
Total	573	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	11	2
16.7	10	2
33.3	20	4
50	37	6
66.7	72	13
83.3	84	15
100	340	59
Total	574	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	130	23
11.1	98	17
22.2	92	16
33.3	80	14
44.4	64	11
55.6	45	8
66.7	26	5
77.8	10	2
88.9	18	3
100	5	1
Total	568	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	479	82
16.7	66	11
33.3	24	4
50	11	2
66.7	1	0
83.3	2	0
100	0	0
Total	583	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	259	45
16.7	124	22
33.3	78	14
50	49	9
66.7	33	6
83.3	20	4
100	8	1
Total	571	

**Head and neck cancer: ≥70  
Single Items**

		<b>Not at all</b>		<b>A little</b>		<b>Quite a bit</b>		<b>Very much</b>		<b>Total</b>	
		<b>N</b>	<b>(%)</b>	<b>N</b>	<b>(%)</b>	<b>N</b>	<b>(%)</b>	<b>N</b>	<b>(%)</b>	<b>N</b>	
1)	Strenuous activities	PF	110	33	83	25	81	24	62	19	336
2)	Long walk	PF	110	33	78	23	88	26	61	18	337
3)	Short walk	PF	227	68	76	23	20	6	11	3	334
4)	Bed or chair	PF	216	64	66	20	44	13	12	4	338
5)	Self care	PF	303	90	19	6	6	2	9	3	337
6)	Limited in work	RF	329	57	116	20	94	16	39	7	578
7)	Limited in leisure	RF	365	63	105	18	68	12	38	7	576
8)	Dyspnoea	DY	339	58	154	26	64	11	27	5	584
9)	Pain	PA	299	51	159	27	98	17	26	5	582
10)	Need to rest	FA	212	36	224	38	114	20	34	6	584
11)	Insomnia	SL	320	55	131	23	92	16	40	7	583
12)	Felt weak	FA	307	53	172	30	79	14	22	4	580
13)	Appetite loss	AP	409	70	95	16	57	10	25	4	586
14)	Nausea	NV	491	84	75	13	13	2	6	1	585
15)	Vomiting	NV	546	94	34	6	4	1	0	0	584
16)	Constipation	CO	417	71	96	16	57	10	14	2	584
17)	Diarrhoea	DI	518	89	43	7	12	2	7	1	580
18)	Felt tired	FA	218	38	242	42	92	16	23	4	575
19)	Pain interference	PA	383	67	118	21	52	9	20	4	573
20)	Concentration	CF	427	74	112	19	33	6	6	1	578
21)	Tension	EF	299	52	182	32	76	13	21	4	578
22)	Worry	EF	254	44	204	35	89	15	33	6	580
23)	Irritability	EF	371	64	140	24	58	10	12	2	581
24)	Depression	EF	337	59	153	27	71	12	15	3	576
25)	Memory trouble	CF	339	59	170	30	64	11	4	1	577
26)	Family life	SF	425	74	90	16	46	8	15	3	576
27)	Social activities	SF	376	65	116	20	57	10	28	5	577
28)	Financial difficulties	FI	452	78	80	14	32	6	15	3	579
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>	
			<b>(very poor)</b>						<b>(excellent)</b>		
29)	Overall health	QL	8	34	61	140	160	99	68	570	
			1	6	11	25	28	17	12		
30)	Overall quality of life	QL	12	33	61	93	151	132	89	571	
			2	6	11	16	26	23	16		

## Head and neck cancer: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	5	1
v +3	291	31
v 2.0	16	2
v 3.0	634	67
Total	946	

#### Age

	N	(%)
<40	32	3
40-49	90	10
50-59	247	26
60-69	327	35
70-79	208	22
80+	42	4
Not known	0	0
Total	946	

#### Gender

	N	(%)
Male	751	79
Female	195	21
Not known	0	0
Total	946	

#### Primary disease site

	N	(%)
Head and neck: oral cavity	43	5
Head and neck: oropharynx	2	0
Head and neck: hypopharynx	10	1
Head and neck: larynx	212	22
Head & neck: oral cavity/oropharynx Maxilla	1	0
Head and neck: not known	677	72
Total	946	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	66.8	(22.8)	66.7	[50-83.3]
Physical functioning	PF	81.5	(20.5)	86.7	[66.7-100]
Role Functioning	RF	80.7	(27.2)	100	[66.7-100]
Emotional functioning	EF	74.2	(24.3)	83.3	[58.3-91.7]
Cognitive functioning	CF	85.9	(20.3)	100	[83.3-100]
Social functioning	SF	85.3	(23.2)	100	[66.7-100]
Fatigue	FA	24.0	(23.4)	22.2	[0-33.3]
Nausea and vomiting	NV	4.1	(11.9)	0	[0-0]
Pain	PA	19.0	(24.1)	16.7	[0-33.3]
Dyspnoea	DY	18.3	(27.2)	0	[0-33.3]
Insomnia	SL	24.7	(30.6)	0	[0-33.3]
Appetite loss	AP	13.2	(24.6)	0	[0-33.3]
Constipation	CO	8.9	(19.8)	0	[0-0]
Diarrhoea	DI	5.4	(16)	0	[0-0]
Financial difficulties	FI	14.7	(26.7)	0	[0-33.3]

**Head and neck cancer: stage I-II  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	5	1
8.3	4	0
16.7	28	3
25	16	2
33.3	64	7
41.7	46	5
50	118	13
58.3	68	7
66.7	166	18
75	88	10
83.3	156	17
91.7	51	6
100	118	13
<b>Total</b>	<b>928</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	3	1
6.7	3	1
13.3	1	0
20	6	1
26.7	4	1
33.3	6	1
40	5	1
46.7	19	3
53.3	36	6
60	34	6
66.7	42	7
73.3	45	7
80	65	10
86.7	64	10
93.3	84	14
100	206	33
<b>Total</b>	<b>623</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	28	3
16.7	19	2
33.3	71	8
50	49	5
66.7	141	15
83.3	102	11
100	520	56
<b>Total</b>	<b>930</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	12	1
8.3	11	1
16.7	18	2
25	17	2
33.3	22	2
41.7	48	5
50	51	6
58.3	70	8
66.7	105	11
75	107	11
83.3	130	14
91.7	126	14
100	218	23
<b>Total</b>	<b>935</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	9	1
16.7	7	1
33.3	26	3
50	54	6
66.7	111	12
83.3	215	23
100	513	55
<b>Total</b>	<b>935</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	17	2
16.7	11	1
33.3	36	4
50	50	5
66.7	122	13
83.3	129	14
100	569	61
<b>Total</b>	<b>934</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	277	30
11.1	140	15
22.2	151	16
33.3	156	17
44.4	82	9
55.6	51	6
66.7	36	4
77.8	10	1
88.9	15	2
100	12	1
<b>Total</b>	<b>930</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	802	85
16.7	87	9
33.3	35	4
50	7	1
66.7	7	1
83.3	4	0
100	1	0
<b>Total</b>	<b>943</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	436	47
16.7	209	22
33.3	140	15
50	63	7
66.7	47	5
83.3	24	3
100	13	1
<b>Total</b>	<b>932</b>	

**Head and neck cancer: stage I-II**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	261	41	170	27	133	21	68	11	632
2) Long walk	PF	301	48	147	23	115	18	69	11	632
3) Short walk	PF	493	79	95	15	24	4	13	2	625
4) Bed or chair	PF	417	66	142	23	57	9	15	2	631
5) Self care	PF	607	96	12	2	7	1	6	1	632
6) Limited in work	RF	560	60	203	22	121	13	52	6	936
7) Limited in leisure	RF	628	67	169	18	91	10	45	5	933
8) Dyspnoea	DY	588	62	229	24	92	10	35	4	944
9) Pain	PA	494	53	298	32	119	13	30	3	941
10) Need to rest	FA	410	43	354	38	146	15	35	4	945
11) Insomnia	SL	501	53	235	25	156	17	50	5	942
12) Felt weak	FA	538	57	273	29	100	11	33	4	944
13) Appetite loss	AP	695	74	147	16	82	9	21	2	945
14) Nausea	NV	815	86	100	11	23	2	7	1	945
15) Vomiting	NV	893	95	38	4	12	1	1	0	944
16) Constipation	CO	753	80	138	15	41	4	11	1	943
17) Diarrhoea	DI	829	88	80	9	27	3	6	1	942
18) Felt tired	FA	389	42	396	42	123	13	25	3	933
19) Pain interference	PA	637	68	184	20	85	9	30	3	936
20) Concentration	CF	672	71	188	20	67	7	14	1	941
21) Tension	EF	389	42	353	38	149	16	47	5	938
22) Worry	EF	343	37	341	36	183	19	74	8	941
23) Irritability	EF	529	56	288	31	89	9	36	4	942
24) Depression	EF	507	54	286	30	111	12	36	4	940
25) Memory trouble	CF	616	66	230	25	70	8	21	2	937
26) Family life	SF	677	72	171	18	60	6	27	3	935
27) Social activities	SF	635	68	186	20	82	9	36	4	939
28) Financial difficulties	FI	676	72	151	16	78	8	36	4	941
<hr/>										
		1	2	3	4	5	6	7	Total	
		(very poor)							(excellent)	
29) Overall health	QL	9	48	107	184	234	208	141	931	
		1	5	12	20	25	22	15		
30) Overall quality of life	QL	12	34	101	151	207	251	176	932	
		1	4	11	16	22	27	19		

## Head and neck cancer: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	17	1
v +3	395	23
v 2.0	381	22
v 3.0	929	54
Total	1,722	

#### Age

	N	(%)
<40	54	3
40-49	337	20
50-59	599	35
60-69	437	25
70-79	243	14
80+	51	3
Not known	1	0
Total	1,722	

#### Gender

	N	(%)
Male	1,401	81
Female	316	18
Not known	5	0
Total	1,722	

#### Primary disease site

	N	(%)
Head and neck: oral cavity	143	8
Head and neck: oropharynx	78	5
Head and neck: hypopharynx	64	4
Head and neck: larynx	146	8
Head and neck: oral cavity/larynx	1	0
Head & neck: oral cavity/oropharynx	2	0
Maxilla	1	0
Head and neck: not known	1,287	75
Total	1,722	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	63.1	(22.4)	66.7	[50-83.3]
Physical functioning	PF	81.2	(20.2)	86.7	[73.3-100]
Role Functioning	RF	78.8	(27.9)	100	[66.7-100]
Emotional functioning	EF	71.2	(24.1)	75	[58.3-91.7]
Cognitive functioning	CF	86.4	(19.1)	100	[83.3-100]
Social functioning	SF	82.2	(24.7)	100	[66.7-100]
Fatigue	FA	27.6	(25)	22.2	[0-44.4]
Nausea and vomiting	NV	5.2	(13.3)	0	[0-0]
Pain	PA	24.9	(26.3)	16.7	[0-33.3]
Dyspnoea	DY	18.0	(26.6)	0	[0-33.3]
Insomnia	SL	28.5	(32.4)	33.3	[0-66.7]
Appetite loss	AP	19.4	(29.3)	0	[0-33.3]
Constipation	CO	11.7	(23.2)	0	[0-0]
Diarrhoea	DI	6.1	(16.7)	0	[0-0]
Financial difficulties	FI	18.8	(30.2)	0	[0-33.3]

**Head and neck cancer: stage III-IV  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	21	1
8.3	4	0
16.7	50	3
25	32	2
33.3	121	7
41.7	106	6
50	266	16
58.3	162	10
66.7	312	19
75	129	8
83.3	255	15
91.7	64	4
100	151	9
<b>Total</b>	<b>1,673</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	2	0
6.7	2	0
13.3	2	0
20	10	1
26.7	9	1
33.3	12	1
40	23	3
46.7	24	3
53.3	34	4
60	40	4
66.7	69	8
73.3	67	7
80	97	11
86.7	120	13
93.3	143	16
100	263	29
<b>Total</b>	<b>917</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	64	4
16.7	41	2
33.3	115	7
50	108	6
66.7	275	16
83.3	221	13
100	865	51
<b>Total</b>	<b>1,689</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	11	1
8.3	29	2
16.7	38	2
25	33	2
33.3	70	4
41.7	82	5
50	120	7
58.3	144	9
66.7	215	13
75	200	12
83.3	243	14
91.7	208	12
100	303	18
<b>Total</b>	<b>1,696</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	6	0
16.7	12	1
33.3	37	2
50	109	6
66.7	235	14
83.3	352	21
100	950	56
<b>Total</b>	<b>1,701</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	30	2
16.7	34	2
33.3	87	5
50	116	7
66.7	270	16
83.3	239	14
100	930	55
<b>Total</b>	<b>1,706</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	453	27
11.1	208	12
22.2	263	16
33.3	303	18
44.4	144	9
55.6	128	8
66.7	100	6
77.8	36	2
88.9	31	2
100	27	2
<b>Total</b>	<b>1,693</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	1,404	82
16.7	175	10
33.3	83	5
50	33	2
66.7	12	1
83.3	3	0
100	5	0
<b>Total</b>	<b>1,715</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	608	36
16.7	398	23
33.3	307	18
50	174	10
66.7	113	7
83.3	64	4
100	41	2
<b>Total</b>	<b>1,705</b>	

**Head and neck cancer: stage III-IV  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	371	40	248	27	198	21	110	12	927	
2) Long walk	PF	433	47	229	25	165	18	97	11	924	
3) Short walk	PF	737	80	127	14	43	5	18	2	925	
4) Bed or chair	PF	636	69	194	21	72	8	22	2	924	
5) Self care	PF	850	92	45	5	21	2	11	1	927	
6) Limited in work	RF	968	57	404	24	222	13	101	6	1,695	
7) Limited in leisure	RF	1,058	62	368	22	180	11	90	5	1,696	
8) Dyspnoea	DY	1,061	62	445	26	152	9	60	4	1,718	
9) Pain	PA	684	40	604	35	324	19	104	6	1,716	
10) Need to rest	FA	631	37	689	40	304	18	89	5	1,713	
11) Insomnia	SL	818	48	465	27	300	18	134	8	1,717	
12) Felt weak	FA	844	49	549	32	246	14	75	4	1,714	
13) Appetite loss	AP	1,081	63	357	21	187	11	89	5	1,714	
14) Nausea	NV	1,446	84	204	12	56	3	13	1	1,719	
15) Vomiting	NV	1,575	92	115	7	18	1	10	1	1,718	
16) Constipation	CO	1,294	76	270	16	109	6	37	2	1,710	
17) Diarrhoea	DI	1,475	86	177	10	48	3	13	1	1,713	
18) Felt tired	FA	686	40	705	41	247	15	70	4	1,708	
19) Pain interference	PA	1,023	60	436	26	188	11	63	4	1,710	
20) Concentration	CF	1,200	70	357	21	123	7	30	2	1,710	
21) Tension	EF	659	38	667	39	289	17	99	6	1,714	
22) Worry	EF	479	28	699	41	350	20	188	11	1,716	
23) Irritability	EF	862	50	571	33	209	12	70	4	1,712	
24) Depression	EF	856	50	568	33	219	13	69	4	1,712	
25) Memory trouble	CF	1,169	68	399	23	123	7	20	1	1,711	
26) Family life	SF	1,146	67	362	21	148	9	54	3	1,710	
27) Social activities	SF	1,043	61	407	24	179	11	82	5	1,711	
28) Financial difficulties	FI	1,124	66	315	19	158	9	110	6	1,707	
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>	
			<b>(very poor)</b>							<b>(excellent)</b>	
29) Overall health	QL	34	73	193	424	443	324	188		1,679	
		2	4	12	25	26	19	11			
30) Overall quality of life	QL	39	70	186	351	446	373	225		1,690	
		2	4	11	21	26	22	13			



## Head and neck cancer: hypopharynx/larynx

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	5	1
v +3	150	34
v 2.0	0	0
v 3.0	281	64
Total	436	

#### Age

	N	(%)
<40	7	2
40-49	45	10
50-59	113	26
60-69	149	34
70-79	103	24
80+	19	4
Not known	0	0
Total	436	

#### Gender

	N	(%)
Male	387	89
Female	49	11
Not known	0	0
Total	436	

#### Stage

	N	(%)
Stage I-II	222	51
Stage III-IV	210	48
Recurrent/metastatic	0	0
Not known	4	1
Total	436	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	62.3	(23.1)	66.7	[50-83.3]
Physical functioning	PF	73.0	(22)	73.3	[60-93.3]
Role Functioning	RF	72.8	(30.9)	83.3	[50-100]
Emotional functioning	EF	69.4	(26)	75	[50-91.7]
Cognitive functioning	CF	83.7	(20.5)	83.3	[66.7-100]
Social functioning	SF	78.5	(27.4)	83.3	[66.7-100]
Fatigue	FA	32.0	(26.8)	33.3	[11.1-44.4]
Nausea and vomiting	NV	5.3	(13.7)	0	[0-0]
Pain	PA	22.3	(27.6)	16.7	[0-33.3]
Dyspnoea	DY	28.4	(32.8)	33.3	[0-66.7]
Insomnia	SL	27.7	(34.5)	0	[0-66.7]
Appetite loss	AP	15.4	(26.9)	0	[0-33.3]
Constipation	CO	7.5	(19.3)	0	[0-0]
Diarrhoea	DI	7.6	(19.8)	0	[0-0]
Financial difficulties	FI	24.8	(34.8)	0	[0-33.3]

**Head and neck cancer: hypopharynx/larynx  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	5	1
8.3	2	1
16.7	15	4
25	5	1
33.3	40	10
41.7	22	5
50	73	18
58.3	33	8
66.7	79	19
75	27	7
83.3	58	14
91.7	17	4
100	40	10
<b>Total</b>	<b>416</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	3	1
6.7	1	0
13.3	1	0
20	2	1
26.7	5	2
33.3	6	2
40	11	4
46.7	11	4
53.3	20	7
60	19	7
66.7	33	12
73.3	32	12
80	33	12
86.7	23	8
93.3	33	12
100	44	16
<b>Total</b>	<b>277</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	23	5
16.7	18	4
33.3	42	10
50	33	8
66.7	76	18
83.3	49	12
100	185	43
<b>Total</b>	<b>426</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	5	1
8.3	11	3
16.7	15	4
25	9	2
33.3	13	3
41.7	25	6
50	36	8
58.3	34	8
66.7	53	12
75	41	10
83.3	58	14
91.7	51	12
100	79	18
<b>Total</b>	<b>430</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	2	1
16.7	6	1
33.3	11	3
50	33	8
66.7	68	16
83.3	103	24
100	211	49
<b>Total</b>	<b>434</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	16	4
16.7	10	2
33.3	25	6
50	35	8
66.7	68	16
83.3	70	16
100	208	48
<b>Total</b>	<b>432</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	99	23
11.1	41	10
22.2	60	14
33.3	81	19
44.4	56	13
55.6	32	7
66.7	28	7
77.8	11	3
88.9	10	2
100	15	4
<b>Total</b>	<b>433</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	351	81
16.7	53	12
33.3	19	4
50	6	1
66.7	2	1
83.3	2	1
100	2	1
<b>Total</b>	<b>435</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	196	45
16.7	83	19
33.3	61	14
50	39	9
66.7	23	5
83.3	15	4
100	15	4
<b>Total</b>	<b>432</b>	

**Head and neck cancer: hypopharynx/larynx**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	64	23	56	20	83	30	78	28	281	
2) Long walk	PF	92	33	58	21	76	27	55	20	281	
3) Short walk	PF	193	69	53	19	25	9	8	3	279	
4) Bed or chair	PF	196	71	51	18	20	7	11	4	278	
5) Self care	PF	251	89	12	4	9	3	9	3	281	
6) Limited in work	RF	208	49	115	27	71	17	35	8	429	
7) Limited in leisure	RF	228	53	97	23	68	16	35	8	428	
8) Dyspnoea	DY	213	49	110	25	78	18	35	8	436	
9) Pain	PA	230	53	115	26	67	15	23	5	435	
10) Need to rest	FA	137	31	157	36	109	25	33	8	436	
11) Insomnia	SL	234	54	83	19	76	18	42	10	435	
12) Felt weak	FA	202	46	129	30	68	16	37	9	436	
13) Appetite loss	AP	308	71	69	16	45	10	14	3	436	
14) Nausea	NV	359	83	60	14	9	2	7	2	435	
15) Vomiting	NV	406	93	22	5	5	1	3	1	436	
16) Constipation	CO	366	84	43	10	20	5	5	1	434	
17) Diarrhoea	DI	369	85	39	9	23	5	5	1	436	
18) Felt tired	FA	158	37	172	40	79	18	24	6	433	
19) Pain interference	PA	266	61	97	22	44	10	26	6	433	
20) Concentration	CF	302	69	90	21	36	8	8	2	436	
21) Tension	EF	168	39	161	37	77	18	29	7	435	
22) Worry	EF	142	33	145	33	94	22	54	12	435	
23) Irritability	EF	186	43	150	35	66	15	32	7	434	
24) Depression	EF	218	50	133	31	58	13	25	6	434	
25) Memory trouble	CF	261	60	115	27	49	11	9	2	434	
26) Family life	SF	272	63	95	22	42	10	24	6	433	
27) Social activities	SF	239	55	108	25	55	13	30	7	432	
28) Financial difficulties	FI	258	59	76	18	53	12	47	11	434	
<hr/>											
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>	
		<b>(very poor)</b>					<b>(excellent)</b>				
<hr/>											
29) Overall health	QL	7	24	52	106	105	75	49		418	
		2	6	12	25	25	18	12			
<hr/>											
30) Overall quality of life	QL	11	15	54	98	99	86	58		421	
		3	4	13	23	24	20	14			

## Head and neck cancer: oral cavity/oropharynx

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	14	5
v +3	244	90
v 2.0	0	0
v 3.0	14	5
Total	272	

#### Age

	N	(%)
<40	10	4
40-49	40	15
50-59	95	35
60-69	46	17
70-79	59	22
80+	21	8
Not known	1	0
Total	272	

#### Gender

	N	(%)
Male	182	67
Female	90	33
Not known	0	0
Total	272	

#### Stage

	N	(%)
Stage I-II	45	17
Stage III-IV	224	82
Recurrent/metastatic	3	1
Not known	0	0
Total	272	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	64.4	(23.6)	66.7	[50-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	78.1	(29)	100	[66.7-100]
Emotional functioning	EF	66.9	(23.6)	66.7	[50-83.3]
Cognitive functioning	CF	85.3	(21.1)	100	[66.7-100]
Social functioning	SF	83.8	(24.2)	100	[66.7-100]
Fatigue	FA	26.9	(27.1)	22.2	[0-44.4]
Nausea and vomiting	NV	4.8	(13.7)	0	[0-0]
Pain	PA	28.5	(27.2)	16.7	[0-50]
Dyspnoea	DY	13.0	(22.2)	0	[0-33.3]
Insomnia	SL	29.7	(33.3)	33.3	[0-66.7]
Appetite loss	AP	17.4	(28.9)	0	[0-33.3]
Constipation	CO	8.8	(21.7)	0	[0-0]
Diarrhoea	DI	5.9	(17.8)	0	[0-0]
Financial difficulties	FI	12.5	(26.4)	0	[0-0]

**Head and neck cancer: oral cavity/oropharynx  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	5	2
8.3	1	0
16.7	7	3
25	8	3
33.3	13	5
41.7	18	7
50	32	13
58.3	25	10
66.7	41	16
75	24	9
83.3	44	17
91.7	13	5
100	26	10
Total	257	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	2	1
16.7	2	1
33.3	9	3
50	20	7
66.7	38	14
83.3	45	17
100	155	57
Total	271	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	5	2
16.7	6	2
33.3	11	4
50	13	5
66.7	41	15
83.3	38	14
100	156	58
Total	270	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	80	30
11.1	38	14
22.2	42	16
33.3	35	13
44.4	22	8
55.6	20	7
66.7	12	5
77.8	2	1
88.9	11	4
100	7	3
Total	269	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	12	5
16.7	3	1
33.3	26	10
50	11	4
66.7	40	16
83.3	33	13
100	132	51
Total	257	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	229	84
16.7	27	10
33.3	4	2
50	7	3
66.7	4	2
83.3	0	0
100	1	0
Total	272	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	2	1
8.3	4	2
16.7	5	2
25	9	3
33.3	19	7
41.7	14	5
50	16	6
58.3	33	12
66.7	39	14
75	38	14
83.3	35	13
91.7	26	10
100	31	11
Total	271	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	72	27
16.7	81	30
33.3	47	17
50	23	9
66.7	25	9
83.3	15	6
100	7	3
Total	270	

**Head and neck cancer: oral cavity/oropharynx  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	146	57	59	23	39	15	14	5	258
7) Limited in leisure	RF	160	62	51	20	30	12	16	6	257
8) Dyspnoea	DY	189	70	65	24	13	5	5	2	272
9) Pain	PA	80	29	110	40	59	22	23	9	272
10) Need to rest	FA	106	39	100	37	46	17	19	7	271
11) Insomnia	SL	129	47	67	25	53	20	23	9	272
12) Felt weak	FA	159	59	68	25	28	10	16	6	271
13) Appetite loss	AP	183	67	51	19	23	9	15	6	272
14) Nausea	NV	235	86	24	9	10	4	3	1	272
15) Vomiting	NV	254	93	12	4	5	2	1	0	272
16) Constipation	CO	225	83	28	10	13	5	6	2	272
17) Diarrhoea	DI	239	88	22	8	7	3	4	2	272
18) Felt tired	FA	113	42	100	37	39	14	19	7	271
19) Pain interference	PA	163	60	60	22	35	13	12	4	270
20) Concentration	CF	177	65	60	22	28	10	6	2	271
21) Tension	EF	72	27	110	40	67	25	23	9	272
22) Worry	EF	46	17	112	41	78	29	35	13	271
23) Irritability	EF	146	54	89	33	26	10	11	4	272
24) Depression	EF	122	45	96	35	42	15	12	4	272
25) Memory trouble	CF	193	71	56	21	19	7	4	2	272
26) Family life	SF	193	72	46	17	23	9	8	3	270
27) Social activities	SF	174	64	61	22	24	9	13	5	272
28) Financial difficulties	FI	211	78	32	12	17	6	12	4	272
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	10	14	19	55	68	58	33		257
		4	5	7	21	27	23	13		
30) Overall quality of life	QL	7	12	25	53	67	65	41		270
		3	4	9	20	25	24	15		

## Acute myelogenous leukaemia

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	155	100
v +3	0	0
v 2.0	0	0
v 3.0	0	0
Total	155	

#### Age

	N	(%)
<40	79	51
40-49	30	19
50-59	40	26
60-69	6	4
70-79	0	0
80+	0	0
Not known	0	0
Total	155	

#### Gender

	N	(%)
Male	73	47
Female	82	53
Not known	0	0
Total	155	

#### Stage

	N	(%)
Stage I-II	0	0
Stage III-IV	0	0
Recurrent/metastatic	0	0
Not known	155	100
Total	155	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	<i>Previous version of this scale used</i>			
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	<i>Previous version of this scale used</i>			
Emotional functioning	EF	82.2	(18.9)	83.3	[75-100]
Cognitive functioning	CF	86.1	(18.5)	100	[83.3-100]
Social functioning	SF	66.1	(31)	66.7	[33.3-100]
Fatigue	FA	36.2	(22.7)	33.3	[22.2-55.6]
Nausea and vomiting	NV	9.0	(18.3)	0	[0-16.7]
Pain	PA	13.7	(20.4)	0	[0-16.7]
Dyspnoea	DY	11.3	(17.1)	0	[0-33.3]
Insomnia	SL	20.4	(26.1)	0	[0-33.3]
Appetite loss	AP	18.0	(30.5)	0	[0-33.3]
Constipation	CO	7.9	(19.1)	0	[0-0]
Diarrhoea	DI	12.6	(25.1)	0	[0-33.3]
Financial difficulties	FI	18.7	(28.8)	0	[0-33.3]

**Acute myelogenous leukaemia  
Constructed scales**

**QL**

Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	0	0
16.7	0	0
33.3	5	3
50	11	7
66.7	20	13
83.3	35	23
100	82	54
Total	153	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	7	5
16.7	9	6
33.3	24	17
50	11	8
66.7	29	20
83.3	21	15
100	44	30
Total	145	

**PF**

Previous version of this scale used

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	18	12
11.1	12	8
22.2	18	12
33.3	47	32
44.4	14	9
55.6	11	7
66.7	20	13
77.8	7	5
88.9	2	1
100	0	0
Total	149	

**RF**

Previous version of this scale used

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	115	74
16.7	14	9
33.3	16	10
50	6	4
66.7	0	0
83.3	4	3
100	0	0
Total	155	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	1	1
8.3	0	0
16.7	1	1
25	1	1
33.3	3	2
41.7	2	1
50	3	2
58.3	10	7
66.7	11	7
75	22	15
83.3	23	15
91.7	31	20
100	44	29
Total	152	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	89	59
16.7	24	16
33.3	22	15
50	8	5
66.7	5	3
83.3	1	1
100	1	1
Total	150	





## Liver/bile/pancreas cancer

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	14	2
v +3	0	0
v 2.0	487	65
v 3.0	249	33
Total	750	

#### Primary disease site

	N	(%)
Liver/bile	452	60
Pancreas	298	40
Total	750	

#### Age

	N	(%)
<40	58	8
40-49	88	12
50-59	175	23
60-69	247	33
70-79	161	22
80+	18	2
Not known	3	0
Total	750	

#### Gender

	N	(%)
Male	463	62
Female	228	30
Not known	59	8
Total	750	

#### Stage

	N	(%)
Stage I-II	41	6
Stage III-IV	225	30
Recurrent/metastatic	336	45
Not known	148	20
Total	750	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	55.9	(25.1)	58.3	[41.7-75]
Physical functioning	PF	74.1	(25.7)	80	[60-93.3]
Role Functioning	RF	65.2	(36.3)	83.3	[33.3-100]
Emotional functioning	EF	69.8	(25.5)	75	[50-91.7]
Cognitive functioning	CF	79.0	(23.1)	83.3	[66.7-100]
Social functioning	SF	69.0	(31.7)	83.3	[50-100]
Fatigue	FA	41.2	(30)	33.3	[22.2-66.7]
Nausea and vomiting	NV	12.4	(22.5)	0	[0-16.7]
Pain	PA	29.6	(32.8)	16.7	[0-50]
Dyspnoea	DY	20.8	(28.7)	0	[0-33.3]
Insomnia	SL	32.2	(34.4)	33.3	[0-66.7]
Appetite loss	AP	32.3	(37.2)	33.3	[0-66.7]
Constipation	CO	20.4	(31.3)	0	[0-33.3]
Diarrhoea	DI	11.1	(23.9)	0	[0-0]
Financial difficulties	FI	21.9	(32.5)	0	[0-33.3]

**Liver/bile/pancreas cancer  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	24	3
8.3	12	2
16.7	52	7
25	24	3
33.3	61	8
41.7	48	7
50	122	17
58.3	58	8
66.7	130	18
75	44	6
83.3	89	12
91.7	23	3
100	42	6
<b>Total</b>	<b>729</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	0
6.7	2	1
13.3	7	3
20	2	1
26.7	9	4
33.3	6	3
40	13	5
46.7	7	3
53.3	10	4
60	16	7
66.7	14	6
73.3	11	5
80	29	12
86.7	34	14
93.3	24	10
100	59	24
<b>Total</b>	<b>244</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	105	15
16.7	25	4
33.3	74	10
50	51	7
66.7	101	14
83.3	97	14
100	267	37
<b>Total</b>	<b>720</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	8	1
8.3	9	1
16.7	17	2
25	27	4
33.3	40	6
41.7	44	6
50	54	7
58.3	51	7
66.7	72	10
75	91	12
83.3	91	12
91.7	98	13
100	131	18
<b>Total</b>	<b>733</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	9	1
16.7	18	2
33.3	27	4
50	75	10
66.7	128	17
83.3	196	27
100	286	39
<b>Total</b>	<b>739</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	56	8
16.7	33	5
33.3	59	8
50	80	11
66.7	131	18
83.3	115	16
100	253	35
<b>Total</b>	<b>727</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	92	13
11.1	90	12
22.2	97	13
33.3	122	17
44.4	71	10
55.6	58	8
66.7	70	10
77.8	41	6
88.9	49	7
100	45	6
<b>Total</b>	<b>735</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	494	66
16.7	109	15
33.3	67	9
50	32	4
66.7	18	2
83.3	10	1
100	16	2
<b>Total</b>	<b>746</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	291	39
16.7	126	17
33.3	100	14
50	57	8
66.7	62	8
83.3	49	7
100	54	7
<b>Total</b>	<b>739</b>	

**Liver/bile/pancreas cancer  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	87	35	68	28	40	16	51	21	246
2) Long walk	PF	100	40	53	21	46	19	49	20	248
3) Short walk	PF	189	76	27	11	21	8	12	5	249
4) Bed or chair	PF	131	53	47	19	46	19	24	10	248
5) Self care	PF	219	88	16	6	12	5	2	1	249
6) Limited in work	RF	306	42	168	23	119	16	131	18	724
7) Limited in leisure	RF	362	50	140	19	102	14	124	17	728
8) Dyspnoea	DY	430	58	196	26	80	11	36	5	742
9) Pain	PA	313	42	232	31	112	15	88	12	745
10) Need to rest	FA	186	25	261	35	183	25	113	15	743
11) Insomnia	SL	325	44	207	28	129	17	85	11	746
12) Felt weak	FA	232	31	256	34	148	20	111	15	747
13) Appetite loss	AP	362	49	160	21	109	15	115	15	746
14) Nausea	NV	504	67	147	20	58	8	39	5	748
15) Vomiting	NV	630	85	71	10	25	3	20	3	746
16) Constipation	CO	474	64	137	18	80	11	53	7	744
17) Diarrhoea	DI	578	78	109	15	30	4	26	4	743
18) Felt tired	FA	199	27	284	38	146	20	113	15	742
19) Pain interference	PA	418	56	134	18	108	15	84	11	744
20) Concentration	CF	432	58	173	23	92	12	48	6	745
21) Tension	EF	330	44	237	32	127	17	50	7	744
22) Worry	EF	230	31	240	32	162	22	111	15	743
23) Irritability	EF	346	47	251	34	119	16	26	4	742
24) Depression	EF	355	48	224	30	103	14	59	8	741
25) Memory trouble	CF	410	55	249	34	60	8	22	3	741
26) Family life	SF	359	49	195	27	98	13	82	11	734
27) Social activities	SF	330	45	187	26	112	15	105	14	734
28) Financial difficulties	FI	454	62	140	19	76	10	63	9	733
		1 (very poor)		3		5		7 (excellent)		Total
29) Overall health	QL	40	67	97	188	174	115	51		732
		6	9	13	26	24	16	7		
30) Overall quality of life	QL	40	63	101	172	162	123	82		743
		5	9	14	23	22	17	11		

## Lung cancer: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	1,125	34
v +3	38	1
v 2.0	836	25
v 3.0	1,333	40
Total	3,332	

#### Primary disease site

	N	(%)
Lung: small cell	658	20
Lung: non-small cell	1,262	38
Mesothelioma	236	7
Lung: not known	1,176	35
Total	3,332	

#### Age

	N	(%)
<40	85	3
40-49	416	13
50-59	971	29
60-69	1,108	33
70-79	596	18
80+	60	2
Not known	96	3
Total	3,332	

#### Gender

	N	(%)
Male	1,925	58
Female	830	25
Not known	577	17
Total	3,332	

#### Stage

	N	(%)
Stage I-II	538	16
Stage III-IV	1,313	39
Recurrent/metastatic	307	9
Not known	1,174	35
Total	3,332	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	56.6	(24.3)	58.3	[41.7-75]
Physical functioning	PF	71.9	(22.9)	80	[60-86.7]
Role Functioning	RF	61.5	(33.9)	66.7	[33.3-100]
Emotional functioning	EF	68.9	(24.4)	75	[50-91.7]
Cognitive functioning	CF	82.3	(22)	83.3	[66.7-100]
Social functioning	SF	71.3	(29.4)	83.3	[50-100]
Fatigue	FA	41.1	(27.2)	33.3	[22.2-55.6]
Nausea and vomiting	NV	10.8	(19.7)	0	[0-16.7]
Pain	PA	29.7	(30.7)	16.7	[0-50]
Dyspnoea	DY	37.9	(32.2)	33.3	[0-66.7]
Insomnia	SL	31.6	(32.6)	33.3	[0-66.7]
Appetite loss	AP	28.1	(33.5)	0	[0-66.7]
Constipation	CO	19.2	(29.7)	0	[0-33.3]
Diarrhoea	DI	7.4	(17.9)	0	[0-0]
Financial difficulties	FI	17.4	(28.9)	0	[0-33.3]

**Lung cancer: all stages  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	80	4
8.3	31	1
16.7	95	4
25	59	3
33.3	221	10
41.7	121	6
50	412	19
58.3	185	9
66.7	371	17
75	147	7
83.3	264	12
91.7	79	4
100	110	5
<b>Total</b>	<b>2,175</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	5	0
6.7	12	1
13.3	12	1
20	26	2
26.7	44	3
33.3	27	2
40	40	3
46.7	47	4
53.3	83	6
60	99	8
66.7	125	10
73.3	128	10
80	150	12
86.7	197	15
93.3	157	12
100	156	12
<b>Total</b>	<b>1,308</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	249	12
16.7	111	5
33.3	302	14
50	207	10
66.7	417	19
83.3	255	12
100	609	28
<b>Total</b>	<b>2,150</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	35	1
8.3	38	1
16.7	72	2
25	93	3
33.3	158	5
41.7	173	5
50	272	8
58.3	279	9
66.7	444	14
75	405	13
83.3	399	12
91.7	338	11
100	519	16
<b>Total</b>	<b>3,225</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	32	1
16.7	50	2
33.3	136	4
50	229	7
66.7	496	15
83.3	822	25
100	1,517	46
<b>Total</b>	<b>3,282</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	154	5
16.7	117	4
33.3	312	10
50	354	11
66.7	650	20
83.3	475	15
100	1,188	37
<b>Total</b>	<b>3,250</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	358	11
11.1	270	8
22.2	437	13
33.3	692	21
44.4	390	12
55.6	344	11
66.7	314	10
77.8	157	5
88.9	141	4
100	161	5
<b>Total</b>	<b>3,264</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	2,227	68
16.7	491	15
33.3	315	10
50	118	4
66.7	76	2
83.3	23	1
100	38	1
<b>Total</b>	<b>3,288</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	1,171	36
16.7	561	17
33.3	548	17
50	337	10
66.7	306	9
83.3	157	5
100	191	6
<b>Total</b>	<b>3,271</b>	

**Lung cancer: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	257	20	498	38	346	26	219	17	1,320
2) Long walk	PF	341	26	435	33	342	26	208	16	1,326
3) Short walk	PF	818	62	340	26	124	9	46	4	1,328
4) Bed or chair	PF	654	49	395	30	201	15	80	6	1,330
5) Self care	PF	1,174	88	103	8	39	3	15	1	1,331
6) Limited in work	RF	716	33	613	28	490	23	355	16	2,174
7) Limited in leisure	RF	850	39	584	27	403	19	327	15	2,164
8) Dyspnoea	DY	972	30	1,264	38	692	21	368	11	3,296
9) Pain	PA	1,311	40	1,079	33	605	18	308	9	3,303
10) Need to rest	FA	651	20	1,408	43	852	26	389	12	3,300
11) Insomnia	SL	1,370	42	1,019	31	611	19	292	9	3,292
12) Felt weak	FA	938	28	1,229	37	769	23	366	11	3,302
13) Appetite loss	AP	1,663	50	811	25	519	16	311	9	3,304
14) Nausea	NV	2,307	70	659	20	245	7	96	3	3,307
15) Vomiting	NV	2,789	85	373	11	92	3	48	2	3,302
16) Constipation	CO	2,105	64	671	20	324	10	193	6	3,293
17) Diarrhoea	DI	2,719	83	436	13	104	3	29	1	3,288
18) Felt tired	FA	684	21	1,489	45	801	24	325	10	3,299
19) Pain interference	PA	1,706	52	800	24	487	15	294	9	3,287
20) Concentration	CF	2,097	63	740	22	343	10	125	4	3,305
21) Tension	EF	1,168	35	1,324	40	585	18	223	7	3,300
22) Worry	EF	908	28	1,220	37	775	24	388	12	3,291
23) Irritability	EF	1,603	49	1,143	35	415	13	117	4	3,278
24) Depression	EF	1,315	40	1,265	39	484	15	214	7	3,278
25) Memory trouble	CF	2,003	61	949	29	263	8	76	2	3,291
26) Family life	SF	1,734	53	856	26	458	14	226	7	3,274
27) Social activities	SF	1,394	43	923	28	601	18	357	11	3,275
28) Financial difficulties	FI	2,217	68	579	18	309	9	171	5	3,276
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	115	138	318	573	538	370	130		2,182
		5	6	15	26	25	17	6		
30) Overall quality of life	QL	164	217	473	761	767	579	317		3,278
		5	7	14	23	23	18	10		

## Lung cancer: males

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	807	42
v +3	30	2
v 2.0	241	13
v 3.0	847	44
Total	1,925	

#### Primary disease site

	N	(%)
Lung: small cell	407	21
Lung: non-small cell	514	27
Mesothelioma	183	10
Lung: not known	821	43
Total	1,925	

### Age

	N	(%)
<40	36	2
40-49	188	10
50-59	548	29
60-69	692	36
70-79	416	22
80+	41	2
Not known	4	0
Total	1,925	

### Stage

	N	(%)
Stage I-II	385	20
Stage III-IV	580	30
Recurrent/metastatic	197	10
Not known	763	40
Total	1,925	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	56.9	(24.5)	58.3	[41.7-75]
Physical functioning	PF	72.9	(23.1)	80	[60-93.3]
Role Functioning	RF	63.6	(33.5)	66.7	[33.3-100]
Emotional functioning	EF	71.6	(23.5)	75	[58.3-91.7]
Cognitive functioning	CF	82.7	(21.6)	83.3	[66.7-100]
Social functioning	SF	72.7	(28.3)	83.3	[50-100]
Fatigue	FA	39.8	(26.7)	33.3	[22.2-55.6]
Nausea and vomiting	NV	9.5	(18.3)	0	[0-16.7]
Pain	PA	27.4	(29.6)	16.7	[0-50]
Dyspnoea	DY	38.2	(32.1)	33.3	[0-66.7]
Insomnia	SL	29.7	(31.9)	33.3	[0-66.7]
Appetite loss	AP	26.8	(33.1)	0	[0-33.3]
Constipation	CO	20.1	(30.2)	0	[0-33.3]
Diarrhoea	DI	7.3	(17.7)	0	[0-0]
Financial difficulties	FI	18.2	(29.4)	0	[0-33.3]



**Lung cancer: males**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	39	4
8.3	18	2
16.7	55	5
25	23	2
33.3	105	10
41.7	61	6
50	209	19
58.3	96	9
66.7	182	17
75	77	7
83.3	148	13
91.7	31	3
100	61	6
<b>Total</b>	<b>1,105</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	4	1
6.7	7	1
13.3	10	1
20	18	2
26.7	27	3
33.3	12	1
40	25	3
46.7	24	3
53.3	48	6
60	53	6
66.7	79	10
73.3	85	10
80	104	13
86.7	117	14
93.3	110	13
100	109	13
<b>Total</b>	<b>832</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	118	11
16.7	48	4
33.3	133	12
50	110	10
66.7	220	20
83.3	126	12
100	334	31
<b>Total</b>	<b>1,089</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	21	1
8.3	12	1
16.7	32	2
25	36	2
33.3	83	4
41.7	84	5
50	150	8
58.3	161	9
66.7	242	13
75	248	13
83.3	240	13
91.7	224	12
100	347	19
<b>Total</b>	<b>1,880</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	16	1
16.7	24	1
33.3	78	4
50	134	7
66.7	284	15
83.3	484	25
100	885	47
<b>Total</b>	<b>1,905</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	73	4
16.7	60	3
33.3	168	9
50	211	11
66.7	375	20
83.3	298	16
100	699	37
<b>Total</b>	<b>1,884</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	214	11
11.1	166	9
22.2	255	14
33.3	417	22
44.4	245	13
55.6	192	10
66.7	165	9
77.8	78	4
88.9	76	4
100	85	5
<b>Total</b>	<b>1,893</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	1,342	70
16.7	278	15
33.3	164	9
50	56	3
66.7	40	2
83.3	13	1
100	14	1
<b>Total</b>	<b>1,907</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	730	38
16.7	319	17
33.3	340	18
50	185	10
66.7	161	9
83.3	70	4
100	96	5
<b>Total</b>	<b>1,901</b>	

**Lung cancer: males**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	181	22	308	37	224	27	129	15	842	
2) Long walk	PF	236	28	284	34	197	23	126	15	843	
3) Short walk	PF	532	63	213	25	71	8	28	3	844	
4) Bed or chair	PF	435	52	237	28	120	14	53	6	845	
5) Self care	PF	747	88	60	7	28	3	11	1	846	
6) Limited in work	RF	395	36	307	28	230	21	169	15	1,101	
7) Limited in leisure	RF	454	41	307	28	185	17	150	14	1,096	
8) Dyspnoea	DY	558	29	717	38	425	22	205	11	1,905	
9) Pain	PA	818	43	627	33	323	17	148	8	1,916	
10) Need to rest	FA	403	21	824	43	476	25	206	11	1,909	
11) Insomnia	SL	839	44	583	31	337	18	147	8	1,906	
12) Felt weak	FA	538	28	735	38	448	23	191	10	1,912	
13) Appetite loss	AP	998	52	454	24	294	15	166	9	1,912	
14) Nausea	NV	1,387	72	359	19	128	7	43	2	1,917	
15) Vomiting	NV	1,657	87	184	10	51	3	20	1	1,912	
16) Constipation	CO	1,195	63	390	20	209	11	115	6	1,909	
17) Diarrhoea	DI	1,583	83	253	13	58	3	16	1	1,910	
18) Felt tired	FA	423	22	888	46	437	23	166	9	1,914	
19) Pain interference	PA	1,030	54	471	25	257	14	148	8	1,906	
20) Concentration	CF	1,255	66	412	22	185	10	62	3	1,914	
21) Tension	EF	774	41	768	40	278	15	92	5	1,912	
22) Worry	EF	620	33	727	38	394	21	168	9	1,909	
23) Irritability	EF	923	49	683	36	238	13	59	3	1,903	
24) Depression	EF	829	44	711	37	257	14	106	6	1,903	
25) Memory trouble	CF	1,138	60	568	30	161	8	43	2	1,910	
26) Family life	SF	1,011	53	504	27	271	14	113	6	1,899	
27) Social activities	SF	837	44	561	30	323	17	175	9	1,896	
28) Financial difficulties	FI	1,261	66	343	18	192	10	104	6	1,900	
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>		
		<b>(very poor)</b>							<b>(excellent)</b>		
29) Overall health	QL	60	73	151	284	276	194	69		1,107	
		5	7	14	26	25	18	6			
30) Overall quality of life	QL	83	130	261	444	436	361	186		1,901	
		4	7	14	23	23	19	10			

## Lung cancer: females

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	298	36
v +3	8	1
v 2.0	136	16
v 3.0	388	47
Total	830	

#### Primary disease site

	N	(%)
Lung: small cell	236	28
Lung: non small cell	201	24
Mesothelioma	51	6
Lung: not known	342	41
Total	830	

#### Age

	N	(%)
<40	21	3
40-49	124	15
50-59	254	31
60-69	276	33
70-79	135	16
80+	19	2
Not known	1	0
Total	830	

#### Stage

	N	(%)
Stage I-II	149	18
Stage III-IV	187	23
Recurrent/metastatic	98	12
Not known	396	48
Total	830	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	56.1	(26)	58.3	[33.3-75]
Physical functioning	PF	69.3	(22.8)	73.3	[53.3-86.7]
Role Functioning	RF	60.7	(35.1)	66.7	[33.3-100]
Emotional functioning	EF	65.7	(26)	66.7	[50-83.3]
Cognitive functioning	CF	80.7	(24.2)	83.3	[66.7-100]
Social functioning	SF	67.4	(31.6)	66.7	[50-100]
Fatigue	FA	44.2	(28.4)	38.9	[22.2-66.7]
Nausea and vomiting	NV	13.8	(23.2)	0	[0-16.7]
Pain	PA	30.7	(32)	16.7	[0-50]
Dyspnoea	DY	38.2	(32.9)	33.3	[0-66.7]
Insomnia	SL	32.7	(32.8)	33.3	[0-66.7]
Appetite loss	AP	30.2	(34.7)	33.3	[0-66.7]
Constipation	CO	20.6	(30.8)	0	[0-33.3]
Diarrhoea	DI	8.1	(18.7)	0	[0-0]
Financial difficulties	FI	17.7	(28.8)	0	[0-33.3]

**Lung cancer: females**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	26	5
8.3	8	2
16.7	23	4
25	22	4
33.3	54	10
41.7	25	5
50	91	17
58.3	35	7
66.7	82	16
75	35	7
83.3	68	13
91.7	22	4
100	31	6
<b>Total</b>	<b>522</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	0
6.7	5	1
13.3	2	1
20	7	2
26.7	14	4
33.3	13	3
40	11	3
46.7	20	5
53.3	30	8
60	36	10
66.7	36	10
73.3	31	8
80	39	10
86.7	66	17
93.3	35	9
100	34	9
<b>Total</b>	<b>380</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	67	13
16.7	32	6
33.3	71	14
50	42	8
66.7	89	17
83.3	66	13
100	149	29
<b>Total</b>	<b>516</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	10	1
8.3	18	2
16.7	24	3
25	37	5
33.3	48	6
41.7	51	6
50	57	7
58.3	66	8
66.7	108	14
75	95	12
83.3	106	13
91.7	64	8
100	116	15
<b>Total</b>	<b>800</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	15	2
16.7	20	3
33.3	35	4
50	56	7
66.7	127	16
83.3	190	23
100	371	46
<b>Total</b>	<b>814</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	52	6
16.7	47	6
33.3	92	11
50	83	10
66.7	156	19
83.3	103	13
100	275	34
<b>Total</b>	<b>808</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	85	10
11.1	61	8
22.2	94	12
33.3	167	21
44.4	74	9
55.6	94	12
66.7	91	11
77.8	58	7
88.9	41	5
100	49	6
<b>Total</b>	<b>814</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	512	63
16.7	126	15
33.3	88	11
50	37	5
66.7	28	3
83.3	8	1
100	19	2
<b>Total</b>	<b>818</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	287	36
16.7	149	18
33.3	112	14
50	82	10
66.7	73	9
83.3	52	6
100	53	7
<b>Total</b>	<b>808</b>	

**Lung cancer: females**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total						
		N	(%)	N	(%)	N	(%)	N	(%)	N						
1) Strenuous activities	PF	50	13	158	41	102	27	72	19	382						
2) Long walk	PF	81	21	120	31	118	31	67	17	386						
3) Short walk	PF	222	58	105	27	43	11	16	4	386						
4) Bed or chair	PF	173	45	123	32	66	17	25	7	387						
5) Self care	PF	337	87	36	9	10	3	4	1	387						
6) Limited in work	RF	169	32	147	28	116	22	93	18	525						
7) Limited in leisure	RF	217	42	115	22	99	19	90	17	521						
8) Dyspnoea	DY	244	30	316	39	157	19	104	13	821						
9) Pain	PA	323	39	268	33	142	17	86	11	819						
10) Need to rest	FA	143	17	334	41	228	28	116	14	821						
11) Insomnia	SL	326	40	263	32	155	19	78	10	822						
12) Felt weak	FA	217	27	284	35	192	23	127	16	820						
13) Appetite loss	AP	394	48	205	25	130	16	93	11	822						
14) Nausea	NV	530	65	177	22	74	9	39	5	820						
15) Vomiting	NV	657	80	116	14	29	4	22	3	824						
16) Constipation	CO	508	62	174	21	81	10	57	7	820						
17) Diarrhoea	DI	664	82	112	14	32	4	7	1	815						
18) Felt tired	FA	156	19	342	42	232	28	92	11	822						
19) Pain interference	PA	426	52	175	22	123	15	90	11	814						
20) Concentration	CF	512	62	187	23	84	10	40	5	823						
21) Tension	EF	258	32	323	39	151	18	88	11	820						
22) Worry	EF	204	25	296	36	183	22	134	16	817						
23) Irritability	EF	407	50	264	32	106	13	42	5	819						
24) Depression	EF	284	35	317	39	133	16	80	10	814						
25) Memory trouble	CF	472	58	245	30	72	9	28	3	817						
26) Family life	SF	404	50	202	25	125	15	82	10	813						
27) Social activities	SF	320	39	218	27	154	19	125	15	817						
28) Financial difficulties	FI	542	67	155	19	74	9	43	5	814						
		<b>1</b>		<b>2</b>		<b>3</b>		<b>4</b>		<b>5</b>		<b>6</b>		<b>7</b>		<b>Total</b>
		<b>(very poor)</b>										<b>(excellent)</b>				
29) Overall health	QL	33	36	86	121	117	97	35			525					
		6	7	16	23	22	19	7								
30) Overall quality of life	QL	63	56	120	180	171	134	88			812					
		8	7	15	22	21	17	11								

## Lung cancer: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	105	21
v +3	3	1
v 2.0	188	38
v 3.0	205	41
Total	501	

#### Primary disease site

	N	(%)
Lung: small cell	84	17
Lung: non small cell	200	40
Mesothelioma	46	9
Lung: not known	171	34
Total	501	

#### Age

	N	(%)
<40	85	17
40-49	416	83
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	501	

#### Gender

	N	(%)
Male	224	45
Female	145	29
Not known	132	26
Total	501	

#### Stage

	N	(%)
Stage I-II	65	13
Stage III-IV	176	35
Recurrent/metastatic	44	9
Not known	216	43
Total	501	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	57.6	(22.2)	58.3	[41.7-75]
Physical functioning	PF	74.3	(21.1)	80	[60-93.3]
Role Functioning	RF	62.6	(31.6)	66.7	[33.3-83.3]
Emotional functioning	EF	65.2	(25.1)	66.7	[50-83.3]
Cognitive functioning	CF	83.1	(20.7)	83.3	[66.7-100]
Social functioning	SF	67.8	(28.3)	66.7	[50-100]
Fatigue	FA	39.5	(25.2)	33.3	[22.2-55.6]
Nausea and vomiting	NV	11.4	(19.5)	0	[0-16.7]
Pain	PA	32.3	(29.1)	33.3	[0-50]
Dyspnoea	DY	33.9	(30.5)	33.3	[0-66.7]
Insomnia	SL	36.4	(32.9)	33.3	[0-66.7]
Appetite loss	AP	24.8	(30.3)	0	[0-33.3]
Constipation	CO	14.5	(26.3)	0	[0-33.3]
Diarrhoea	DI	7.5	(17.8)	0	[0-0]
Financial difficulties	FI	25.2	(32.1)	0	[0-33.3]

**Lung cancer: <50**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	8	2
8.3	1	0
16.7	14	4
25	11	3
33.3	47	12
41.7	22	6
50	77	20
58.3	38	10
66.7	65	17
75	28	7
83.3	51	13
91.7	14	4
100	15	4
<b>Total</b>	<b>391</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	4	2
13.3	1	1
20	0	0
26.7	4	2
33.3	2	1
40	4	2
46.7	6	3
53.3	14	7
60	23	11
66.7	17	8
73.3	25	12
80	22	11
86.7	27	13
93.3	21	10
100	32	16
<b>Total</b>	<b>202</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	36	9
16.7	15	4
33.3	54	14
50	50	13
66.7	79	20
83.3	59	15
100	96	25
<b>Total</b>	<b>389</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	11	2
8.3	5	1
16.7	10	2
25	17	4
33.3	32	7
41.7	27	6
50	48	10
58.3	43	9
66.7	80	17
75	57	12
83.3	42	9
91.7	45	9
100	64	13
<b>Total</b>	<b>481</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	4	1
16.7	6	1
33.3	16	3
50	28	6
66.7	83	17
83.3	130	27
100	224	46
<b>Total</b>	<b>491</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	18	4
16.7	20	4
33.3	61	13
50	63	13
66.7	120	25
83.3	64	13
100	143	29
<b>Total</b>	<b>489</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	52	11
11.1	39	8
22.2	70	14
33.3	114	23
44.4	54	11
55.6	59	12
66.7	55	11
77.8	16	3
88.9	23	5
100	10	2
<b>Total</b>	<b>492</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	319	65
16.7	78	16
33.3	64	13
50	12	2
66.7	14	3
83.3	1	0
100	6	1
<b>Total</b>	<b>494</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	138	28
16.7	94	19
33.3	99	20
50	59	12
66.7	60	12
83.3	25	5
100	21	4
<b>Total</b>	<b>496</b>	

**Lung cancer: <50  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	43	21	84	41	57	28	19	9	203
2) Long walk	PF	62	30	64	31	62	30	17	8	205
3) Short walk	PF	132	64	55	27	13	6	5	2	205
4) Bed or chair	PF	93	46	71	35	28	14	12	6	204
5) Self care	PF	183	89	16	8	4	2	2	1	205
6) Limited in work	RF	116	30	134	34	89	23	53	14	392
7) Limited in leisure	RF	152	39	113	29	79	20	47	12	391
8) Dyspnoea	DY	164	33	202	41	92	19	40	8	498
9) Pain	PA	166	33	188	38	102	20	43	9	499
10) Need to rest	FA	93	19	229	46	137	28	39	8	498
11) Insomnia	SL	165	34	172	35	102	21	54	11	493
12) Felt weak	FA	151	30	187	38	124	25	36	7	498
13) Appetite loss	AP	256	51	142	29	71	14	29	6	498
14) Nausea	NV	336	67	121	24	30	6	13	3	500
15) Vomiting	NV	400	81	75	15	11	2	8	2	494
16) Constipation	CO	352	71	93	19	30	6	21	4	496
17) Diarrhoea	DI	405	82	69	14	15	3	4	1	493
18) Felt tired	FA	98	20	229	46	129	26	41	8	497
19) Pain interference	PA	215	43	151	30	101	20	31	6	498
20) Concentration	CF	282	57	141	28	54	11	18	4	495
21) Tension	EF	144	29	218	44	97	20	39	8	498
22) Worry	EF	105	21	192	39	133	27	67	14	497
23) Irritability	EF	197	40	192	39	71	15	28	6	488
24) Depression	EF	172	35	207	42	84	17	28	6	491
25) Memory trouble	CF	333	67	130	26	22	5	9	2	494
26) Family life	SF	222	45	153	31	84	17	33	7	492
27) Social activities	SF	169	34	163	33	114	23	46	9	492
28) Financial difficulties	FI	261	54	123	25	64	13	39	8	487
<hr/>										
		1	2	3	4	5	6	7	Total	
		(very poor)						(excellent)		
29) Overall health	QL	10	18	65	105	101	74	18	391	
		3	5	17	27	26	19	5		
30) Overall quality of life	QL	15	27	85	113	123	87	44	494	
		3	6	17	23	25	18	9		



## Lung cancer: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	280	29
v +3	5	1
v 2.0	259	27
v 3.0	427	44
Total	971	

#### Primary disease site

	N	(%)
Lung: small cell	227	23
Lung: non small cell	340	35
Mesothelioma	92	9
Lung: not known	312	32
Total	971	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	971	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	971	

#### Gender

	N	(%)
Male	548	56
Female	254	26
Not known	169	17
Total	971	

#### Stage

	N	(%)
Stage I-II	130	13
Stage III-IV	362	37
Recurrent/metastatic	76	8
Not known	403	42
Total	971	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	57.7	(23.5)	58.3	[41.7-75]
Physical functioning	PF	73.9	(21.2)	80	[60-86.7]
Role Functioning	RF	60.6	(33.8)	66.7	[33.3-100]
Emotional functioning	EF	67.2	(24)	66.7	[50-83.3]
Cognitive functioning	CF	82.9	(22.3)	83.3	[66.7-100]
Social functioning	SF	68.6	(29.9)	66.7	[50-100]
Fatigue	FA	40.0	(26.9)	33.3	[22.2-55.6]
Nausea and vomiting	NV	11.3	(19.8)	0	[0-16.7]
Pain	PA	31.3	(31.6)	16.7	[0-50]
Dyspnoea	DY	34.5	(32)	33.3	[0-66.7]
Insomnia	SL	32.4	(32.1)	33.3	[0-66.7]
Appetite loss	AP	27.0	(32.2)	0	[0-33.3]
Constipation	CO	16.3	(27.1)	0	[0-33.3]
Diarrhoea	DI	7.6	(17.9)	0	[0-0]
Financial difficulties	FI	22.0	(31.6)	0	[0-33.3]

**Lung cancer: 50-59**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	20	3
8.3	9	1
16.7	27	4
25	17	3
33.3	66	10
41.7	37	5
50	128	19
58.3	57	8
66.7	127	19
75	45	7
83.3	95	14
91.7	21	3
100	32	5
<b>Total</b>	<b>681</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	1	0
13.3	3	1
20	10	2
26.7	8	2
33.3	7	2
40	14	3
46.7	13	3
53.3	32	8
60	26	6
66.7	44	10
73.3	32	8
80	56	13
86.7	72	17
93.3	51	12
100	53	13
<b>Total</b>	<b>422</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	79	12
16.7	32	5
33.3	107	16
50	71	11
66.7	120	18
83.3	85	13
100	183	27
<b>Total</b>	<b>677</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	6	1
8.3	12	1
16.7	26	3
25	29	3
33.3	44	5
41.7	62	7
50	95	10
58.3	90	10
66.7	122	13
75	137	15
83.3	104	11
91.7	79	8
100	138	15
<b>Total</b>	<b>944</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	13	1
16.7	13	1
33.3	34	4
50	65	7
66.7	145	15
83.3	217	23
100	471	49
<b>Total</b>	<b>958</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	55	6
16.7	34	4
33.3	105	11
50	109	12
66.7	206	22
83.3	135	14
100	307	32
<b>Total</b>	<b>951</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	106	11
11.1	78	8
22.2	134	14
33.3	222	23
44.4	117	12
55.6	85	9
66.7	80	8
77.8	45	5
88.9	41	4
100	45	5
<b>Total</b>	<b>953</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	632	66
16.7	154	16
33.3	97	10
50	37	4
66.7	23	2
83.3	9	1
100	9	1
<b>Total</b>	<b>961</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	321	34
16.7	177	19
33.3	155	16
50	95	10
66.7	94	10
83.3	49	5
100	68	7
<b>Total</b>	<b>959</b>	

**Lung cancer: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total						
		N	(%)	N	(%)	N	(%)	N	(%)	N						
1) Strenuous activities	PF	83	20	159	37	119	28	64	15	425						
2) Long walk	PF	118	28	148	35	106	25	52	12	424						
3) Short walk	PF	277	65	97	23	44	10	8	2	426						
4) Bed or chair	PF	216	51	135	32	62	15	12	3	425						
5) Self care	PF	391	92	24	6	9	2	2	1	426						
6) Limited in work	RF	209	31	187	27	174	26	113	17	683						
7) Limited in leisure	RF	268	39	181	27	132	19	99	15	680						
8) Dyspnoea	DY	326	34	374	39	162	17	99	10	961						
9) Pain	PA	364	38	318	33	180	19	104	11	966						
10) Need to rest	FA	199	21	441	46	222	23	102	11	964						
11) Insomnia	SL	379	40	309	32	191	20	80	8	959						
12) Felt weak	FA	272	28	384	40	195	20	112	12	963						
13) Appetite loss	AP	486	51	242	25	162	17	71	7	961						
14) Nausea	NV	655	68	209	22	73	8	27	3	964						
15) Vomiting	NV	809	84	112	12	34	4	12	1	967						
16) Constipation	CO	651	68	193	20	80	8	39	4	963						
17) Diarrhoea	DI	785	82	135	14	32	3	7	1	959						
18) Felt tired	FA	191	20	470	49	208	22	93	10	962						
19) Pain interference	PA	485	51	237	25	137	14	101	11	960						
20) Concentration	CF	592	61	227	23	111	12	36	4	966						
21) Tension	EF	314	33	386	40	196	20	69	7	965						
22) Worry	EF	216	23	358	37	253	26	130	14	957						
23) Irritability	EF	455	47	347	36	132	14	26	3	960						
24) Depression	EF	364	38	385	40	145	15	63	7	957						
25) Memory trouble	CF	633	66	247	26	56	6	23	2	959						
26) Family life	SF	462	48	263	28	152	16	77	8	954						
27) Social activities	SF	369	39	283	30	194	20	113	12	959						
28) Financial difficulties	FI	575	60	206	22	103	11	73	8	957						
		<b>1</b>		<b>2</b>		<b>3</b>		<b>4</b>		<b>5</b>		<b>6</b>		<b>7</b>		<b>Total</b>
		<b>(very poor)</b>										<b>(excellent)</b>				
29) Overall health	QL	29	45	107	160	181	121	41		684						
		4	7	16	23	27	18	6								
30) Overall quality of life	QL	40	60	136	201	244	187	89		957						
		4	6	14	21	26	20	9								

## Lung cancer: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	430	39
v +3	19	2
v 2.0	245	22
v 3.0	414	37
Total	1,108	

#### Primary disease site

	N	(%)
Lung: small cell	238	21
Lung: non small cell	380	34
Mesothelioma	79	7
Lung: not known	411	37
Total	1,108	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	1,108	100
70-79	0	0
80+	0	0
Not known	0	0
Total	1,108	

#### Gender

	N	(%)
Male	692	63
Female	276	25
Not known	140	13
Total	1,108	

#### Stage

	N	(%)
Stage I-II	183	17
Stage III-IV	418	38
Recurrent/metastatic	110	10
Not known	397	36
Total	1,108	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	56.3	(25.2)	58.3	[41.7-75]
Physical functioning	PF	69.9	(24.1)	73.3	[53.3-86.7]
Role Functioning	RF	61.4	(35.6)	66.7	[33.3-100]
Emotional functioning	EF	70.2	(23.9)	75	[58.3-91.7]
Cognitive functioning	CF	82.6	(21.9)	83.3	[66.7-100]
Social functioning	SF	73.2	(29.4)	83.3	[50-100]
Fatigue	FA	41.6	(27.6)	33.3	[22.2-55.6]
Nausea and vomiting	NV	10.5	(19.9)	0	[0-16.7]
Pain	PA	29.2	(31)	16.7	[0-50]
Dyspnoea	DY	39.9	(32.5)	33.3	[0-66.7]
Insomnia	SL	29.9	(32.5)	33.3	[0-66.7]
Appetite loss	AP	29.6	(34.6)	33.3	[0-66.7]
Constipation	CO	20.7	(30.9)	0	[0-33.3]
Diarrhoea	DI	7.7	(18.5)	0	[0-0]
Financial difficulties	FI	14.9	(27.3)	0	[0-33.3]

**Lung cancer: 60-69**  
**Constructed scales**

QL	N	(%)
0	29	4
8.3	11	2
16.7	33	5
25	14	2
33.3	68	10
41.7	36	5
50	132	20
58.3	54	8
66.7	105	16
75	45	7
83.3	78	12
91.7	24	4
100	42	6
Total	671	

PF	N	(%)
0	2	1
6.7	4	1
13.3	5	1
20	10	3
26.7	20	5
33.3	10	3
40	12	3
46.7	18	5
53.3	24	6
60	30	7
66.7	33	8
73.3	44	11
80	43	11
86.7	56	14
93.3	49	12
100	43	11
Total	403	

RF	N	(%)
0	90	14
16.7	36	5
33.3	92	14
50	43	7
66.7	123	19
83.3	67	10
100	210	32
Total	661	

EF	N	(%)
0	13	1
8.3	13	1
16.7	19	2
25	28	3
33.3	49	5
41.7	51	5
50	74	7
58.3	94	9
66.7	148	14
75	141	13
83.3	156	15
91.7	120	11
100	170	16
Total	1,076	

CF	N	(%)
0	10	1
16.7	16	2
33.3	48	4
50	70	6
66.7	160	15
83.3	275	25
100	513	47
Total	1,092	

SF	N	(%)
0	53	5
16.7	36	3
33.3	93	9
50	106	10
66.7	197	18
83.3	167	15
100	436	40
Total	1,088	

FA	N	(%)
0	128	12
11.1	86	8
22.2	134	12
33.3	216	20
44.4	133	12
55.6	118	11
66.7	110	10
77.8	59	5
88.9	48	4
100	54	5
Total	1,086	

NV	N	(%)
0	755	69
16.7	153	14
33.3	94	9
50	45	4
66.7	22	2
83.3	11	1
100	12	1
Total	1,092	

PA	N	(%)
0	404	37
16.7	179	17
33.3	185	17
50	106	10
66.7	93	9
83.3	54	5
100	66	6
Total	1,087	

**Lung cancer: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	79	19	142	35	102	25	85	21	408	
2) Long walk	PF	91	22	132	32	101	25	88	21	412	
3) Short walk	PF	239	58	111	27	41	10	20	5	411	
4) Bed or chair	PF	211	51	108	26	62	15	33	8	414	
5) Self care	PF	362	87	36	9	12	3	4	1	414	
6) Limited in work	RF	245	37	166	25	134	20	120	18	665	
7) Limited in leisure	RF	270	41	160	24	118	18	118	18	666	
8) Dyspnoea	DY	303	28	404	37	255	23	131	12	1,093	
9) Pain	PA	450	41	347	32	199	18	104	10	1,100	
10) Need to rest	FA	228	21	424	39	310	28	137	13	1,099	
11) Insomnia	SL	492	45	321	29	196	18	92	8	1,101	
12) Felt weak	FA	313	28	387	35	271	25	130	12	1,101	
13) Appetite loss	AP	543	49	257	23	183	17	119	11	1,102	
14) Nausea	NV	778	71	203	19	82	8	36	3	1,099	
15) Vomiting	NV	933	85	117	11	29	3	16	2	1,095	
16) Constipation	CO	681	62	221	20	117	11	75	7	1,094	
17) Diarrhoea	DI	900	82	148	14	33	3	13	1	1,094	
18) Felt tired	FA	238	22	471	43	287	26	101	9	1,097	
19) Pain interference	PA	582	53	255	23	154	14	102	9	1,093	
20) Concentration	CF	723	66	231	21	103	9	42	4	1,099	
21) Tension	EF	396	36	454	41	181	17	66	6	1,097	
22) Worry	EF	327	30	419	38	235	22	114	10	1,095	
23) Irritability	EF	556	51	375	34	122	11	40	4	1,093	
24) Depression	EF	447	41	416	38	155	14	73	7	1,091	
25) Memory trouble	CF	659	60	316	29	95	9	24	2	1,094	
26) Family life	SF	623	57	266	24	135	12	71	7	1,095	
27) Social activities	SF	503	46	290	27	174	16	125	11	1,092	
28) Financial difficulties	FI	793	72	160	15	97	9	45	4	1,095	
		<b>1</b>		<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>	
		<b>(very poor)</b>									
29) Overall health	QL	40	47	78	202	152	107	46		672	
		6	7	12	30	23	16	7			
30) Overall quality of life	QL	57	75	156	276	220	198	107		1,089	
		5	7	14	25	20	18	10			

## Lung cancer: ≥70

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	308	47
v +3	11	2
v 2.0	140	21
v 3.0	197	30
Total	656	

#### Primary disease site

	N	(%)
Lung: small cell	109	17
Lung: non small cell	252	38
Mesothelioma	19	3
Lung: not known	276	42
Total	656	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	596	91
80+	60	9
Not known	0	0
Total	656	

#### Gender

	N	(%)
Male	457	70
Female	154	24
Not known	45	7
Total	656	

#### Stage

	N	(%)
Stage I-II	154	24
Stage III-IV	267	41
Recurrent/metastatic	77	12
Not known	158	24
Total	656	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	54.4	(26.7)	58.3	[33.3-75]
Physical functioning	PF	68.2	(25.6)	73.3	[53.3-86.7]
Role Functioning	RF	61.3	(33.9)	66.7	[33.3-100]
Emotional functioning	EF	72.9	(24.8)	75	[58.3-91.7]
Cognitive functioning	CF	79.8	(23)	83.3	[66.7-100]
Social functioning	SF	74.9	(28.8)	83.3	[58.3-100]
Fatigue	FA	43.0	(28.7)	33.3	[22.2-66.7]
Nausea and vomiting	NV	9.9	(19.8)	0	[0-16.7]
Pain	PA	25.4	(30.6)	16.7	[0-50]
Dyspnoea	DY	42.4	(32.5)	33.3	[33.3-66.7]
Insomnia	SL	28.9	(32.7)	33.3	[0-33.3]
Appetite loss	AP	29.4	(36)	0	[0-66.7]
Constipation	CO	25.5	(33)	0	[0-33.3]
Diarrhoea	DI	6.4	(17)	0	[0-0]
Financial difficulties	FI	8.7	(21)	0	[0-0]

**Lung cancer: ≥70  
Constructed scales**

QL	N	(%)
0	21	6
8.3	8	2
16.7	18	5
25	15	4
33.3	29	9
41.7	16	5
50	54	16
58.3	28	8
66.7	58	17
75	25	7
83.3	33	10
91.7	15	4
100	18	5
Total	338	

PF	N	(%)
0	3	2
6.7	3	2
13.3	3	2
20	5	3
26.7	9	5
33.3	7	4
40	7	4
46.7	7	4
53.3	8	4
60	11	6
66.7	22	11
73.3	16	8
80	23	12
86.7	28	15
93.3	26	14
100	15	8
Total	193	

RF	N	(%)
0	36	11
16.7	24	7
33.3	39	12
50	35	11
66.7	69	21
83.3	32	10
100	95	29
Total	330	

EF	N	(%)
0	5	1
8.3	8	1
16.7	14	2
25	16	3
33.3	30	5
41.7	25	4
50	40	6
58.3	43	7
66.7	72	11
75	62	10
83.3	91	15
91.7	84	13
100	139	22
Total	629	

CF	N	(%)
0	5	1
16.7	15	2
33.3	33	5
50	60	9
66.7	94	15
83.3	176	27
100	262	41
Total	645	

SF	N	(%)
0	25	4
16.7	24	4
33.3	44	7
50	64	10
66.7	104	17
83.3	98	16
100	269	43
Total	628	

FA	N	(%)
0	67	11
11.1	58	9
22.2	81	13
33.3	114	18
44.4	78	12
55.6	71	11
66.7	62	10
77.8	31	5
88.9	28	4
100	47	7
Total	637	

NV	N	(%)
0	462	72
16.7	82	13
33.3	52	8
50	22	3
66.7	15	2
83.3	2	0
100	10	2
Total	645	

PA	N	(%)
0	290	46
16.7	89	14
33.3	87	14
50	58	9
66.7	50	8
83.3	25	4
100	34	5
Total	633	



**Lung cancer: ≥70  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	27	14	83	42	50	26	36	18	196
2) Long walk	PF	48	25	61	31	49	25	38	19	196
3) Short walk	PF	109	56	58	30	18	9	11	6	196
4) Bed or chair	PF	93	47	49	25	34	17	21	11	197
5) Self care	PF	155	79	21	11	13	7	7	4	196
6) Limited in work	RF	114	33	93	27	76	22	58	17	341
7) Limited in leisure	RF	126	38	97	29	58	17	52	16	333
8) Dyspnoea	DY	158	24	242	37	162	25	86	13	648
9) Pain	PA	313	49	181	28	93	15	55	9	642
10) Need to rest	FA	118	18	260	40	164	26	101	16	643
11) Insomnia	SL	302	47	181	28	104	16	56	9	643
12) Felt weak	FA	175	27	229	36	159	25	81	13	644
13) Appetite loss	AP	336	52	134	21	94	15	83	13	647
14) Nausea	NV	476	74	100	15	55	9	17	3	648
15) Vomiting	NV	563	87	59	9	17	3	11	2	650
16) Constipation	CO	354	55	145	23	90	14	56	9	645
17) Diarrhoea	DI	551	85	71	11	19	3	5	1	646
18) Felt tired	FA	144	22	266	41	156	24	81	13	647
19) Pain interference	PA	381	60	123	19	82	13	54	8	640
20) Concentration	CF	439	68	117	18	66	10	27	4	649
21) Tension	EF	289	45	223	35	88	14	44	7	644
22) Worry	EF	248	38	211	33	123	19	64	10	646
23) Irritability	EF	359	56	184	29	77	12	22	3	642
24) Depression	EF	304	47	209	33	86	13	45	7	644
25) Memory trouble	CF	320	49	222	34	86	13	20	3	648
26) Family life	SF	385	60	134	21	79	12	40	6	638
27) Social activities	SF	316	50	156	25	100	16	65	10	637
28) Financial difficulties	FI	530	83	65	10	38	6	9	1	642
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	32	24	51	74	84	54	22		341
		9	7	15	22	25	16	7		
30) Overall quality of life	QL	49	48	82	142	156	96	69		642
		8	8	13	22	24	15	11		

## Lung cancer: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	242	45
v +3	2	0
v 2.0	249	46
v 3.0	45	8
Total	538	

#### Primary disease site

	N	(%)
Lung: small cell	4	1
Lung: non small cell	17	3
Lung: not known	517	96
Total	538	

#### Age

	N	(%)
<40	13	2
40-49	52	10
50-59	130	24
60-69	183	34
70-79	140	26
80+	14	3
Not known	6	1
Total	538	

#### Gender

	N	(%)
Male	385	72
Female	149	28
Not known	4	1
Total	538	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	52.1	(25.9)	50	[33.3-66.7]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	64.9	(35.8)	66.7	[33.3-100]
Emotional functioning	EF	66.3	(26.4)	66.7	[50-91.7]
Cognitive functioning	CF	81.5	(21.8)	83.3	[66.7-100]
Social functioning	SF	71.0	(30.3)	83.3	[50-100]
Fatigue	FA	38.6	(28)	33.3	[16.7-55.6]
Nausea and vomiting	NV	8.6	(19.2)	0	[0-0]
Pain	PA	28.3	(31)	16.7	[0-50]
Dyspnoea	DY	42.7	(34.4)	33.3	[0-66.7]
Insomnia	SL	31.6	(33.9)	33.3	[0-66.7]
Appetite loss	AP	24.1	(33.7)	0	[0-33.3]
Constipation	CO	15.0	(26.9)	0	[0-33.3]
Diarrhoea	DI	6.7	(17.1)	0	[0-0]
Financial difficulties	FI	16.5	(28.1)	0	[0-33.3]

**Lung cancer: stage I-II  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	17	6
8.3	3	1
16.7	18	6
25	13	5
33.3	39	14
41.7	17	6
50	47	16
58.3	27	9
66.7	42	15
75	12	4
83.3	27	9
91.7	10	4
100	15	5
Total	287	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	4	1
16.7	7	1
33.3	21	4
50	49	9
66.7	86	16
83.3	129	24
100	237	45
Total	533	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	28	5
16.7	26	5
33.3	40	8
50	65	12
66.7	95	18
83.3	75	14
100	198	38
Total	527	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	79	15
11.1	53	10
22.2	70	13
33.3	99	19
44.4	50	10
55.6	55	10
66.7	48	9
77.8	31	6
88.9	25	5
100	18	3
Total	528	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	34	12
16.7	19	7
33.3	23	8
50	27	10
66.7	37	13
83.3	35	13
100	101	37
Total	276	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	405	76
16.7	63	12
33.3	28	5
50	17	3
66.7	10	2
83.3	6	1
100	6	1
Total	535	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	8	2
8.3	10	2
16.7	15	3
25	23	4
33.3	32	6
41.7	31	6
50	45	9
58.3	53	10
66.7	45	9
75	59	11
83.3	64	12
91.7	58	11
100	79	15
Total	522	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	211	40
16.7	78	15
33.3	79	15
50	54	10
66.7	48	9
83.3	25	5
100	29	6
Total	524	

**Lung cancer: stage I-II  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	1	2	16	36	15	34	12	27	44
2) Long walk	PF	4	9	18	40	14	31	9	20	45
3) Short walk	PF	14	32	24	55	4	9	2	5	44
4) Bed or chair	PF	8	18	17	38	16	36	4	9	45
5) Self care	PF	33	73	6	13	6	13	0	0	45
6) Limited in work	RF	110	39	57	20	61	21	57	20	285
7) Limited in leisure	RF	148	53	50	18	43	15	39	14	280
8) Dyspnoea	DY	147	28	169	32	133	25	82	15	531
9) Pain	PA	241	45	148	28	98	18	45	9	532
10) Need to rest	FA	133	25	204	38	131	25	65	12	533
11) Insomnia	SL	235	44	144	27	99	19	54	10	532
12) Felt weak	FA	196	37	150	28	123	23	61	12	530
13) Appetite loss	AP	314	59	106	20	60	11	53	10	533
14) Nausea	NV	418	78	73	14	24	5	21	4	536
15) Vomiting	NV	473	88	42	8	13	2	8	2	536
16) Constipation	CO	384	72	81	15	51	10	19	4	535
17) Diarrhoea	DI	450	84	65	12	15	3	4	1	534
18) Felt tired	FA	143	27	220	41	129	24	44	8	536
19) Pain interference	PA	288	54	110	21	83	16	48	9	529
20) Concentration	CF	332	62	123	23	61	11	21	4	537
21) Tension	EF	220	41	167	31	97	18	48	9	532
22) Worry	EF	132	25	174	33	127	24	99	19	532
23) Irritability	EF	257	48	169	32	79	15	28	5	533
24) Depression	EF	218	41	162	31	95	18	55	10	530
25) Memory trouble	CF	317	59	162	30	42	8	13	2	534
26) Family life	SF	276	52	129	24	81	15	45	9	531
27) Social activities	SF	245	46	137	26	85	16	64	12	531
28) Financial difficulties	FI	367	69	83	16	58	11	21	4	529
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
29) Overall health	QL	23	23	56	69	56	45	17		289
		8	8	19	24	19	16	6		
30) Overall quality of life	QL	30	43	85	123	113	79	53		526
		6	8	16	23	22	15	10		

## Lung cancer: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	498	38
v +3	0	0
v 2.0	472	36
v 3.0	343	26
Total	1,313	

#### Primary disease

	N	(%)
Lung: small cell	1	0
Lung: non small cell	1,046	80
Lung: not known	266	20
Total	1,313	

#### Age

	N	(%)
<40	34	3
40-49	142	11
50-59	362	28
60-69	418	32
70-79	238	18
80+	29	2
Not known	90	7
Total	1,313	

#### Gender

	N	(%)
Male	580	44
Female	187	14
Not known	546	42
Total	1,313	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	54.7	(23.8)	58.3	[41.7-66.7]
Physical functioning	PF	65.9	(25.6)	73.3	[46.7-86.7]
Role Functioning	RF	55.5	(34.5)	66.7	[33.3-83.3]
Emotional functioning	EF	67.3	(24.1)	66.7	[50-83.3]
Cognitive functioning	CF	81.6	(22.7)	83.3	[66.7-100]
Social functioning	SF	69.8	(30.3)	66.7	[50-100]
Fatigue	FA	44.2	(27.5)	44.4	[22.2-66.7]
Nausea and vomiting	NV	10.8	(19.1)	0	[0-16.7]
Pain	PA	34.7	(32.3)	33.3	[0-66.7]
Dyspnoea	DY	40.7	(32.2)	33.3	[0-66.7]
Insomnia	SL	34.8	(33.4)	33.3	[0-66.7]
Appetite loss	AP	31.1	(34.6)	33.3	[0-66.7]
Constipation	CO	22.2	(31.7)	0	[0-33.3]
Diarrhoea	DI	7.3	(18.1)	0	[0-0]
Financial difficulties	FI	15.0	(27.9)	0	[0-33.3]

**Lung cancer: stage III-IV  
Constructed scales**

QL	N	(%)
0	30	4
8.3	11	1
16.7	38	5
25	23	3
33.3	96	12
41.7	49	6
50	152	19
58.3	76	10
66.7	140	18
75	49	6
83.3	78	10
91.7	28	4
100	32	4
Total	802	

PF	N	(%)
0	2	1
6.7	4	1
13.3	6	2
20	14	4
26.7	21	6
33.3	8	2
40	17	5
46.7	13	4
53.3	26	8
60	28	8
66.7	27	8
73.3	34	10
80	32	10
86.7	41	12
93.3	30	9
100	35	10
Total	338	

RF	N	(%)
0	121	15
16.7	48	6
33.3	135	17
50	83	10
66.7	152	19
83.3	84	11
100	179	22
Total	802	

EF	N	(%)
0	10	1
8.3	18	1
16.7	29	2
25	39	3
33.3	66	5
41.7	72	6
50	133	11
58.3	117	9
66.7	173	14
75	153	12
83.3	142	11
91.7	138	11
100	169	13
Total	1,259	

CF	N	(%)
0	11	1
16.7	24	2
33.3	65	5
50	95	7
66.7	193	15
83.3	310	24
100	593	46
Total	1,291	

SF	N	(%)
0	69	5
16.7	50	4
33.3	139	11
50	146	11
66.7	244	19
83.3	170	13
100	459	36
Total	1,277	

FA	N	(%)
0	120	9
11.1	93	7
22.2	150	12
33.3	245	19
44.4	177	14
55.6	142	11
66.7	148	12
77.8	68	5
88.9	66	5
100	74	6
Total	1,283	

NV	N	(%)
0	871	67
16.7	179	14
33.3	151	12
50	52	4
66.7	21	2
83.3	9	1
100	12	1
Total	1,295	

PA	N	(%)
0	391	30
16.7	205	16
33.3	209	16
50	148	12
66.7	154	12
83.3	84	7
100	96	8
Total	1,287	

**Lung cancer: stage III-IV  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	62	18	101	30	100	29	78	23	341
2) Long walk	PF	71	21	87	26	100	29	83	24	341
3) Short walk	PF	174	51	102	30	45	13	21	6	342
4) Bed or chair	PF	150	44	82	24	80	23	31	9	343
5) Self care	PF	281	82	39	11	18	5	4	1	342
6) Limited in work	RF	213	27	216	27	207	26	169	21	805
7) Limited in leisure	RF	257	32	229	28	165	21	154	19	805
8) Dyspnoea	DY	341	26	490	38	315	24	156	12	1,302
9) Pain	PA	445	34	404	31	294	23	160	12	1,303
10) Need to rest	FA	209	16	530	41	378	29	188	14	1,305
11) Insomnia	SL	486	38	405	31	268	21	137	11	1,296
12) Felt weak	FA	332	25	481	37	337	26	155	12	1,305
13) Appetite loss	AP	610	47	315	24	241	19	140	11	1,306
14) Nausea	NV	901	69	270	21	100	8	34	3	1,305
15) Vomiting	NV	1,092	84	157	12	30	2	18	1	1,297
16) Constipation	CO	779	60	266	21	155	12	95	7	1,295
17) Diarrhoea	DI	1,079	83	163	13	41	3	13	1	1,296
18) Felt tired	FA	238	18	551	43	354	27	151	12	1,294
19) Pain interference	PA	589	46	326	25	234	18	146	11	1,295
20) Concentration	CF	798	61	291	22	161	12	51	4	1,301
21) Tension	EF	405	31	508	39	293	23	95	7	1,301
22) Worry	EF	323	25	458	35	361	28	154	12	1,296
23) Irritability	EF	628	49	454	35	165	13	36	3	1,283
24) Depression	EF	474	37	525	41	209	16	80	6	1,288
25) Memory trouble	CF	804	62	342	26	114	9	34	3	1,294
26) Family life	SF	683	53	319	25	192	15	93	7	1,287
27) Social activities	SF	525	41	326	25	282	22	157	12	1,290
28) Financial difficulties	FI	941	73	186	14	103	8	63	5	1,293
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	43	58	128	224	196	114	42		805
		5	7	16	28	24	14	5		
30) Overall quality of life	QL	66	92	213	291	323	202	106		1,293
		5	7	17	23	25	16	8		

## Lung cancer: recurrent/metastatic

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	116	38
v +3	5	2
v 2.0	89	29
v 3.0	97	32
Total	307	

#### Primary disease site

	N	(%)
Lung: small cell	115	37
Lung: non small cell	11	4
Mesothelioma	6	2
Lung: not known	175	57
Total	307	

#### Age

	N	(%)
<40	4	1
40-49	40	13
50-59	76	25
60-69	110	36
70-79	68	22
80+	9	3
Not known	0	0
Total	307	

#### Gender

	N	(%)
Male	197	64
Female	98	32
Not known	12	4
Total	307	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	43.5	(28.2)	50	[16.7-66.7]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	47.0	(33.9)	50	[16.7-66.7]
Emotional functioning	EF	64.7	(25.7)	66.7	[50-83.3]
Cognitive functioning	CF	74.6	(26.6)	83.3	[66.7-100]
Social functioning	SF	64.6	(31.4)	66.7	[33.3-100]
Fatigue	FA	51.6	(28.7)	44.4	[33.3-66.7]
Nausea and vomiting	NV	16.1	(26.2)	0	[0-16.7]
Pain	PA	40.5	(33.5)	33.3	[16.7-66.7]
Dyspnoea	DY	42.8	(34.3)	33.3	[0-66.7]
Insomnia	SL	36.4	(32.8)	33.3	[0-66.7]
Appetite loss	AP	34.7	(37)	33.3	[0-66.7]
Constipation	CO	34.0	(36.5)	33.3	[0-66.7]
Diarrhoea	DI	12.4	(23.4)	0	[0-33.3]
Financial difficulties	FI	22.3	(31.3)	0	[0-33.3]



**Lung cancer: recurrent/metastatic  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	22	12
8.3	10	5
16.7	17	9
25	7	4
33.3	22	12
41.7	12	7
50	40	22
58.3	7	4
66.7	13	7
75	10	5
83.3	12	7
91.7	6	3
100	7	4
Total	185	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	9	3
16.7	9	3
33.3	21	7
50	35	12
66.7	48	16
83.3	77	25
100	104	34
Total	303	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	21	7
16.7	14	5
33.3	42	14
50	39	13
66.7	53	18
83.3	43	15
100	85	29
Total	297	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	15	5
11.1	17	6
22.2	29	10
33.3	59	20
44.4	35	12
55.6	28	9
66.7	43	14
77.8	19	6
88.9	20	7
100	34	11
Total	299	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	39	21
16.7	12	7
33.3	35	19
50	22	12
66.7	35	19
83.3	15	8
100	26	14
Total	184	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	180	60
16.7	45	15
33.3	35	12
50	12	4
66.7	11	4
83.3	3	1
100	13	4
Total	299	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	8	3
8.3	3	1
16.7	9	3
25	10	3
33.3	22	7
41.7	17	6
50	30	10
58.3	21	7
66.7	32	11
75	45	15
83.3	46	15
91.7	21	7
100	35	12
Total	299	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	68	23
16.7	51	17
33.3	53	18
50	35	12
66.7	36	12
83.3	23	8
100	35	12
Total	301	

**Lung cancer: recurrent/metastatic**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	35	19	57	30	45	24	51	27	188
7) Limited in leisure	RF	43	23	46	25	43	23	54	29	186
8) Dyspnoea	DY	79	26	109	36	65	22	50	17	303
9) Pain	PA	81	27	104	34	70	23	48	16	303
10) Need to rest	FA	30	10	119	40	96	32	55	18	300
11) Insomnia	SL	102	34	101	33	68	23	31	10	302
12) Felt weak	FA	45	15	105	35	89	29	64	21	303
13) Appetite loss	AP	131	43	78	26	45	15	49	16	303
14) Nausea	NV	186	62	63	21	34	11	19	6	302
15) Vomiting	NV	238	79	38	13	11	4	15	5	302
16) Constipation	CO	133	44	75	25	49	16	45	15	302
17) Diarrhoea	DI	222	74	52	17	21	7	6	2	301
18) Felt tired	FA	48	16	113	37	84	28	58	19	303
19) Pain interference	PA	116	39	82	27	47	16	56	19	301
20) Concentration	CF	169	56	71	23	38	13	26	9	304
21) Tension	EF	85	28	137	45	54	18	27	9	303
22) Worry	EF	83	28	103	34	76	25	40	13	302
23) Irritability	EF	130	43	97	32	54	18	20	7	301
24) Depression	EF	103	34	118	39	49	16	33	11	303
25) Memory trouble	CF	136	45	112	37	41	14	14	5	303
26) Family life	SF	137	46	74	25	57	19	31	10	299
27) Social activities	SF	101	34	95	32	52	17	51	17	299
28) Financial difficulties	FI	176	59	69	23	33	11	22	7	300
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	30	25	33	45	25	20	8		186
		16	13	18	24	13	11	4		
30) Overall quality of life	QL	39	34	50	76	42	33	23		297
		13	11	17	26	14	11	8		

## Small cell lung cancer: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N (%)	
v 1.0	211	32
v +3	0	0
v 2.0	8	1
v 3.0	439	67
Total	658	

#### Age

	N (%)	
<40	5	1
40-49	79	12
50-59	227	35
60-69	238	36
70-79	105	16
80+	4	1
Not known	0	0
Total	658	

#### Gender

	N (%)	
Male	407	62
Female	236	36
Not known	15	2
Total	658	

#### Stage

	N (%)	
Stage I-II	4	1
Stage III-IV	1	0
Recurrent/metastatic	115	18
Not known	538	82
Total	658	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	67.1	(20.4)	66.7	[50-83.3]
Physical functioning	PF	78.7	(18.7)	86.7	[66.7-93.3]
Role Functioning	RF	73.9	(29.8)	83.3	[66.7-100]
Emotional functioning	EF	75.9	(21.7)	83.3	[66.7-91.7]
Cognitive functioning	CF	85.7	(19.7)	100	[83.3-100]
Social functioning	SF	76.0	(26.1)	83.3	[66.7-100]
Fatigue	FA	36.4	(25.3)	33.3	[22.2-55.6]
Nausea and vomiting	NV	9.9	(17.6)	0	[0-16.7]
Pain	PA	18.4	(24.8)	0	[0-33.3]
Dyspnoea	DY	31.8	(29.8)	33.3	[0-33.3]
Insomnia	SL	23.1	(27.8)	0	[0-33.3]
Appetite loss	AP	24.3	(30.4)	0	[0-33.3]
Constipation	CO	15.6	(26.1)	0	[0-33.3]
Diarrhoea	DI	7.3	(16)	0	[0-0]
Financial difficulties	FI	17.0	(28.8)	0	[0-33.3]

**Small cell lung cancer: all stages**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	1	0
8.3	1	0
16.7	11	3
25	3	1
33.3	23	5
41.7	20	5
50	69	16
58.3	32	7
66.7	94	21
75	39	9
83.3	92	21
91.7	22	5
100	38	9
Total	445	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	0	0
13.3	1	0
20	3	1
26.7	5	1
33.3	7	2
40	8	2
46.7	16	4
53.3	20	5
60	23	5
66.7	40	9
73.3	35	8
80	51	12
86.7	76	18
93.3	78	18
100	68	16
Total	431	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	25	6
16.7	11	3
33.3	38	9
50	33	8
66.7	80	18
83.3	70	16
100	181	41
Total	438	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	6	1
8.3	2	0
16.7	11	2
25	9	1
33.3	10	2
41.7	21	3
50	33	5
58.3	43	7
66.7	94	15
75	84	13
83.3	100	16
91.7	85	13
100	137	22
Total	635	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	6	1
16.7	5	1
33.3	16	3
50	29	5
66.7	86	13
83.3	171	27
100	332	52
Total	645	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	18	3
16.7	18	3
33.3	38	6
50	57	9
66.7	141	22
83.3	120	19
100	250	39
Total	642	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	82	13
11.1	60	9
22.2	87	14
33.3	180	28
44.4	67	11
55.6	54	8
66.7	49	8
77.8	21	3
88.9	18	3
100	22	3
Total	640	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	427	66
16.7	121	19
33.3	56	9
50	23	4
66.7	10	2
83.3	2	0
100	5	1
Total	644	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	334	52
16.7	109	17
33.3	97	15
50	46	7
66.7	35	5
83.3	8	1
100	15	2
Total	644	

**Small cell lung cancer: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	111	26	177	41	103	24	44	10	435
2) Long walk	PF	141	32	154	35	93	21	47	11	435
3) Short walk	PF	330	76	77	18	25	6	5	1	437
4) Bed or chair	PF	268	61	116	27	45	10	9	2	438
5) Self care	PF	423	97	11	3	3	1	1	0	438
6) Limited in work	RF	209	47	124	28	77	17	32	7	442
7) Limited in leisure	RF	240	55	118	27	47	11	35	8	440
8) Dyspnoea	DY	226	35	271	42	103	16	47	7	647
9) Pain	PA	358	55	207	32	63	10	20	3	648
10) Need to rest	FA	157	24	318	49	131	20	40	6	646
11) Insomnia	SL	331	51	205	32	87	14	23	4	646
12) Felt weak	FA	179	28	281	44	127	20	59	9	646
13) Appetite loss	AP	342	53	177	27	88	14	39	6	646
14) Nausea	NV	443	68	149	23	45	7	12	2	649
15) Vomiting	NV	558	86	78	12	11	2	5	1	652
16) Constipation	CO	437	68	141	22	45	7	24	4	647
17) Diarrhoea	DI	519	81	106	17	16	3	1	0	642
18) Felt tired	FA	138	21	348	54	119	18	44	7	649
19) Pain interference	PA	427	66	139	22	55	9	24	4	645
20) Concentration	CF	474	73	122	19	34	5	18	3	648
21) Tension	EF	280	43	279	43	63	10	27	4	649
22) Worry	EF	242	38	278	43	82	13	43	7	645
23) Irritability	EF	351	54	230	35	51	8	17	3	649
24) Depression	EF	302	47	259	40	57	9	24	4	642
25) Memory trouble	CF	386	60	220	34	31	5	11	2	648
26) Family life	SF	367	57	181	28	66	10	31	5	645
27) Social activities	SF	299	46	215	33	84	13	47	7	645
28) Financial difficulties	FI	440	68	118	18	52	8	36	6	646
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	2	12	39	95	138	117	42		445
		0	3	9	21	31	26	9		
30) Overall quality of life	QL	16	31	73	129	155	153	88		645
		3	5	11	20	24	24	14		

## Small cell lung cancer: limited disease

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	97	18
v +3	0	0
v 2.0	0	0
v 3.0	439	82
Total	536	

#### Age

	N	(%)
<40	5	1
40-49	72	13
50-59	195	36
60-69	184	34
70-79	77	14
80+	3	1
Not known	0	0
Total	536	

#### Gender

	N	(%)
Male	328	61
Female	197	37
Not known	11	2
Total	536	

#### Stage

	N	(%)
Stage I-II	0	0
Stage III-IV	0	0
Recurrent/metastatic	0	0
Not known	536	100
Total	536	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	67.0	(20.3)	66.7	[50-83.3]
Physical functioning	PF	78.7	(18.7)	86.7	[66.7-93.3]
Role Functioning	RF	73.9	(29.5)	83.3	[66.7-100]
Emotional functioning	EF	76.9	(21.4)	83.3	[66.7-91.7]
Cognitive functioning	CF	86.3	(19.1)	100	[83.3-100]
Social functioning	SF	76.2	(26.2)	83.3	[66.7-100]
Fatigue	FA	34.9	(25.2)	33.3	[22.2-44.4]
Nausea and vomiting	NV	9.6	(17.4)	0	[0-16.7]
Pain	PA	15.1	(22.6)	0	[0-33.3]
Dyspnoea	DY	29.1	(29.2)	33.3	[0-33.3]
Insomnia	SL	21.5	(27.4)	0	[0-33.3]
Appetite loss	AP	22.8	(29.9)	0	[0-33.3]
Constipation	CO	12.8	(23.9)	0	[0-33.3]
Diarrhoea	DI	6.1	(14.8)	0	[0-0]
Financial difficulties	FI	18.0	(29.4)	0	[0-33.3]

**Small cell lung cancer: limited disease  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	1	0
8.3	1	0
16.7	11	3
25	3	1
33.3	22	5
41.7	20	5
50	68	16
58.3	32	7
66.7	92	21
75	39	9
83.3	91	21
91.7	21	5
100	36	8
<b>Total</b>	<b>437</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	0	0
13.3	1	0
20	3	1
26.7	5	1
33.3	7	2
40	8	2
46.7	16	4
53.3	20	5
60	23	5
66.7	40	9
73.3	35	8
80	51	12
86.7	76	18
93.3	78	18
100	68	16
<b>Total</b>	<b>431</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	23	5
16.7	11	3
33.3	38	9
50	33	8
66.7	80	19
83.3	69	16
100	176	41
<b>Total</b>	<b>430</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	4	1
8.3	2	0
16.7	9	2
25	8	2
33.3	6	1
41.7	14	3
50	22	4
58.3	38	7
66.7	79	15
75	61	12
83.3	79	15
91.7	75	15
100	120	23
<b>Total</b>	<b>517</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	5	1
16.7	4	1
33.3	10	2
50	20	4
66.7	71	14
83.3	138	26
100	277	53
<b>Total</b>	<b>525</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	16	3
16.7	13	3
33.3	30	6
50	47	9
66.7	115	22
83.3	96	18
100	207	40
<b>Total</b>	<b>524</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	75	14
11.1	49	9
22.2	77	15
33.3	146	28
44.4	51	10
55.6	45	9
66.7	34	7
77.8	15	3
88.9	13	3
100	18	3
<b>Total</b>	<b>523</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	354	67
16.7	95	18
33.3	42	8
50	20	4
66.7	9	2
83.3	2	0
100	3	1
<b>Total</b>	<b>525</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	303	58
16.7	88	17
33.3	70	13
50	33	6
66.7	20	4
83.3	2	0
100	10	2
<b>Total</b>	<b>526</b>	

**Small cell lung cancer: limited disease  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	111	26	177	41	103	24	44	10	435
2) Long walk	PF	141	32	154	35	93	21	47	11	435
3) Short walk	PF	330	76	77	18	25	6	5	1	437
4) Bed or chair	PF	268	61	116	27	45	10	9	2	438
5) Self care	PF	423	97	11	3	3	1	1	0	438
6) Limited in work	RF	204	47	123	28	77	18	30	7	434
7) Limited in leisure	RF	234	54	118	27	47	11	33	8	432
8) Dyspnoea	DY	206	39	215	41	73	14	33	6	527
9) Pain	PA	326	62	156	30	34	6	13	3	529
10) Need to rest	FA	143	27	258	49	95	18	32	6	528
11) Insomnia	SL	287	55	156	30	66	13	17	3	526
12) Felt weak	FA	161	31	228	43	91	17	47	9	527
13) Appetite loss	AP	292	56	138	26	67	13	29	6	526
14) Nausea	NV	366	69	116	22	37	7	10	2	529
15) Vomiting	NV	458	86	60	11	10	2	3	1	531
16) Constipation	CO	383	73	104	20	25	5	16	3	528
17) Diarrhoea	DI	439	84	75	14	9	2	1	0	524
18) Felt tired	FA	114	22	289	55	93	18	34	6	530
19) Pain interference	PA	375	71	101	19	38	7	13	3	527
20) Concentration	CF	392	74	98	19	25	5	13	2	528
21) Tension	EF	244	46	220	42	45	9	20	4	529
22) Worry	EF	204	39	225	43	61	12	35	7	525
23) Irritability	EF	290	55	189	36	39	7	12	2	530
24) Depression	EF	256	49	205	39	42	8	20	4	523
25) Memory trouble	CF	322	61	173	33	25	5	8	2	528
26) Family life	SF	301	57	150	29	49	9	27	5	527
27) Social activities	SF	249	47	168	32	72	14	38	7	527
28) Financial difficulties	FI	350	66	100	19	46	9	31	6	527
<hr/>										
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
<hr/>										
29) Overall health	QL	2	12	38	95	136	114	40		437
		1	3	9	22	31	26	9		
<hr/>										
30) Overall quality of life	QL	7	20	50	101	135	137	78		528
		1	4	10	19	26	26	15		



## Small cell lung cancer: extensive disease

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	114	100
v +3	0	0
v 2.0	0	0
v 3.0	0	0
Total	114	

#### Age

	N	(%)
<40	0	0
40-49	7	6
50-59	29	25
60-69	52	46
70-79	26	23
80+	0	0
Not known	0	0
Total	114	

#### Gender

	N	(%)
Male	74	65
Female	36	32
Not known	4	4
Total	114	

#### Stage

	N	(%)
Stage I-II	0	0
Stage III-IV	0	0
Recurrent/metastatic	114	100
Not known	0	0
Total	114	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	<i>Previous version of this scale used</i>			
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	<i>Previous version of this scale used</i>			
Emotional functioning	EF	71.4	(22.4)	75	[58.3-83.3]
Cognitive functioning	CF	82.9	(21.2)	83.3	[66.7-100]
Social functioning	SF	74.8	(25.4)	83.3	[66.7-100]
Fatigue	FA	43.5	(24.2)	33.3	[33.3-66.7]
Nausea and vomiting	NV	10.8	(18.2)	0	[0-16.7]
Pain	PA	33.3	(28.1)	33.3	[16.7-50]
Dyspnoea	DY	44.0	(28.7)	33.3	[33.3-66.7]
Insomnia	SL	29.8	(28.8)	33.3	[0-33.3]
Appetite loss	AP	31.5	(32.2)	33.3	[0-66.7]
Constipation	CO	29.7	(31.6)	33.3	[0-66.7]
Diarrhoea	DI	12.1	(20.1)	0	[0-33.3]
Financial difficulties	FI	12.3	(25)	0	[0-0]

**Small cell lung cancer: extensive disease  
Constructed scales**

<b>QL</b>	<b>CF</b>	<b>N</b>	<b>(%)</b>
Previous version of this scale used	0	1	1
	16.7	1	1
	33.3	4	4
	50	9	8
	66.7	15	13
	83.3	31	28
	100	51	46
	Total	112	

<b>PF</b>	<b>SF</b>	<b>N</b>	<b>(%)</b>
Previous version of this scale used	0	1	1
	16.7	5	5
	33.3	8	7
	50	10	9
	66.7	26	24
	83.3	21	19
	100	39	36
	Total	110	

<b>RF</b>	<b>FA</b>	<b>N</b>	<b>(%)</b>
Previous version of this scale used	0	6	6
	11.1	8	7
	22.2	9	8
	33.3	33	30
	44.4	16	15
	55.6	9	8
	66.7	14	13
	77.8	6	6
	88.9	5	5
	100	3	3
	Total	109	

<b>EF</b>	<b>NV</b>	<b>N</b>	<b>(%)</b>
0	0	68	61
8.3	16.7	25	23
16.7	33.3	14	13
25	50	1	1
33.3	66.7	1	1
41.7	83.3	0	0
50	100	2	2
58.3	Total	111	
66.7			
75			
83.3			
91.7			
100			
Total			

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	27	25
16.7	20	18
33.3	26	24
50	13	12
66.7	15	14
83.3	5	5
100	4	4
Total	110	

**Small cell lung cancer: extensive disease  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	<i>Previous version of this scale used</i>								
7) Limited in leisure	RF	<i>Previous version of this scale used</i>								
8) Dyspnoea	DY	17	15	54	48	29	26	12	11	112
9) Pain	PA	28	25	50	45	27	24	6	5	111
10) Need to rest	FA	10	9	58	53	35	32	7	6	110
11) Insomnia	SL	43	38	43	38	21	19	5	5	112
12) Felt weak	FA	13	12	52	47	35	32	11	10	111
13) Appetite loss	AP	45	40	38	34	19	17	10	9	112
14) Nausea	NV	71	63	33	30	6	5	2	2	112
15) Vomiting	NV	95	84	15	13	1	1	2	2	113
16) Constipation	CO	48	43	35	32	20	18	8	7	111
17) Diarrhoea	DI	77	70	26	24	7	6	0	0	110
18) Felt tired	FA	23	21	54	49	25	23	9	8	111
19) Pain interference	PA	46	42	38	35	17	16	9	8	110
20) Concentration	CF	76	68	24	21	8	7	4	4	112
21) Tension	EF	33	30	56	50	16	14	7	6	112
22) Worry	EF	37	33	48	43	20	18	7	6	112
23) Irritability	EF	57	51	38	34	11	10	5	5	111
24) Depression	EF	43	39	50	45	14	13	4	4	111
25) Memory trouble	CF	60	54	44	39	5	5	3	3	112
26) Family life	SF	59	54	31	28	17	16	3	3	110
27) Social activities	SF	46	42	44	40	12	11	8	7	110
28) Financial difficulties	FI	84	76	17	15	6	5	4	4	111
		1	2	3	4	5	6	7		Total
		<b>(very poor)</b>						<b>(excellent)</b>		
29) Overall health	QL	<i>Previous version of this scale used</i>								
30) Overall quality of life	QL	9	10	22	28	18	15	7		109
		8	9	20	26	17	14	6		

## Non-small cell lung cancer: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	556	44
v +3	0	0
v 2.0	516	41
v 3.0	190	15
Total	1,262	

#### Age

	N	(%)
<40	37	3
40-49	163	13
50-59	340	27
60-69	380	30
70-79	225	18
80+	27	2
Not known	90	7
Total	1,262	

#### Gender

	N	(%)
Male	514	41
Female	201	16
Not known	547	43
Total	1,262	

#### Stage

	N	(%)
Stage I-II	17	1
Stage III-IV	1,046	83
Recurrent/metastatic	11	1
Not known	188	15
Total	1,262	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	58.8	(22.5)	58.3	[50-75]
Physical functioning	PF	78.4	(19.3)	86.7	[66.7-93.3]
Role Functioning	RF	60.7	(33.1)	66.7	[33.3-100]
Emotional functioning	EF	68.1	(24.2)	66.7	[50-91.7]
Cognitive functioning	CF	84.0	(21.1)	100	[66.7-100]
Social functioning	SF	73.6	(28.9)	83.3	[50-100]
Fatigue	FA	40.4	(27)	33.3	[22.2-55.6]
Nausea and vomiting	NV	9.7	(18.3)	0	[0-16.7]
Pain	PA	29.7	(30.3)	16.7	[0-50]
Dyspnoea	DY	38.5	(31.7)	33.3	[0-66.7]
Insomnia	SL	32.4	(32.7)	33.3	[0-66.7]
Appetite loss	AP	27.9	(33.5)	0	[0-66.7]
Constipation	CO	17.4	(27.9)	0	[0-33.3]
Diarrhoea	DI	6.8	(17.4)	0	[0-0]
Financial difficulties	FI	12.8	(25.8)	0	[0-0]

**Non-small cell lung cancer: all stages**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	18	3
8.3	6	1
16.7	15	2
25	19	3
33.3	69	10
41.7	41	6
50	129	19
58.3	67	10
66.7	136	20
75	52	8
83.3	82	12
91.7	29	4
100	33	5
<b>Total</b>	<b>696</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	0	0
13.3	1	1
20	2	1
26.7	3	2
33.3	1	1
40	4	2
46.7	4	2
53.3	9	5
60	15	8
66.7	16	9
73.3	19	10
80	17	9
86.7	35	19
93.3	25	13
100	35	19
<b>Total</b>	<b>186</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	73	11
16.7	38	6
33.3	110	16
50	63	9
66.7	150	22
83.3	76	11
100	182	26
<b>Total</b>	<b>692</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	10	1
8.3	17	1
16.7	26	2
25	39	3
33.3	62	5
41.7	62	5
50	116	10
58.3	109	9
66.7	173	14
75	152	13
83.3	136	11
91.7	131	11
100	181	15
<b>Total</b>	<b>1,214</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	7	1
16.7	17	1
33.3	48	4
50	80	6
66.7	165	13
83.3	302	24
100	623	50
<b>Total</b>	<b>1,242</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	49	4
16.7	42	3
33.3	107	9
50	124	10
66.7	233	19
83.3	169	14
100	502	41
<b>Total</b>	<b>1,226</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	143	12
11.1	100	8
22.2	172	14
33.3	244	20
44.4	162	13
55.6	131	11
66.7	119	10
77.8	54	4
88.9	51	4
100	56	5
<b>Total</b>	<b>1,232</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	872	70
16.7	173	14
33.3	115	9
50	42	3
66.7	28	2
83.3	7	1
100	8	1
<b>Total</b>	<b>1,245</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	430	35
16.7	225	18
33.3	211	17
50	124	10
66.7	123	10
83.3	60	5
100	66	5
<b>Total</b>	<b>1,239</b>	

**Non-small cell lung cancer: all stages**  
**Single Items**

		<b>Not at all</b>		<b>A little</b>		<b>Quite a bit</b>		<b>Very much</b>		<b>Total</b>	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
<b>1) Strenuous activities</b>	<b>PF</b>	54	29	72	39	42	23	19	10	187	
<b>2) Long walk</b>	<b>PF</b>	60	32	56	30	50	27	22	12	188	
<b>3) Short walk</b>	<b>PF</b>	135	71	38	20	14	7	3	2	190	
<b>4) Bed or chair</b>	<b>PF</b>	126	66	44	23	18	10	2	1	190	
<b>5) Self care</b>	<b>PF</b>	180	95	7	4	3	2	0	0	190	
<b>6) Limited in work</b>	<b>RF</b>	210	30	214	31	166	24	105	15	695	
<b>7) Limited in leisure</b>	<b>RF</b>	249	36	210	30	134	19	103	15	696	
<b>8) Dyspnoea</b>	<b>DY</b>	351	28	491	39	278	22	134	11	1,254	
<b>9) Pain</b>	<b>PA</b>	479	38	412	33	243	19	119	10	1,253	
<b>10) Need to rest</b>	<b>FA</b>	248	20	543	43	320	26	142	11	1,253	
<b>11) Insomnia</b>	<b>SL</b>	501	40	393	32	237	19	115	9	1,246	
<b>12) Felt weak</b>	<b>FA</b>	379	30	463	37	296	24	115	9	1,253	
<b>13) Appetite loss</b>	<b>AP</b>	638	51	294	23	211	17	112	9	1,255	
<b>14) Nausea</b>	<b>NV</b>	905	72	231	18	93	7	25	2	1,254	
<b>15) Vomiting</b>	<b>NV</b>	1,070	86	127	10	38	3	11	1	1,246	
<b>16) Constipation</b>	<b>CO</b>	819	66	256	21	113	9	56	5	1,244	
<b>17) Diarrhoea</b>	<b>DI</b>	1,048	84	153	12	35	3	11	1	1,247	
<b>18) Felt tired</b>	<b>FA</b>	258	21	563	45	299	24	125	10	1,245	
<b>19) Pain interference</b>	<b>PA</b>	650	52	310	25	196	16	90	7	1,246	
<b>20) Concentration</b>	<b>CF</b>	816	65	263	21	132	11	40	3	1,251	
<b>21) Tension</b>	<b>EF</b>	394	32	493	39	274	22	90	7	1,251	
<b>22) Worry</b>	<b>EF</b>	300	24	446	36	345	28	155	12	1,246	
<b>23) Irritability</b>	<b>EF</b>	645	52	406	33	151	12	33	3	1,235	
<b>24) Depression</b>	<b>EF</b>	497	40	504	41	172	14	69	6	1,242	
<b>25) Memory trouble</b>	<b>CF</b>	830	67	299	24	93	8	23	2	1,245	
<b>26) Family life</b>	<b>SF</b>	721	58	295	24	154	12	68	6	1,238	
<b>27) Social activities</b>	<b>SF</b>	561	45	315	26	240	19	120	10	1,236	
<b>28) Financial difficulties</b>	<b>FI</b>	944	76	165	13	85	7	47	4	1,241	
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>	
			<b>(very poor)</b>						<b>(excellent)</b>		
<b>29) Overall health</b>	<b>QL</b>	27	31	93	203	185	117	42		698	
		4	4	13	29	27	17	6			
<b>30) Overall quality of life</b>	<b>QL</b>	45	63	186	271	328	235	117		1,245	
		4	5	15	22	26	19	9			

## Mesothelioma

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	0	0
v 2.0	0	0
v 3.0	236	100
Total	236	

#### Age

	N	(%)
<40	10	4
40-49	36	15
50-59	92	39
60-69	79	34
70-79	18	8
80+	1	0
Not known	0	0
Total	236	

#### Gender

	N	(%)
Male	183	78
Female	51	22
Not known	2	1
Total	236	

#### Stage

	N	(%)
Stage I-II	0	0
Stage III-IV	0	0
Recurrent/metastatic	6	3
Not known	230	98
Total	236	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	55.0	(22)	50	[50-66.7]
Physical functioning	PF	71.5	(22.1)	73.3	[60-86.7]
Role Functioning	RF	58.6	(31.7)	66.7	[33.3-83.3]
Emotional functioning	EF	68.3	(25.1)	66.7	[50-91.7]
Cognitive functioning	CF	87.2	(18.6)	100	[83.3-100]
Social functioning	SF	67.7	(29)	66.7	[50-100]
Fatigue	FA	38.5	(25.4)	33.3	[22.2-55.6]
Nausea and vomiting	NV	8.8	(16.1)	0	[0-16.7]
Pain	PA	36.5	(28.9)	33.3	[16.7-50]
Dyspnoea	DY	39.5	(30.4)	33.3	[33.3-66.7]
Insomnia	SL	31.5	(32.4)	33.3	[0-66.7]
Appetite loss	AP	27.5	(31)	33.3	[0-33.3]
Constipation	CO	16.3	(24.9)	0	[0-33.3]
Diarrhoea	DI	5.3	(16)	0	[0-0]
Financial difficulties	FI	22.5	(29.8)	0	[0-33.3]

**Mesothelioma  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	6	3
8.3	6	3
16.7	7	3
25	6	3
33.3	22	9
41.7	9	4
50	68	29
58.3	22	9
66.7	41	17
75	13	6
83.3	20	9
91.7	7	3
100	8	3
<b>Total</b>	<b>235</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	0
6.7	2	1
13.3	0	0
20	6	3
26.7	3	1
33.3	7	3
40	7	3
46.7	11	5
53.3	18	8
60	21	9
66.7	24	10
73.3	16	7
80	35	15
86.7	28	12
93.3	22	10
100	30	13
<b>Total</b>	<b>231</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	22	10
16.7	10	4
33.3	47	20
50	23	10
66.7	56	24
83.3	20	9
100	52	23
<b>Total</b>	<b>230</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	2	1
8.3	3	1
16.7	7	3
25	4	2
33.3	11	5
41.7	21	9
50	18	8
58.3	16	7
66.7	34	15
75	28	12
83.3	22	10
91.7	17	8
100	45	20
<b>Total</b>	<b>228</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	0	0
16.7	3	1
33.3	7	3
50	8	3
66.7	27	12
83.3	58	25
100	130	56
<b>Total</b>	<b>233</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	13	6
16.7	7	3
33.3	26	11
50	25	11
66.7	60	26
83.3	34	15
100	65	28
<b>Total</b>	<b>230</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	27	12
11.1	18	8
22.2	37	16
33.3	50	22
44.4	28	12
55.6	31	13
66.7	16	7
77.8	13	6
88.9	6	3
100	7	3
<b>Total</b>	<b>233</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	160	69
16.7	42	18
33.3	19	8
50	7	3
66.7	4	2
83.3	0	0
100	1	0
<b>Total</b>	<b>233</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	45	19
16.7	49	21
33.3	50	21
50	37	16
66.7	25	11
83.3	15	6
100	13	6
<b>Total</b>	<b>234</b>	



**Mesothelioma  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	43	18	84	36	66	28	41	18	234	
2) Long walk	PF	60	26	71	30	70	30	34	15	235	
3) Short walk	PF	129	55	74	32	25	11	7	3	235	
4) Bed or chair	PF	113	48	82	35	26	11	14	6	235	
5) Self care	PF	214	91	17	7	3	1	2	1	236	
6) Limited in work	RF	57	24	82	35	64	27	31	13	234	
7) Limited in leisure	RF	74	32	66	29	63	27	28	12	231	
8) Dyspnoea	DY	55	24	101	44	52	23	23	10	231	
9) Pain	PA	52	22	100	43	56	24	27	12	235	
10) Need to rest	FA	44	19	105	45	64	27	21	9	234	
11) Insomnia	SL	96	41	79	34	39	17	22	9	236	
12) Felt weak	FA	76	32	98	42	47	20	15	6	236	
13) Appetite loss	AP	109	47	73	31	36	15	16	7	234	
14) Nausea	NV	166	71	50	21	14	6	4	2	234	
15) Vomiting	NV	206	88	26	11	2	1	1	0	235	
16) Constipation	CO	151	64	58	25	21	9	5	2	235	
17) Diarrhoea	DI	204	88	21	9	5	2	2	1	232	
18) Felt tired	FA	47	20	111	47	63	27	14	6	235	
19) Pain interference	PA	92	39	83	35	40	17	20	9	235	
20) Concentration	CF	158	67	52	22	19	8	7	3	236	
21) Tension	EF	80	34	104	44	37	16	13	6	234	
22) Worry	EF	61	26	87	37	56	24	32	14	236	
23) Irritability	EF	102	44	92	40	29	13	7	3	230	
24) Depression	EF	96	41	83	36	42	18	12	5	233	
25) Memory trouble	CF	178	76	43	19	11	5	1	0	233	
26) Family life	SF	99	43	80	35	34	15	19	8	232	
27) Social activities	SF	77	33	87	38	47	20	21	9	232	
28) Financial difficulties	FI	128	56	62	27	27	12	13	6	230	
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>		
		<b>(very poor)</b>							<b>(excellent)</b>		
29) Overall health	QL	9	12	31	84	61	28	10		235	
		4	5	13	36	26	12	4			
30) Overall quality of life	QL	10	16	28	78	55	33	15		235	
		4	7	12	33	23	14	6			

## Malignant lymphoma

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	162	41
v +3	4	1
v 2.0	198	50
v 3.0	32	8
Total	396	

#### Age

	N	(%)
<40	122	31
40-49	79	20
50-59	90	23
60-69	55	14
70-79	45	11
80+	5	1
Not known	0	0
Total	396	

#### Gender

	N	(%)
Male	220	56
Female	176	44
Not known	0	0
Total	396	

#### Stage

	N	(%)
Stage I-II	33	8
Stage III-IV	0	0
Recurrent/metastatic	11	3
Not known	352	89
Total	396	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	58.0	(26.8)	58.3	[41.7-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	59.8	(36.1)	66.7	[33.3-100]
Emotional functioning	EF	70.4	(24.6)	75	[58.3-91.7]
Cognitive functioning	CF	73.5	(28.9)	83.3	[50-100]
Social functioning	SF	64.4	(33.1)	66.7	[33.3-100]
Fatigue	FA	39.5	(28.4)	33.3	[22.2-55.6]
Nausea and vomiting	NV	9.0	(19)	0	[0-16.7]
Pain	PA	23.8	(29.8)	16.7	[0-33.3]
Dyspnoea	DY	18.7	(25.9)	0	[0-33.3]
Insomnia	SL	29.5	(31.5)	33.3	[0-33.3]
Appetite loss	AP	18.3	(28.9)	0	[0-33.3]
Constipation	CO	17.5	(28.1)	0	[0-33.3]
Diarrhoea	DI	10.1	(19.7)	0	[0-0]
Financial difficulties	FI	19.5	(29.9)	0	[0-33.3]

**Malignant lymphoma  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	6	3
8.3	6	3
16.7	18	8
25	9	4
33.3	15	7
41.7	12	5
50	34	15
58.3	22	10
66.7	27	12
75	23	10
83.3	29	13
91.7	7	3
100	22	10
Total	230	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	18	5
16.7	14	4
33.3	31	8
50	42	11
66.7	54	14
83.3	91	23
100	145	37
Total	395	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	33	8
16.7	26	7
33.3	53	14
50	38	10
66.7	63	16
83.3	58	15
100	121	31
Total	392	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	58	15
11.1	31	8
22.2	47	12
33.3	92	24
44.4	39	10
55.6	29	7
66.7	34	9
77.8	20	5
88.9	25	6
100	16	4
Total	391	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	31	14
16.7	16	7
33.3	37	16
50	9	4
66.7	42	19
83.3	22	10
100	70	31
Total	227	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	290	73
16.7	50	13
33.3	28	7
50	13	3
66.7	5	1
83.3	5	1
100	4	1
Total	395	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	3	1
8.3	2	1
16.7	16	4
25	9	2
33.3	19	5
41.7	19	5
50	21	5
58.3	37	10
66.7	42	11
75	53	14
83.3	56	15
91.7	38	10
100	71	18
Total	386	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	177	45
16.7	73	19
33.3	55	14
50	28	7
66.7	24	6
83.3	13	3
100	22	6
Total	392	

## Malignant lymphoma Single Items

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	78	34	66	29	41	18	42	19	227
7) Limited in leisure	RF	86	38	58	25	39	17	46	20	229
8) Dyspnoea	DY	231	59	118	30	34	9	12	3	395
9) Pain	PA	191	49	123	31	46	12	32	8	392
10) Need to rest	FA	96	24	148	38	99	25	52	13	395
11) Insomnia	SL	168	43	137	35	57	14	33	8	395
12) Felt weak	FA	118	30	162	41	71	18	43	11	394
13) Appetite loss	AP	255	65	85	22	33	8	22	6	395
14) Nausea	NV	293	74	71	18	21	5	10	3	395
15) Vomiting	NV	348	88	30	8	10	3	7	2	395
16) Constipation	CO	261	66	79	20	37	9	18	5	395
17) Diarrhoea	DI	296	76	76	19	15	4	4	1	391
18) Felt tired	FA	86	22	182	46	84	21	41	10	393
19) Pain interference	PA	247	63	74	19	44	11	30	8	395
20) Concentration	CF	206	52	100	25	60	15	29	7	395
21) Tension	EF	140	36	162	41	67	17	25	6	394
22) Worry	EF	110	28	154	39	91	23	36	9	391
23) Irritability	EF	192	49	142	36	44	11	12	3	390
24) Depression	EF	168	43	148	38	50	13	25	6	391
25) Memory trouble	CF	196	50	113	29	52	13	35	9	396
26) Family life	SF	179	46	94	24	80	20	40	10	393
27) Social activities	SF	147	37	101	26	69	18	77	20	394
28) Financial difficulties	FI	237	63	81	22	33	9	24	6	375
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
29) Overall health	QL	10	17	36	43	57	43	24		230
		4	7	16	19	25	19	10		
30) Overall quality of life	QL	18	40	32	66	88	79	69		392
		5	10	8	17	22	20	18		

## Non-Hodgkin lymphoma

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	84	32
v +3	3	1
v 2.0	180	67
v 3.0	0	0
Total	267	

#### Age

	N	(%)
<40	57	21
40-49	54	20
50-59	74	28
60-69	42	16
70-79	38	14
80+	2	1
Not known	0	0
Total	267	

#### Gender

	N	(%)
Male	146	55
Female	121	45
Not known	0	0
Total	267	

#### Stage

	N	(%)
Stage I-II	5	2
Stage III-IV	0	0
Recurrent/metastatic	1	0
Not known	261	98
Total	267	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	56.1	(27.1)	58.3	[33.3-75]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	57.3	(36.2)	66.7	[33.3-100]
Emotional functioning	EF	66.8	(25.2)	75	[50-83.3]
Cognitive functioning	CF	68.5	(30.8)	83.3	[50-100]
Social functioning	SF	60.4	(34.1)	66.7	[33.3-100]
Fatigue	FA	41.9	(28.9)	33.3	[22.2-66.7]
Nausea and vomiting	NV	10.0	(19.7)	0	[0-16.7]
Pain	PA	24.5	(30.1)	16.7	[0-33.3]
Dyspnoea	DY	16.9	(24.6)	0	[0-33.3]
Insomnia	SL	30.7	(31.5)	33.3	[0-33.3]
Appetite loss	AP	19.9	(29.4)	0	[0-33.3]
Constipation	CO	18.2	(27.8)	0	[0-33.3]
Diarrhoea	DI	9.5	(19.1)	0	[0-0]
Financial difficulties	FI	17.8	(28.8)	0	[0-33.3]

**Non-Hodgkin lymphoma  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	6	3
8.3	4	2
16.7	17	9
25	8	4
33.3	13	7
41.7	9	5
50	24	13
58.3	19	11
66.7	20	11
75	17	9
83.3	23	13
91.7	7	4
100	13	7
Total	180	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	17	6
16.7	12	5
33.3	26	10
50	36	14
66.7	35	13
83.3	58	22
100	82	31
Total	266	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	30	11
16.7	17	7
33.3	40	15
50	25	10
66.7	43	16
83.3	39	15
100	69	26
Total	263	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	36	14
11.1	15	6
22.2	35	13
33.3	54	21
44.4	31	12
55.6	20	8
66.7	24	9
77.8	15	6
88.9	19	7
100	13	5
Total	262	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	26	15
16.7	13	7
33.3	32	18
50	7	4
66.7	32	18
83.3	17	10
100	49	28
Total	176	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	188	71
16.7	36	14
33.3	22	8
50	9	3
66.7	5	2
83.3	3	1
100	3	1
Total	266	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	3	1
8.3	2	1
16.7	12	5
25	7	3
33.3	17	7
41.7	15	6
50	15	6
58.3	29	11
66.7	23	9
75	40	16
83.3	41	16
91.7	16	6
100	38	15
Total	258	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	117	44
16.7	48	18
33.3	38	14
50	21	8
66.7	14	5
83.3	11	4
100	15	6
Total	264	

**Non-Hodgkin lymphoma  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	54	31	50	28	36	21	36	21	176
7) Limited in leisure	RF	62	35	46	26	34	19	36	20	178
8) Dyspnoea	DY	164	62	75	28	21	8	6	2	266
9) Pain	PA	127	48	82	31	32	12	23	9	264
10) Need to rest	FA	58	22	89	34	77	29	42	16	266
11) Insomnia	SL	107	40	96	36	40	15	23	9	266
12) Felt weak	FA	75	28	109	41	49	19	32	12	265
13) Appetite loss	AP	162	61	65	24	23	9	16	6	266
14) Nausea	NV	191	72	52	20	16	6	7	3	266
15) Vomiting	NV	229	86	24	9	8	3	5	2	266
16) Constipation	CO	170	64	57	21	29	11	10	4	266
17) Diarrhoea	DI	201	76	52	20	7	3	3	1	263
18) Felt tired	FA	54	21	119	45	57	22	34	13	264
19) Pain interference	PA	163	61	53	20	29	11	21	8	266
20) Concentration	CF	116	44	74	28	51	19	25	9	266
21) Tension	EF	81	31	115	43	52	20	17	6	265
22) Worry	EF	54	21	105	40	72	28	31	12	262
23) Irritability	EF	120	46	96	37	33	13	12	5	261
24) Depression	EF	101	38	99	38	41	16	22	8	263
25) Memory trouble	CF	121	45	72	27	41	15	33	12	267
26) Family life	SF	112	42	62	24	55	21	35	13	264
27) Social activities	SF	84	32	70	26	49	19	62	23	265
28) Financial difficulties	FI	162	66	52	21	19	8	14	6	247
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
29) Overall health	QL	8	15	30	32	45	35	15		180
		4	8	17	18	25	19	8		
30) Overall quality of life	QL	17	34	28	40	61	49	35		264
		6	13	11	15	23	19	13		

## Malignant melanoma: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	23	2
v +3	0	0
v 2.0	1,155	96
v 3.0	22	2
Total	1,200	

#### Age

	N	(%)
<40	287	24
40-49	319	27
50-59	294	25
60-69	233	19
70-79	62	5
80+	5	0
Not known	0	0
Total	1,200	

#### Gender

	N	(%)
Male	671	56
Female	529	44
Not known	0	0
Total	1,200	

#### Stage

	N	(%)
Stage I-II	223	19
Stage III-IV	585	49
Recurrent/metastatic	387	32
Not known	5	0
Total	1,200	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	68.2	(21)	66.7	[50-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	71.2	(31.2)	83.3	[50-100]
Emotional functioning	EF	73.1	(22.3)	75	[58.3-91.7]
Cognitive functioning	CF	88.3	(17.8)	100	[83.3-100]
Social functioning	SF	79.0	(26.2)	83.3	[66.7-100]
Fatigue	FA	27.0	(25)	22.2	[0-44.4]
Nausea and vomiting	NV	5.6	(14.4)	0	[0-0]
Pain	PA	20.7	(25.8)	16.7	[0-33.3]
Dyspnoea	DY	11.0	(21.4)	0	[0-33.3]
Insomnia	SL	25.0	(29.9)	0	[0-33.3]
Appetite loss	AP	13.2	(25.2)	0	[0-33.3]
Constipation	CO	9.5	(21.6)	0	[0-0]
Diarrhoea	DI	5.5	(15.6)	0	[0-0]
Financial difficulties	FI	15.3	(26.9)	0	[0-33.3]



**Malignant melanoma: all stages**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	14	1
8.3	1	0
16.7	12	1
25	18	2
33.3	55	5
41.7	51	4
50	148	13
58.3	92	8
66.7	238	21
75	103	9
83.3	245	21
91.7	60	5
100	122	11
<b>Total</b>	<b>1,159</b>	

**PF**  
 Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	4	0
16.7	6	1
33.3	21	2
50	53	5
66.7	145	12
83.3	239	20
100	708	60
<b>Total</b>	<b>1,176</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	29	3
16.7	30	3
33.3	75	6
50	83	7
66.7	213	18
83.3	187	16
100	563	48
<b>Total</b>	<b>1,180</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	310	26
11.1	164	14
22.2	186	16
33.3	222	19
44.4	95	8
55.6	57	5
66.7	76	7
77.8	24	2
88.9	23	2
100	20	2
<b>Total</b>	<b>1,177</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	76	7
16.7	37	3
33.3	125	11
50	90	8
66.7	220	19
83.3	143	12
100	462	40
<b>Total</b>	<b>1,153</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	967	81
16.7	125	11
33.3	56	5
50	18	2
66.7	16	1
83.3	6	1
100	3	0
<b>Total</b>	<b>1,191</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	8	1
8.3	7	1
16.7	17	2
25	25	2
33.3	39	3
41.7	60	5
50	64	6
58.3	79	7
66.7	171	15
75	166	14
83.3	176	15
91.7	159	14
100	198	17
<b>Total</b>	<b>1,169</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	553	47
16.7	198	17
33.3	216	18
50	86	7
66.7	62	5
83.3	28	2
100	30	3
<b>Total</b>	<b>1,173</b>	

**Malignant melanoma: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	509	44	380	33	173	15	104	9	1,166
7) Limited in leisure	RF	584	50	288	25	167	14	120	10	1,159
8) Dyspnoea	DY	892	75	227	19	54	5	20	2	1,193
9) Pain	PA	619	52	385	32	135	11	50	4	1,189
10) Need to rest	FA	427	36	495	42	200	17	72	6	1,194
11) Insomnia	SL	600	50	358	30	172	14	65	5	1,195
12) Felt weak	FA	621	52	395	33	123	10	54	5	1,193
13) Appetite loss	AP	881	74	190	16	86	7	37	3	1,194
14) Nausea	NV	982	82	160	13	33	3	19	2	1,194
15) Vomiting	NV	1,100	92	71	6	18	2	5	0	1,194
16) Constipation	CO	954	80	163	14	50	4	26	2	1,193
17) Diarrhoea	DI	1,031	87	128	11	21	2	9	1	1,189
18) Felt tired	FA	456	38	527	44	159	13	45	4	1,187
19) Pain interference	PA	713	60	315	27	107	9	49	4	1,184
20) Concentration	CF	864	73	222	19	76	6	18	2	1,180
21) Tension	EF	489	41	484	41	167	14	46	4	1,186
22) Worry	EF	289	24	514	43	263	22	122	10	1,188
23) Irritability	EF	656	55	405	34	95	8	30	3	1,186
24) Depression	EF	602	51	415	35	126	11	43	4	1,186
25) Memory trouble	CF	860	72	266	22	49	4	15	1	1,190
26) Family life	SF	720	61	312	26	102	9	50	4	1,184
27) Social activities	SF	652	55	316	27	150	13	71	6	1,189
28) Financial difficulties	FI	822	70	212	18	91	8	48	4	1,173
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	17	17	85	233	333	324	153		1,162
		2	2	7	20	29	28	13		
30) Overall quality of life	QL	24	23	96	204	330	322	184		1,183
		2	2	8	17	28	27	16		

## Malignant melanoma: males

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	12	2
v +3	0	0
v 2.0	648	97
v 3.0	11	2
Total	671	

#### Age

	N	(%)
<40	155	23
40-49	174	26
50-59	170	25
60-69	133	20
70-79	38	6
80+	1	0
Not known	0	0
Total	671	

#### Stage

	N	(%)
Stage I-II	114	17
Stage III-IV	336	50
Recurrent/metastatic	220	33
Not known	1	0
Total	671	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	68.7	(21.5)	66.7	[58.3-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	70.2	(31.6)	83.3	[50-100]
Emotional functioning	EF	74.5	(22.7)	75	[66.7-91.7]
Cognitive functioning	CF	89.4	(16.9)	100	[83.3-100]
Social functioning	SF	78.8	(26.1)	83.3	[66.7-100]
Fatigue	FA	26.0	(25.4)	22.2	[0-33.3]
Nausea and vomiting	NV	5.0	(13.3)	0	[0-0]
Pain	PA	20.7	(26.2)	16.7	[0-33.3]
Dyspnoea	DY	12.1	(22.8)	0	[0-33.3]
Insomnia	SL	22.1	(28.7)	0	[0-33.3]
Appetite loss	AP	12.4	(24.8)	0	[0-0]
Constipation	CO	8.0	(20.6)	0	[0-0]
Diarrhoea	DI	5.9	(16.3)	0	[0-0]
Financial difficulties	FI	15.0	(26.5)	0	[0-33.3]

**Malignant melanoma: males**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	9	1
8.3	1	0
16.7	6	1
25	10	2
33.3	33	5
41.7	31	5
50	72	11
58.3	48	7
66.7	133	20
75	56	9
83.3	141	22
91.7	40	6
100	71	11
Total	651	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	3	1
16.7	2	0
33.3	6	1
50	32	5
66.7	67	10
83.3	139	21
100	410	62
Total	659	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	16	2
16.7	18	3
33.3	40	6
50	46	7
66.7	122	19
83.3	112	17
100	307	46
Total	661	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	191	29
11.1	96	15
22.2	95	14
33.3	120	18
44.4	46	7
55.6	26	4
66.7	45	7
77.8	14	2
88.9	14	2
100	11	2
Total	658	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	47	7
16.7	21	3
33.3	71	11
50	51	8
66.7	127	20
83.3	82	13
100	250	39
Total	649	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	551	82
16.7	69	10
33.3	30	5
50	8	1
66.7	8	1
83.3	1	0
100	2	0
Total	669	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	4	1
8.3	5	1
16.7	8	1
25	12	2
33.3	22	3
41.7	36	6
50	33	5
58.3	39	6
66.7	90	14
75	86	13
83.3	89	14
91.7	93	14
100	138	21
Total	655	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	315	48
16.7	108	16
33.3	118	18
50	47	7
66.7	35	5
83.3	16	2
100	19	3
Total	658	

**Malignant melanoma: males  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total						
		N	(%)	N	(%)	N	(%)	N	(%)	N						
1) Strenuous activities	PF	<i>Previous version of this scale used</i>														
2) Long walk	PF	<i>Previous version of this scale used</i>														
3) Short walk	PF	<i>Previous version of this scale used</i>														
4) Bed or chair	PF	<i>Previous version of this scale used</i>														
5) Self care	PF	<i>Previous version of this scale used</i>														
6) Limited in work	RF	281	43	214	33	94	14	66	10	655						
7) Limited in leisure	RF	318	49	164	25	98	15	71	11	651						
8) Dyspnoea	DY	490	73	130	19	34	5	15	2	669						
9) Pain	PA	355	53	212	32	68	10	31	5	666						
10) Need to rest	FA	261	39	263	39	106	16	38	6	668						
11) Insomnia	SL	364	55	199	30	71	11	34	5	668						
12) Felt weak	FA	360	54	202	30	75	11	31	5	668						
13) Appetite loss	AP	507	76	94	14	47	7	20	3	668						
14) Nausea	NV	559	83	88	13	17	3	6	1	670						
15) Vomiting	NV	621	93	37	6	8	1	3	0	669						
16) Constipation	CO	557	84	74	11	21	3	15	2	667						
17) Diarrhoea	DI	573	86	71	11	16	2	5	1	665						
18) Felt tired	FA	275	42	280	42	82	12	26	4	663						
19) Pain interference	PA	397	60	172	26	66	10	28	4	663						
20) Concentration	CF	497	75	117	18	35	5	11	2	660						
21) Tension	EF	309	47	229	35	95	14	29	4	662						
22) Worry	EF	185	28	274	41	142	22	61	9	662						
23) Irritability	EF	373	56	228	34	50	8	13	2	664						
24) Depression	EF	359	54	214	32	69	10	21	3	663						
25) Memory trouble	CF	494	74	141	21	24	4	5	1	664						
26) Family life	SF	388	59	193	29	55	8	26	4	662						
27) Social activities	SF	366	55	177	27	83	13	40	6	666						
28) Financial difficulties	FI	466	71	114	17	57	9	23	4	660						
		1		2		3		4		5		6		7		Total
		(very poor)										(excellent)				
29) Overall health	QL	10	9	52	119	183	186	94							653	
		2	1	8	18	28	29	14								
30) Overall quality of life	QL	16	10	58	107	180	188	105							664	
		2	2	9	16	27	28	16								

## Malignant melanoma: females

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	11	2
v +3	0	0
v 2.0	507	96
v 3.0	11	2
Total	529	

#### Age

	N	(%)
<40	132	25
40-49	145	27
50-59	124	23
60-69	100	19
70-79	24	5
80+	4	1
Not known	0	0
Total	529	

#### Stage

	N	(%)
Stage I-II	109	21
Stage III-IV	249	47
Recurrent/metastatic	167	32
Not known	4	1
Total	529	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	67.6	(20.5)	66.7	[50-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	72.4	(30.7)	83.3	[50-100]
Emotional functioning	EF	71.3	(21.7)	75	[58.3-83.3]
Cognitive functioning	CF	86.9	(18.8)	100	[83.3-100]
Social functioning	SF	79.3	(26.4)	83.3	[66.7-100]
Fatigue	FA	28.2	(24.3)	22.2	[11.1-44.4]
Nausea and vomiting	NV	6.4	(15.7)	0	[0-0]
Pain	PA	20.6	(25.2)	16.7	[0-33.3]
Dyspnoea	DY	9.7	(19.4)	0	[0-0]
Insomnia	SL	28.7	(30.9)	33.3	[0-66.7]
Appetite loss	AP	14.3	(25.6)	0	[0-33.3]
Constipation	CO	11.4	(22.6)	0	[0-0]
Diarrhoea	DI	5.0	(14.7)	0	[0-0]
Financial difficulties	FI	15.7	(27.4)	0	[0-33.3]

**Malignant melanoma: females  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	5	1
8.3	0	0
16.7	6	1
25	8	2
33.3	22	4
41.7	20	4
50	76	15
58.3	44	9
66.7	105	21
75	47	9
83.3	104	21
91.7	20	4
100	51	10
<b>Total</b>	<b>508</b>	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	1	0
16.7	4	1
33.3	15	3
50	21	4
66.7	78	15
83.3	100	19
100	298	58
<b>Total</b>	<b>517</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	13	3
16.7	12	2
33.3	35	7
50	37	7
66.7	91	18
83.3	75	15
100	256	49
<b>Total</b>	<b>519</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	119	23
11.1	68	13
22.2	91	18
33.3	102	20
44.4	49	9
55.6	31	6
66.7	31	6
77.8	10	2
88.9	9	2
100	9	2
<b>Total</b>	<b>519</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	29	6
16.7	16	3
33.3	54	11
50	39	8
66.7	93	19
83.3	61	12
100	212	42
<b>Total</b>	<b>504</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	416	80
16.7	56	11
33.3	26	5
50	10	2
66.7	8	2
83.3	5	1
100	1	0
<b>Total</b>	<b>522</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	4	1
8.3	2	0
16.7	9	2
25	13	3
33.3	17	3
41.7	24	5
50	31	6
58.3	40	8
66.7	81	16
75	80	16
83.3	87	17
91.7	66	13
100	60	12
<b>Total</b>	<b>514</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	238	46
16.7	90	18
33.3	98	19
50	39	8
66.7	27	5
83.3	12	2
100	11	2
<b>Total</b>	<b>515</b>	

**Malignant melanoma: females**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	228	45	166	33	79	16	38	7	511
7) Limited in leisure	RF	266	52	124	24	69	14	49	10	508
8) Dyspnoea	DY	402	77	97	19	20	4	5	1	524
9) Pain	PA	264	51	173	33	67	13	19	4	523
10) Need to rest	FA	166	32	232	44	94	18	34	7	526
11) Insomnia	SL	236	45	159	30	101	19	31	6	527
12) Felt weak	FA	261	50	193	37	48	9	23	4	525
13) Appetite loss	AP	374	71	96	18	39	7	17	3	526
14) Nausea	NV	423	81	72	14	16	3	13	3	524
15) Vomiting	NV	479	91	34	7	10	2	2	0	525
16) Constipation	CO	397	76	89	17	29	6	11	2	526
17) Diarrhoea	DI	458	87	57	11	5	1	4	1	524
18) Felt tired	FA	181	35	247	47	77	15	19	4	524
19) Pain interference	PA	316	61	143	27	41	8	21	4	521
20) Concentration	CF	367	71	105	20	41	8	7	1	520
21) Tension	EF	180	34	255	49	72	14	17	3	524
22) Worry	EF	104	20	240	46	121	23	61	12	526
23) Irritability	EF	283	54	177	34	45	9	17	3	522
24) Depression	EF	243	47	201	38	57	11	22	4	523
25) Memory trouble	CF	366	70	125	24	25	5	10	2	526
26) Family life	SF	332	64	119	23	47	9	24	5	522
27) Social activities	SF	286	55	139	27	67	13	31	6	523
28) Financial difficulties	FI	356	69	98	19	34	7	25	5	513
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	7	8	33	114	150	138	59		509
		1	2	7	22	30	27	12		
30) Overall quality of life	QL	8	13	38	97	150	134	79		519
		2	3	7	19	29	26	15		



## Malignant melanoma: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	4	1
v +3	0	0
v 2.0	600	99
v 3.0	2	0
Total	606	

#### Age

	N	(%)
<40	287	47
40-49	319	53
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	606	

#### Gender

	N	(%)
Male	329	54
Female	277	46
Not known	0	0
Total	606	

#### Stage

	N	(%)
Stage I-II	106	18
Stage III-IV	309	51
Recurrent/metastatic	189	31
Not known	2	0
Total	606	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	68.5	(20.5)	66.7	[50-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	69.8	(31.8)	83.3	[50-100]
Emotional functioning	EF	73.1	(21.8)	75	[66.7-91.7]
Cognitive functioning	CF	89.4	(17.1)	100	[83.3-100]
Social functioning	SF	77.5	(26.5)	83.3	[66.7-100]
Fatigue	FA	27.1	(24.4)	22.2	[0-33.3]
Nausea and vomiting	NV	5.6	(14)	0	[0-0]
Pain	PA	21.1	(24.7)	16.7	[0-33.3]
Dyspnoea	DY	10.2	(21.3)	0	[0-0]
Insomnia	SL	25.6	(30.7)	0	[0-33.3]
Appetite loss	AP	12.9	(24.5)	0	[0-33.3]
Constipation	CO	8.5	(20.3)	0	[0-0]
Diarrhoea	DI	6.1	(15.6)	0	[0-0]
Financial difficulties	FI	18.4	(28.4)	0	[0-33.3]

**Malignant melanoma: <50  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	4	1
8.3	0	0
16.7	8	1
25	10	2
33.3	28	5
41.7	27	5
50	75	13
58.3	47	8
66.7	119	20
75	54	9
83.3	137	23
91.7	28	5
100	59	10
Total	596	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	1	0
16.7	3	1
33.3	9	2
50	27	5
66.7	67	11
83.3	108	18
100	385	64
Total	600	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	16	3
16.7	16	3
33.3	45	8
50	37	6
66.7	126	21
83.3	98	16
100	266	44
Total	604	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	151	25
11.1	81	14
22.2	99	17
33.3	122	20
44.4	49	8
55.6	32	5
66.7	32	5
77.8	14	2
88.9	13	2
100	8	1
Total	601	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	43	7
16.7	23	4
33.3	64	11
50	48	8
66.7	110	19
83.3	83	14
100	222	37
Total	593	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	489	81
16.7	63	10
33.3	34	6
50	7	1
66.7	6	1
83.3	4	1
100	1	0
Total	604	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	4	1
8.3	4	1
16.7	9	2
25	12	2
33.3	15	3
41.7	31	5
50	29	5
58.3	45	8
66.7	93	16
75	84	14
83.3	100	17
91.7	80	13
100	93	16
Total	599	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	262	44
16.7	105	18
33.3	128	22
50	44	7
66.7	30	5
83.3	15	3
100	11	2
Total	595	

**Malignant melanoma: <50**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	249	42	204	34	85	14	62	10	600
7) Limited in leisure	RF	289	49	147	25	90	15	68	11	594
8) Dyspnoea	DY	465	77	107	18	20	3	13	2	605
9) Pain	PA	294	49	218	36	66	11	22	4	600
10) Need to rest	FA	214	35	251	42	101	17	39	6	605
11) Insomnia	SL	304	50	177	29	85	14	39	6	605
12) Felt weak	FA	307	51	216	36	56	9	25	4	604
13) Appetite loss	AP	446	74	97	16	46	8	15	3	604
14) Nausea	NV	495	82	87	14	14	2	8	1	604
15) Vomiting	NV	553	91	42	7	9	2	1	0	605
16) Constipation	CO	495	82	77	13	22	4	11	2	605
17) Diarrhoea	DI	513	85	77	13	12	2	3	1	605
18) Felt tired	FA	222	37	281	47	81	13	20	3	604
19) Pain interference	PA	347	58	179	30	53	9	22	4	601
20) Concentration	CF	440	73	115	19	38	6	8	1	601
21) Tension	EF	249	41	253	42	78	13	24	4	604
22) Worry	EF	139	23	279	46	117	19	68	11	603
23) Irritability	EF	319	53	225	37	46	8	15	3	605
24) Depression	EF	315	52	211	35	56	9	20	3	602
25) Memory trouble	CF	470	78	108	18	19	3	7	1	604
26) Family life	SF	345	57	175	29	55	9	30	5	605
27) Social activities	SF	315	52	172	29	81	13	36	6	604
28) Financial difficulties	FI	381	64	131	22	56	9	29	5	597
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	6	10	44	119	161	182	75		597
		1	2	7	20	27	31	13		
30) Overall quality of life	QL	9	11	60	93	173	167	88		601
		2	2	10	16	29	28	15		

## Malignant melanoma: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	8	3
v +3	0	0
v 2.0	280	95
v 3.0	6	2
Total	294	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	294	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	294	

#### Gender

	N	(%)
Male	170	58
Female	124	42
Not known	0	0
Total	294	

#### Stage

	N	(%)
Stage I-II	53	18
Stage III-IV	134	46
Recurrent/metastatic	107	36
Not known	0	0
Total	294	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	68.6	(19.5)	66.7	[58.3-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	72.8	(30)	83.3	[50-100]
Emotional functioning	EF	71.0	(22.4)	75	[58.3-91.7]
Cognitive functioning	CF	87.8	(18)	100	[83.3-100]
Social functioning	SF	80.2	(25.1)	83.3	[66.7-100]
Fatigue	FA	25.3	(24.1)	22.2	[0-33.3]
Nausea and vomiting	NV	4.3	(12.1)	0	[0-0]
Pain	PA	20.3	(25.4)	16.7	[0-33.3]
Dyspnoea	DY	10.5	(20.4)	0	[0-0]
Insomnia	SL	24.3	(28.6)	33.3	[0-33.3]
Appetite loss	AP	11.5	(22.6)	0	[0-0]
Constipation	CO	7.6	(17.8)	0	[0-0]
Diarrhoea	DI	5.1	(14.9)	0	[0-0]
Financial difficulties	FI	11.7	(24.1)	0	[0-0]

**Malignant melanoma: 50-59  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	1	0
8.3	0	0
16.7	1	0
25	3	1
33.3	17	6
41.7	13	5
50	33	12
58.3	25	9
66.7	64	23
75	26	9
83.3	51	18
91.7	21	8
100	25	9
Total	280	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	1	0
16.7	3	1
33.3	5	2
50	10	4
66.7	33	12
83.3	73	26
100	161	56
Total	286	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	6	2
16.7	6	2
33.3	13	5
50	28	10
66.7	46	16
83.3	49	17
100	141	49
Total	289	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	81	28
11.1	43	15
22.2	48	17
33.3	51	18
44.4	18	6
55.6	13	5
66.7	21	7
77.8	6	2
88.9	5	2
100	2	1
Total	288	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	14	5
16.7	8	3
33.3	29	11
50	21	8
66.7	62	22
83.3	25	9
100	118	43
Total	277	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	241	83
16.7	36	12
33.3	7	2
50	4	1
66.7	0	0
83.3	0	0
100	2	1
Total	290	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	2	1
8.3	1	0
16.7	3	1
25	9	3
33.3	15	5
41.7	13	5
50	18	6
58.3	17	6
66.7	50	18
75	35	13
83.3	43	15
91.7	38	14
100	37	13
Total	281	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	139	48
16.7	48	17
33.3	47	16
50	26	9
66.7	15	5
83.3	8	3
100	5	2
Total	288	

**Malignant melanoma: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	125	45	91	33	45	16	18	7	279
7) Limited in leisure	RF	144	51	75	27	39	14	23	8	281
8) Dyspnoea	DY	221	75	55	19	14	5	3	1	293
9) Pain	PA	162	56	87	30	33	11	10	3	292
10) Need to rest	FA	105	36	124	43	51	18	12	4	292
11) Insomnia	SL	146	50	95	32	40	14	13	4	294
12) Felt weak	FA	166	57	87	30	28	10	13	4	294
13) Appetite loss	AP	220	75	48	16	19	7	5	2	292
14) Nausea	NV	246	85	37	13	4	1	4	1	291
15) Vomiting	NV	280	96	9	3	1	0	2	1	292
16) Constipation	CO	238	82	43	15	7	2	3	1	291
17) Diarrhoea	DI	253	88	30	10	4	1	2	1	289
18) Felt tired	FA	122	42	120	41	40	14	8	3	290
19) Pain interference	PA	171	59	78	27	31	11	10	3	290
20) Concentration	CF	205	71	66	23	13	5	4	1	288
21) Tension	EF	106	37	123	43	47	16	12	4	288
22) Worry	EF	53	19	128	45	78	27	28	10	287
23) Irritability	EF	162	56	97	34	24	8	5	2	288
24) Depression	EF	128	44	111	38	40	14	12	4	291
25) Memory trouble	CF	202	70	72	25	11	4	5	2	290
26) Family life	SF	181	63	74	26	27	9	7	2	289
27) Social activities	SF	162	56	78	27	36	12	15	5	291
28) Financial difficulties	FI	219	76	44	15	15	5	9	3	287
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	1	4	21	54	89	79	33		281
		0	1	8	19	32	28	12		
30) Overall quality of life	QL	2	5	24	56	83	74	44		288
		1	2	8	19	29	26	15		

## Malignant melanoma: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	6	3
v +3	0	0
v 2.0	225	97
v 3.0	2	1
Total	233	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	233	100
70-79	0	0
80+	0	0
Not known	0	0
Total	233	

#### Gender

	N	(%)
Male	133	57
Female	100	43
Not known	0	0
Total	233	

#### Stage

	N	(%)
Stage I-II	50	22
Stage III-IV	106	46
Recurrent/metastatic	75	32
Not known	2	1
Total	233	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	68.4	(22.8)	66.7	[50-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	74.6	(29.8)	83.3	[50-100]
Emotional functioning	EF	74.7	(22.6)	75	[58.3-91.7]
Cognitive functioning	CF	88.4	(17)	100	[83.3-100]
Social functioning	SF	81.5	(26.5)	100	[66.7-100]
Fatigue	FA	27.4	(26.4)	22.2	[0-44.4]
Nausea and vomiting	NV	5.6	(14.4)	0	[0-0]
Pain	PA	19.0	(27.8)	0	[0-33.3]
Dyspnoea	DY	13.1	(22.6)	0	[0-33.3]
Insomnia	SL	25.4	(30.2)	0	[0-33.3]
Appetite loss	AP	11.6	(24.1)	0	[0-0]
Constipation	CO	12.6	(25.8)	0	[0-0]
Diarrhoea	DI	4.4	(15)	0	[0-0]
Financial difficulties	FI	11.5	(24.5)	0	[0-0]

**Malignant melanoma: 60-69**  
**Constructed scales**

QL	N	(%)
0	7	3
8.3	0	0
16.7	2	1
25	3	1
33.3	7	3
41.7	8	4
50	30	14
58.3	16	7
66.7	45	20
75	19	9
83.3	48	22
91.7	9	4
100	29	13
Total	223	

**PF**  
 Previous version of this scale used

CF	N	(%)
0	1	0
16.7	0	0
33.3	2	1
50	11	5
66.7	33	15
83.3	44	20
100	135	60
Total	226	

SF	N	(%)
0	6	3
16.7	6	3
33.3	11	5
50	15	7
66.7	32	14
83.3	28	13
100	124	56
Total	222	

FA	N	(%)
0	64	28
11.1	30	13
22.2	33	15
33.3	36	16
44.4	24	11
55.6	7	3
66.7	19	8
77.8	2	1
88.9	4	2
100	7	3
Total	226	

RF	N	(%)
0	10	5
16.7	5	2
33.3	27	12
50	15	7
66.7	39	17
83.3	25	11
100	103	46
Total	224	

NV	N	(%)
0	191	83
16.7	18	8
33.3	12	5
50	4	2
66.7	6	3
83.3	0	0
100	0	0
Total	231	

EF	N	(%)
0	1	0
8.3	2	1
16.7	3	1
25	2	1
33.3	6	3
41.7	16	7
50	14	6
58.3	15	7
66.7	23	10
75	36	16
83.3	24	11
91.7	32	14
100	50	22
Total	224	

PA	N	(%)
0	126	56
16.7	30	13
33.3	33	15
50	10	4
66.7	13	6
83.3	4	2
100	10	4
Total	226	



**Malignant melanoma: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	113	50	65	29	34	15	14	6	226
7) Limited in leisure	RF	124	55	50	22	32	14	18	8	224
8) Dyspnoea	DY	161	70	49	21	16	7	3	1	229
9) Pain	PA	133	58	60	26	24	10	14	6	231
10) Need to rest	FA	83	36	92	40	41	18	14	6	230
11) Insomnia	SL	116	50	65	28	37	16	12	5	230
12) Felt weak	FA	125	54	66	29	28	12	11	5	230
13) Appetite loss	AP	178	77	34	15	13	6	7	3	232
14) Nausea	NV	194	83	27	12	10	4	2	1	233
15) Vomiting	NV	211	91	14	6	5	2	1	0	231
16) Constipation	CO	176	76	33	14	12	5	10	4	231
17) Diarrhoea	DI	207	90	16	7	4	2	2	1	229
18) Felt tired	FA	87	38	103	45	28	12	12	5	230
19) Pain interference	PA	154	68	44	19	18	8	12	5	228
20) Concentration	CF	175	77	31	14	17	8	4	2	227
21) Tension	EF	103	45	82	36	37	16	7	3	229
22) Worry	EF	64	28	87	38	60	26	21	9	232
23) Irritability	EF	138	61	66	29	19	8	5	2	228
24) Depression	EF	123	54	74	33	23	10	8	4	228
25) Memory trouble	CF	159	69	61	26	10	4	1	0	231
26) Family life	SF	152	68	49	22	13	6	11	5	225
27) Social activities	SF	138	61	49	22	25	11	16	7	228
28) Financial difficulties	FI	175	78	28	13	14	6	7	3	224
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	7	0	16	44	69	53	34		223
		3	0	7	20	31	24	15		
30) Overall quality of life	QL	9	4	11	42	57	67	39		229
		4	2	5	18	25	29	17		

## Malignant melanoma: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	17	8
v +3	0	0
v 2.0	205	92
v 3.0	1	0
Total	223	

#### Age

	N	(%)
<40	55	25
40-49	51	23
50-59	53	24
60-69	50	22
70-79	12	5
80+	2	1
Not known	0	0
Total	223	

#### Gender

	N	(%)
Male	114	51
Female	109	49
Not known	0	0
Total	223	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	73.2	(18.1)	75	[66.7-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	81.2	(27.4)	100	[66.7-100]
Emotional functioning	EF	77.5	(21.4)	83.3	[66.7-91.7]
Cognitive functioning	CF	91.6	(14.8)	100	[83.3-100]
Social functioning	SF	85.7	(21.4)	100	[66.7-100]
Fatigue	FA	20.7	(22.1)	22.2	[0-33.3]
Nausea and vomiting	NV	3.3	(11.4)	0	[0-0]
Pain	PA	15.1	(20.5)	0	[0-33.3]
Dyspnoea	DY	6.6	(16.1)	0	[0-0]
Insomnia	SL	20.9	(27.2)	0	[0-33.3]
Appetite loss	AP	9.0	(21.2)	0	[0-0]
Constipation	CO	8.3	(18.7)	0	[0-0]
Diarrhoea	DI	5.9	(15.9)	0	[0-0]
Financial difficulties	FI	13.9	(25.1)	0	[0-33.3]

**Malignant melanoma: stage I-II  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	0	0
8.3	0	0
16.7	1	1
25	0	0
33.3	8	4
41.7	3	2
50	23	11
58.3	15	7
66.7	47	23
75	14	7
83.3	52	26
91.7	12	6
100	28	14
Total	203	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	0	0
16.7	0	0
33.3	3	1
50	6	3
66.7	22	10
83.3	35	16
100	151	70
Total	217	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	1	1
16.7	3	1
33.3	10	5
50	10	5
66.7	32	15
83.3	34	16
100	130	59
Total	220	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	73	34
11.1	35	16
22.2	41	19
33.3	35	16
44.4	12	6
55.6	7	3
66.7	5	2
77.8	4	2
88.9	3	1
100	2	1
Total	217	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	8	4
16.7	2	1
33.3	13	7
50	12	6
66.7	29	15
83.3	22	11
100	114	57
Total	200	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	194	88
16.7	18	8
33.3	3	1
50	1	1
66.7	3	1
83.3	1	1
100	0	0
Total	220	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	1	1
8.3	1	1
16.7	4	2
25	3	1
33.3	6	3
41.7	8	4
50	6	3
58.3	11	5
66.7	25	11
75	28	13
83.3	40	18
91.7	41	19
100	45	21
Total	219	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	115	54
16.7	39	18
33.3	37	17
50	13	6
66.7	5	2
83.3	3	1
100	1	1
Total	213	

**Malignant melanoma: stage I-II**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	122	61	49	24	19	10	11	6	201
7) Limited in leisure	RF	137	67	35	17	19	9	13	6	204
8) Dyspnoea	DY	185	83	31	14	5	2	1	1	222
9) Pain	PA	129	59	72	33	12	6	6	3	219
10) Need to rest	FA	101	46	89	40	22	10	10	5	222
11) Insomnia	SL	122	55	71	32	21	9	9	4	223
12) Felt weak	FA	132	60	71	32	11	5	7	3	221
13) Appetite loss	AP	182	82	26	12	11	5	4	2	223
14) Nausea	NV	196	89	18	8	5	2	2	1	221
15) Vomiting	NV	214	97	4	2	3	1	0	0	221
16) Constipation	CO	179	81	33	15	8	4	2	1	222
17) Diarrhoea	DI	190	86	27	12	3	1	2	1	222
18) Felt tired	FA	109	50	90	41	17	8	4	2	220
19) Pain interference	PA	148	68	52	24	13	6	4	2	217
20) Concentration	CF	179	82	32	15	8	4	0	0	219
21) Tension	EF	117	53	74	34	24	11	6	3	221
22) Worry	EF	74	34	97	44	32	15	18	8	221
23) Irritability	EF	130	59	71	32	15	7	4	2	220
24) Depression	EF	124	56	72	33	16	7	8	4	220
25) Memory trouble	CF	166	76	46	21	5	2	2	1	219
26) Family life	SF	160	72	45	20	10	5	6	3	221
27) Social activities	SF	144	66	53	24	16	7	7	3	220
28) Financial difficulties	FI	156	71	42	19	14	6	7	3	219
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	0	1	9	34	58	65	36		203
		0	1	4	17	29	32	18		
30) Overall quality of life	QL	0	2	12	34	61	67	44		220
		0	1	6	16	28	31	20		

## Malignant melanoma: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	0	0
v 2.0	580	99
v 3.0	5	1
Total	585	

#### Age

	N	(%)
<40	155	27
40-49	154	26
50-59	134	23
60-69	106	18
70-79	35	6
80+	1	0
Not known	0	0
Total	585	

#### Gender

	N	(%)
Male	336	57
Female	249	43
Not known	0	0
Total	585	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	69.7	(19.9)	66.7	[58.3-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	71.1	(30.1)	83.3	[50-100]
Emotional functioning	EF	75.0	(21.3)	75	[66.7-91.7]
Cognitive functioning	CF	88.8	(16.6)	100	[83.3-100]
Social functioning	SF	81.5	(24)	100	[66.7-100]
Fatigue	FA	25.1	(23)	22.2	[0-33.3]
Nausea and vomiting	NV	3.2	(9.6)	0	[0-0]
Pain	PA	20.8	(24.1)	16.7	[0-33.3]
Dyspnoea	DY	7.6	(16.6)	0	[0-0]
Insomnia	SL	23.9	(29.1)	0	[0-33.3]
Appetite loss	AP	8.2	(18)	0	[0-0]
Constipation	CO	7.7	(19.2)	0	[0-0]
Diarrhoea	DI	4.6	(14)	0	[0-0]
Financial difficulties	FI	15.0	(26.9)	0	[0-33.3]

**Malignant melanoma: stage III-IV  
Constructed scales**

QL	N	(%)
0	4	1
8.3	0	0
16.7	5	1
25	6	1
33.3	19	3
41.7	25	4
50	80	14
58.3	40	7
66.7	131	23
75	53	9
83.3	111	19
91.7	36	6
100	67	12
Total	577	

**PF**  
Previous version of this scale used

CF	N	(%)
0	1	0
16.7	4	1
33.3	3	1
50	26	5
66.7	70	12
83.3	126	22
100	341	60
Total	571	

SF	N	(%)
0	8	1
16.7	14	2
33.3	26	5
50	35	6
66.7	108	19
83.3	95	17
100	289	50
Total	575	

FA	N	(%)
0	160	28
11.1	79	14
22.2	85	15
33.3	122	21
44.4	48	8
55.6	21	4
66.7	38	7
77.8	9	2
88.9	8	1
100	3	1
Total	573	

RF	N	(%)
0	34	6
16.7	14	2
33.3	65	11
50	49	9
66.7	116	20
83.3	87	15
100	212	37
Total	577	

NV	N	(%)
0	504	87
16.7	54	9
33.3	17	3
50	3	1
66.7	4	1
83.3	0	0
100	0	0
Total	582	

EF	N	(%)
0	3	1
8.3	2	0
16.7	8	1
25	10	2
33.3	15	3
41.7	20	4
50	34	6
58.3	34	6
66.7	86	15
75	84	15
83.3	92	16
91.7	71	12
100	112	20
Total	571	

PA	N	(%)
0	249	43
16.7	110	19
33.3	122	21
50	40	7
66.7	34	6
83.3	9	2
100	10	2
Total	574	

**Malignant melanoma: stage III-IV  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	236	40	211	36	89	15	48	8	584
7) Limited in leisure	RF	285	49	158	27	82	14	52	9	577
8) Dyspnoea	DY	466	80	102	18	9	2	4	1	581
9) Pain	PA	288	50	211	36	67	12	13	2	579
10) Need to rest	FA	213	37	250	43	93	16	24	4	580
11) Insomnia	SL	298	51	176	30	78	13	28	5	580
12) Felt weak	FA	315	54	196	34	56	10	15	3	582
13) Appetite loss	AP	469	80	87	15	25	4	2	0	583
14) Nausea	NV	509	87	64	11	9	2	2	0	584
15) Vomiting	NV	559	96	19	3	4	1	0	0	582
16) Constipation	CO	482	83	75	13	15	3	10	2	582
17) Diarrhoea	DI	516	89	52	9	11	2	2	0	581
18) Felt tired	FA	232	40	262	45	70	12	14	2	578
19) Pain interference	PA	332	57	177	31	53	9	18	3	580
20) Concentration	CF	430	75	101	18	36	6	6	1	573
21) Tension	EF	247	43	249	43	67	12	16	3	579
22) Worry	EF	154	27	264	46	115	20	46	8	579
23) Irritability	EF	326	56	192	33	43	7	17	3	578
24) Depression	EF	312	54	200	35	47	8	19	3	578
25) Memory trouble	CF	416	72	135	23	23	4	6	1	580
26) Family life	SF	367	64	155	27	39	7	15	3	576
27) Social activities	SF	329	57	167	29	57	10	28	5	581
28) Financial difficulties	FI	409	71	103	18	41	7	25	4	578
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	6	2	33	123	183	152	79		578
		1	0	6	21	32	26	14		
30) Overall quality of life	QL	9	9	35	101	172	149	102		577
		2	2	6	18	30	26	18		

## Malignant melanoma: recurrent/metastatic

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	1	0
v +3	0	0
v 2.0	370	96
v 3.0	16	4
Total	387	

#### Age

	N	(%)
<40	75	19
40-49	114	30
50-59	107	28
60-69	75	19
70-79	14	4
80+	2	1
Not known	0	0
Total	387	

#### Gender

	N	(%)
Male	220	57
Female	167	43
Not known	0	0
Total	387	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	63.4	(23.2)	66.7	[50-83.3]
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	66.0	(33.6)	66.7	[33.3-100]
Emotional functioning	EF	67.5	(23.3)	66.7	[50-83.3]
Cognitive functioning	CF	85.7	(20.6)	100	[83.3-100]
Social functioning	SF	71.3	(30)	83.3	[50-100]
Fatigue	FA	33.3	(27.9)	33.3	[11.1-55.6]
Nausea and vomiting	NV	10.7	(19.8)	0	[0-16.7]
Pain	PA	23.5	(30)	16.7	[0-33.3]
Dyspnoea	DY	18.7	(27.7)	0	[0-33.3]
Insomnia	SL	29.3	(32)	33.3	[0-66.7]
Appetite loss	AP	23.4	(32.6)	0	[0-33.3]
Constipation	CO	12.9	(25.7)	0	[0-0]
Diarrhoea	DI	6.7	(17.6)	0	[0-0]
Financial difficulties	FI	16.6	(28)	0	[0-33.3]



**Malignant melanoma: recurrent/metastatic  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	10	3
8.3	1	0
16.7	6	2
25	12	3
33.3	28	7
41.7	23	6
50	45	12
58.3	37	10
66.7	60	16
75	36	10
83.3	82	22
91.7	12	3
100	27	7
<b>Total</b>	<b>379</b>	

**PF**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	3	1
16.7	2	1
33.3	15	4
50	20	5
66.7	53	14
83.3	75	20
100	215	56
<b>Total</b>	<b>383</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	20	5
16.7	13	3
33.3	39	10
50	38	10
66.7	71	19
83.3	58	15
100	141	37
<b>Total</b>	<b>380</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	76	20
11.1	48	13
22.2	60	16
33.3	64	17
44.4	35	9
55.6	28	7
66.7	33	9
77.8	11	3
88.9	12	3
100	15	4
<b>Total</b>	<b>382</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	34	9
16.7	21	6
33.3	47	13
50	29	8
66.7	75	20
83.3	34	9
100	136	36
<b>Total</b>	<b>376</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	264	69
16.7	53	14
33.3	36	9
50	14	4
66.7	9	2
83.3	5	1
100	3	1
<b>Total</b>	<b>384</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	4	1
8.3	4	1
16.7	5	1
25	12	3
33.3	18	5
41.7	32	9
50	24	6
58.3	34	9
66.7	59	16
75	52	14
83.3	44	12
91.7	46	12
100	40	11
<b>Total</b>	<b>374</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	188	49
16.7	48	13
33.3	55	14
50	33	9
66.7	23	6
83.3	15	4
100	19	5
<b>Total</b>	<b>381</b>	

**Malignant melanoma: recurrent/metastatic  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	<i>Previous version of this scale used</i>								
2) Long walk	PF	<i>Previous version of this scale used</i>								
3) Short walk	PF	<i>Previous version of this scale used</i>								
4) Bed or chair	PF	<i>Previous version of this scale used</i>								
5) Self care	PF	<i>Previous version of this scale used</i>								
6) Limited in work	RF	151	40	120	32	65	17	45	12	381
7) Limited in leisure	RF	162	43	95	25	66	18	55	15	378
8) Dyspnoea	DY	239	62	91	24	40	10	15	4	385
9) Pain	PA	201	52	100	26	54	14	31	8	386
10) Need to rest	FA	111	29	155	40	83	21	38	10	387
11) Insomnia	SL	176	46	110	28	73	19	28	7	387
12) Felt weak	FA	171	44	127	33	55	14	32	8	385
13) Appetite loss	AP	226	59	76	20	50	13	31	8	383
14) Nausea	NV	272	71	78	20	19	5	15	4	384
15) Vomiting	NV	322	83	48	12	11	3	5	1	386
16) Constipation	CO	289	75	55	14	26	7	14	4	384
17) Diarrhoea	DI	321	84	48	13	7	2	5	1	381
18) Felt tired	FA	112	29	173	45	72	19	27	7	384
19) Pain interference	PA	230	60	85	22	41	11	26	7	382
20) Concentration	CF	251	66	88	23	32	8	12	3	383
21) Tension	EF	123	32	159	42	75	20	24	6	381
22) Worry	EF	59	15	150	39	116	30	58	15	383
23) Irritability	EF	198	52	139	36	37	10	9	2	383
24) Depression	EF	162	42	142	37	63	16	16	4	383
25) Memory trouble	CF	277	72	82	21	20	5	7	2	386
26) Family life	SF	189	50	112	29	52	14	29	8	382
27) Social activities	SF	175	46	96	25	76	20	36	9	383
28) Financial difficulties	FI	254	69	65	18	36	10	16	4	371
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	11	14	43	76	92	107	38		381
		3	4	11	20	24	28	10		
30) Overall quality of life	QL	15	12	49	68	97	105	35		381
		4	3	13	18	26	28	9		

## Myeloma: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	744	79
v +3	0	0
v 2.0	2	0
v 3.0	198	21
Total	944	

#### Age

	N	(%)
<40	15	2
40-49	106	11
50-59	314	33
60-69	264	28
70-79	226	24
80+	17	2
Not known	2	0
Total	944	

#### Gender

	N	(%)
Male	561	59
Female	381	40
Not known	2	0
Total	944	

#### Stage

	N	(%)
Stage I-II	295	31
Stage III-IV	647	69
Recurrent/metastatic	2	0
Not known	0	0
Total	944	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	55.7	(22.8)	58.3	[41.7-75]
Physical functioning	PF	67.7	(23.4)	73.3	[53.3-86.7]
Role Functioning	RF	60.1	(33.4)	66.7	[33.3-83.3]
Emotional functioning	EF	71.3	(22.7)	75	[58.3-91.7]
Cognitive functioning	CF	78.1	(23.8)	83.3	[66.7-100]
Social functioning	SF	63.2	(31)	66.7	[33.3-83.3]
Fatigue	FA	48.7	(26.7)	44.4	[33.3-66.7]
Nausea and vomiting	NV	10.5	(19.2)	0	[0-16.7]
Pain	PA	47.1	(33.6)	50	[16.7-66.7]
Dyspnoea	DY	26.0	(27.3)	33.3	[0-33.3]
Insomnia	SL	28.9	(30.6)	33.3	[0-33.3]
Appetite loss	AP	23.2	(30.2)	0	[0-33.3]
Constipation	CO	23.2	(29.9)	0	[0-33.3]
Diarrhoea	DI	9.6	(19.4)	0	[0-0]
Financial difficulties	FI	16.1	(26.6)	0	[0-33.3]

**Myeloma: all stages**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	5	3
8.3	0	0
16.7	9	5
25	6	3
33.3	28	14
41.7	18	9
50	33	17
58.3	16	8
66.7	31	16
75	15	8
83.3	24	12
91.7	9	5
100	5	3
Total	199	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	1	1
13.3	3	2
20	5	3
26.7	4	2
33.3	10	5
40	9	5
46.7	15	8
53.3	13	7
60	15	8
66.7	18	9
73.3	19	10
80	18	9
86.7	25	13
93.3	15	8
100	21	11
Total	191	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	24	12
16.7	11	6
33.3	28	14
50	16	8
66.7	45	23
83.3	28	14
100	47	24
Total	199	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	3	0
8.3	11	1
16.7	14	2
25	25	3
33.3	43	5
41.7	36	4
50	51	6
58.3	84	9
66.7	135	15
75	134	15
83.3	128	14
91.7	107	12
100	144	16
Total	915	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	16	2
16.7	15	2
33.3	56	6
50	80	9
66.7	175	19
83.3	241	26
100	352	38
Total	935	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	73	8
16.7	45	5
33.3	117	13
50	115	13
66.7	199	22
83.3	138	15
100	223	25
Total	910	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	56	6
11.1	57	6
22.2	67	7
33.3	202	22
44.4	126	14
55.6	107	12
66.7	126	14
77.8	68	7
88.9	57	6
100	59	6
Total	925	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	618	67
16.7	170	18
33.3	79	9
50	24	3
66.7	21	2
83.3	8	1
100	10	1
Total	930	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	167	18
16.7	111	12
33.3	170	18
50	92	10
66.7	158	17
83.3	105	11
100	121	13
Total	924	



## Myeloma: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	295	100
v +3	0	0
v 2.0	0	0
v 3.0	0	0
Total	295	

#### Age

	N	(%)
<40	3	1
40-49	27	9
50-59	92	31
60-69	89	30
70-79	80	27
80+	4	1
Not known	0	0
Total	295	

#### Gender

	N	(%)
Male	172	58
Female	123	42
Not known	0	0
Total	295	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	<i>Previous version of this scale used</i>			
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	<i>Previous version of this scale used</i>			
Emotional functioning	EF	71.1	(22.7)	75	[58.3-91.7]
Cognitive functioning	CF	81.1	(22.5)	83.3	[66.7-100]
Social functioning	SF	68.6	(30.1)	66.7	[50-100]
Fatigue	FA	44.1	(26.5)	44.4	[22.2-66.7]
Nausea and vomiting	NV	9.9	(17.8)	0	[0-16.7]
Pain	PA	43.1	(32.9)	33.3	[16.7-66.7]
Dyspnoea	DY	24.8	(26.5)	33.3	[0-33.3]
Insomnia	SL	28.0	(30.7)	33.3	[0-33.3]
Appetite loss	AP	21.3	(29.4)	0	[0-33.3]
Constipation	CO	22.5	(30)	0	[0-33.3]
Diarrhoea	DI	10.0	(20.8)	0	[0-0]
Financial difficulties	FI	12.9	(23.5)	0	[0-33.3]

**Myeloma: stage I-II  
Constructed scales**

**QL**  
Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	6	2
16.7	2	1
33.3	11	4
50	19	7
66.7	55	19
83.3	75	26
100	125	43
Total	293	

**PF**  
Previous version of this scale used

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	17	6
16.7	15	5
33.3	25	9
50	28	10
66.7	69	24
83.3	43	15
100	91	32
Total	288	

**RF**  
Previous version of this scale used

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	22	8
11.1	29	10
22.2	23	8
33.3	69	24
44.4	29	10
55.6	39	13
66.7	35	12
77.8	15	5
88.9	19	7
100	10	3
Total	290	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	1	0
8.3	3	1
16.7	4	1
25	10	4
33.3	14	5
41.7	9	3
50	17	6
58.3	27	9
66.7	39	14
75	45	16
83.3	43	15
91.7	30	11
100	45	16
Total	287	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	193	67
16.7	53	18
33.3	26	9
50	9	3
66.7	6	2
83.3	1	0
100	2	1
Total	290	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	62	22
16.7	30	10
33.3	64	22
50	29	10
66.7	51	18
83.3	20	7
100	33	11
Total	289	

**Myeloma: stage I-II  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total							
		N	(%)	N	(%)	N	(%)	N	(%)	N							
1) Strenuous activities	PF	<i>Previous version of this scale used</i>															
2) Long walk	PF	<i>Previous version of this scale used</i>															
3) Short walk	PF	<i>Previous version of this scale used</i>															
4) Bed or chair	PF	<i>Previous version of this scale used</i>															
5) Self care	PF	<i>Previous version of this scale used</i>															
6) Limited in work	RF	<i>Previous version of this scale used</i>															
7) Limited in leisure	RF	<i>Previous version of this scale used</i>															
8) Dyspnoea	DY	129	44	122	42	32	11	11	4	294							
9) Pain	PA	65	22	105	36	78	27	45	15	293							
10) Need to rest	FA	45	15	120	41	95	32	35	12	295							
11) Insomnia	SL	130	44	104	35	39	13	22	8	295							
12) Felt weak	FA	63	22	124	43	71	24	34	12	292							
13) Appetite loss	AP	168	57	82	28	26	9	18	6	294							
14) Nausea	NV	198	68	66	23	22	8	6	2	292							
15) Vomiting	NV	253	87	33	11	4	1	2	1	292							
16) Constipation	CO	164	56	76	26	35	12	17	6	292							
17) Diarrhoea	DI	224	77	50	17	11	4	5	2	290							
18) Felt tired	FA	53	18	128	44	78	27	32	11	291							
19) Pain interference	PA	94	32	83	29	66	23	48	17	291							
20) Concentration	CF	171	58	81	28	27	9	14	5	293							
21) Tension	EF	108	37	121	42	43	15	18	6	290							
22) Worry	EF	85	29	121	42	64	22	20	7	290							
23) Irritability	EF	165	56	97	33	23	8	8	3	293							
24) Depression	EF	99	34	125	43	48	17	19	7	291							
25) Memory trouble	CF	170	58	98	33	18	6	7	2	293							
26) Family life	SF	135	47	100	35	32	11	22	8	289							
27) Social activities	SF	115	40	80	28	56	19	40	14	291							
28) Financial difficulties	FI	211	72	58	20	17	6	7	2	293							
		<b>1</b>		<b>2</b>		<b>3</b>		<b>4</b>		<b>5</b>		<b>6</b>		<b>7</b>		<b>Total</b>	
		<b>(very poor)</b>										<b>(excellent)</b>					
29) Overall health	QL	<i>Previous version of this scale used</i>															
30) Overall quality of life	QL	21	27	46	65	63	44	21		287							
		7	9	16	23	22	15	7									



## Myeloma: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	449	69
v +3	0	0
v 2.0	0	0
v 3.0	198	31
Total	647	

#### Age

	N	(%)
<40	12	2
40-49	79	12
50-59	222	34
60-69	174	27
70-79	145	22
80+	13	2
Not known	2	0
Total	647	

#### Gender

	N	(%)
Male	388	60
Female	257	40
Not known	2	0
Total	647	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	55.8	(22.9)	58.3	[41.7-75]
Physical functioning	PF	67.7	(23.4)	73.3	[53.3-86.7]
Role Functioning	RF	60.7	(33)	66.7	[33.3-83.3]
Emotional functioning	EF	71.5	(22.7)	75	[58.3-91.7]
Cognitive functioning	CF	76.9	(24.2)	83.3	[66.7-100]
Social functioning	SF	60.8	(31)	66.7	[33.3-83.3]
Fatigue	FA	50.7	(26.6)	44.4	[33.3-66.7]
Nausea and vomiting	NV	10.7	(19.8)	0	[0-16.7]
Pain	PA	48.8	(33.8)	50	[16.7-83.3]
Dyspnoea	DY	26.3	(27.4)	33.3	[0-33.3]
Insomnia	SL	29.4	(30.5)	33.3	[0-33.3]
Appetite loss	AP	23.9	(30.4)	0	[0-33.3]
Constipation	CO	23.6	(29.8)	0	[0-33.3]
Diarrhoea	DI	9.5	(18.8)	0	[0-0]
Financial difficulties	FI	17.6	(27.8)	0	[0-33.3]

**Myeloma: stage III-IV  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	5	3
8.3	0	0
16.7	9	5
25	6	3
33.3	28	14
41.7	18	9
50	31	16
58.3	16	8
66.7	31	16
75	15	8
83.3	24	12
91.7	9	5
100	5	3
Total	197	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	1	1
13.3	3	2
20	5	3
26.7	4	2
33.3	10	5
40	9	5
46.7	15	8
53.3	13	7
60	15	8
66.7	18	9
73.3	19	10
80	18	9
86.7	25	13
93.3	15	8
100	21	11
Total	191	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	22	11
16.7	11	6
33.3	28	14
50	16	8
66.7	45	23
83.3	28	14
100	47	24
Total	197	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	2	0
8.3	8	1
16.7	10	2
25	15	2
33.3	28	5
41.7	27	4
50	34	5
58.3	57	9
66.7	96	15
75	88	14
83.3	85	14
91.7	77	12
100	99	16
Total	626	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	10	2
16.7	13	2
33.3	44	7
50	61	10
66.7	119	19
83.3	166	26
100	227	36
Total	640	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	55	9
16.7	30	5
33.3	91	15
50	87	14
66.7	130	21
83.3	95	15
100	132	21
Total	620	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	34	5
11.1	28	4
22.2	44	7
33.3	133	21
44.4	97	15
55.6	68	11
66.7	91	14
77.8	51	8
88.9	38	6
100	49	8
Total	633	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	424	67
16.7	117	18
33.3	52	8
50	15	2
66.7	15	2
83.3	7	1
100	8	1
Total	638	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	105	17
16.7	81	13
33.3	106	17
50	63	10
66.7	106	17
83.3	84	13
100	88	14
Total	633	

**Myeloma: stage III-IV  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	30	15	68	35	46	24	51	26	195
2) Long walk	PF	42	22	52	27	47	24	54	28	195
3) Short walk	PF	110	56	57	29	21	11	9	5	197
4) Bed or chair	PF	88	45	65	33	33	17	9	5	195
5) Self care	PF	172	88	19	10	3	2	2	1	196
6) Limited in work	RF	66	34	65	33	35	18	31	16	197
7) Limited in leisure	RF	60	31	63	32	48	24	26	13	197
8) Dyspnoea	DY	277	43	245	38	98	15	22	3	642
9) Pain	PA	119	19	200	31	187	29	137	21	643
10) Need to rest	FA	59	9	243	38	224	35	117	18	643
11) Insomnia	SL	263	41	240	37	92	14	48	8	643
12) Felt weak	FA	102	16	261	41	174	27	106	17	643
13) Appetite loss	AP	343	53	182	28	79	12	41	6	645
14) Nausea	NV	433	67	149	23	43	7	18	3	643
15) Vomiting	NV	555	87	56	9	21	3	8	1	640
16) Constipation	CO	337	53	195	30	69	11	40	6	641
17) Diarrhoea	DI	483	77	122	19	21	3	5	1	631
18) Felt tired	FA	72	11	268	42	209	33	91	14	640
19) Pain interference	PA	186	29	153	24	162	25	136	21	637
20) Concentration	CF	337	53	181	28	89	14	33	5	640
21) Tension	EF	250	39	256	40	101	16	31	5	638
22) Worry	EF	177	28	284	45	123	19	54	9	638
23) Irritability	EF	338	53	232	36	58	9	12	2	640
24) Depression	EF	236	37	274	43	94	15	34	5	638
25) Memory trouble	CF	323	50	227	35	76	12	18	3	644
26) Family life	SF	231	37	208	33	123	20	64	10	626
27) Social activities	SF	172	27	187	30	160	25	112	18	631
28) Financial difficulties	FI	414	65	134	21	60	9	27	4	635
<hr/>										
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
<hr/>										
29) Overall health	QL	7	12	42	43	56	32	5		197
		4	6	21	22	28	16	3		
<hr/>										
30) Overall quality of life	QL	46	65	126	157	131	65	42		632
		7	10	20	25	21	10	7		

## Oesophageal cancer

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	56	5
v +3	0	0
v 2.0	71	7
v 3.0	904	88
Total	1,031	

#### Age

	N	(%)
<40	9	1
40-49	101	10
50-59	237	23
60-69	346	34
70-79	270	26
80+	68	7
Not known	0	0
Total	1,031	

#### Gender

	N	(%)
Male	772	75
Female	248	24
Not known	11	1
Total	1,031	

#### Stage

	N	(%)
Stage I-II	118	11
Stage III-IV	47	5
Recurrent/metastatic	347	34
Not known	519	50
Total	1,031	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	55.6	(24.1)	50	[41.7-75]
Physical functioning	PF	77.3	(23.9)	86.7	[66.7-93.3]
Role Functioning	RF	69.0	(33.5)	83.3	[50-100]
Emotional functioning	EF	70.6	(24.2)	75	[58.3-91.7]
Cognitive functioning	CF	83.3	(21.5)	83.3	[66.7-100]
Social functioning	SF	75.6	(28)	83.3	[66.7-100]
Fatigue	FA	36.6	(26.6)	33.3	[22.2-55.6]
Nausea and vomiting	NV	16.8	(23.3)	0	[0-33.3]
Pain	PA	26.5	(27)	16.7	[0-33.3]
Dyspnoea	DY	19.2	(27.3)	0	[0-33.3]
Insomnia	SL	29.8	(32.8)	33.3	[0-66.7]
Appetite loss	AP	33.7	(37.4)	33.3	[0-66.7]
Constipation	CO	25.5	(31.1)	0	[0-33.3]
Diarrhoea	DI	7.3	(18.9)	0	[0-0]
Financial difficulties	FI	15.4	(27.7)	0	[0-33.3]

**Oesophageal cancer  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	29	3
8.3	11	1
16.7	46	5
25	43	5
33.3	95	10
41.7	87	9
50	173	18
58.3	78	8
66.7	141	15
75	69	7
83.3	113	12
91.7	31	3
100	48	5
<b>Total</b>	<b>964</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	11	1
6.7	3	0
13.3	9	1
20	14	2
26.7	19	2
33.3	19	2
40	27	3
46.7	23	3
53.3	32	4
60	39	4
66.7	76	9
73.3	72	8
80	72	8
86.7	113	13
93.3	142	16
100	218	25
<b>Total</b>	<b>889</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	89	9
16.7	40	4
33.3	104	11
50	65	7
66.7	162	17
83.3	122	13
100	380	40
<b>Total</b>	<b>962</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	8	1
8.3	11	1
16.7	23	2
25	33	3
33.3	30	3
41.7	71	7
50	68	7
58.3	81	8
66.7	116	12
75	133	13
83.3	145	14
91.7	112	11
100	177	18
<b>Total</b>	<b>1,008</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	8	1
16.7	15	2
33.3	39	4
50	67	7
66.7	151	15
83.3	246	24
100	498	49
<b>Total</b>	<b>1,024</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	40	4
16.7	27	3
33.3	67	7
50	107	11
66.7	168	17
83.3	177	18
100	423	42
<b>Total</b>	<b>1,009</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	143	14
11.1	103	10
22.2	174	17
33.3	190	19
44.4	119	12
55.6	100	10
66.7	88	9
77.8	34	3
88.9	27	3
100	42	4
<b>Total</b>	<b>1,020</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	543	53
16.7	199	20
33.3	135	13
50	71	7
66.7	43	4
83.3	17	2
100	15	2
<b>Total</b>	<b>1,023</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	341	34
16.7	234	23
33.3	194	19
50	95	9
66.7	91	9
83.3	29	3
100	33	3
<b>Total</b>	<b>1,017</b>	

**Oesophageal cancer  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total						
		N	(%)	N	(%)	N	(%)	N	(%)	N						
1) Strenuous activities	PF	340	38	257	29	173	19	130	14	900						
2) Long walk	PF	377	42	209	23	161	18	150	17	897						
3) Short walk	PF	673	75	135	15	55	6	38	4	901						
4) Bed or chair	PF	511	57	224	25	122	14	44	5	901						
5) Self care	PF	815	91	51	6	14	2	21	2	901						
6) Limited in work	RF	443	46	223	23	155	16	145	15	966						
7) Limited in leisure	RF	506	52	210	22	128	13	121	13	965						
8) Dyspnoea	DY	616	60	264	26	108	11	37	4	1,025						
9) Pain	PA	390	38	377	37	197	19	59	6	1,023						
10) Need to rest	FA	317	31	405	39	224	22	81	8	1,027						
11) Insomnia	SL	466	46	286	28	183	18	88	9	1,023						
12) Felt weak	FA	319	31	378	37	213	21	116	11	1,026						
13) Appetite loss	AP	477	47	214	21	168	17	160	16	1,019						
14) Nausea	NV	642	63	259	25	80	8	45	4	1,026						
15) Vomiting	NV	704	69	206	20	74	7	42	4	1,026						
16) Constipation	CO	536	52	259	25	172	17	61	6	1,028						
17) Diarrhoea	DI	866	84	116	11	32	3	15	2	1,029						
18) Felt tired	FA	278	27	452	44	206	20	90	9	1,026						
19) Pain interference	PA	590	58	248	24	125	12	60	6	1,023						
20) Concentration	CF	701	68	208	20	79	8	40	4	1,028						
21) Tension	EF	412	40	389	38	162	16	58	6	1,021						
22) Worry	EF	293	29	375	37	219	21	138	14	1,025						
23) Irritability	EF	535	52	332	33	113	11	42	4	1,022						
24) Depression	EF	470	46	335	33	168	16	51	5	1,024						
25) Memory trouble	CF	611	60	303	30	88	9	23	2	1,025						
26) Family life	SF	619	61	222	22	123	12	52	5	1,016						
27) Social activities	SF	505	50	267	26	142	14	104	10	1,018						
28) Financial difficulties	FI	730	72	153	15	91	9	45	4	1,019						
		<b>1</b>		<b>2</b>		<b>3</b>		<b>4</b>		<b>5</b>		<b>6</b>		<b>7</b>		<b>Total</b>
		<b>(very poor)</b>										<b>(excellent)</b>				
29) Overall health	QL	48	74	175	266	190	150	63								966
		5	8	18	28	20	16	7								
30) Overall quality of life	QL	52	80	147	221	219	197	103								1,019
		5	8	14	22	22	19	10								

## Oesophageal cancer: males

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	51	7
v +3	0	0
v 2.0	58	8
v 3.0	663	86
Total	772	

#### Age

	N	(%)
<40	8	1
40-49	79	10
50-59	182	24
60-69	280	36
70-79	178	23
80+	45	6
Not known	0	0
Total	772	

#### Stage

	N	(%)
Stage I-II	78	10
Stage III-IV	32	4
Recurrent/metastatic	268	35
Not known	394	51
Total	772	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	57.4	(23.5)	58.3	[41.7-75]
Physical functioning	PF	80.0	(22.8)	86.7	[66.7-100]
Role Functioning	RF	71.3	(32.9)	83.3	[50-100]
Emotional functioning	EF	72.3	(23.2)	75	[58.3-91.7]
Cognitive functioning	CF	84.5	(20.3)	100	[66.7-100]
Social functioning	SF	76.8	(27.5)	83.3	[66.7-100]
Fatigue	FA	34.1	(26.4)	33.3	[11.1-55.6]
Nausea and vomiting	NV	15.8	(22.8)	0	[0-33.3]
Pain	PA	25.0	(26.5)	16.7	[0-33.3]
Dyspnoea	DY	18.5	(26.6)	0	[0-33.3]
Insomnia	SL	28.9	(32.8)	33.3	[0-66.7]
Appetite loss	AP	32.0	(37.2)	33.3	[0-66.7]
Constipation	CO	23.8	(30.6)	0	[0-33.3]
Diarrhoea	DI	7.0	(18.2)	0	[0-0]
Financial difficulties	FI	14.9	(27.6)	0	[0-33.3]

**Oesophageal cancer: males  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	17	2
8.3	7	1
16.7	28	4
25	28	4
33.3	65	9
41.7	60	8
50	128	18
58.3	60	8
66.7	118	17
75	50	7
83.3	86	12
91.7	28	4
100	37	5
<b>Total</b>	<b>712</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	7	1
6.7	2	0
13.3	5	1
20	5	1
26.7	11	2
33.3	19	3
40	13	2
46.7	15	2
53.3	20	3
60	23	4
66.7	52	8
73.3	45	7
80	51	8
86.7	85	13
93.3	111	17
100	188	29
<b>Total</b>	<b>652</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	62	9
16.7	27	4
33.3	63	9
50	44	6
66.7	121	17
83.3	94	13
100	301	42
<b>Total</b>	<b>712</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	2	0
8.3	6	1
16.7	19	3
25	22	3
33.3	17	2
41.7	48	6
50	44	6
58.3	61	8
66.7	88	12
75	111	15
83.3	105	14
91.7	89	12
100	142	19
<b>Total</b>	<b>754</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	5	1
16.7	7	1
33.3	26	3
50	44	6
66.7	110	14
83.3	190	25
100	384	50
<b>Total</b>	<b>766</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	26	3
16.7	19	3
33.3	55	7
50	69	9
66.7	119	16
83.3	136	18
100	333	44
<b>Total</b>	<b>757</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	123	16
11.1	87	11
22.2	138	18
33.3	150	20
44.4	73	10
55.6	66	9
66.7	59	8
77.8	20	3
88.9	19	3
100	29	4
<b>Total</b>	<b>764</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	424	55
16.7	145	19
33.3	94	12
50	50	7
66.7	28	4
83.3	15	2
100	9	1
<b>Total</b>	<b>765</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	273	36
16.7	173	23
33.3	142	19
50	66	9
66.7	65	9
83.3	17	2
100	23	3
<b>Total</b>	<b>759</b>	



**Oesophageal cancer: males**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	294	45	177	27	113	17	75	11	659
2) Long walk	PF	297	45	167	25	95	14	100	15	659
3) Short walk	PF	516	78	88	13	33	5	23	4	660
4) Bed or chair	PF	397	60	158	24	77	12	28	4	660
5) Self care	PF	605	92	34	5	8	1	14	2	661
6) Limited in work	RF	353	49	165	23	103	14	95	13	716
7) Limited in leisure	RF	393	55	153	21	83	12	86	12	715
8) Dyspnoea	DY	468	61	196	26	81	11	23	3	768
9) Pain	PA	315	41	270	35	144	19	36	5	765
10) Need to rest	FA	259	34	309	40	147	19	55	7	770
11) Insomnia	SL	361	47	211	28	128	17	66	9	766
12) Felt weak	FA	268	35	276	36	149	19	76	10	769
13) Appetite loss	AP	375	49	159	21	114	15	115	15	763
14) Nausea	NV	504	66	173	23	59	8	32	4	768
15) Vomiting	NV	537	70	149	19	53	7	29	4	768
16) Constipation	CO	420	55	195	25	110	14	45	6	770
17) Diarrhoea	DI	651	85	86	11	24	3	9	1	770
18) Felt tired	FA	225	29	353	46	132	17	57	7	767
19) Pain interference	PA	453	59	181	24	87	11	43	6	764
20) Concentration	CF	538	70	148	19	58	8	25	3	769
21) Tension	EF	323	42	300	39	109	14	32	4	764
22) Worry	EF	234	30	292	38	153	20	90	12	769
23) Irritability	EF	395	52	261	34	81	11	26	3	763
24) Depression	EF	367	48	257	34	111	15	31	4	766
25) Memory trouble	CF	475	62	221	29	56	7	15	2	767
26) Family life	SF	472	62	157	21	97	13	35	5	761
27) Social activities	SF	398	52	193	25	107	14	64	8	762
28) Financial difficulties	FI	551	72	117	15	58	8	36	5	762
<hr/>										
		<b>1</b>		<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
		<b>(very poor)</b>							<b>(excellent)</b>	
<hr/>										
29) Overall health	QL	32	47	112	200	157	114	52		714
		5	7	16	28	22	16	7		
<hr/>										
30) Overall quality of life	QL	30	53	109	166	171	149	83		761
		4	7	14	22	23	20	11		

## Oesophageal cancer: females

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	5	2
v +3	0	0
v 2.0	12	5
v 3.0	231	93
Total	248	

#### Age

	N	(%)
<40	1	0
40-49	21	9
50-59	53	21
60-69	61	25
70-79	90	36
80+	22	9
Not known	0	0
Total	248	

#### Stage

	N	(%)
Stage I-II	39	16
Stage III-IV	15	6
Recurrent/metastatic	76	31
Not known	118	48
Total	248	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	50.4	(25.3)	50	[33.3-66.7]
Physical functioning	PF	69.7	(25.6)	73.3	[53.3-93.3]
Role Functioning	RF	61.3	(34.5)	66.7	[33.3-100]
Emotional functioning	EF	65.2	(26.6)	66.7	[41.7-83.3]
Cognitive functioning	CF	79.4	(24.8)	83.3	[66.7-100]
Social functioning	SF	71.3	(29.3)	83.3	[50-100]
Fatigue	FA	44.4	(25.7)	44.4	[22.2-66.7]
Nausea and vomiting	NV	20.3	(24.7)	16.7	[0-33.3]
Pain	PA	31.0	(28)	33.3	[0-50]
Dyspnoea	DY	21.4	(29.7)	0	[0-33.3]
Insomnia	SL	32.8	(32.7)	33.3	[0-66.7]
Appetite loss	AP	38.9	(37.9)	33.3	[0-66.7]
Constipation	CO	30.4	(32)	33.3	[0-66.7]
Diarrhoea	DI	8.6	(21.2)	0	[0-0]
Financial difficulties	FI	16.9	(28.5)	0	[0-33.3]

**Oesophageal cancer: females  
Constructed scales**

QL	N	(%)
0	12	5
8.3	4	2
16.7	16	7
25	15	6
33.3	29	12
41.7	26	11
50	43	18
58.3	16	7
66.7	22	9
75	19	8
83.3	25	10
91.7	3	1
100	11	5
Total	241	

PF	N	(%)
0	4	2
6.7	1	0
13.3	4	2
20	9	4
26.7	8	4
33.3	0	0
40	14	6
46.7	8	4
53.3	11	5
60	15	7
66.7	24	11
73.3	23	10
80	20	9
86.7	28	12
93.3	30	13
100	29	13
Total	228	

RF	N	(%)
0	27	11
16.7	13	5
33.3	40	17
50	21	9
66.7	40	17
83.3	25	11
100	73	31
Total	239	

EF	N	(%)
0	6	3
8.3	5	2
16.7	4	2
25	11	5
33.3	12	5
41.7	23	10
50	23	10
58.3	17	7
66.7	28	12
75	19	8
83.3	39	16
91.7	22	9
100	34	14
Total	243	

CF	N	(%)
0	3	1
16.7	8	3
33.3	13	5
50	23	9
66.7	37	15
83.3	53	22
100	110	45
Total	247	

SF	N	(%)
0	14	6
16.7	8	3
33.3	12	5
50	37	15
66.7	48	20
83.3	36	15
100	86	36
Total	241	

FA	N	(%)
0	17	7
11.1	16	7
22.2	35	14
33.3	40	16
44.4	43	18
55.6	32	13
66.7	28	11
77.8	13	5
88.9	8	3
100	13	5
Total	245	

NV	N	(%)
0	111	45
16.7	52	21
33.3	40	16
50	21	9
66.7	15	6
83.3	2	1
100	6	2
Total	247	

PA	N	(%)
0	64	26
16.7	59	24
33.3	49	20
50	28	11
66.7	26	11
83.3	12	5
100	9	4
Total	247	

**Oesophageal cancer: females**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	43	19	78	34	56	24	54	23	231
2) Long walk	PF	77	34	42	18	61	27	49	21	229
3) Short walk	PF	149	65	46	20	21	9	15	7	231
4) Bed or chair	PF	109	47	61	26	45	20	16	7	231
5) Self care	PF	200	87	17	7	6	3	7	3	230
6) Limited in work	RF	83	35	55	23	51	21	50	21	239
7) Limited in leisure	RF	105	44	55	23	44	18	35	15	239
8) Dyspnoea	DY	143	58	62	25	27	11	14	6	246
9) Pain	PA	71	29	104	42	50	20	22	9	247
10) Need to rest	FA	55	22	90	37	75	31	26	11	246
11) Insomnia	SL	99	40	73	30	53	22	21	9	246
12) Felt weak	FA	48	20	100	41	58	24	40	16	246
13) Appetite loss	AP	98	40	52	21	53	22	43	18	246
14) Nausea	NV	130	53	83	34	21	9	13	5	247
15) Vomiting	NV	157	64	56	23	21	9	13	5	247
16) Constipation	CO	111	45	61	25	61	25	14	6	247
17) Diarrhoea	DI	204	82	30	12	8	3	6	2	248
18) Felt tired	FA	49	20	96	39	72	29	31	13	248
19) Pain interference	PA	129	52	65	26	38	15	16	7	248
20) Concentration	CF	157	63	56	23	20	8	15	6	248
21) Tension	EF	88	36	83	34	50	20	25	10	246
22) Worry	EF	56	23	79	32	63	26	47	19	245
23) Irritability	EF	134	54	67	27	32	13	15	6	248
24) Depression	EF	97	39	74	30	56	23	20	8	247
25) Memory trouble	CF	130	53	77	31	32	13	8	3	247
26) Family life	SF	140	57	61	25	26	11	17	7	244
27) Social activities	SF	101	41	70	29	34	14	40	16	245
28) Financial difficulties	FI	171	70	34	14	32	13	9	4	246
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	16	25	62	62	31	34	11		241
		7	10	26	26	13	14	5		
30) Overall quality of life	QL	22	24	38	51	46	46	20		247
		9	10	15	21	19	19	8		

## Oesophageal cancer: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	13	12
v +3	0	0
v 2.0	4	4
v 3.0	93	85
Total	110	

#### Age

	N	(%)
<40	9	8
40-49	101	92
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	110	

#### Gender

	N	(%)
Male	87	79
Female	22	20
Not known	1	1
Total	110	

#### Stage

	N	(%)
Stage I-II	16	15
Stage III-IV	7	6
Recurrent/metastatic	28	26
Not known	59	54
Total	110	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	<i>Previous version of this scale used</i>			
Physical functioning	PF	<i>Previous version of this scale used</i>			
Role Functioning	RF	<i>Previous version of this scale used</i>			
Emotional functioning	EF	62.0	(26.6)	66.7	[50-83.3]
Cognitive functioning	CF	85.6	(21.8)	100	[83.3-100]
Social functioning	SF	73.9	(29.9)	83.3	[50-100]
Fatigue	FA	34.1	(22.5)	33.3	[22.2-44.4]
Nausea and vomiting	NV	15.0	(21.7)	0	[0-33.3]
Pain	PA	33.9	(25.8)	33.3	[16.7-50]
Dyspnoea	DY	13.9	(21.4)	0	[0-33.3]
Insomnia	SL	36.7	(36.4)	33.3	[0-66.7]
Appetite loss	AP	30.9	(35.8)	33.3	[0-66.7]
Constipation	CO	22.0	(28.4)	0	[0-33.3]
Diarrhoea	DI	6.4	(17.2)	0	[0-0]
Financial difficulties	FI	21.2	(30.2)	0	[0-33.3]

**Oesophageal cancer: <50**  
**Constructed scales**

**QL**

Previous version of this scale used

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	1	1
16.7	2	2
33.3	3	3
50	8	7
66.7	10	9
83.3	23	21
100	63	57
Total	110	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	6	6
16.7	3	3
33.3	10	9
50	9	8
66.7	16	15
83.3	21	19
100	44	40
Total	109	

**PF**

Previous version of this scale used

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	13	12
11.1	12	11
22.2	19	17
33.3	22	20
44.4	19	17
55.6	11	10
66.7	7	6
77.8	3	3
88.9	2	2
100	1	1
Total	109	

**RF**

Previous version of this scale used

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	62	57
16.7	19	17
33.3	14	13
50	8	7
66.7	4	4
83.3	1	1
100	1	1
Total	109	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	4	4
8.3	2	2
16.7	4	4
25	4	4
33.3	3	3
41.7	9	8
50	16	15
58.3	10	9
66.7	8	7
75	19	18
83.3	9	8
91.7	7	7
100	13	12
Total	108	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	20	18
16.7	22	20
33.3	34	31
50	14	13
66.7	11	10
83.3	6	6
100	3	3
Total	110	

**Oesophageal cancer: <50  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total	
		N	(%)	N	(%)	N	(%)	N	(%)	N	
1) Strenuous activities	PF	<i>Previous version of this scale used</i>									
2) Long walk	PF	<i>Previous version of this scale used</i>									
3) Short walk	PF	<i>Previous version of this scale used</i>									
4) Bed or chair	PF	<i>Previous version of this scale used</i>									
5) Self care	PF	<i>Previous version of this scale used</i>									
6) Limited in work	RF	<i>Previous version of this scale used</i>									
7) Limited in leisure	RF	<i>Previous version of this scale used</i>									
8) Dyspnoea	DY	72	66	31	28	6	6	1	1	110	
9) Pain	PA	28	26	41	37	31	28	10	9	110	
10) Need to rest	FA	39	36	44	40	19	17	8	7	110	
11) Insomnia	SL	43	39	30	27	20	18	17	16	110	
12) Felt weak	FA	30	27	50	46	20	18	10	9	110	
13) Appetite loss	AP	52	47	29	26	14	13	15	14	110	
14) Nausea	NV	73	66	26	24	7	6	4	4	110	
15) Vomiting	NV	74	68	25	23	7	6	3	3	109	
16) Constipation	CO	59	54	33	30	12	11	5	5	109	
17) Diarrhoea	DI	94	86	12	11	3	3	1	1	110	
18) Felt tired	FA	31	28	50	46	19	17	9	8	109	
19) Pain interference	PA	45	41	45	41	14	13	6	6	110	
20) Concentration	CF	78	71	20	18	6	6	6	5	110	
21) Tension	EF	31	28	46	42	22	20	11	10	110	
22) Worry	EF	22	20	35	32	28	26	25	23	110	
23) Irritability	EF	45	42	34	32	17	16	12	11	108	
24) Depression	EF	43	39	39	36	17	16	11	10	110	
25) Memory trouble	CF	76	69	27	25	3	3	4	4	110	
26) Family life	SF	57	52	30	27	14	13	9	8	110	
27) Social activities	SF	55	51	30	28	15	14	9	8	109	
28) Financial difficulties	FI	66	60	24	22	14	13	6	6	110	
				1	2	3	4	5	6	7	Total
				<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	<i>Previous version of this scale used</i>									
30) Overall quality of life	QL	1	7	22	25	23	21	11		110	
		1	6	20	23	21	19	10			

## Oesophageal cancer: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	19	8
v +3	0	0
v 2.0	20	8
v 3.0	198	84
Total	237	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	237	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	237	

#### Gender

	N	(%)
Male	182	77
Female	53	22
Not known	2	1
Total	237	

#### Stage

	N	(%)
Stage I-II	37	16
Stage III-IV	6	3
Recurrent/metastatic	75	32
Not known	119	50
Total	237	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	58.4	(21.4)	50	[41.7-75]
Physical functioning	PF	82.3	(19.8)	86.7	[73.3-100]
Role Functioning	RF	70.0	(33.6)	83.3	[50-100]
Emotional functioning	EF	69.5	(22.4)	75	[58.3-91.7]
Cognitive functioning	CF	86.7	(19.1)	100	[83.3-100]
Social functioning	SF	77.4	(28.2)	83.3	[66.7-100]
Fatigue	FA	33.8	(25.8)	33.3	[11.1-55.6]
Nausea and vomiting	NV	14.6	(22.5)	0	[0-16.7]
Pain	PA	26.1	(28)	16.7	[0-33.3]
Dyspnoea	DY	18.6	(27)	0	[0-33.3]
Insomnia	SL	29.1	(32.6)	33.3	[0-66.7]
Appetite loss	AP	31.3	(35.9)	33.3	[0-66.7]
Constipation	CO	20.1	(28.5)	0	[0-33.3]
Diarrhoea	DI	7.3	(18.7)	0	[0-0]
Financial difficulties	FI	21.6	(31.1)	0	[0-33.3]



**Oesophageal cancer: 50-59**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	2	1
8.3	1	1
16.7	4	2
25	5	2
33.3	25	12
41.7	23	11
50	49	23
58.3	13	6
66.7	34	16
75	12	6
83.3	29	13
91.7	9	4
100	10	5
Total	216	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	1
6.7	0	0
13.3	1	1
20	1	1
26.7	2	1
33.3	2	1
40	5	3
46.7	4	2
53.3	7	4
60	6	3
66.7	13	7
73.3	14	7
80	17	9
86.7	34	18
93.3	30	16
100	57	29
Total	194	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	19	9
16.7	9	4
33.3	22	10
50	16	8
66.7	31	15
83.3	28	13
100	89	42
Total	214	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	1	0
8.3	1	0
16.7	2	1
25	12	5
33.3	9	4
41.7	14	6
50	17	7
58.3	19	8
66.7	38	16
75	31	13
83.3	28	12
91.7	38	16
100	24	10
Total	234	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	1	0
16.7	0	0
33.3	9	4
50	9	4
66.7	39	17
83.3	40	17
100	136	58
Total	234	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	8	3
16.7	7	3
33.3	16	7
50	22	10
66.7	34	15
83.3	33	14
100	112	48
Total	232	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	47	20
11.1	20	9
22.2	31	13
33.3	52	22
44.4	26	11
55.6	18	8
66.7	20	9
77.8	14	6
88.9	5	2
100	3	1
Total	236	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	133	56
16.7	52	22
33.3	28	12
50	10	4
66.7	4	2
83.3	6	3
100	4	2
Total	237	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	83	36
16.7	55	24
33.3	42	18
50	13	6
66.7	27	12
83.3	4	2
100	10	4
Total	234	

**Oesophageal cancer: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	81	41	61	31	33	17	22	11	197
2) Long walk	PF	99	51	48	25	29	15	19	10	195
3) Short walk	PF	162	82	24	12	8	4	3	2	197
4) Bed or chair	PF	130	66	44	22	23	12	1	1	198
5) Self care	PF	184	93	9	5	3	2	2	1	198
6) Limited in work	RF	100	47	41	19	40	19	33	15	214
7) Limited in leisure	RF	125	58	42	19	24	11	25	12	216
8) Dyspnoea	DY	145	61	57	24	27	11	7	3	236
9) Pain	PA	100	42	77	33	46	20	13	6	236
10) Need to rest	FA	83	35	84	36	59	25	10	4	236
11) Insomnia	SL	109	46	67	29	39	17	20	9	235
12) Felt weak	FA	79	33	88	37	50	21	20	8	237
13) Appetite loss	AP	111	48	56	24	35	15	31	13	233
14) Nausea	NV	158	67	57	24	11	5	11	5	237
15) Vomiting	NV	171	72	42	18	18	8	6	3	237
16) Constipation	CO	142	60	57	24	28	12	10	4	237
17) Diarrhoea	DI	200	84	24	10	11	5	2	1	237
18) Felt tired	FA	77	33	91	38	59	25	10	4	237
19) Pain interference	PA	138	59	49	21	34	15	14	6	235
20) Concentration	CF	160	68	50	21	20	9	6	3	236
21) Tension	EF	87	37	93	40	46	20	9	4	235
22) Worry	EF	56	24	92	39	58	25	31	13	237
23) Irritability	EF	114	48	89	38	25	11	8	3	236
24) Depression	EF	105	44	81	34	43	18	8	3	237
25) Memory trouble	CF	169	72	52	22	12	5	2	1	235
26) Family life	SF	142	61	48	21	31	13	11	5	232
27) Social activities	SF	133	57	49	21	33	14	20	9	235
28) Financial difficulties	FI	143	61	47	20	30	13	15	6	235
<hr/>										
		1		3	4	5	6	7		Total
		(very poor)						(excellent)		
<hr/>										
29) Overall health	QL	9	5	47	64	35	41	15		216
		4	2	22	30	16	19	7		
<hr/>										
30) Overall quality of life	QL	4	13	34	59	52	51	21		234
		2	6	15	25	22	22	9		

## Oesophageal cancer: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	16	5
v +3	0	0
v 2.0	32	9
v 3.0	298	86
Total	346	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	346	100
70-79	0	0
80+	0	0
Not known	0	0
Total	346	

#### Gender

	N	(%)
Male	280	81
Female	61	18
Not known	5	1
Total	346	

#### Stage

	N	(%)
Stage I-II	42	12
Stage III-IV	21	6
Recurrent/metastatic	106	31
Not known	177	51
Total	346	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	55.2	(25.7)	58.3	[33.3-75]
Physical functioning	PF	77.7	(24)	86.7	[66.7-100]
Role Functioning	RF	72.2	(31.9)	83.3	[50-100]
Emotional functioning	EF	69.9	(25.3)	75	[58.3-91.7]
Cognitive functioning	CF	82.0	(22.9)	83.3	[66.7-100]
Social functioning	SF	75.5	(28)	83.3	[66.7-100]
Fatigue	FA	35.9	(27.5)	33.3	[22.2-55.6]
Nausea and vomiting	NV	16.5	(23.4)	0	[0-33.3]
Pain	PA	27.4	(27.9)	16.7	[0-50]
Dyspnoea	DY	20.4	(28.2)	0	[0-33.3]
Insomnia	SL	30.4	(32.3)	33.3	[0-66.7]
Appetite loss	AP	33.0	(38.1)	33.3	[0-66.7]
Constipation	CO	24.0	(30.8)	0	[0-33.3]
Diarrhoea	DI	8.3	(20.8)	0	[0-0]
Financial difficulties	FI	15.3	(29.1)	0	[0-33.3]

**Oesophageal cancer: 60-69**  
**Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	15	5
8.3	3	1
16.7	17	5
25	19	6
33.3	32	10
41.7	21	7
50	48	15
58.3	29	9
66.7	49	15
75	25	8
83.3	39	12
91.7	8	3
100	20	6
<b>Total</b>	<b>325</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	0
6.7	1	0
13.3	5	2
20	5	2
26.7	7	2
33.3	6	2
40	9	3
46.7	8	3
53.3	12	4
60	14	5
66.7	25	9
73.3	20	7
80	19	7
86.7	34	12
93.3	47	16
100	80	27
<b>Total</b>	<b>293</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	21	6
16.7	16	5
33.3	31	10
50	18	6
66.7	61	19
83.3	37	11
100	142	44
<b>Total</b>	<b>326</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	3	1
8.3	6	2
16.7	11	3
25	9	3
33.3	13	4
41.7	29	9
50	12	4
58.3	26	8
66.7	37	11
75	43	13
83.3	60	18
91.7	29	9
100	62	18
<b>Total</b>	<b>340</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	3	1
16.7	9	3
33.3	14	4
50	24	7
66.7	49	14
83.3	83	24
100	163	47
<b>Total</b>	<b>345</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	14	4
16.7	9	3
33.3	23	7
50	31	9
66.7	62	18
83.3	60	18
100	140	41
<b>Total</b>	<b>339</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	52	15
11.1	33	10
22.2	65	19
33.3	62	18
44.4	39	11
55.6	34	10
66.7	18	5
77.8	10	3
88.9	9	3
100	20	6
<b>Total</b>	<b>342</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	188	55
16.7	65	19
33.3	36	11
50	30	9
66.7	15	4
83.3	6	2
100	4	1
<b>Total</b>	<b>344</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	111	33
16.7	81	24
33.3	62	18
50	31	9
66.7	31	9
83.3	12	4
100	13	4
<b>Total</b>	<b>341</b>	

**Oesophageal cancer: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	116	39	79	27	66	22	37	12	298
2) Long walk	PF	128	43	62	21	56	19	50	17	296
3) Short walk	PF	221	74	43	15	20	7	13	4	297
4) Bed or chair	PF	176	59	72	24	34	11	15	5	297
5) Self care	PF	264	89	21	7	6	2	6	2	297
6) Limited in work	RF	162	49	75	23	51	16	40	12	328
7) Limited in leisure	RF	184	56	69	21	42	13	32	10	327
8) Dyspnoea	DY	200	58	92	27	37	11	15	4	344
9) Pain	PA	126	37	133	39	65	19	20	6	344
10) Need to rest	FA	111	32	143	41	64	19	27	8	345
11) Insomnia	SL	149	43	104	30	63	18	28	8	344
12) Felt weak	FA	111	32	121	35	68	20	45	13	345
13) Appetite loss	AP	171	50	60	17	58	17	55	16	344
14) Nausea	NV	218	63	81	24	29	8	17	5	345
15) Vomiting	NV	242	70	67	19	24	7	12	4	345
16) Constipation	CO	189	55	84	24	52	15	20	6	345
17) Diarrhoea	DI	286	83	43	12	8	2	9	3	346
18) Felt tired	FA	96	28	161	47	52	15	34	10	343
19) Pain interference	PA	201	59	71	21	43	13	28	8	343
20) Concentration	CF	229	66	73	21	27	8	17	5	346
21) Tension	EF	137	40	131	38	55	16	23	7	346
22) Worry	EF	90	26	134	39	68	20	52	15	344
23) Irritability	EF	185	54	107	31	37	11	15	4	344
24) Depression	EF	155	45	112	33	54	16	22	6	343
25) Memory trouble	CF	200	58	102	30	34	10	9	3	345
26) Family life	SF	203	59	77	22	45	13	18	5	343
27) Social activities	SF	170	50	93	27	45	13	33	10	341
28) Financial difficulties	FI	250	74	45	13	24	7	21	6	340
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	19	32	50	85	68	46	26		326
		6	10	15	26	21	14	8		
30) Overall quality of life	QL	21	29	49	66	76	64	37		342
		6	9	14	19	22	19	11		

## Oesophageal cancer:≥70

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	8	2
v +3	0	0
v 2.0	15	4
v 3.0	315	93
Total	338	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	270	80
80+	68	20
Not known	0	0
Total	338	

#### Gender

	N	(%)
Male	223	66
Female	112	33
Not known	3	1
Total	338	

#### Stage

	N	(%)
Stage I-II	23	7
Stage III-IV	13	4
Recurrent/metastatic	138	41
Not known	164	49
Total	338	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	53.6	(25.2)	50	[33.3-75]
Physical functioning	PF	70.9	(26.4)	73.3	[60-93.3]
Role Functioning	RF	64.5	(36)	66.7	[33.3-100]
Emotional functioning	EF	74.9	(22.6)	83.3	[58.3-91.7]
Cognitive functioning	CF	81.4	(21.3)	83.3	[66.7-100]
Social functioning	SF	75.0	(27.1)	83.3	[50-100]
Fatigue	FA	40.0	(27.1)	33.3	[22.2-55.6]
Nausea and vomiting	NV	19.1	(24.1)	16.7	[0-33.3]
Pain	PA	23.3	(25.3)	16.7	[0-33.3]
Dyspnoea	DY	20.1	(28.3)	0	[0-33.3]
Insomnia	SL	27.5	(32.1)	33.3	[0-66.7]
Appetite loss	AP	36.9	(38.3)	33.3	[0-66.7]
Constipation	CO	31.9	(33)	33.3	[0-66.7]
Diarrhoea	DI	6.5	(17.4)	0	[0-0]
Financial difficulties	FI	9.2	(20.9)	0	[0-0]

**Oesophageal cancer:≥70  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	12	4
8.3	6	2
16.7	24	7
25	16	5
33.3	24	7
41.7	35	11
50	55	17
58.3	24	7
66.7	43	13
75	29	9
83.3	32	10
91.7	10	3
100	16	5
Total	326	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	8	3
6.7	2	1
13.3	3	1
20	8	3
26.7	10	3
33.3	11	4
40	13	4
46.7	9	3
53.3	13	4
60	16	5
66.7	32	10
73.3	30	10
80	27	9
86.7	31	10
93.3	46	15
100	50	16
Total	309	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	44	14
16.7	14	4
33.3	38	12
50	24	7
66.7	48	15
83.3	38	12
100	119	37
Total	325	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	0	0
8.3	2	1
16.7	6	2
25	8	3
33.3	5	2
41.7	19	6
50	23	7
58.3	26	8
66.7	33	10
75	40	12
83.3	48	15
91.7	38	12
100	78	24
Total	326	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	3	1
16.7	4	1
33.3	13	4
50	26	8
66.7	53	16
83.3	100	30
100	136	41
Total	335	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	12	4
16.7	8	2
33.3	18	6
50	45	14
66.7	56	17
83.3	63	19
100	127	39
Total	329	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	31	9
11.1	38	11
22.2	59	18
33.3	54	16
44.4	35	11
55.6	37	11
66.7	43	13
77.8	7	2
88.9	11	3
100	18	5
Total	333	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	160	48
16.7	63	19
33.3	57	17
50	23	7
66.7	20	6
83.3	4	1
100	6	2
Total	333	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	127	38
16.7	76	23
33.3	56	17
50	37	11
66.7	22	7
83.3	7	2
100	7	2
Total	332	

**Oesophageal cancer:≥70**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	98	31	87	28	62	20	65	21	312
2) Long walk	PF	97	31	71	23	67	21	78	25	313
3) Short walk	PF	208	66	59	19	26	8	21	7	314
4) Bed or chair	PF	141	45	87	28	60	19	25	8	313
5) Self care	PF	276	88	20	6	5	2	12	4	313
6) Limited in work	RF	143	44	72	22	53	16	59	18	327
7) Limited in leisure	RF	148	46	71	22	49	15	57	18	325
8) Dyspnoea	DY	199	59	84	25	38	11	14	4	335
9) Pain	PA	136	41	126	38	55	17	16	5	333
10) Need to rest	FA	84	25	134	40	82	24	36	11	336
11) Insomnia	SL	165	49	85	25	61	18	23	7	334
12) Felt weak	FA	99	30	119	36	75	23	41	12	334
13) Appetite loss	AP	143	43	69	21	61	18	59	18	332
14) Nausea	NV	193	58	95	28	33	10	13	4	334
15) Vomiting	NV	217	65	72	22	25	8	21	6	335
16) Constipation	CO	146	43	85	25	80	24	26	8	337
17) Diarrhoea	DI	286	85	37	11	10	3	3	1	336
18) Felt tired	FA	74	22	150	45	76	23	37	11	337
19) Pain interference	PA	206	62	83	25	34	10	12	4	335
20) Concentration	CF	234	70	65	19	26	8	11	3	336
21) Tension	EF	157	48	119	36	39	12	15	5	330
22) Worry	EF	125	37	114	34	65	20	30	9	334
23) Irritability	EF	191	57	102	31	34	10	7	2	334
24) Depression	EF	167	50	103	31	54	16	10	3	334
25) Memory trouble	CF	166	50	122	36	39	12	8	2	335
26) Family life	SF	217	66	67	20	33	10	14	4	331
27) Social activities	SF	147	44	95	29	49	15	42	13	333
28) Financial difficulties	FI	271	81	37	11	23	7	3	1	334
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	18	33	63	83	63	49	18		327
		6	10	19	25	19	15	6		
30) Overall quality of life	QL	26	31	42	71	68	61	34		333
		8	9	13	21	20	18	10		



## Gastric cancer: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	1	0
v 2.0	50	7
v 3.0	713	93
Total	764	

#### Age

	N	(%)
<40	15	2
40-49	83	11
50-59	159	21
60-69	226	30
70-79	188	25
80+	92	12
Not known	1	0
Total	764	

#### Gender

	N	(%)
Male	485	64
Female	276	36
Not known	3	0
Total	764	

#### Stage

	N	(%)
Stage I-II	39	5
Stage III-IV	187	25
Recurrent/metastatic	295	39
Not known	243	32
Total	764	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	53.1	(26.5)	50	[33.3-66.7]
Physical functioning	PF	79.6	(21.8)	86.7	[66.7-100]
Role Functioning	RF	58.7	(37.4)	66.7	[33.3-100]
Emotional functioning	EF	68.8	(25.4)	75	[50-91.7]
Cognitive functioning	CF	80.1	(23.7)	83.3	[66.7-100]
Social functioning	SF	66.8	(33.3)	66.7	[50-100]
Fatigue	FA	44.5	(31.2)	44.4	[22.2-66.7]
Nausea and vomiting	NV	18.8	(27.4)	0	[0-33.3]
Pain	PA	31.4	(31.7)	16.7	[0-50]
Dyspnoea	DY	20.9	(29.7)	0	[0-33.3]
Insomnia	SL	31.7	(33.6)	33.3	[0-66.7]
Appetite loss	AP	37.6	(38.3)	33.3	[0-66.7]
Constipation	CO	26.4	(33.6)	0	[0-33.3]
Diarrhoea	DI	15.9	(27.6)	0	[0-33.3]
Financial difficulties	FI	12.6	(26.4)	0	[0-0]

**Gastric cancer: all stages  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	45	6
8.3	8	1
16.7	48	7
25	38	5
33.3	74	10
41.7	55	7
50	129	17
58.3	48	7
66.7	114	15
75	42	6
83.3	73	10
91.7	22	3
100	48	7
Total	744	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	8	1
6.7	2	0
13.3	5	1
20	3	0
26.7	8	1
33.3	15	2
40	12	2
46.7	27	4
53.3	14	2
60	36	5
66.7	47	7
73.3	57	8
80	70	10
86.7	123	18
93.3	79	11
100	187	27
Total	693	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	129	17
16.7	48	6
33.3	93	13
50	51	7
66.7	114	15
83.3	83	11
100	228	31
Total	746	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	10	1
8.3	13	2
16.7	18	2
25	19	3
33.3	40	5
41.7	45	6
50	51	7
58.3	73	10
66.7	82	11
75	93	13
83.3	79	11
91.7	102	14
100	119	16
Total	744	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	8	1
16.7	20	3
33.3	34	5
50	65	9
66.7	132	18
83.3	160	21
100	336	45
Total	755	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	65	9
16.7	45	6
33.3	73	10
50	75	10
66.7	118	16
83.3	107	14
100	258	35
Total	741	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	101	14
11.1	71	10
22.2	80	11
33.3	113	15
44.4	69	9
55.6	57	8
66.7	96	13
77.8	51	7
88.9	41	6
100	65	9
Total	744	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	405	54
16.7	141	19
33.3	82	11
50	41	5
66.7	35	5
83.3	18	2
100	32	4
Total	754	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	254	34
16.7	138	19
33.3	109	15
50	76	10
66.7	73	10
83.3	51	7
100	46	6
Total	747	

**Gastric cancer: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	267	38	254	36	101	14	84	12	706
2) Long walk	PF	284	40	240	34	105	15	78	11	707
3) Short walk	PF	521	74	126	18	39	6	20	3	706
4) Bed or chair	PF	431	61	181	26	68	10	30	4	710
5) Self care	PF	635	90	51	7	13	2	10	1	709
6) Limited in work	RF	265	35	176	23	145	19	167	22	753
7) Limited in leisure	RF	303	40	157	21	131	17	162	22	753
8) Dyspnoea	DY	456	60	167	22	97	13	38	5	758
9) Pain	PA	281	37	246	33	158	21	72	10	757
10) Need to rest	FA	181	24	245	33	213	28	115	15	754
11) Insomnia	SL	325	43	220	29	135	18	77	10	757
12) Felt weak	FA	221	29	222	29	168	22	144	19	755
13) Appetite loss	AP	319	42	162	21	138	18	139	18	758
14) Nausea	NV	447	59	171	23	85	11	54	7	757
15) Vomiting	NV	549	73	108	14	57	8	43	6	757
16) Constipation	CO	410	54	163	22	114	15	69	9	756
17) Diarrhoea	DI	522	69	141	19	56	7	36	5	755
18) Felt tired	FA	175	23	259	34	211	28	110	15	755
19) Pain interference	PA	389	52	171	23	103	14	90	12	753
20) Concentration	CF	472	62	145	19	95	13	46	6	758
21) Tension	EF	302	40	246	33	147	20	58	8	753
22) Worry	EF	234	31	224	30	176	23	121	16	755
23) Irritability	EF	379	50	260	34	93	12	27	4	759
24) Depression	EF	328	43	247	33	125	17	58	8	758
25) Memory trouble	CF	440	58	220	29	81	11	17	2	758
26) Family life	SF	365	49	166	22	123	17	90	12	744
27) Social activities	SF	326	44	174	23	110	15	140	19	750
28) Financial difficulties	FI	587	78	82	11	57	8	30	4	756
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	63	60	121	191	157	102	57		751
		8	8	16	25	21	14	8		
30) Overall quality of life	QL	57	65	123	169	146	111	75		746
		8	9	17	23	20	15	10		

## Prostate cancer: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	313	9
v +3	7	0
v 2.0	2,193	65
v 3.0	848	25
Total	3,361	

#### Age

	N	(%)
<40	1	0
40-49	39	1
50-59	336	10
60-69	1,327	40
70-79	1,480	44
80+	177	5
Not known	1	0
Total	3,361	

#### Stage

	N	(%)
Stage I-II	959	29
Stage III-IV	1,511	45
Recurrent/metastatic	640	19
Not known	251	8
Total	3,361	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	68.4	(22.2)	66.7	[50-83.3]
Physical functioning	PF	80.2	(25.6)	93.3	[66.7-100]
Role Functioning	RF	82.7	(28.2)	100	[66.7-100]
Emotional functioning	EF	76.6	(23)	83.3	[66.7-100]
Cognitive functioning	CF	83.2	(20.8)	83.3	[66.7-100]
Social functioning	SF	80.2	(27.2)	100	[66.7-100]
Fatigue	FA	26.9	(26.6)	22.2	[0-44.4]
Nausea and vomiting	NV	5.1	(14.2)	0	[0-0]
Pain	PA	23.3	(30.3)	0	[0-33.3]
Dyspnoea	DY	16.8	(25.7)	0	[0-33.3]
Insomnia	SL	24.5	(30.5)	0	[0-33.3]
Appetite loss	AP	10.4	(23.6)	0	[0-0]
Constipation	CO	14.6	(27.2)	0	[0-33.3]
Diarrhoea	DI	8.4	(19.4)	0	[0-0]
Financial difficulties	FI	9.0	(21.5)	0	[0-0]

**Prostate cancer: all stages  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	32	1
8.3	11	0
16.7	48	2
25	36	1
33.3	180	6
41.7	109	4
50	443	15
58.3	178	6
66.7	554	18
75	213	7
83.3	677	23
91.7	135	5
100	387	13
<b>Total</b>	<b>3,003</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	7	1
6.7	12	1
13.3	12	1
20	14	2
26.7	14	2
33.3	15	2
40	23	3
46.7	23	3
53.3	19	2
60	49	6
66.7	36	4
73.3	37	4
80	52	6
86.7	79	10
93.3	110	13
100	332	40
<b>Total</b>	<b>834</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	141	5
16.7	65	2
33.3	157	5
50	119	4
66.7	302	10
83.3	367	12
100	1,867	62
<b>Total</b>	<b>3,018</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	21	1
8.3	23	1
16.7	39	1
25	68	2
33.3	104	3
41.7	122	4
50	189	6
58.3	235	7
66.7	331	10
75	358	11
83.3	445	14
91.7	488	15
100	875	27
<b>Total</b>	<b>3,298</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	27	1
16.7	40	1
33.3	101	3
50	236	7
66.7	479	14
83.3	910	27
100	1,528	46
<b>Total</b>	<b>3,321</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	107	3
16.7	89	3
33.3	198	6
50	205	6
66.7	497	15
83.3	452	14
100	1,771	53
<b>Total</b>	<b>3,319</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	1,031	31
11.1	395	12
22.2	476	14
33.3	488	15
44.4	264	8
55.6	199	6
66.7	224	7
77.8	83	3
88.9	77	2
100	66	2
<b>Total</b>	<b>3,303</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	2,798	84
16.7	292	9
33.3	145	4
50	44	1
66.7	32	1
83.3	17	1
100	15	0
<b>Total</b>	<b>3,343</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	1,696	51
16.7	424	13
33.3	379	11
50	251	8
66.7	285	9
83.3	132	4
100	149	5
<b>Total</b>	<b>3,316</b>	

**Prostate cancer: all stages  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	432	51	184	22	133	16	95	11	844
2) Long walk	PF	416	49	179	21	98	12	151	18	844
3) Short walk	PF	622	74	111	13	58	7	51	6	842
4) Bed or chair	PF	573	68	127	15	85	10	54	6	839
5) Self care	PF	766	91	45	5	23	3	10	1	844
6) Limited in work	RF	1,978	65	598	20	273	9	182	6	3,031
7) Limited in leisure	RF	2,189	72	421	14	220	7	200	7	3,030
8) Dyspnoea	DY	2,138	64	812	24	304	9	90	3	3,344
9) Pain	PA	1,834	55	709	21	558	17	246	7	3,347
10) Need to rest	FA	1,383	41	1,145	34	620	19	199	6	3,347
11) Insomnia	SL	1,758	53	909	27	480	14	198	6	3,345
12) Felt weak	FA	1,836	55	932	28	412	12	164	5	3,344
13) Appetite loss	AP	2,687	80	381	11	182	5	100	3	3,350
14) Nausea	NV	2,829	85	356	11	120	4	44	1	3,349
15) Vomiting	NV	3,141	94	141	4	46	1	21	1	3,349
16) Constipation	CO	2,435	73	498	15	264	8	146	4	3,343
17) Diarrhoea	DI	2,708	81	466	14	128	4	40	1	3,342
18) Felt tired	FA	1,365	41	1,228	37	551	17	179	5	3,323
19) Pain interference	PA	2,097	63	593	18	401	12	238	7	3,329
20) Concentration	CF	2,404	72	641	19	230	7	66	2	3,341
21) Tension	EF	1,699	51	1,135	34	402	12	96	3	3,332
22) Worry	EF	1,303	39	1,227	37	567	17	245	7	3,342
23) Irritability	EF	1,838	55	1,042	31	350	11	104	3	3,334
24) Depression	EF	1,875	56	948	29	389	12	111	3	3,323
25) Memory trouble	CF	1,765	53	1,153	35	329	10	82	3	3,329
26) Family life	SF	2,116	64	696	21	333	10	186	6	3,331
27) Social activities	SF	2,057	62	721	22	344	10	212	6	3,334
28) Financial difficulties	FI	2,726	82	388	12	153	5	70	2	3,337
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>						<b>(excellent)</b>	
29) Overall health	QL	48	82	240	620	742	835	451		3,018
		2	3	8	21	25	28	15		
30) Overall quality of life	QL	60	103	299	656	788	888	526		3,320
		2	3	9	20	24	27	16		

## Prostate cancer: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	23	7
v +3	0	0
v 2.0	186	55
v 3.0	127	38
Total	336	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	336	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	336	

#### Stage

	N	(%)
Stage I-II	141	42
Stage III-IV	114	34
Recurrent/metastatic	51	15
Not known	30	9
Total	336	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	67.2	(24.2)	66.7	[50-83.3]
Physical functioning	PF	88.7	(21.4)	100	[86.7-100]
Role Functioning	RF	84.1	(27.2)	100	[83.3-100]
Emotional functioning	EF	68.9	(24.3)	66.7	[50-91.7]
Cognitive functioning	CF	84.9	(20.5)	100	[83.3-100]
Social functioning	SF	75.3	(29.8)	83.3	[66.7-100]
Fatigue	FA	26.5	(27.1)	22.2	[0-44.4]
Nausea and vomiting	NV	5.0	(16.1)	0	[0-0]
Pain	PA	23.2	(30.8)	0	[0-33.3]
Dyspnoea	DY	11.5	(21.7)	0	[0-33.3]
Insomnia	SL	27.7	(32.7)	16.7	[0-50]
Appetite loss	AP	10.4	(24.3)	0	[0-0]
Constipation	CO	9.1	(22.1)	0	[0-0]
Diarrhoea	DI	8.7	(20.4)	0	[0-0]
Financial difficulties	FI	15.5	(27.2)	0	[0-33.3]

**Prostate cancer: 50-59  
Constructed scales**

QL	N	(%)
0	8	3
8.3	1	0
16.7	5	2
25	3	1
33.3	22	7
41.7	15	5
50	39	13
58.3	20	7
66.7	55	18
75	23	7
83.3	59	19
91.7	14	5
100	46	15
Total	310	

PF	N	(%)
0	2	2
6.7	1	1
13.3	0	0
20	1	1
26.7	0	0
33.3	2	2
40	0	0
46.7	1	1
53.3	4	3
60	6	5
66.7	3	2
73.3	2	2
80	2	2
86.7	10	8
93.3	17	14
100	75	60
Total	126	

RF	N	(%)
0	13	4
16.7	9	3
33.3	11	4
50	12	4
66.7	20	6
83.3	53	17
100	193	62
Total	311	

EF	N	(%)
0	7	2
8.3	2	1
16.7	5	2
25	7	2
33.3	16	5
41.7	17	5
50	29	9
58.3	33	10
66.7	49	15
75	37	11
83.3	42	13
91.7	31	9
100	54	16
Total	329	

CF	N	(%)
0	4	1
16.7	2	1
33.3	7	2
50	23	7
66.7	47	14
83.3	77	23
100	174	52
Total	334	

SF	N	(%)
0	16	5
16.7	11	3
33.3	30	9
50	22	7
66.7	56	17
83.3	47	14
100	153	46
Total	335	

FA	N	(%)
0	112	34
11.1	36	11
22.2	43	13
33.3	48	15
44.4	29	9
55.6	21	6
66.7	18	5
77.8	10	3
88.9	7	2
100	8	2
Total	332	

NV	N	(%)
0	287	86
16.7	25	8
33.3	6	2
50	7	2
66.7	2	1
83.3	2	1
100	4	1
Total	333	

PA	N	(%)
0	174	52
16.7	39	12
33.3	38	11
50	22	7
66.7	30	9
83.3	13	4
100	16	5
Total	332	



**Prostate cancer: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total						
		N	(%)	N	(%)	N	(%)	N	(%)	N						
1) Strenuous activities	PF	92	73	15	12	13	10	6	5	126						
2) Long walk	PF	86	68	21	17	9	7	10	8	126						
3) Short walk	PF	111	88	7	6	4	3	4	3	126						
4) Bed or chair	PF	99	79	12	10	9	7	6	5	126						
5) Self care	PF	120	95	3	2	2	2	2	2	127						
6) Limited in work	RF	206	66	61	20	27	9	17	6	311						
7) Limited in leisure	RF	241	77	34	11	18	6	20	6	313						
8) Dyspnoea	DY	247	74	64	19	18	5	5	2	334						
9) Pain	PA	186	56	65	19	61	18	23	7	335						
10) Need to rest	FA	152	45	115	34	47	14	21	6	335						
11) Insomnia	SL	168	50	84	25	57	17	27	8	336						
12) Felt weak	FA	185	55	93	28	39	12	18	5	335						
13) Appetite loss	AP	270	81	37	11	14	4	13	4	334						
14) Nausea	NV	288	86	28	8	11	3	7	2	334						
15) Vomiting	NV	317	95	8	2	5	2	4	1	334						
16) Constipation	CO	274	82	41	12	10	3	10	3	335						
17) Diarrhoea	DI	271	81	45	14	12	4	6	2	334						
18) Felt tired	FA	135	41	115	35	62	19	21	6	333						
19) Pain interference	PA	210	63	62	19	34	10	27	8	333						
20) Concentration	CF	230	69	75	22	24	7	6	2	335						
21) Tension	EF	115	34	147	44	57	17	16	5	335						
22) Worry	EF	75	22	135	40	83	25	42	13	335						
23) Irritability	EF	144	43	132	40	43	13	14	4	333						
24) Depression	EF	151	46	115	35	49	15	16	5	331						
25) Memory trouble	CF	214	64	88	26	23	7	9	3	334						
26) Family life	SF	174	52	92	28	44	13	25	8	335						
27) Social activities	SF	189	56	79	24	39	12	28	8	335						
28) Financial difficulties	FI	235	70	56	17	30	9	13	4	334						
		<b>1</b>		<b>2</b>		<b>3</b>		<b>4</b>		<b>5</b>		<b>6</b>		<b>7</b>		<b>Total</b>
		<b>(very poor)</b>										<b>(excellent)</b>				
29) Overall health	QL	10	9	29	55	72	78	58								311
		3	3	9	18	23	25	19								
30) Overall quality of life	QL	9	9	40	54	84	78	59								333
		3	3	12	16	25	23	18								

## Prostate cancer: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	117	9
v +3	6	1
v 2.0	915	69
v 3.0	289	22
Total	1,327	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	1,327	100
70-79	0	0
80+	0	0
Not known	0	0
Total	1,327	

#### Stage

	N	(%)
Stage I-II	418	32
Stage III-IV	608	46
Recurrent/metastatic	205	15
Not known	96	7
Total	1,327	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	69.8	(21.6)	75	[50-83.3]
Physical functioning	PF	85.2	(22.5)	100	[80-100]
Role Functioning	RF	86.1	(24.8)	100	[83.3-100]
Emotional functioning	EF	75.5	(23.8)	83.3	[58.3-100]
Cognitive functioning	CF	84.5	(20.3)	83.3	[83.3-100]
Social functioning	SF	80.2	(26.8)	100	[66.7-100]
Fatigue	FA	25.2	(26.1)	22.2	[0-44.4]
Nausea and vomiting	NV	4.3	(13.2)	0	[0-0]
Pain	PA	21.1	(29.2)	0	[0-33.3]
Dyspnoea	DY	15.3	(24.2)	0	[0-33.3]
Insomnia	SL	25.2	(31)	0	[0-33.3]
Appetite loss	AP	8.4	(20.8)	0	[0-0]
Constipation	CO	12.6	(25.7)	0	[0-0]
Diarrhoea	DI	8.6	(19.7)	0	[0-0]
Financial difficulties	FI	10.4	(23)	0	[0-0]

**Prostate cancer: 60-69  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	10	1
8.3	2	0
16.7	18	2
25	13	1
33.3	58	5
41.7	42	4
50	173	15
58.3	73	6
66.7	202	17
75	89	8
83.3	298	25
91.7	50	4
100	166	14
<b>Total</b>	<b>1,194</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	2	1
6.7	1	0
13.3	1	0
20	4	1
26.7	3	1
33.3	4	1
40	10	4
46.7	6	2
53.3	1	0
60	14	5
66.7	10	4
73.3	14	5
80	16	6
86.7	17	6
93.3	34	12
100	147	52
<b>Total</b>	<b>284</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	37	3
16.7	17	1
33.3	44	4
50	43	4
66.7	121	10
83.3	147	12
100	790	66
<b>Total</b>	<b>1,199</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	7	1
8.3	9	1
16.7	19	2
25	38	3
33.3	49	4
41.7	49	4
50	76	6
58.3	100	8
66.7	131	10
75	131	10
83.3	170	13
91.7	184	14
100	343	26
<b>Total</b>	<b>1,306</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	7	1
16.7	17	1
33.3	41	3
50	77	6
66.7	179	14
83.3	345	26
100	647	49
<b>Total</b>	<b>1,313</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	36	3
16.7	35	3
33.3	84	6
50	82	6
66.7	196	15
83.3	189	14
100	688	53
<b>Total</b>	<b>1,310</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	444	34
11.1	157	12
22.2	191	15
33.3	182	14
44.4	98	8
55.6	66	5
66.7	92	7
77.8	31	2
88.9	22	2
100	23	2
<b>Total</b>	<b>1,306</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	1,138	86
16.7	100	8
33.3	54	4
50	7	1
66.7	12	1
83.3	5	0
100	6	1
<b>Total</b>	<b>1,322</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	704	54
16.7	180	14
33.3	141	11
50	89	7
66.7	104	8
83.3	40	3
100	53	4
<b>Total</b>	<b>1,311</b>	

**Prostate cancer: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	172	60	51	18	39	14	24	8	286
2) Long walk	PF	172	60	52	18	31	11	32	11	287
3) Short walk	PF	229	80	33	12	14	5	11	4	287
4) Bed or chair	PF	218	77	34	12	25	9	8	3	285
5) Self care	PF	268	93	15	5	2	1	2	1	287
6) Limited in work	RF	829	69	241	20	88	7	47	4	1,205
7) Limited in leisure	RF	922	77	164	14	62	5	55	5	1,203
8) Dyspnoea	DY	871	66	324	25	99	8	28	2	1,322
9) Pain	PA	756	57	287	22	200	15	81	6	1,324
10) Need to rest	FA	594	45	427	32	235	18	66	5	1,322
11) Insomnia	SL	681	52	363	28	189	14	86	7	1,319
12) Felt weak	FA	758	57	347	26	163	12	55	4	1,323
13) Appetite loss	AP	1,101	83	142	11	56	4	26	2	1,325
14) Nausea	NV	1,145	86	129	10	36	3	15	1	1,325
15) Vomiting	NV	1,259	95	42	3	15	1	7	1	1,323
16) Constipation	CO	1,008	76	174	13	89	7	49	4	1,320
17) Diarrhoea	DI	1,069	81	184	14	51	4	18	1	1,322
18) Felt tired	FA	574	44	483	37	195	15	60	5	1,312
19) Pain interference	PA	870	66	217	17	143	11	83	6	1,313
20) Concentration	CF	964	73	241	18	95	7	20	2	1,320
21) Tension	EF	675	51	427	33	175	13	37	3	1,314
22) Worry	EF	491	37	496	38	217	16	116	9	1,320
23) Irritability	EF	704	54	394	30	170	13	48	4	1,316
24) Depression	EF	731	56	370	28	167	13	48	4	1,316
25) Memory trouble	CF	747	57	424	32	114	9	29	2	1,314
26) Family life	SF	817	62	287	22	138	11	74	6	1,316
27) Social activities	SF	807	61	304	23	136	10	67	5	1,314
28) Financial difficulties	FI	1,042	79	173	13	69	5	34	3	1,318
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>	
		<b>(very poor)</b>							<b>(excellent)</b>	
29) Overall health	QL	16	24	85	238	281	362	195	1,201	
		1	2	7	20	23	30	16		
30) Overall quality of life	QL	23	43	96	264	290	382	214	1,312	
		2	3	7	20	22	29	16		

## Prostate cancer: ≥70

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	165	10
v +3	1	0
v 2.0	1,075	65
v 3.0	416	25
Total	1,657	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	1,480	89
80+	177	11
Not known	0	0
Total	1,657	

#### Stage

	N	(%)
Stage I-II	385	23
Stage III-IV	779	47
Recurrent/metastatic	375	23
Not known	118	7
Total	1,657	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	67.4	(22.2)	66.7	[50-83.3]
Physical functioning	PF	73.7	(27.4)	86.7	[60-96.7]
Role Functioning	RF	79.6	(30.6)	100	[66.7-100]
Emotional functioning	EF	79.2	(21.6)	83.3	[66.7-100]
Cognitive functioning	CF	81.9	(21.1)	83.3	[66.7-100]
Social functioning	SF	81.4	(26.8)	100	[66.7-100]
Fatigue	FA	28.3	(26.8)	22.2	[0-44.4]
Nausea and vomiting	NV	5.7	(14.6)	0	[0-0]
Pain	PA	24.8	(30.8)	16.7	[0-50]
Dyspnoea	DY	19.5	(27.4)	0	[0-33.3]
Insomnia	SL	23.2	(29.4)	0	[0-33.3]
Appetite loss	AP	12.1	(25.4)	0	[0-0]
Constipation	CO	17.3	(29.1)	0	[0-33.3]
Diarrhoea	DI	8.2	(18.8)	0	[0-0]
Financial difficulties	FI	6.3	(17.8)	0	[0-0]

**Prostate cancer:  $\geq 70$   
Constructed scales**

QL	N	(%)
0	14	1
8.3	8	1
16.7	25	2
25	20	1
33.3	95	7
41.7	52	4
50	227	16
58.3	83	6
66.7	291	20
75	98	7
83.3	317	22
91.7	64	4
100	172	12
Total	1,466	

PF	N	(%)
0	3	1
6.7	10	3
13.3	11	3
20	9	2
26.7	11	3
33.3	9	2
40	13	3
46.7	15	4
53.3	14	3
60	29	7
66.7	23	6
73.3	21	5
80	34	8
86.7	50	12
93.3	54	13
100	102	25
Total	408	

RF	N	(%)
0	90	6
16.7	39	3
33.3	101	7
50	62	4
66.7	159	11
83.3	165	11
100	859	58
Total	1,475	

EF	N	(%)
0	6	0
8.3	11	1
16.7	14	1
25	22	1
33.3	36	2
41.7	56	4
50	82	5
58.3	99	6
66.7	145	9
75	185	11
83.3	226	14
91.7	266	16
100	474	29
Total	1,622	

CF	N	(%)
0	15	1
16.7	19	1
33.3	53	3
50	135	8
66.7	247	15
83.3	480	29
100	684	42
Total	1,633	

SF	N	(%)
0	52	3
16.7	42	3
33.3	80	5
50	99	6
66.7	238	15
83.3	207	13
100	915	56
Total	1,633	

FA	N	(%)
0	465	29
11.1	194	12
22.2	238	15
33.3	252	16
44.4	133	8
55.6	110	7
66.7	112	7
77.8	42	3
88.9	45	3
100	34	2
Total	1,625	

NV	N	(%)
0	1,338	81
16.7	164	10
33.3	83	5
50	30	2
66.7	18	1
83.3	9	1
100	5	0
Total	1,647	

PA	N	(%)
0	799	49
16.7	199	12
33.3	199	12
50	138	9
66.7	146	9
83.3	74	5
100	77	5
Total	1,632	

**Prostate cancer:  $\geq 70$   
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	155	37	116	28	81	20	64	15	416
2) Long walk	PF	147	35	102	25	58	14	108	26	415
3) Short walk	PF	267	65	71	17	39	9	36	9	413
4) Bed or chair	PF	242	59	80	19	50	12	40	10	412
5) Self care	PF	362	87	27	7	19	5	6	1	414
6) Limited in work	RF	917	62	292	20	156	11	117	8	1,482
7) Limited in leisure	RF	1,000	68	219	15	138	9	124	8	1,481
8) Dyspnoea	DY	985	60	419	25	186	11	57	4	1,647
9) Pain	PA	872	53	350	21	289	18	136	8	1,647
10) Need to rest	FA	620	38	589	36	331	20	109	7	1,649
11) Insomnia	SL	889	54	451	27	230	14	79	5	1,649
12) Felt weak	FA	873	53	480	29	204	12	89	5	1,646
13) Appetite loss	AP	1,282	78	199	12	109	7	60	4	1,650
14) Nausea	NV	1,360	83	195	12	73	4	21	1	1,649
15) Vomiting	NV	1,527	93	90	6	24	2	10	1	1,651
16) Constipation	CO	1,126	68	273	17	162	10	86	5	1,647
17) Diarrhoea	DI	1,335	81	231	14	64	4	15	1	1,645
18) Felt tired	FA	639	39	617	38	287	18	94	6	1,637
19) Pain interference	PA	993	61	309	19	219	13	121	7	1,642
20) Concentration	CF	1,182	72	316	19	109	7	38	2	1,645
21) Tension	EF	897	55	539	33	166	10	40	2	1,642
22) Worry	EF	728	44	574	35	262	16	82	5	1,646
23) Irritability	EF	973	59	499	30	133	8	39	2	1,644
24) Depression	EF	974	60	450	28	166	10	45	3	1,635
25) Memory trouble	CF	777	47	631	39	190	12	42	3	1,640
26) Family life	SF	1,107	68	301	18	148	9	83	5	1,639
27) Social activities	SF	1,040	63	328	20	163	10	113	7	1,644
28) Financial difficulties	FI	1,419	86	156	10	50	3	19	1	1,644
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	22	48	121	322	383	387	190		1,473
		2	3	8	22	26	26	13		
30) Overall quality of life	QL	28	50	154	334	403	418	247		1,634
		2	3	9	20	25	26	15		

## Prostate cancer: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	5	1
v +3	7	1
v 2.0	448	47
v 3.0	499	52
Total	959	

#### Age

	N	(%)
<40	0	0
40-49	14	2
50-59	141	15
60-69	418	44
70-79	368	38
80+	17	2
Not known	1	0
Total	959	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	70.8	(20.5)	75	[58.3-83.3]
Physical functioning	PF	93.0	(12)	100	[93.3-100]
Role Functioning	RF	90.6	(20.3)	100	[83.3-100]
Emotional functioning	EF	78.0	(22.8)	83.3	[66.7-100]
Cognitive functioning	CF	86.1	(19.3)	100	[83.3-100]
Social functioning	SF	83.9	(25)	100	[66.7-100]
Fatigue	FA	18.9	(22.7)	11.1	[0-33.3]
Nausea and vomiting	NV	2.4	(9.1)	0	[0-0]
Pain	PA	14.6	(24.5)	0	[0-16.7]
Dyspnoea	DY	12.2	(22.6)	0	[0-33.3]
Insomnia	SL	20.9	(28.8)	0	[0-33.3]
Appetite loss	AP	4.9	(16.3)	0	[0-0]
Constipation	CO	8.8	(20.3)	0	[0-0]
Diarrhoea	DI	8.5	(20.2)	0	[0-0]
Financial difficulties	FI	8.5	(21.2)	0	[0-0]



**Prostate cancer: stage I-II  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	6	1
8.3	0	0
16.7	7	1
25	8	1
33.3	39	4
41.7	38	4
50	136	14
58.3	52	6
66.7	180	19
75	72	8
83.3	227	24
91.7	40	4
100	137	15
Total	942	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	0	0
6.7	0	0
13.3	0	0
20	1	0
26.7	0	0
33.3	0	0
40	3	1
46.7	4	1
53.3	1	0
60	12	2
66.7	10	2
73.3	16	3
80	27	5
86.7	45	9
93.3	85	17
100	292	59
Total	496	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	17	2
16.7	6	1
33.3	25	3
50	20	2
66.7	59	6
83.3	124	13
100	699	74
Total	950	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	8	1
8.3	2	0
16.7	13	1
25	18	2
33.3	25	3
41.7	33	4
50	50	5
58.3	60	6
66.7	94	10
75	94	10
83.3	123	13
91.7	146	15
100	279	30
Total	945	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	5	1
16.7	7	1
33.3	25	3
50	50	5
66.7	123	13
83.3	231	24
100	508	54
Total	949	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	27	3
16.7	14	2
33.3	38	4
50	50	5
66.7	127	13
83.3	131	14
100	565	59
Total	952	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	409	43
11.1	133	14
22.2	126	13
33.3	120	13
44.4	61	6
55.6	35	4
66.7	37	4
77.8	12	1
88.9	9	1
100	8	1
Total	950	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	866	91
16.7	54	6
33.3	27	3
50	3	0
66.7	1	0
83.3	1	0
100	2	0
Total	954	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	615	65
16.7	101	11
33.3	97	10
50	59	6
66.7	43	5
83.3	14	2
100	20	2
Total	949	

**Prostate cancer: stage I-II  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	359	72	86	17	41	8	12	2	498
2) Long walk	PF	350	70	92	18	43	9	14	3	499
3) Short walk	PF	467	94	23	5	5	1	3	1	498
4) Bed or chair	PF	452	91	37	7	7	1	1	0	497
5) Self care	PF	492	99	5	1	1	0	0	0	498
6) Limited in work	RF	732	77	152	16	40	4	27	3	951
7) Limited in leisure	RF	810	85	88	9	30	3	25	3	953
8) Dyspnoea	DY	697	73	188	20	54	6	18	2	957
9) Pain	PA	661	69	162	17	99	10	34	4	956
10) Need to rest	FA	531	55	296	31	108	11	23	2	958
11) Insomnia	SL	561	59	232	24	123	13	41	4	957
12) Felt weak	FA	636	67	224	24	74	8	21	2	955
13) Appetite loss	AP	859	90	69	7	16	2	13	1	957
14) Nausea	NV	872	91	64	7	13	1	6	1	955
15) Vomiting	NV	932	98	19	2	3	0	2	0	956
16) Constipation	CO	774	81	122	13	45	5	13	1	954
17) Diarrhoea	DI	776	81	127	13	33	4	17	2	953
18) Felt tired	FA	514	54	299	31	110	12	30	3	953
19) Pain interference	PA	709	75	139	15	71	8	32	3	951
20) Concentration	CF	735	77	164	17	45	5	11	1	955
21) Tension	EF	510	54	322	34	93	10	28	3	953
22) Worry	EF	411	43	320	34	155	16	68	7	954
23) Irritability	EF	542	57	274	29	103	11	35	4	954
24) Depression	EF	582	61	243	26	94	10	30	3	949
25) Memory trouble	CF	563	59	287	30	81	9	19	2	950
26) Family life	SF	635	67	193	20	83	9	43	5	954
27) Social activities	SF	662	69	189	20	64	7	39	4	954
28) Financial difficulties	FI	798	84	91	10	49	5	18	2	956
<hr/>										
		1		3		5		7		Total
		(very poor)						(excellent)		
<hr/>										
29) Overall health	QL	9	12	63	188	237	273	166		948
		1	1	7	20	25	29	18		
<hr/>										
30) Overall quality of life	QL	10	10	60	184	220	293	170		947
		1	1	6	19	23	31	18		

## Prostate cancer: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	0	0
v 2.0	1,293	86
v 3.0	218	14
Total	1,511	

#### Age

	N	(%)
<40	0	0
40-49	10	1
50-59	114	8
60-69	608	40
70-79	704	47
80+	75	5
Not known	0	0
Total	1,511	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	68.3	(22.4)	66.7	[50-83.3]
Physical functioning	PF	53.2	(28.8)	53.3	[33.3-80]
Role Functioning	RF	81.4	(29.3)	100	[66.7-100]
Emotional functioning	EF	77.7	(22.5)	83.3	[66.7-100]
Cognitive functioning	CF	82.8	(21.3)	83.3	[66.7-100]
Social functioning	SF	81.5	(26.5)	100	[66.7-100]
Fatigue	FA	26.2	(26.5)	22.2	[0-44.4]
Nausea and vomiting	NV	4.7	(13.8)	0	[0-0]
Pain	PA	20.4	(29.1)	0	[0-33.3]
Dyspnoea	DY	17.6	(26.7)	0	[0-33.3]
Insomnia	SL	23.0	(29.6)	0	[0-33.3]
Appetite loss	AP	8.8	(22)	0	[0-0]
Constipation	CO	13.0	(26)	0	[0-0]
Diarrhoea	DI	7.8	(18.5)	0	[0-0]
Financial difficulties	FI	8.3	(20.5)	0	[0-0]

**Prostate cancer: stage III-IV  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	17	1
8.3	9	1
16.7	26	2
25	16	1
33.3	92	6
41.7	50	3
50	197	13
58.3	91	6
66.7	283	19
75	111	8
83.3	335	23
91.7	65	4
100	190	13
Total	1,482	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	6	3
6.7	11	5
13.3	11	5
20	12	6
26.7	12	6
33.3	14	7
40	17	8
46.7	16	7
53.3	14	7
60	22	10
66.7	16	7
73.3	10	5
80	13	6
86.7	12	6
93.3	11	5
100	18	8
Total	215	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	86	6
16.7	34	2
33.3	71	5
50	61	4
66.7	162	11
83.3	185	12
100	890	60
Total	1,489	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	7	1
8.3	10	1
16.7	14	1
25	31	2
33.3	43	3
41.7	52	4
50	76	5
58.3	97	7
66.7	143	10
75	155	11
83.3	210	14
91.7	226	15
100	412	28
Total	1,476	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	14	1
16.7	21	1
33.3	44	3
50	119	8
66.7	203	14
83.3	415	28
100	677	45
Total	1,493	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	42	3
16.7	36	2
33.3	85	6
50	81	5
66.7	222	15
83.3	195	13
100	827	56
Total	1,488	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	482	33
11.1	163	11
22.2	232	16
33.3	221	15
44.4	106	7
55.6	76	5
66.7	106	7
77.8	38	3
88.9	24	2
100	34	2
Total	1,482	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	1,273	85
16.7	126	8
33.3	58	4
50	18	1
66.7	13	1
83.3	10	1
100	5	0
Total	1,503	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	818	55
16.7	214	14
33.3	155	10
50	82	6
66.7	103	7
83.3	58	4
100	58	4
Total	1,488	

**Prostate cancer: stage III-IV  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total						
		N	(%)	N	(%)	N	(%)	N	(%)	N						
1) Strenuous activities	PF	37	17	45	21	67	31	68	31	217						
2) Long walk	PF	35	16	29	13	35	16	117	54	216						
3) Short walk	PF	78	36	50	23	46	21	43	20	217						
4) Bed or chair	PF	50	23	46	21	73	34	48	22	217						
5) Self care	PF	162	75	25	12	21	10	9	4	217						
6) Limited in work	RF	946	63	311	21	136	9	106	7	1,499						
7) Limited in leisure	RF	1,052	70	223	15	110	7	112	8	1,497						
8) Dyspnoea	DY	956	64	349	23	148	10	49	3	1,502						
9) Pain	PA	887	59	320	21	207	14	88	6	1,502						
10) Need to rest	FA	610	41	532	35	275	18	85	6	1,502						
11) Insomnia	SL	819	55	405	27	199	13	77	5	1,500						
12) Felt weak	FA	839	56	421	28	172	12	70	5	1,502						
13) Appetite loss	AP	1,248	83	152	10	65	4	39	3	1,504						
14) Nausea	NV	1,285	85	149	10	52	4	20	1	1,506						
15) Vomiting	NV	1,423	95	56	4	19	1	8	1	1,506						
16) Constipation	CO	1,136	76	214	14	94	6	61	4	1,505						
17) Diarrhoea	DI	1,235	82	201	13	54	4	14	1	1,504						
18) Felt tired	FA	645	43	543	36	226	15	78	5	1,492						
19) Pain interference	PA	1,009	67	238	16	150	10	100	7	1,497						
20) Concentration	CF	1,076	72	282	19	113	8	32	2	1,503						
21) Tension	EF	775	52	493	33	189	13	38	3	1,495						
22) Worry	EF	604	40	556	37	245	16	95	6	1,500						
23) Irritability	EF	843	56	469	31	142	10	40	3	1,494						
24) Depression	EF	894	60	401	27	151	10	47	3	1,493						
25) Memory trouble	CF	779	52	521	35	156	10	39	3	1,495						
26) Family life	SF	983	66	297	20	135	9	79	5	1,494						
27) Social activities	SF	953	64	311	21	147	10	85	6	1,496						
28) Financial difficulties	FI	1,237	83	175	12	54	4	30	2	1,496						
		<b>1</b>		<b>2</b>		<b>3</b>		<b>4</b>		<b>5</b>		<b>6</b>		<b>7</b>		<b>Total</b>
		<b>(very poor)</b>										<b>(excellent)</b>				
29) Overall health	QL	29	43	116	287	384	418	213								1,490
		2	3	8	19	26	28	14								
30) Overall quality of life	QL	29	42	116	251	373	417	260								1,488
		2	3	8	17	25	28	18								

## Prostate cancer: recurrent/metastatic

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	202	32
v +3	0	0
v 2.0	317	50
v 3.0	121	19
Total	640	

#### Age

	N	(%)
<40	1	0
40-49	8	1
50-59	51	8
60-69	205	32
70-79	307	48
80+	68	11
Not known	0	0
Total	640	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	62.1	(24.3)	66.7	[50-83.3]
Physical functioning	PF	74.9	(21.9)	80	[60-93.3]
Role Functioning	RF	67.0	(34.3)	66.7	[33.3-100]
Emotional functioning	EF	72.6	(22.9)	75	[58.3-91.7]
Cognitive functioning	CF	80.5	(21.1)	83.3	[66.7-100]
Social functioning	SF	73.2	(29.8)	83.3	[50-100]
Fatigue	FA	38.3	(27.7)	33.3	[11.1-55.6]
Nausea and vomiting	NV	9.2	(18.1)	0	[0-16.7]
Pain	PA	38.6	(32.7)	33.3	[0-66.7]
Dyspnoea	DY	21.5	(26.4)	0	[0-33.3]
Insomnia	SL	30.7	(32.1)	33.3	[0-66.7]
Appetite loss	AP	21.3	(30.7)	0	[0-33.3]
Constipation	CO	27.1	(34.4)	0	[0-66.7]
Diarrhoea	DI	9.5	(20)	0	[0-0]
Financial difficulties	FI	11.1	(23.3)	0	[0-0]

**Prostate cancer: recurrent/metastatic  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	8	2
8.3	2	1
16.7	14	3
25	12	3
33.3	44	10
41.7	17	4
50	85	20
58.3	24	6
66.7	68	16
75	21	5
83.3	76	18
91.7	21	5
100	42	10
Total	434	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	1
6.7	1	1
13.3	1	1
20	1	1
26.7	2	2
33.3	1	1
40	3	3
46.7	3	3
53.3	4	4
60	14	12
66.7	9	8
73.3	11	10
80	12	11
86.7	20	18
93.3	11	10
100	19	17
Total	113	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	38	9
16.7	25	6
33.3	59	14
50	34	8
66.7	65	15
83.3	39	9
100	174	40
Total	434	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	2	0
8.3	6	1
16.7	10	2
25	13	2
33.3	24	4
41.7	29	5
50	44	7
58.3	63	10
66.7	75	12
75	82	13
83.3	79	13
91.7	82	13
100	120	19
Total	629	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	4	1
16.7	9	1
33.3	27	4
50	47	8
66.7	113	18
83.3	192	31
100	238	38
Total	630	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	27	4
16.7	26	4
33.3	62	10
50	54	9
66.7	117	19
83.3	80	13
100	265	42
Total	631	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	93	15
11.1	68	11
22.2	78	12
33.3	111	18
44.4	71	11
55.6	63	10
66.7	68	11
77.8	22	4
88.9	34	5
100	19	3
Total	627	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	455	72
16.7	88	14
33.3	52	8
50	18	3
66.7	15	2
83.3	4	1
100	4	1
Total	636	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	169	27
16.7	87	14
33.3	99	16
50	79	13
66.7	100	16
83.3	46	7
100	52	8
Total	632	

**Prostate cancer: recurrent/metastatic  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	29	24	52	44	23	19	15	13	119
2) Long walk	PF	28	24	54	45	18	15	19	16	119
3) Short walk	PF	68	58	37	32	7	6	5	4	117
4) Bed or chair	PF	62	54	43	37	5	4	5	4	115
5) Self care	PF	102	86	15	13	1	1	1	1	119
6) Limited in work	RF	195	45	100	23	92	21	49	11	436
7) Limited in leisure	RF	205	47	90	21	77	18	63	15	435
8) Dyspnoea	DY	336	53	210	33	75	12	17	3	638
9) Pain	PA	186	29	181	28	184	29	89	14	640
10) Need to rest	FA	166	26	222	35	183	29	66	10	637
11) Insomnia	SL	271	43	197	31	118	19	51	8	637
12) Felt weak	FA	233	37	216	34	127	20	62	10	638
13) Appetite loss	AP	387	61	135	21	77	12	40	6	639
14) Nausea	NV	465	73	115	18	45	7	13	2	638
15) Vomiting	NV	555	87	60	9	17	3	5	1	637
16) Constipation	CO	349	55	116	18	110	17	60	9	635
17) Diarrhoea	DI	495	78	107	17	25	4	8	1	635
18) Felt tired	FA	139	22	282	45	163	26	48	8	632
19) Pain interference	PA	261	41	162	26	130	21	79	13	632
20) Concentration	CF	419	66	144	23	53	8	18	3	634
21) Tension	EF	285	45	240	38	89	14	21	3	635
22) Worry	EF	196	31	263	41	124	19	55	9	638
23) Irritability	EF	328	52	221	35	71	11	16	3	636
24) Depression	EF	265	42	235	37	108	17	24	4	632
25) Memory trouble	CF	298	47	249	39	76	12	11	2	634
26) Family life	SF	346	55	153	24	91	14	45	7	635
27) Social activities	SF	306	48	162	26	105	17	61	10	634
28) Financial difficulties	FI	492	78	91	14	36	6	16	3	635
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	9	25	54	109	90	97	51		435
		2	6	12	25	21	22	12		
30) Overall quality of life	QL	16	36	102	163	135	116	66		634
		3	6	16	26	21	18	10		



## Testicular cancer

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	26	7
v +3	1	0
v 2.0	170	44
v 3.0	187	49
Total	384	

#### Age

	N	(%)
<40	322	84
40-49	50	13
50-59	9	2
60-69	2	1
70-79	1	0
80+	0	0
Not known	0	0
Total	384	

#### Stage

	N	(%)
Stage I-II	27	7
Stage III-IV	0	0
Recurrent/metastatic	356	93
Not known	1	0
Total	384	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	58.4	(23.5)	58.3	[41.7-83.3]
Physical functioning	PF	81.6	(23.3)	93.3	[66.7-100]
Role Functioning	RF	55.4	(36.2)	50	[33.3-100]
Emotional functioning	EF	82.4	(22.9)	91.7	[66.7-100]
Cognitive functioning	CF	86.8	(19.5)	100	[83.3-100]
Social functioning	SF	72.7	(31.4)	83.3	[50-100]
Fatigue	FA	37.7	(29.1)	33.3	[11.1-55.6]
Nausea and vomiting	NV	10.4	(17.4)	0	[0-16.7]
Pain	PA	39.7	(35.3)	33.3	[0-66.7]
Dyspnoea	DY	18.3	(27.1)	0	[0-33.3]
Insomnia	SL	32.4	(34.5)	33.3	[0-66.7]
Appetite loss	AP	27.8	(32.4)	33.3	[0-33.3]
Constipation	CO	16.4	(27.9)	0	[0-33.3]
Diarrhoea	DI	8.7	(19.3)	0	[0-0]
Financial difficulties	FI	14.5	(27)	0	[0-33.3]

**Testicular cancer  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	3	2
8.3	2	1
16.7	5	3
25	12	6
33.3	17	9
41.7	19	10
50	27	14
58.3	17	9
66.7	19	10
75	17	9
83.3	33	18
91.7	13	7
100	4	2
<b>Total</b>	<b>188</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	1	1
6.7	0	0
13.3	2	1
20	2	1
26.7	4	2
33.3	1	1
40	3	2
46.7	6	4
53.3	9	5
60	7	4
66.7	8	5
73.3	9	5
80	10	6
86.7	15	9
93.3	23	14
100	66	40
<b>Total</b>	<b>166</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	28	15
16.7	17	9
33.3	30	16
50	19	10
66.7	29	16
83.3	12	6
100	52	28
<b>Total</b>	<b>187</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	3	1
8.3	2	1
16.7	1	0
25	8	2
33.3	11	3
41.7	11	3
50	16	4
58.3	9	2
66.7	37	10
75	30	8
83.3	35	9
91.7	40	11
100	172	46
<b>Total</b>	<b>375</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	1	1
16.7	2	1
33.3	6	3
50	11	5
66.7	25	12
83.3	47	22
100	122	57
<b>Total</b>	<b>214</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	24	7
16.7	18	5
33.3	25	7
50	29	8
66.7	67	18
83.3	47	13
100	158	43
<b>Total</b>	<b>368</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	41	19
11.1	21	10
22.2	21	10
33.3	39	18
44.4	18	9
55.6	23	11
66.7	21	10
77.8	11	5
88.9	10	5
100	8	4
<b>Total</b>	<b>213</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	139	65
16.7	37	17
33.3	26	12
50	5	2
66.7	5	2
83.3	2	1
100	0	0
<b>Total</b>	<b>214</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	62	29
16.7	28	13
33.3	33	15
50	18	8
66.7	28	13
83.3	20	9
100	25	12
<b>Total</b>	<b>214</b>	

**Testicular cancer  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	102	55	38	21	29	16	15	8	184
2) Long walk	PF	101	55	39	21	23	13	21	11	184
3) Short walk	PF	143	78	25	14	10	5	6	3	184
4) Bed or chair	PF	95	56	40	24	27	16	7	4	169
5) Self care	PF	166	90	16	9	1	1	2	1	185
6) Limited in work	RF	57	31	45	24	44	24	41	22	187
7) Limited in leisure	RF	62	33	46	25	42	22	38	20	188
8) Dyspnoea	DY	132	61	57	27	17	8	9	4	215
9) Pain	PA	68	32	55	26	49	23	42	20	214
10) Need to rest	FA	57	27	67	31	59	28	31	15	214
11) Insomnia	SL	94	44	57	27	40	19	24	11	215
12) Felt weak	FA	81	38	74	34	41	19	19	9	215
13) Appetite loss	AP	105	49	58	27	35	16	17	8	215
14) Nausea	NV	144	67	56	26	10	5	4	2	214
15) Vomiting	NV	177	82	30	14	8	4	0	0	215
16) Constipation	CO	146	68	43	20	15	7	11	5	215
17) Diarrhoea	DI	171	80	35	16	6	3	3	1	215
18) Felt tired	FA	56	26	96	45	47	22	15	7	214
19) Pain interference	PA	89	41	50	23	45	21	31	14	215
20) Concentration	CF	138	64	53	25	18	8	6	3	215
21) Tension	EF	228	60	105	28	33	9	13	3	379
22) Worry	EF	203	53	110	29	43	11	27	7	383
23) Irritability	EF	264	70	80	21	25	7	11	3	380
24) Depression	EF	262	69	87	23	25	7	8	2	382
25) Memory trouble	CF	331	87	38	10	11	3	2	1	382
26) Family life	SF	201	53	104	28	44	12	28	7	377
27) Social activities	SF	184	50	88	24	52	14	48	13	372
28) Financial difficulties	FI	274	73	61	16	26	7	17	5	378
<hr/>										
		<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>		<b>Total</b>
		<b>(very poor)</b>						<b>(excellent)</b>		
29) Overall health	QL	106	66	44	45	35	48	11		355
		30	19	12	13	10	14	3		
30) Overall quality of life	QL	5	12	31	39	47	47	33		214
		2	6	15	18	22	22	15		

## General population

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	608	8
v +3	1,963	25
v 2.0	91	1
v 3.0	5,140	66
Total	7,802	

#### Country

	N	(%)
Germany	4,165	53
Norway	1,963	25
Austria	975	13
Denmark	608	8
USA	91	1
Total	7,802	

#### Age

	N	(%)
<40	2,283	29
40-49	1,457	19
50-59	1,593	20
60-69	1,414	18
70-79	741	10
80+	182	2
Not known	132	2
Total	7,802	

#### Gender

	N	(%)
Male	4,046	52
Female	3,749	48
Not known	7	0
Total	7,802	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Global health status/QoL	QL	71.2	(22.4)	75	[58.3-83.3]
Physical functioning	PF	89.8	(16.2)	100	[86.7-100]
Role Functioning	RF	84.7	(25.4)	100	[66.7-100]
Emotional functioning	EF	76.3	(22.8)	83.3	[66.7-100]
Cognitive functioning	CF	86.1	(20)	100	[83.3-100]
Social functioning	SF	87.5	(22.9)	100	[83.3-100]
Fatigue	FA	24.1	(24)	22.2	[0-33.3]
Nausea and vomiting	NV	3.7	(11.7)	0	[0-0]
Pain	PA	20.9	(27.6)	0	[0-33.3]
Dyspnoea	DY	11.8	(22.8)	0	[0-33.3]
Insomnia	SL	21.8	(29.7)	0	[0-33.3]
Appetite loss	AP	6.7	(18.3)	0	[0-0]
Constipation	CO	6.7	(18.4)	0	[0-0]
Diarrhoea	DI	7.0	(18)	0	[0-0]
Financial difficulties	FI	9.5	(23.3)	0	[0-0]

**General population  
Constructed scales**

<b>QL</b>	<b>N</b>	<b>(%)</b>
0	57	1
8.3	34	1
16.7	129	2
25	93	1
33.3	352	5
41.7	276	4
50	753	11
58.3	432	6
66.7	1,059	15
75	721	10
83.3	1,495	21
91.7	649	9
100	1,086	15
<b>Total</b>	<b>7,136</b>	

<b>PF</b>	<b>N</b>	<b>(%)</b>
0	6	0
6.7	5	0
13.3	10	0
20	19	0
26.7	15	0
33.3	33	1
40	47	1
46.7	73	1
53.3	87	2
60	111	2
66.7	176	4
73.3	209	4
80	329	7
86.7	509	10
93.3	794	16
100	2,664	52
<b>Total</b>	<b>5,087</b>	

<b>RF</b>	<b>N</b>	<b>(%)</b>
0	189	3
16.7	115	2
33.3	358	5
50	309	4
66.7	826	12
83.3	742	11
100	4,480	64
<b>Total</b>	<b>7,019</b>	

<b>EF</b>	<b>N</b>	<b>(%)</b>
0	49	1
8.3	49	1
16.7	108	1
25	154	2
33.3	249	3
41.7	276	4
50	395	5
58.3	461	6
66.7	886	12
75	939	12
83.3	1,084	14
91.7	1,061	14
100	1,945	25
<b>Total</b>	<b>7,656</b>	

<b>CF</b>	<b>N</b>	<b>(%)</b>
0	45	1
16.7	95	1
33.3	206	3
50	412	5
66.7	948	12
83.3	1,741	23
100	4,275	55
<b>Total</b>	<b>7,722</b>	

<b>SF</b>	<b>N</b>	<b>(%)</b>
0	121	2
16.7	115	2
33.3	304	4
50	289	4
66.7	869	11
83.3	666	9
100	5,324	69
<b>Total</b>	<b>7,688</b>	

<b>FA</b>	<b>N</b>	<b>(%)</b>
0	2,294	30
11.1	1,219	16
22.2	1,294	17
33.3	1,164	15
44.4	542	7
55.6	436	6
66.7	350	5
77.8	172	2
88.9	115	2
100	90	1
<b>Total</b>	<b>7,676</b>	

<b>NV</b>	<b>N</b>	<b>(%)</b>
0	6,701	87
16.7	617	8
33.3	242	3
50	74	1
66.7	48	1
83.3	21	0
100	17	0
<b>Total</b>	<b>7,720</b>	

<b>PA</b>	<b>N</b>	<b>(%)</b>
0	3,938	51
16.7	1,116	15
33.3	1,069	14
50	547	7
66.7	570	7
83.3	221	3
100	229	3
<b>Total</b>	<b>7,690</b>	

**General population  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Strenuous activities	PF	2,888	56	1,165	23	698	14	374	7	5,125
2) Long walk	PF	3,668	72	765	15	426	8	267	5	5,126
3) Short walk	PF	4,467	87	418	8	165	3	66	1	5,116
4) Bed or chair	PF	4,604	90	343	7	122	2	39	1	5,108
5) Self care	PF	4,995	98	77	2	36	1	15	0	5,123
6) Limited in work	RF	4,892	69	1,281	18	625	9	283	4	7,081
7) Limited in leisure	RF	5,030	71	1,191	17	564	8	307	4	7,092
8) Dyspnoea	DY	5,781	75	1,303	17	501	7	142	2	7,727
9) Pain	PA	4,289	56	1,935	25	1,123	15	383	5	7,730
10) Need to rest	FA	3,679	48	2,680	35	1,045	14	325	4	7,729
11) Insomnia	SL	4,467	58	1,914	25	951	12	415	5	7,747
12) Felt weak	FA	4,557	59	2,164	28	788	10	234	3	7,743
13) Appetite loss	AP	6,627	86	761	10	262	3	94	1	7,744
14) Nausea	NV	6,747	87	740	10	192	3	60	1	7,739
15) Vomiting	NV	7,422	96	201	3	72	1	32	0	7,727
16) Constipation	CO	6,635	86	759	10	239	3	106	1	7,739
17) Diarrhoea	DI	6,512	84	885	12	237	3	84	1	7,718
18) Felt tired	FA	3,036	39	3,099	40	1,222	16	385	5	7,742
19) Pain interference	PA	4,912	63	1,621	21	842	11	370	5	7,745
20) Concentration	CF	5,828	75	1,365	18	406	5	144	2	7,743
21) Tension	EF	3,891	50	2,650	34	912	12	272	4	7,725
22) Worry	EF	3,443	45	2,628	34	1,165	15	499	7	7,735
23) Irritability	EF	3,528	46	3,009	39	930	12	264	3	7,731
24) Depression	EF	4,404	57	2,248	29	787	10	290	4	7,729
25) Memory trouble	CF	4,806	62	2,168	28	621	8	155	2	7,750
26) Family life	SF	5,770	75	1,278	17	473	6	190	3	7,711
27) Social activities	SF	5,718	74	1,233	16	507	7	269	4	7,727
28) Financial difficulties	FI	6,381	83	725	9	379	5	242	3	7,727
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>Total</b>
			<b>(very poor)</b>					<b>(excellent)</b>		
29) Overall health	QL	90	228	618	1,106	1,491	2,076	1,542		7,151
		1	3	9	16	21	29	22		
30) Overall quality of life	QL	109	204	549	1,143	1,696	2,378	1,658		7,737
		1	3	7	15	22	31	21		

## Breast module: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	559	20
v +3	95	3
v 2.0	583	21
v 3.0	1,545	56
Total	2,782	

#### Age

	N	(%)
<40	246	9
40-49	690	25
50-59	786	28
60-69	523	19
70-79	223	8
80+	28	1
Not known	286	10
Total	2,782	

#### Stage

	N	(%)
Stage I-II	464	17
Stage III-IV	376	14
Recurrent/metastatic	1,147	41
Not known	795	29
Total	2,782	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Body image	BRBI	82.7	(22.9)	91.7	[66.7-100]
Sexual functioning	BRSEF	19.5	(22.8)	16.7	[0-33.3]
Sexual enjoyment	BRSEE	53.1	(27.1)	66.7	[33.3-66.7]
Future perspective	BRFU	47.3	(33.7)	66.7	[33.3-66.7]
Systemic therapy	BRCT	15.5	(13.5)	14.3	[4.8-23.8]
Breast systems	BRRT	16.2	(16.8)	8.3	[0-25]
Arm symptoms	BRSY	18.7	(20.5)	11.1	[0-33.3]
Hair loss	BRHL	5.0	(18.2)	0	[0-0]

**Breast module: all stages**  
**Constructed scales**

<b>BRBI</b>	<b>N</b>	<b>(%)</b>
0	11	1
8.3	5	1
16.7	14	1
25	7	1
33.3	23	2
41.7	13	1
50	43	4
58.3	46	5
66.7	89	9
75	78	8
83.3	83	9
91.7	115	12
100	450	46
<b>Total</b>	<b>977</b>	

<b>BRRT</b>	<b>N</b>	<b>(%)</b>
0	269	28
8.3	220	23
16.7	189	19
25	127	13
33.3	67	7
41.7	37	4
50	27	3
58.3	18	2
66.7	6	1
75	5	1
83.3	2	0
91.7	3	0
100	2	0
<b>Total</b>	<b>972</b>	

<b>BRSEF</b>	<b>N</b>	<b>(%)</b>
0	433	49
16.7	77	9
33.3	248	28
50	44	5
66.7	67	8
83.3	5	1
100	5	1
<b>Total</b>	<b>879</b>	

<b>BRSY</b>	<b>N</b>	<b>(%)</b>
0	337	34
11.1	225	22
22.2	189	19
33.3	112	11
44.4	51	5
55.6	40	4
66.7	26	3
77.8	9	1
88.9	9	1
100	6	1
<b>Total</b>	<b>1,004</b>	

<b>BRCT</b>	<b>N</b>	<b>(%)</b>
0	142	15
4.8	160	17
9.5	150	16
14.3	133	14
19	121	13
23.8	81	8
28.6	64	7
33.3	35	4
38.1	32	3
42.9	17	2
47.6	9	1
52.4	4	0
57.1	6	1
61.9	2	0
66.7	1	0
71.4	3	0
76.2	2	0
81	0	0
85.7	1	0
90.5	1	0
95.2	0	0
100	0	0
<b>Total</b>	<b>964</b>	



**Breast module: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Dry mouth	BRCT	522	52	320	32	136	13	34	3	1,012
2) Food and drink	BRCT	831	82	130	13	42	4	11	1	1,014
3) Painful eyes	BRCT	762	75	197	20	41	4	10	1	1,010
4) Lost hair	BRCT	852	85	99	10	25	3	28	3	1,004
5) Upset by hair loss	BRHL	116	52	58	26	19	9	29	13	222
6) Feel ill or unwell	BRCT	563	57	299	30	111	11	18	2	991
7) Hot flushes	BRCT	508	51	289	29	158	16	48	5	1,003
8) Headaches	BRCT	609	61	304	30	70	7	23	2	1,006
9) Less attractive	BRBI	625	63	244	24	93	9	36	4	998
10) Less feminine	BRBI	667	67	193	19	104	10	34	3	998
11) Look at self naked	BRBI	667	66	218	22	79	8	43	4	1,007
12) Dissatisfied with body	BRBI	621	62	244	24	95	10	38	4	998
13) Worried about health	BRFU	150	15	364	36	253	25	241	24	1,008
14) Interested in sex	BRSEF	497	55	305	34	92	10	10	1	904
15) Sexually active	BRSEF	468	53	313	36	90	10	9	1	880
16) Sex enjoyable	BRSEE	26	7	152	41	143	38	52	14	373
17) Pain in arm or shoulder	BRSY	411	41	417	41	140	14	42	4	1,010
18) Swollen arm or hand	BRSY	777	77	159	16	51	5	24	2	1,011
19) Difficulty raising arm	BRSY	619	61	273	27	77	8	42	4	1,011
20) Pain in breast	BRRT	457	46	444	44	80	8	22	2	1,003
21) Breast swollen	BRRT	697	70	221	22	59	6	18	2	995
22) Breast oversensitive	BRRT	545	55	336	34	91	9	21	2	993
23) Skin problems	BRRT	775	77	159	16	55	6	14	1	1,003

## Breast module: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	89	10
v +3	41	4
v 2.0	261	28
v 3.0	545	58
Total	936	

#### Age

	N	(%)
<40	246	26
40-49	690	74
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	936	

#### Stage

	N	(%)
Stage I-II	217	23
Stage III-IV	135	14
Recurrent/metastatic	289	31
Not known	295	32
Total	936	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Body image	BRBI	81.3	(23.3)	91.7	[66.7-100]
Sexual functioning	BRSEF	26.7	(24.2)	33.3	[0-33.3]
Sexual enjoyment	BRSEE	55.2	(27.1)	66.7	[33.3-66.7]
Future perspective	BRFU	37.9	(33.2)	33.3	[0-66.7]
Systemic therapy	BRCT	15.3	(13)	14.3	[4.8-23.8]
Breast systems	BRRT	14.9	(15.4)	8.3	[0-25]
Arm symptoms	BRSY	15.7	(17.9)	11.1	[0-22.2]
Hair loss	BRHL	4.3	(16.7)	0	[0-0]

**Breast module: <50  
Constructed scales**

<b>BRBI</b>	<b>N</b>	<b>(%)</b>
0	5	1
8.3	1	0
16.7	5	1
25	4	1
33.3	6	2
41.7	9	3
50	17	5
58.3	23	6
66.7	29	8
75	30	8
83.3	37	10
91.7	40	11
100	152	43
<b>Total</b>	<b>358</b>	

<b>BRRT</b>	<b>N</b>	<b>(%)</b>
0	98	28
8.3	90	25
16.7	72	20
25	42	12
33.3	23	7
41.7	12	3
50	9	3
58.3	3	1
66.7	2	1
75	1	0
83.3	1	0
91.7	0	0
100	1	0
<b>Total</b>	<b>354</b>	

<b>BRSEF</b>	<b>N</b>	<b>(%)</b>
0	118	35
16.7	26	8
33.3	123	37
50	20	6
66.7	44	13
83.3	4	1
100	2	1
<b>Total</b>	<b>337</b>	

<b>BRSY</b>	<b>N</b>	<b>(%)</b>
0	141	39
11.1	82	23
22.2	71	20
33.3	31	9
44.4	14	4
55.6	17	5
66.7	6	2
77.8	2	1
88.9	1	0
100	0	0
<b>Total</b>	<b>365</b>	

<b>BRCT</b>	<b>N</b>	<b>(%)</b>
0	51	15
4.8	63	18
9.5	55	16
14.3	45	13
19	43	12
23.8	28	8
28.6	28	8
33.3	13	4
38.1	12	3
42.9	5	1
47.6	4	1
52.4	0	0
57.1	2	1
61.9	1	0
66.7	0	0
71.4	1	0
76.2	1	0
81	0	0
85.7	0	0
90.5	0	0
95.2	0	0
100	0	0
<b>Total</b>	<b>352</b>	

**Breast module: <50**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Dry mouth	BRCT	196	54	108	30	54	15	6	2	364
2) Food and drink	BRCT	294	80	53	15	16	4	3	1	366
3) Painful eyes	BRCT	298	82	54	15	11	3	1	0	364
4) Lost hair	BRCT	311	86	35	10	11	3	6	2	363
5) Upset by hair loss	BRHL	<i>Insufficient data available</i>								
6) Feel ill or unwell	BRCT	189	53	115	32	50	14	5	1	359
7) Hot flushes	BRCT	192	53	96	26	64	18	11	3	363
8) Headaches	BRCT	204	56	128	35	29	8	2	1	363
9) Less attractive	BRBI	216	60	93	26	41	11	12	3	362
10) Less feminine	BRBI	220	60	75	21	55	15	14	4	364
11) Look at self naked	BRBI	243	67	80	22	26	7	16	4	365
12) Dissatisfied with body	BRBI	222	61	90	25	34	9	16	4	362
13) Worried about health	BRFU	32	9	113	31	93	26	127	35	365
14) Interested in sex	BRSEF	138	40	144	42	56	16	6	2	344
15) Sexually active	BRSEF	130	39	150	45	52	15	5	2	337
16) Sex enjoyable	BRSEE	10	5	79	41	74	38	32	16	195
17) Pain in arm or shoulder	BRSY	165	45	152	42	38	10	10	3	365
18) Swollen arm or hand	BRSY	292	80	55	15	15	4	3	1	365
19) Difficulty raising arm	BRSY	242	66	90	25	25	7	8	2	365
20) Pain in breast	BRRT	162	45	168	46	25	7	7	2	362
21) Breast swollen	BRRT	254	71	84	23	18	5	3	1	359
22) Breast oversensitive	BRRT	215	60	110	31	27	8	5	1	357
23) Skin problems	BRRT	284	78	61	17	12	3	7	2	364

## Breast module: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	96	12
v +3	25	3
v 2.0	145	18
v 3.0	520	66
Total	786	

#### Stage

	N	(%)
Stage I-II	140	18
Stage III-IV	109	14
Recurrent/metastatic	267	34
Not known	270	34
Total	786	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Body image	BRBI	80.5	(24)	91.7	[66.7-100]
Sexual functioning	BRSEF	20.7	(22.6)	16.7	[0-33.3]
Sexual enjoyment	BRSEE	51.9	(26.8)	66.7	[33.3-66.7]
Future perspective	BRFU	49.4	(31.8)	66.7	[33.3-66.7]
Systemic therapy	BRCT	16.0	(12.9)	14.3	[4.8-23.8]
Breast systems	BRRT	17.1	(17.2)	16.7	[4.2-25]
Arm symptoms	BRSY	21.1	(22.2)	11.1	[0-33.3]
Hair loss	BRHL	4.5	(17.5)	0	[0-0]

**Breast module: 50-59**  
**Constructed scales**

<b>BRBI</b>	<b>N</b>	<b>(%)</b>
0	5	2
8.3	2	1
16.7	5	2
25	3	1
33.3	9	3
41.7	2	1
50	15	5
58.3	15	5
66.7	31	10
75	26	9
83.3	29	10
91.7	40	13
100	122	40
<b>Total</b>	<b>304</b>	

<b>BRRT</b>	<b>N</b>	<b>(%)</b>
0	75	25
8.3	69	23
16.7	57	19
25	47	16
33.3	22	7
41.7	9	3
50	7	2
58.3	7	2
66.7	2	1
75	2	1
83.3	1	0
91.7	2	1
100	0	0
<b>Total</b>	<b>300</b>	

<b>BRSEF</b>	<b>N</b>	<b>(%)</b>
0	123	45
16.7	32	12
33.3	81	29
50	16	6
66.7	21	8
83.3	1	0
100	2	1
<b>Total</b>	<b>276</b>	

<b>BRSY</b>	<b>N</b>	<b>(%)</b>
0	94	30
11.1	66	21
22.2	57	18
33.3	37	12
44.4	21	7
55.6	12	4
66.7	12	4
77.8	3	1
88.9	4	1
100	3	1
<b>Total</b>	<b>309</b>	

<b>BRCT</b>	<b>N</b>	<b>(%)</b>
0	36	12
4.8	50	17
9.5	44	15
14.3	45	15
19	42	14
23.8	29	10
28.6	21	7
33.3	12	4
38.1	7	2
42.9	4	1
47.6	2	1
52.4	3	1
57.1	3	1
61.9	1	0
66.7	0	0
71.4	0	0
76.2	1	0
81	0	0
85.7	0	0
90.5	0	0
95.2	0	0
100	0	0
<b>Total</b>	<b>300</b>	

**Breast module: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Dry mouth	BRCT	163	52	104	33	37	12	9	3	313
2) Food and drink	BRCT	266	86	31	10	10	3	4	1	311
3) Painful eyes	BRCT	227	73	69	22	10	3	6	2	312
4) Lost hair	BRCT	263	85	31	10	7	2	9	3	310
5) Upset by hair loss	BRHL	<i>Insufficient data available</i>								
6) Feel ill or unwell	BRCT	175	57	98	32	26	9	6	2	305
7) Hot flushes	BRCT	130	42	109	35	49	16	23	7	311
8) Headaches	BRCT	183	59	100	32	17	6	11	4	311
9) Less attractive	BRBI	189	62	80	26	23	8	15	5	307
10) Less feminine	BRBI	202	65	68	22	26	8	14	5	310
11) Look at self naked	BRBI	184	60	75	24	32	10	18	6	309
12) Dissatisfied with body	BRBI	173	56	83	27	40	13	13	4	309
13) Worried about health	BRFU	42	14	126	41	83	27	60	19	311
14) Interested in sex	BRSEF	145	51	109	38	28	10	3	1	285
15) Sexually active	BRSEF	138	50	105	38	32	12	2	1	277
16) Sex enjoyable	BRSEE	9	7	51	42	47	39	15	12	122
17) Pain in arm or shoulder	BRSY	114	37	125	40	57	18	14	5	310
18) Swollen arm or hand	BRSY	231	75	51	17	18	6	10	3	310
19) Difficulty raising arm	BRSY	177	57	86	28	32	10	16	5	311
20) Pain in breast	BRRT	135	44	136	44	28	9	9	3	308
21) Breast swollen	BRRT	212	69	68	22	21	7	8	3	309
22) Breast oversensitive	BRRT	162	53	105	34	33	11	6	2	306
23) Skin problems	BRRT	240	78	45	15	18	6	3	1	306

## Breast module: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	70	13
v +3	24	5
v 2.0	124	24
v 3.0	305	58
Total	523	

#### Stage

	N	(%)
Stage I-II	77	15
Stage III-IV	73	14
Recurrent/metastatic	193	37
Not known	180	34
Total	523	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Body image	BRBI	85.0	(21.7)	100	[75-100]
Sexual functioning	BRSEF	11.3	(17.8)	0	[0-33.3]
Sexual enjoyment	BRSEE	49.1	(25.8)	33.3	[33.3-66.7]
Future perspective	BRFU	52.4	(34.3)	66.7	[33.3-66.7]
Systemic therapy	BRCT	16.0	(14.6)	14.3	[4.8-23.8]
Breast systems	BRRT	16.2	(16.9)	8.3	[0-25]
Arm symptoms	BRSY	20.8	(21.9)	11.1	[0-33.3]
Hair loss	BRHL	7.3	(21.6)	0	[0-0]



**Breast module: 60-69**  
**Constructed scales**

<b>BRBI</b>	<b>N</b>	<b>(%)</b>
0	1	0
8.3	2	1
16.7	2	1
25	0	0
33.3	7	3
41.7	2	1
50	10	4
58.3	8	4
66.7	22	10
75	15	7
83.3	14	6
91.7	23	10
100	120	53
<b>Total</b>	<b>226</b>	

<b>BRRT</b>	<b>N</b>	<b>(%)</b>
0	73	32
8.3	42	18
16.7	37	16
25	32	14
33.3	17	8
41.7	12	5
50	7	3
58.3	6	3
66.7	0	0
75	1	0
83.3	0	0
91.7	1	0
100	0	0
<b>Total</b>	<b>228</b>	

<b>BRSEF</b>	<b>N</b>	<b>(%)</b>
0	130	66
16.7	15	8
33.3	42	21
50	7	4
66.7	2	1
83.3	0	0
100	1	1
<b>Total</b>	<b>197</b>	

<b>BRSY</b>	<b>N</b>	<b>(%)</b>
0	69	29
11.1	60	25
22.2	38	16
33.3	31	13
44.4	14	6
55.6	10	4
66.7	8	3
77.8	3	1
88.9	3	1
100	2	1
<b>Total</b>	<b>238</b>	

<b>BRCT</b>	<b>N</b>	<b>(%)</b>
0	34	15
4.8	31	14
9.5	41	18
14.3	32	14
19	28	12
23.8	18	8
28.6	13	6
33.3	7	3
38.1	9	4
42.9	6	3
47.6	3	1
52.4	0	0
57.1	0	0
61.9	0	0
66.7	1	0
71.4	1	0
76.2	0	0
81	0	0
85.7	1	0
90.5	1	0
95.2	0	0
100	0	0
<b>Total</b>	<b>226</b>	

**Breast module: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Dry mouth	BRCT	118	49	80	33	32	13	12	5	242
2) Food and drink	BRCT	199	82	31	13	11	5	3	1	244
3) Painful eyes	BRCT	170	70	55	23	15	6	2	1	242
4) Lost hair	BRCT	199	83	22	9	6	3	12	5	239
5) Upset by hair loss	BRHL	<i>Insufficient data available</i>								
6) Feel ill or unwell	BRCT	134	57	67	28	31	13	5	2	237
7) Hot flushes	BRCT	132	55	64	27	31	13	13	5	240
8) Headaches	BRCT	154	64	60	25	19	8	8	3	241
9) Less attractive	BRBI	150	63	53	22	27	11	8	3	238
10) Less feminine	BRBI	169	72	39	17	21	9	5	2	234
11) Look at self naked	BRBI	168	69	50	21	18	7	6	3	242
12) Dissatisfied with body	BRBI	159	67	56	24	16	7	6	3	237
13) Worried about health	BRFU	51	21	81	34	62	26	46	19	240
14) Interested in sex	BRSEF	148	72	50	24	7	3	1	1	206
15) Sexually active	BRSEF	138	70	51	26	6	3	2	1	197
16) Sex enjoyable	BRSEE	<i>Insufficient data available</i>								
17) Pain in arm or shoulder	BRSY	90	37	105	43	31	13	17	7	243
18) Swollen arm or hand	BRSY	179	74	44	18	12	5	8	3	243
19) Difficulty raising arm	BRSY	143	59	68	28	15	6	16	7	242
20) Pain in breast	BRRT	117	49	100	42	19	8	4	2	240
21) Breast swollen	BRRT	166	71	52	22	15	6	2	1	235
22) Breast oversensitive	BRRT	123	52	84	35	26	11	6	3	239
23) Skin problems	BRRT	183	76	39	16	16	7	2	1	240

## Breast module: recurrent/metastatic

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	291	25
v +3	0	0
v 2.0	202	18
v 3.0	654	57
Total	1,147	

#### Age

	N	(%)
<40	85	7
40-49	204	18
50-59	267	23
60-69	193	17
70-79	98	9
80+	14	1
Not known	286	25
Total	1,147	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Body image	BRBI	81.9	(22.6)	91.7	[66.7-100]
Sexual functioning	BRSEF	19.2	(23.2)	0	[0-33.3]
Sexual enjoyment	BRSEE	55.1	(25.6)	66.7	[33.3-66.7]
Future perspective	BRFU	47.6	(34.1)	66.7	[33.3-66.7]
Systemic therapy	BRCT	15.8	(14.3)	14.3	[4.8-23.8]
Breast systems	BRRT	17.6	(17.4)	16.7	[0-25]
Arm symptoms	BRSY	21.0	(21.1)	22.2	[0-33.3]
Hair loss	BRHL	5.3	(19.3)	0	[0-0]

**Breast module: recurrent/metastatic  
Constructed scales**

<b>BRBI</b>	<b>N</b>	<b>(%)</b>
0	6	1
8.3	3	1
16.7	7	1
25	5	1
33.3	14	2
41.7	10	2
50	28	5
58.3	34	6
66.7	57	9
75	59	10
83.3	48	8
91.7	71	12
100	263	44
<b>Total</b>	<b>605</b>	

<b>BRRT</b>	<b>N</b>	<b>(%)</b>
0	153	26
8.3	124	21
16.7	119	20
25	83	14
33.3	49	8
41.7	27	5
50	19	3
58.3	11	2
66.7	5	1
75	4	1
83.3	2	0
91.7	1	0
100	2	0
<b>Total</b>	<b>599</b>	

<b>BRSEF</b>	<b>N</b>	<b>(%)</b>
0	279	51
16.7	46	8
33.3	149	27
50	25	5
66.7	42	8
83.3	4	1
100	4	1
<b>Total</b>	<b>549</b>	

<b>BRSY</b>	<b>N</b>	<b>(%)</b>
0	181	29
11.1	128	21
22.2	132	21
33.3	79	13
44.4	38	6
55.6	27	4
66.7	21	3
77.8	6	1
88.9	7	1
100	4	1
<b>Total</b>	<b>623</b>	

<b>BRCT</b>	<b>N</b>	<b>(%)</b>
0	89	15
4.8	99	17
9.5	89	15
14.3	89	15
19	73	12
23.8	47	8
28.6	38	6
33.3	20	3
38.1	16	3
42.9	14	2
47.6	5	1
52.4	2	0
57.1	6	1
61.9	1	0
66.7	1	0
71.4	3	1
76.2	2	0
81	0	0
85.7	1	0
90.5	1	0
95.2	0	0
100	0	0
<b>Total</b>	<b>596</b>	

**Breast module: recurrent/metastatic  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Dry mouth	BRCT	340	55	178	29	78	13	27	4	623
2) Food and drink	BRCT	510	82	80	13	25	4	9	1	624
3) Painful eyes	BRCT	462	74	128	21	27	4	7	1	624
4) Lost hair	BRCT	526	85	59	10	17	3	18	3	620
5) Upset by hair loss	BRHL	58	50	27	23	11	10	20	17	116
6) Feel ill or unwell	BRCT	340	56	193	32	68	11	10	2	611
7) Hot flushes	BRCT	316	51	178	29	91	15	34	6	619
8) Headaches	BRCT	374	60	186	30	46	7	15	2	621
9) Less attractive	BRBI	370	60	163	26	63	10	21	3	617
10) Less feminine	BRBI	406	66	126	20	63	10	22	4	617
11) Look at self naked	BRBI	402	65	147	24	51	8	23	4	623
12) Dissatisfied with body	BRBI	364	59	168	27	60	10	23	4	615
13) Worried about health	BRFU	98	16	223	36	150	24	152	24	623
14) Interested in sex	BRSEF	314	55	189	33	55	10	9	2	567
15) Sexually active	BRSEF	303	55	184	34	57	10	6	1	550
16) Sex enjoyable	BRSEE	12	5	81	37	100	45	28	13	221
17) Pain in arm or shoulder	BRSY	233	37	263	42	97	16	33	5	626
18) Swollen arm or hand	BRSY	481	77	99	16	30	5	15	2	625
19) Difficulty raising arm	BRSY	330	53	204	33	59	9	33	5	626
20) Pain in breast	BRRT	273	44	272	44	58	9	18	3	621
21) Breast swollen	BRRT	413	67	148	24	41	7	14	2	616
22) Breast oversensitive	BRRT	306	50	220	36	73	12	15	2	614
23) Skin problems	BRRT	489	79	90	15	33	5	8	1	620

## Head and neck module: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	23	1
v +3	688	24
v 2.0	489	17
v 3.0	1,729	59
Total	2,929	

#### Age

	N	(%)
<40	110	4
40-49	480	16
50-59	919	31
60-69	832	28
70-79	489	17
80+	97	3
Not known	2	0
Total	2,929	

#### Gender

	N	(%)
Male	2,318	79
Female	589	20
Not known	22	1
Total	2,929	

#### Stage

	N	(%)
Stage I-II	946	32
Stage III-IV	1,722	59
Recurrent/metastatic	37	1
Not known	224	8
Total	2,929	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	27.1	(24)	25	[8.3-41.7]
Swallowing	HNSW	23.9	(25.3)	16.7	[0-41.7]
Senses	HNSE	19.3	(28.8)	0	[0-33.3]
Speech	HNSP	28.0	(27.6)	22.2	[0-44.4]
Social eating	HNSO	20.9	(25.1)	8.3	[0-33.3]
Social contact	HNSC	13.0	(18.9)	0	[0-20]
Sexuality	HNSX	31.3	(35.2)	16.7	[0-66.7]
Teeth	HNTE	25.5	(33.2)	0	[0-33.3]
Opening mouth	HNOM	19.5	(29.5)	0	[0-33.3]
Dry mouth	HNDR	30.7	(33.4)	33.3	[0-66.7]
Sticky saliva	HNSS	30.5	(33.9)	33.3	[0-66.7]
Coughed	HNCO	33.9	(32.2)	33.3	[0-66.7]
Felt ill	HNFI	21.6	(28.9)	0	[0-33.3]
Pain killers	HNPk	49.5	(50)	0	[0-100]
Nutritional supp	HNNU	26.7	(44.2)	0	[0-100]
Feeding tube	HNFE	19.7	(39.8)	0	[0-0]
Weight loss	HNWL	38.9	(48.8)	0	[0-100]
Weight gain	HNWG	27.3	(44.6)	0	[0-100]

**Head and neck module: all stages**  
**Constructed scales**

<b>HNPA</b>	<b>N</b>	<b>(%)</b>
0	438	20
8.3	341	15
16.7	297	13
25	232	10
33.3	338	15
41.7	144	6
50	134	6
58.3	92	4
66.7	91	4
75	54	2
83.3	39	2
91.7	23	1
100	25	1
<b>Total</b>	<b>2,248</b>	

<b>HNSO</b>	<b>N</b>	<b>(%)</b>
0	865	39
8.3	275	12
16.7	222	10
25	136	6
33.3	299	13
41.7	103	5
50	91	4
58.3	53	2
66.7	42	2
75	45	2
83.3	35	2
91.7	22	1
100	43	2
<b>Total</b>	<b>2,231</b>	

<b>HNSW</b>	<b>N</b>	<b>(%)</b>
0	761	34
8.3	250	11
16.7	192	9
25	174	8
33.3	287	13
41.7	135	6
50	129	6
58.3	91	4
66.7	63	3
75	81	4
83.3	31	1
91.7	15	1
100	26	1
<b>Total</b>	<b>2,235</b>	<b>0</b>

<b>HNSC</b>	<b>N</b>	<b>(%)</b>
0	1114	51
6.7	274	13
13.3	176	8
20	96	4
26.7	78	4
33.3	219	10
40	67	3
46.7	51	2
53.3	33	2
60	22	1
66.7	22	1
73.3	13	1
80	17	1
86.7	9	0
93.3	2	0
100	2	0
<b>Total</b>	<b>2,195</b>	

<b>HNSE</b>	<b>N</b>	<b>(%)</b>
0	1,325	59
16.7	212	9
33.3	300	13
50	142	6
66.7	117	5
83.3	57	3
100	105	5
<b>Total</b>	<b>2,258</b>	

<b>HNSX</b>	<b>N</b>	<b>(%)</b>
0	881	45
16.7	113	6
33.3	376	19
50	90	5
66.7	241	12
83.3	40	2
100	236	12
<b>Total</b>	<b>1,977</b>	

<b>HNSP</b>	<b>N</b>	<b>(%)</b>
0	616	28
11.1	401	18
22.2	279	13
33.3	260	12
44.4	188	9
55.6	138	6
66.7	130	6
77.8	110	5
88.9	47	2
100	54	2
<b>Total</b>	<b>2,223</b>	





## Head and neck module: males

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	20	1
v +3	491	21
v 2.0	396	17
v 3.0	1,411	61
Total	2,318	

#### Age

	N	(%)
<40	71	3
40-49	391	17
50-59	736	32
60-69	682	29
70-79	379	16
80+	57	3
Not known	2	0
Total	2,318	

#### Stage

	N	(%)
Stage I-II	751	32
Stage III-IV	1,401	60
Recurrent/metastatic	20	1
Not known	146	6
Total	2,318	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	27.0	(23.9)	25	[8.3-41.7]
Swallowing	HNSW	24.4	(24.9)	16.7	[0-41.7]
Senses	HNSE	20.1	(29.2)	0	[0-33.3]
Speech	HNSP	29.3	(27.8)	22.2	[0-44.4]
Social eating	HNSO	21.1	(25.1)	8.3	[0-33.3]
Social contact	HNSC	13.5	(19)	6.7	[0-26.7]
Sexuality	HNSX	31.9	(35.2)	33.3	[0-66.7]
Teeth	HNTE	25.8	(32.9)	0	[0-33.3]
Opening mouth	HNOM	19.9	(29.4)	0	[0-33.3]
Dry mouth	HNDR	30.6	(33)	33.3	[0-33.3]
Sticky saliva	HNSS	32.3	(34)	33.3	[0-66.7]
Coughed	HNCO	35.6	(32.3)	33.3	[0-66.7]
Felt ill	HNFI	22.3	(29.3)	0	[0-33.3]
Pain killers	HNPk	48.7	(50)	0	[0-100]
Nutritional supp	HNNU	27.2	(44.5)	0	[0-100]
Feeding tube	HNFE	21.8	(41.3)	0	[0-0]
Weight loss	HNWL	39.9	(49)	0	[0-100]
Weight gain	HNWG	28.9	(45.3)	0	[0-100]

**Head and neck module: males**  
**Constructed scales**

<b>HNSA</b>	N	(%)
0	353	20
8.3	279	16
16.7	228	13
25	178	10
33.3	275	15
41.7	116	7
50	117	7
58.3	66	4
66.7	78	4
75	41	2
83.3	32	2
91.7	17	1
100	18	1
Total	1,798	

<b>HNSO</b>	N	(%)
0	691	39
8.3	222	12
16.7	172	10
25	106	6
33.3	253	14
41.7	82	5
50	76	4
58.3	43	2
66.7	36	2
75	35	2
83.3	26	1
91.7	19	1
100	34	2
Total	1,795	

<b>HNSW</b>	N	(%)
0	583	33
8.3	198	11
16.7	151	8
25	145	8
33.3	246	14
41.7	112	6
50	112	6
58.3	75	4
66.7	48	3
75	68	4
83.3	24	1
91.7	13	1
100	16	1
Total	1,791	0

<b>HNSC</b>	N	(%)
0	877	50
6.7	211	12
13.3	147	8
20	78	4
26.7	62	4
33.3	190	11
40	52	3
46.7	41	2
53.3	32	2
60	18	1
66.7	22	1
73.3	10	1
80	13	1
86.7	6	0
93.3	1	0
100	2	0
Total	1,762	

<b>HNSE</b>	N	(%)
0	1,037	57
16.7	176	10
33.3	244	14
50	113	6
66.7	101	6
83.3	49	3
100	88	5
Total	1,808	

<b>HNSX</b>	N	(%)
0	708	43
16.7	99	6
33.3	314	19
50	74	5
66.7	203	12
83.3	38	2
100	196	12
Total	1,632	

<b>HNSP</b>	N	(%)
0	455	26
11.1	314	18
22.2	225	13
33.3	216	12
44.4	158	9
55.6	118	7
66.7	111	6
77.8	96	5
88.9	43	2
100	42	2
Total	1,778	

**Head and neck module: males  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Pain in mouth	HNPA	838	46	615	34	256	14	115	6	1,824
2) Pain in jaw	HNPA	1,014	56	537	30	176	10	94	5	1,821
3) Soreness in mouth	HNPA	818	45	650	36	241	13	106	6	1,815
4) Painful throat	HNPA	643	35	704	39	301	17	170	9	1,818
5) Problems swallowing liquids	HNSW	929	51	559	31	216	12	121	7	1,825
6) Problems swallowing pureed food	HNSW	1,029	57	527	29	168	9	92	5	1,816
7) Problems swallowing solid food	HNSW	709	39	540	30	275	15	297	16	1,821
8) Choked when swallowing	HNSW	1,188	65	443	24	117	6	69	4	1,817
9) Problems with teeth	HNTE	946	53	461	26	206	12	168	9	1,781
10) Problems opening mouth wide	HNOM	1,111	61	441	24	157	9	111	6	1,820
11) Dry mouth	HNDR	790	43	578	32	271	15	184	10	1,823
12) Sticky saliva	HNSS	765	42	544	30	293	16	207	11	1,809
13) Sense of smell	HNSE	1,233	68	280	15	109	6	195	11	1,817
14) Sense of taste	HNSE	1,126	62	401	22	160	9	132	7	1,819
15) Coughed	HNCO	594	33	712	39	312	17	202	11	1,820
16) Been hoarse	HNPS	675	38	548	31	307	17	263	15	1,793
17) Felt ill	HNFI	991	55	547	30	171	9	110	6	1,819
18) Appearance bothered you	HNSC	1,203	66	432	24	129	7	55	3	1,819
19) Trouble eating	HNSO	811	45	564	31	259	14	188	10	1,822
20) Eating in front of family	HNSO	1,301	72	375	21	76	4	60	3	1,812
21) Eating in front of other people	HNSO	1,176	65	393	22	128	7	115	6	1,812
22) Trouble enjoying meals	HNSO	983	54	515	28	189	10	131	7	1,818
23) Trouble talking to people	HNPS	998	55	467	26	215	12	140	8	1,820
24) Trouble talking on telephone	HNPS	923	51	440	24	244	13	209	12	1,816
25) Social contact with family	HNSC	1,294	71	411	23	80	4	28	2	1,813
26) Social contact with friends	HNSC	1,224	67	440	24	115	6	38	2	1,817
27) Trouble going out in public	HNSC	1,281	70	372	20	110	6	57	3	1,820
28) Trouble with physical contact	HNSC	1,308	73	359	20	84	5	37	2	1,788
29) Less interest in sex	HNSX	759	45	422	25	268	16	233	14	1,682
30) Less sexual enjoyment	HNSX	799	49	362	22	239	15	236	14	1,636
				<b>No</b>	<b>Yes</b>	<b>Total</b>				
				N	N	N				
				(%)	(%)					
31) Used pain-killers	HNPKE	890	51	844	49	1,734				
32) Taken nutritional supplements	HNNU	1,306	73	487	27	1,793				
33) Used feeding tube	HNFE	1,408	78	392	22	1,800				
34) Lost weight	HNWL	1,055	60	701	40	1,756				
35) Gained weight	HNWG	1,216	71	494	29	1,710				

## Head and neck module: females

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	3	1
v +3	197	33
v 2.0	82	14
v 3.0	307	52
Total	589	

#### Age

	N	(%)
<40	38	7
40-49	85	14
50-59	176	30
60-69	143	24
70-79	107	18
80+	40	7
Not known	0	0
Total	589	

#### Stage

	N	(%)
Stage I-II	195	33
Stage III-IV	316	54
Recurrent/metastatic	17	3
Not known	61	10
Total	589	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	27.6	(24.6)	25	[8.3-41.7]
Swallowing	HNSW	21.7	(26.4)	8.3	[0-33.3]
Senses	HNSE	16.0	(26.6)	0	[0-33.3]
Speech	HNSP	22.5	(26.4)	11.1	[0-33.3]
Social eating	HNSO	20.2	(25.1)	8.3	[0-33.3]
Social contact	HNSC	11.5	(18.4)	0	[0-16.7]
Sexuality	HNSX	28.1	(34.6)	0	[0-50]
Teeth	HNTE	24.9	(34.7)	0	[0-33.3]
Opening mouth	HNOM	18.0	(29.9)	0	[0-33.3]
Dry mouth	HNDR	31.6	(35.5)	33.3	[0-66.7]
Sticky saliva	HNSS	23.2	(32.4)	0	[0-33.3]
Coughed	HNCO	27.4	(31.2)	33.3	[0-33.3]
Felt ill	HNFI	18.5	(26.8)	0	[0-33.3]
Pain killers	HNPk	52.4	(50)	100	[0-100]
Nutritional supp	HNNU	24.3	(42.9)	0	[0-0]
Feeding tube	HNFE	11.4	(31.8)	0	[0-0]
Weight loss	HNWL	35.1	(47.8)	0	[0-100]
Weight gain	HNWG	20.8	(40.7)	0	[0-0]

**Head and neck module: females  
Constructed scales**

<b>HNSA</b>	N	(%)
0	83	19
8.3	54	13
16.7	65	15
25	53	12
33.3	62	15
41.7	26	6
50	16	4
58.3	25	6
66.7	13	3
75	13	3
83.3	7	2
91.7	5	1
100	7	2
Total	429	

<b>HNSO</b>	N	(%)
0	165	40
8.3	51	12
16.7	49	12
25	29	7
33.3	44	11
41.7	20	5
50	14	3
58.3	9	2
66.7	6	1
75	10	2
83.3	7	2
91.7	3	1
100	9	2
Total	416	

<b>HNSW</b>	N	(%)
0	171	40
8.3	48	11
16.7	40	10
25	27	6
33.3	41	10
41.7	21	5
50	16	4
58.3	16	4
66.7	14	3
75	10	2
83.3	7	2
91.7	2	1
100	10	2
Total	423	0

<b>HNSC</b>	N	(%)
0	223	54
6.7	58	14
13.3	28	7
20	18	4
26.7	15	4
33.3	29	7
40	15	4
46.7	10	2
53.3	1	0
60	4	1
66.7	0	0
73.3	3	1
80	4	1
86.7	3	1
93.3	1	0
100	0	0
Total	412	

<b>HNSE</b>	N	(%)
0	276	65
16.7	35	8
33.3	52	12
50	26	6
66.7	16	4
83.3	7	2
100	16	4
Total	428	

<b>HNSX</b>	N	(%)
0	164	51
16.7	12	4
33.3	58	18
50	16	5
66.7	36	11
83.3	2	1
100	36	11
Total	324	

<b>HNSP</b>	N	(%)
0	156	37
11.1	81	19
22.2	48	11
33.3	42	10
44.4	29	7
55.6	19	5
66.7	19	5
77.8	14	3
88.9	3	1
100	12	3
Total	423	

**Head and neck module: females**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Pain in mouth	HNPA	187	43	140	32	64	15	44	10	435
2) Pain in jaw	HNPA	244	56	123	28	38	9	29	7	434
3) Soreness in mouth	HNPA	178	41	144	33	69	16	44	10	435
4) Painful throat	HNPA	207	48	128	30	63	15	33	8	431
5) Problems swallowing liquids	HNSW	269	62	89	21	41	9	35	8	434
6) Problems swallowing pureed food	HNSW	284	66	81	19	35	8	29	7	429
7) Problems swallowing solid food	HNSW	199	46	103	24	54	13	75	17	431
8) Choked when swallowing	HNSW	306	71	88	20	20	5	17	4	431
9) Problems with teeth	HNTE	248	59	76	18	50	12	46	11	420
10) Problems opening mouth wide	HNOM	288	67	86	20	27	6	31	7	432
11) Dry mouth	HNDR	202	47	104	24	72	17	54	13	432
12) Sticky saliva	HNSS	251	58	97	23	46	11	37	9	431
13) Sense of smell	HNSE	337	78	46	11	19	4	28	7	430
14) Sense of taste	HNSE	289	67	70	16	43	10	31	7	433
15) Coughed	HNSO	202	46	143	33	57	13	34	8	436
16) Been hoarse	HNSP	231	54	91	21	52	12	54	13	428
17) Felt ill	HNFI	262	60	120	28	35	8	17	4	434
18) Appearance bothered you	HNSC	290	68	78	18	33	8	28	7	429
19) Trouble eating	HNSO	199	46	112	26	61	14	57	13	429
20) Eating in front of family	HNSO	331	78	61	14	19	5	12	3	423
21) Eating in front of other people	HNSO	298	70	71	17	27	6	28	7	424
22) Trouble enjoying meals	HNSO	240	56	93	22	50	12	43	10	426
23) Trouble talking to people	HNSP	273	63	95	22	35	8	29	7	432
24) Trouble talking on telephone	HNSP	268	62	78	18	48	11	38	9	432
25) Social contact with family	HNSC	350	81	58	13	18	4	6	1	432
26) Social contact with friends	HNSC	339	78	69	16	16	4	9	2	433
27) Trouble going out in public	HNSC	319	74	66	15	33	8	16	4	434
28) Trouble with physical contact	HNSC	346	82	54	13	11	3	9	2	420
29) Less interest in sex	HNSX	172	51	66	20	55	16	43	13	336
30) Less sexual enjoyment	HNSX	177	55	69	21	41	13	37	11	324
				<b>No</b>	<b>Yes</b>	<b>Total</b>				
				N	N	N				
				(%)	(%)					
31) Used pain-killers	HNPKE	200	48	220	52	420				
32) Taken nutritional supplements	HNNU	324	76	104	24	428				
33) Used feeding tube	HNFE	380	89	49	11	429				
34) Lost weight	HNWL	274	65	148	35	422				
35) Gained weight	HNWG	323	79	85	21	408				

## Head and neck module: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	8	1
v +3	113	19
v 2.0	116	20
v 3.0	353	60
Total	590	

#### Age

	N	(%)
<40	110	19
40-49	480	81
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	590	

#### Gender

	N	(%)
Male	462	78
Female	123	21
Not known	5	1
Total	590	

#### Stage

	N	(%)
Stage I-II	122	21
Stage III-IV	391	66
Recurrent/metastatic	4	1
Not known	73	12
Total	590	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	27.9	(24)	25	[8.3-41.7]
Swallowing	HNSW	25.6	(25.2)	16.7	[0-41.7]
Senses	HNSE	15.0	(25.4)	0	[0-16.7]
Speech	HNSP	22.9	(25.1)	11.1	[0-33.3]
Social eating	HNSO	21.4	(24.6)	16.7	[0-33.3]
Social contact	HNSC	11.4	(16.9)	6.7	[0-13.3]
Sexuality	HNSX	24.2	(31.4)	0	[0-33.3]
Teeth	HNTE	24.6	(32.5)	0	[0-33.3]
Opening mouth	HNOM	23.5	(31.4)	0	[0-33.3]
Dry mouth	HNDR	25.5	(31.7)	0	[0-33.3]
Sticky saliva	HNSS	29.2	(34.1)	33.3	[0-66.7]
Coughed	HNCO	32.1	(29.6)	33.3	[0-33.3]
Felt ill	HNFI	19.9	(26.5)	0	[0-33.3]
Pain killers	HNPK	46.0	(49.9)	0	[0-100]
Nutritional supp	HNNU	21.9	(41.4)	0	[0-0]
Feeding tube	HNFE	12.7	(33.4)	0	[0-0]
Weight loss	HNWL	34.8	(47.7)	0	[0-100]
Weight gain	HNWG	26.9	(44.4)	0	[0-100]

**Head and neck module: <50  
Constructed scales**

<b>HNSA</b>	N	(%)
0	60	15
8.3	66	16
16.7	75	18
25	50	12
33.3	47	11
41.7	35	9
50	14	3
58.3	18	4
66.7	20	5
75	12	3
83.3	3	1
91.7	8	2
100	5	1
Total	413	

<b>HNSO</b>	N	(%)
0	139	34
8.3	60	15
16.7	51	12
25	41	10
33.3	44	11
41.7	20	5
50	12	3
58.3	8	2
66.7	10	2
75	11	3
83.3	8	2
91.7	4	1
100	6	1
Total	414	

<b>HNSW</b>	N	(%)
0	116	28
8.3	48	12
16.7	48	12
25	37	9
33.3	50	12
41.7	24	6
50	20	5
58.3	22	5
66.7	13	3
75	15	4
83.3	11	3
91.7	3	1
100	2	1
Total	409	0

<b>HNSC</b>	N	(%)
0	203	49
6.7	62	15
13.3	47	11
20	26	6
26.7	20	5
33.3	17	4
40	9	2
46.7	8	2
53.3	9	2
60	4	1
66.7	4	1
73.3	0	0
80	3	1
86.7	1	0
93.3	0	0
100	0	0
Total	413	

<b>HNSE</b>	N	(%)
0	266	64
16.7	45	11
33.3	47	11
50	24	6
66.7	11	3
83.3	8	2
100	13	3
Total	414	

<b>HNSX</b>	N	(%)
0	203	52
16.7	33	8
33.3	70	18
50	15	4
66.7	41	10
83.3	3	1
100	29	7
Total	394	

<b>HNSP</b>	N	(%)
0	125	31
11.1	92	22
22.2	68	17
33.3	38	9
44.4	24	6
55.6	17	4
66.7	22	5
77.8	9	2
88.9	8	2
100	7	2
Total	410	





## Head and neck module: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	8	1
v +3	219	24
v 2.0	185	20
v 3.0	507	55
Total	919	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	919	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	919	

#### Gender

	N	(%)
Male	736	80
Female	176	19
Not known	7	1
Total	919	

#### Stage

	N	(%)
Stage I-II	247	27
Stage III-IV	599	65
Recurrent/metastatic	9	1
Not known	64	7
Total	919	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	27.0	(23.9)	25	[8.3-41.7]
Swallowing	HNSW	24.2	(25.5)	16.7	[0-41.7]
Senses	HNSE	18.1	(27.8)	0	[0-33.3]
Speech	HNSP	25.6	(26.8)	22.2	[0-44.4]
Social eating	HNSO	20.8	(26)	8.3	[0-33.3]
Social contact	HNSC	11.7	(18.1)	0	[0-13.3]
Sexuality	HNSX	28.4	(34.4)	16.7	[0-50]
Teeth	HNTE	24.2	(33)	0	[0-33.3]
Opening mouth	HNOM	19.2	(31.1)	0	[0-33.3]
Dry mouth	HNDR	27.5	(33.1)	33.3	[0-33.3]
Sticky saliva	HNSS	29.5	(34.3)	33.3	[0-66.7]
Coughed	HNCO	31.9	(30.7)	33.3	[0-33.3]
Felt ill	HNFI	21.2	(29.7)	0	[0-33.3]
Pain killers	HNPK	50.3	(50)	100	[0-100]
Nutritional supp	HNNU	24.6	(43.1)	0	[0-0]
Feeding tube	HNFE	15.5	(36.3)	0	[0-0]
Weight loss	HNWL	36.2	(48.1)	0	[0-100]
Weight gain	HNWG	24.1	(42.8)	0	[0-0]

**Head and neck module: 50-59**  
**Constructed scales**

<b>HNPA</b>	<b>N</b>	<b>(%)</b>
0	130	19
8.3	110	16
16.7	94	14
25	85	12
33.3	94	14
41.7	38	6
50	46	7
58.3	30	4
66.7	24	3
75	18	3
83.3	13	2
91.7	5	1
100	9	1
<b>Total</b>	<b>696</b>	

<b>HNSO</b>	<b>N</b>	<b>(%)</b>
0	278	40
8.3	98	14
16.7	63	9
25	43	6
33.3	75	11
41.7	29	4
50	30	4
58.3	16	2
66.7	12	2
75	20	3
83.3	12	2
91.7	6	1
100	16	2
<b>Total</b>	<b>698</b>	

<b>HNSW</b>	<b>N</b>	<b>(%)</b>
0	241	34
8.3	75	11
16.7	54	8
25	72	10
33.3	72	10
41.7	43	6
50	38	5
58.3	33	5
66.7	23	3
75	32	5
83.3	7	1
91.7	2	0
100	9	1
<b>Total</b>	<b>701</b>	<b>0</b>

<b>HNSC</b>	<b>N</b>	<b>(%)</b>
0	359	53
6.7	96	14
13.3	61	9
20	24	4
26.7	28	4
33.3	49	7
40	19	3
46.7	12	2
53.3	10	2
60	8	1
66.7	6	1
73.3	4	1
80	4	1
86.7	3	0
93.3	1	0
100	0	0
<b>Total</b>	<b>684</b>	

<b>HNSE</b>	<b>N</b>	<b>(%)</b>
0	419	60
16.7	82	12
33.3	77	11
50	40	6
66.7	38	5
83.3	22	3
100	24	3
<b>Total</b>	<b>702</b>	

<b>HNSX</b>	<b>N</b>	<b>(%)</b>
0	312	49
16.7	33	5
33.3	109	17
50	28	4
66.7	74	12
83.3	10	2
100	66	10
<b>Total</b>	<b>632</b>	

<b>HNSP</b>	<b>N</b>	<b>(%)</b>
0	222	32
11.1	118	17
22.2	83	12
33.3	80	12
44.4	55	8
55.6	40	6
66.7	38	6
77.8	31	5
88.9	8	1
100	15	2
<b>Total</b>	<b>690</b>	



## Head and neck module: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	3	0
v +3	161	19
v 2.0	138	17
v 3.0	530	64
Total	832	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	832	100
70-79	0	0
80+	0	0
Not known	0	0
Total	832	

#### Gender

	N	(%)
Male	682	82
Female	143	17
Not known	7	1
Total	832	

#### Stage

	N	(%)
Stage I-II	327	39
Stage III-IV	437	53
Recurrent/metastatic	12	1
Not known	56	7
Total	832	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	25.8	(23.7)	25	[8.3-41.7]
Swallowing	HNSW	23.6	(26.1)	16.7	[0-41.7]
Senses	HNSE	21.3	(30.4)	0	[0-33.3]
Speech	HNSP	31.1	(28.4)	22.2	[11.1-44.4]
Social eating	HNSO	21.3	(26.2)	8.3	[0-33.3]
Social contact	HNCS	14.9	(20.7)	6.7	[0-33.3]
Sexuality	HNSX	34.2	(35.3)	33.3	[0-66.7]
Teeth	HNTE	26.6	(34.3)	0	[0-33.3]
Opening mouth	HNOM	18.2	(27.9)	0	[0-33.3]
Dry mouth	HNDR	33.1	(34.1)	33.3	[0-66.7]
Sticky saliva	HNSS	30.5	(33.2)	33.3	[0-66.7]
Coughed	HNCO	36.0	(34)	33.3	[0-66.7]
Felt ill	HNFI	22.8	(29.9)	0	[0-33.3]
Pain killers	HNPK	48.2	(50)	0	[0-100]
Nutritional supp	HNNU	28.9	(45.4)	0	[0-100]
Feeding tube	HNFE	25.1	(43.4)	0	[0-100]
Weight loss	HNWL	40.9	(49.2)	0	[0-100]
Weight gain	HNWG	29.8	(45.8)	0	[0-100]

**Head and neck module: 60-69**  
**Constructed scales**

<b>HNPA</b>	<b>N</b>	<b>(%)</b>
0	143	22
8.3	101	16
16.7	72	11
25	61	10
33.3	104	16
41.7	35	5
50	49	8
58.3	21	3
66.7	18	3
75	16	3
83.3	12	2
91.7	6	1
100	5	1
<b>Total</b>	<b>643</b>	

<b>HNSO</b>	<b>N</b>	<b>(%)</b>
0	269	42
8.3	56	9
16.7	60	9
25	31	5
33.3	97	15
41.7	27	4
50	29	5
58.3	16	3
66.7	11	2
75	8	1
83.3	8	1
91.7	9	1
100	18	3
<b>Total</b>	<b>639</b>	

<b>HNSW</b>	<b>N</b>	<b>(%)</b>
0	244	38
8.3	62	10
16.7	44	7
25	37	6
33.3	84	13
41.7	38	6
50	47	7
58.3	23	4
66.7	15	2
75	17	3
83.3	10	2
91.7	9	1
100	9	1
<b>Total</b>	<b>639</b>	<b>0</b>

<b>HNSC</b>	<b>N</b>	<b>(%)</b>
0	313	50
6.7	68	11
13.3	36	6
20	30	5
26.7	18	3
33.3	81	13
40	23	4
46.7	19	3
53.3	9	1
60	7	1
66.7	6	1
73.3	6	1
80	6	1
86.7	5	1
93.3	0	0
100	2	0
<b>Total</b>	<b>629</b>	

<b>HNSE</b>	<b>N</b>	<b>(%)</b>
0	375	58
16.7	40	6
33.3	94	15
50	37	6
66.7	46	7
83.3	18	3
100	35	5
<b>Total</b>	<b>645</b>	

<b>HNSX</b>	<b>N</b>	<b>(%)</b>
0	233	40
16.7	32	6
33.3	113	20
50	33	6
66.7	81	14
83.3	18	3
100	70	12
<b>Total</b>	<b>580</b>	

<b>HNSP</b>	<b>N</b>	<b>(%)</b>
0	154	24
11.1	110	17
22.2	66	10
33.3	89	14
44.4	61	10
55.6	49	8
66.7	38	6
77.8	35	6
88.9	18	3
100	19	3
<b>Total</b>	<b>639</b>	

**Head and neck module: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Pain in mouth	HNPA	308	47	227	35	76	12	42	6	653
2) Pain in jaw	HNPA	366	56	198	31	51	8	35	5	650
3) Soreness in mouth	HNPA	303	47	241	37	78	12	29	5	651
4) Painful throat	HNPA	239	37	255	39	88	14	66	10	648
5) Problems swallowing liquids	HNSW	351	54	188	29	66	10	47	7	652
6) Problems swallowing pureed food	HNSW	383	59	176	27	54	8	34	5	647
7) Problems swallowing solid food	HNSW	291	45	166	26	86	13	107	17	650
8) Choked when swallowing	HNSW	414	64	160	25	42	7	32	5	648
9) Problems with teeth	HNTE	339	53	160	25	63	10	74	12	636
10) Problems opening mouth wide	HNOM	407	63	164	25	42	7	35	5	648
11) Dry mouth	HNDR	268	41	194	30	113	17	75	12	650
12) Sticky saliva	HNSS	289	45	190	29	108	17	63	10	650
13) Sense of smell	HNSE	433	67	96	15	43	7	78	12	650
14) Sense of taste	HNSE	398	61	136	21	65	10	50	8	649
15) Coughed	HNCO	226	35	229	35	106	16	86	13	647
16) Been hoarse	HNPS	202	31	214	33	116	18	112	17	644
17) Felt ill	HNFI	355	54	192	29	62	10	43	7	652
18) Appearance bothered you	HNSC	413	64	160	25	44	7	33	5	650
19) Trouble eating	HNSO	308	47	188	29	85	13	71	11	652
20) Eating in front of family	HNSO	449	69	140	22	33	5	25	4	647
21) Eating in front of other people	HNSO	409	63	139	22	48	7	50	8	646
22) Trouble enjoying meals	HNSO	358	55	189	29	49	8	53	8	649
23) Trouble talking to people	HNPS	359	55	164	25	72	11	57	9	652
24) Trouble talking on telephone	HNPS	330	51	152	23	93	14	76	12	651
25) Social contact with family	HNSC	454	70	158	24	32	5	8	1	652
26) Social contact with friends	HNSC	435	67	156	24	47	7	15	2	653
27) Trouble going out in public	HNSC	444	68	140	21	44	7	28	4	656
28) Trouble with physical contact	HNSC	452	71	136	21	31	5	20	3	639
29) Less interest in sex	HNSX	252	43	143	24	109	18	88	15	592
30) Less sexual enjoyment	HNSX	265	46	135	23	95	16	86	15	581
		<b>No</b>		<b>Yes</b>		<b>Total</b>				
		N	(%)	N	(%)	N				
31) Used pain-killers	HNPKE	320	52	298	48	618				
32) Taken nutritional supplements	HNNNU	453	71	184	29	637				
33) Used feeding tube	HNFE	484	75	162	25	646				
34) Lost weight	HNWL	367	59	254	41	621				
35) Gained weight	HNWG	425	70	180	30	605				

## Head and neck module: $\geq 70$

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	4	1
v +3	194	33
v 2.0	50	9
v 3.0	338	58
Total	586	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	489	83
80+	97	17
Not known	0	0
Total	586	

#### Gender

	N	(%)
Male	436	74
Female	147	25
Not known	3	1
Total	586	

#### Stage

	N	(%)
Stage I-II	250	43
Stage III-IV	294	50
Recurrent/metastatic	12	2
Not known	30	5
Total	586	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	28.2	(24.6)	25	[8.3-41.7]
Swallowing	HNSW	22.5	(23.8)	16.7	[0-33.3]
Senses	HNSE	22.1	(30)	0	[0-33.3]
Speech	HNSP	31.5	(28.7)	22.2	[11.1-55.6]
Social eating	HNSO	20.1	(22.6)	8.3	[0-33.3]
Social contact	HNSC	13.7	(18.8)	0	[0-33.3]
Sexuality	HNSX	39.1	(37.8)	33.3	[0-66.7]
Teeth	HNTE	26.7	(32.7)	0	[0-33.3]
Opening mouth	HNOM	18.4	(27.1)	0	[0-33.3]
Dry mouth	HNDR	36.7	(33.4)	33.3	[0-66.7]
Sticky saliva	HNSS	33.3	(34.1)	33.3	[0-66.7]
Coughed	HNCO	35.4	(33.8)	33.3	[0-66.7]
Felt ill	HNFI	21.9	(28.2)	0	[0-33.3]
Pain killers	HNPK	53.2	(49.9)	100	[0-100]
Nutritional supp	HNNU	30.7	(46.2)	0	[0-100]
Feeding tube	HNFE	24.3	(42.9)	0	[0-0]
Weight loss	HNWL	43.6	(49.6)	0	[0-100]
Weight gain	HNWG	29.2	(45.5)	0	[0-100]



**Head and neck module:  $\geq 70$   
Constructed scales**

<b>HNPA</b>	<b>N</b>	<b>(%)</b>
0	105	21
8.3	64	13
16.7	55	11
25	36	7
33.3	93	19
41.7	35	7
50	25	5
58.3	23	5
66.7	29	6
75	8	2
83.3	11	2
91.7	4	1
100	6	1
Total	494	

<b>HNSO</b>	<b>N</b>	<b>(%)</b>
0	179	37
8.3	61	13
16.7	48	10
25	21	4
33.3	82	17
41.7	27	6
50	20	4
58.3	12	3
66.7	9	2
75	6	1
83.3	7	2
91.7	3	1
100	3	1
Total	478	

<b>HNSW</b>	<b>N</b>	<b>(%)</b>
0	160	33
8.3	65	13
16.7	46	10
25	28	6
33.3	79	16
41.7	30	6
50	24	5
58.3	13	3
66.7	12	3
75	17	4
83.3	3	1
91.7	1	0
100	6	1
Total	484	0

<b>HNSC</b>	<b>N</b>	<b>(%)</b>
0	239	51
6.7	48	10
13.3	32	7
20	16	3
26.7	12	3
33.3	71	15
40	16	3
46.7	12	3
53.3	4	1
60	3	1
66.7	6	1
73.3	3	1
80	4	1
86.7	0	0
93.3	1	0
100	0	0
Total	467	

<b>HNSE</b>	<b>N</b>	<b>(%)</b>
0	264	53
16.7	45	9
33.3	82	17
50	41	8
66.7	22	4
83.3	9	2
100	32	7
Total	495	

<b>HNSX</b>	<b>N</b>	<b>(%)</b>
0	133	36
16.7	15	4
33.3	84	23
50	14	4
66.7	44	12
83.3	9	2
100	70	19
Total	369	

<b>HNSP</b>	<b>N</b>	<b>(%)</b>
0	115	24
11.1	81	17
22.2	62	13
33.3	52	11
44.4	48	10
55.6	32	7
66.7	31	6
77.8	35	7
88.9	13	3
100	13	3
Total	482	



## Head and neck module: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	5	1
v +3	291	31
v 2.0	16	2
v 3.0	634	67
Total	946	

#### Age

	N	(%)
<40	32	3
40-49	90	10
50-59	247	26
60-69	327	35
70-79	208	22
80+	42	4
Not known	0	0
Total	946	

#### Gender

	N	(%)
Male	751	79
Female	195	21
Not known	0	0
Total	946	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	21.6	(21)	16.7	[0-33.3]
Swallowing	HNSW	16.8	(22)	8.3	[0-33.3]
Senses	HNSE	16.2	(24.6)	0	[0-33.3]
Speech	HNSP	28.8	(28.1)	22.2	[0-44.4]
Social eating	HNSO	15.0	(20.7)	0	[0-33.3]
Social contact	HNSC	11.9	(17.8)	0	[0-20]
Sexuality	HNSX	28.4	(32.9)	16.7	[0-50]
Teeth	HNTE	20.7	(29.1)	0	[0-33.3]
Opening mouth	HNOM	13.7	(23.6)	0	[0-33.3]
Dry mouth	HNDR	29.7	(32.4)	33.3	[0-33.3]
Sticky saliva	HNSS	26.5	(30.7)	33.3	[0-33.3]
Coughed	HNSO	31.1	(31.7)	33.3	[0-33.3]
Felt ill	HNFI	20.2	(27.6)	0	[0-33.3]
Pain killers	HNPK	41.8	(49.4)	0	[0-100]
Nutritional supp	HNNU	24.1	(42.8)	0	[0-0]
Feeding tube	HNFE	20.3	(40.3)	0	[0-0]
Weight loss	HNWL	33.1	(47.1)	0	[0-100]
Weight gain	HNWG	28.6	(45.2)	0	[0-100]

**Head and neck module: stage I-II  
Constructed scales**

<b>HNPA</b>	<b>N</b>	<b>(%)</b>
0	206	26
8.3	130	17
16.7	106	14
25	69	9
33.3	130	17
41.7	39	5
50	38	5
58.3	20	3
66.7	20	3
75	11	1
83.3	8	1
91.7	1	0
100	4	1
<b>Total</b>	<b>782</b>	

<b>HNSO</b>	<b>N</b>	<b>(%)</b>
0	394	50
8.3	90	12
16.7	48	6
25	39	5
33.3	126	16
41.7	30	4
50	15	2
58.3	9	1
66.7	5	1
75	10	1
83.3	6	1
91.7	2	0
100	7	1
<b>Total</b>	<b>781</b>	

<b>HNSW</b>	<b>N</b>	<b>(%)</b>
0	383	49
8.3	74	10
16.7	44	6
25	45	6
33.3	107	14
41.7	33	4
50	35	5
58.3	20	3
66.7	11	1
75	12	2
83.3	6	1
91.7	1	0
100	5	1
<b>Total</b>	<b>776</b>	<b>0</b>

<b>HNSC</b>	<b>N</b>	<b>(%)</b>
0	425	56
6.7	73	10
13.3	53	7
20	27	4
26.7	15	2
33.3	89	12
40	26	3
46.7	25	3
53.3	10	1
60	4	1
66.7	3	0
73.3	5	1
80	1	0
86.7	4	1
93.3	0	0
100	0	0
<b>Total</b>	<b>760</b>	

<b>HNSE</b>	<b>N</b>	<b>(%)</b>
0	473	61
16.7	71	9
33.3	135	17
50	36	5
66.7	37	5
83.3	15	2
100	15	2
<b>Total</b>	<b>782</b>	

<b>HNSX</b>	<b>N</b>	<b>(%)</b>
0	311	46
16.7	40	6
33.3	145	21
50	32	5
66.7	81	12
83.3	7	1
100	62	9
<b>Total</b>	<b>678</b>	

<b>HNSP</b>	<b>N</b>	<b>(%)</b>
0	225	29
11.1	118	15
22.2	92	12
33.3	93	12
44.4	69	9
55.6	60	8
66.7	43	6
77.8	41	5
88.9	16	2
100	21	3
<b>Total</b>	<b>778</b>	

**Head and neck module: stage I-II  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Pain in mouth	HNPA	399	51	272	35	91	12	27	3	789
2) Pain in jaw	HNPA	499	63	220	28	48	6	20	3	787
3) Soreness in mouth	HNPA	381	48	296	38	83	11	29	4	789
4) Painful throat	HNPA	361	46	289	37	98	13	37	5	785
5) Problems swallowing liquids	HNSW	497	63	208	26	55	7	28	4	788
6) Problems swallowing pureed food	HNSW	532	68	198	25	38	5	19	2	787
7) Problems swallowing solid food	HNSW	432	55	223	28	72	9	58	7	785
8) Choked when swallowing	HNSW	565	72	155	20	47	6	22	3	789
9) Problems with teeth	HNTE	459	59	198	25	81	10	41	5	779
10) Problems opening mouth wide	HNOM	543	69	185	24	36	5	22	3	786
11) Dry mouth	HNDR	349	44	247	31	123	16	70	9	789
12) Sticky saliva	HNSS	376	48	245	31	110	14	53	7	784
13) Sense of smell	HNSE	546	70	151	19	42	5	45	6	784
14) Sense of taste	HNSE	513	65	181	23	62	8	31	4	787
15) Coughed	HNCO	310	39	297	38	108	14	75	10	790
16) Been hoarse	HNSP	297	38	199	25	151	19	137	18	784
17) Felt ill	HNFI	450	57	236	30	65	8	37	5	788
18) Appearance bothered you	HNSC	557	71	162	21	38	5	26	3	783
19) Trouble eating	HNSO	450	57	233	30	63	8	41	5	787
20) Eating in front of family	HNSO	594	76	160	20	17	2	12	2	783
21) Eating in front of other people	HNSO	560	71	162	21	36	5	26	3	784
22) Trouble enjoying meals	HNSO	495	63	220	28	44	6	28	4	787
23) Trouble talking to people	HNSP	445	57	210	27	86	11	46	6	787
24) Trouble talking on telephone	HNSP	417	53	194	25	109	14	67	9	787
25) Social contact with family	HNSC	572	73	181	23	26	3	5	1	784
26) Social contact with friends	HNSC	533	68	204	26	43	6	5	1	785
27) Trouble going out in public	HNSC	564	72	156	20	49	6	18	2	787
28) Trouble with physical contact	HNSC	572	74	162	21	26	3	10	1	770
29) Less interest in sex	HNSX	335	47	182	26	110	16	81	11	708
30) Less sexual enjoyment	HNSX	350	52	164	24	97	14	68	10	679
				<b>No</b>	<b>Yes</b>	<b>Total</b>				
				N	N	N				
				(%)	(%)					
31) Used pain-killers	HNPBK	429	58	308	42	737				
32) Taken nutritional supplements	HNNU	586	76	186	24	772				
33) Used feeding tube	HNFE	620	80	158	20	778				
34) Lost weight	HNWL	509	67	252	33	761				
35) Gained weight	HNWG	521	71	209	29	730				

## Head and neck module: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	17	1
v +3	395	23
v 2.0	381	22
v 3.0	929	54
Total	1,722	

#### Age

	N	(%)
<40	54	3
40-49	337	20
50-59	599	35
60-69	437	25
70-79	243	14
80+	51	3
Not known	1	0
Total	1,722	

#### Gender

	N	(%)
Male	1,401	81
Female	316	18
Not known	5	0
Total	1,722	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	29.9	(25.1)	25	[8.3-41.7]
Swallowing	HNSW	27.5	(26.1)	25	[0-41.7]
Senses	HNSE	20.0	(30)	0	[0-33.3]
Speech	HNSP	27.1	(27.2)	22.2	[0-44.4]
Social eating	HNSO	23.9	(26.7)	16.7	[0-33.3]
Social contact	HNSC	13.2	(19.1)	6.7	[0-20]
Sexuality	HNSX	32.3	(36.1)	16.7	[0-66.7]
Teeth	HNTE	27.8	(35)	0	[0-33.3]
Opening mouth	HNOM	22.4	(31.9)	0	[0-33.3]
Dry mouth	HNDR	31.1	(34.2)	33.3	[0-66.7]
Sticky saliva	HNSS	32.4	(35.4)	33.3	[0-66.7]
Coughed	HNCO	34.9	(32.1)	33.3	[0-66.7]
Felt ill	HNFI	21.7	(29.2)	0	[0-33.3]
Pain killers	HNPK	52.8	(49.9)	100	[0-100]
Nutritional supp	HNNU	27.0	(44.4)	0	[0-100]
Feeding tube	HNFE	18.3	(38.7)	0	[0-0]
Weight loss	HNWL	41.3	(49.2)	0	[0-100]
Weight gain	HNWG	25.9	(43.8)	0	[0-100]

**Head and neck module: stage III-IV  
Constructed scales**

<b>HNPA</b>	<b>N</b>	<b>(%)</b>
0	230	16
8.3	204	14
16.7	186	13
25	162	11
33.3	192	14
41.7	101	7
50	92	7
58.3	68	5
66.7	70	5
75	43	3
83.3	31	2
91.7	21	2
100	20	1
<b>Total</b>	<b>1,420</b>	

<b>HNSO</b>	<b>N</b>	<b>(%)</b>
0	462	33
8.3	183	13
16.7	172	12
25	97	7
33.3	159	11
41.7	69	5
50	70	5
58.3	43	3
66.7	36	3
75	35	3
83.3	26	2
91.7	20	1
100	36	3
<b>Total</b>	<b>1,408</b>	

<b>HNSW</b>	<b>N</b>	<b>(%)</b>
0	372	26
8.3	170	12
16.7	147	10
25	127	9
33.3	164	12
41.7	97	7
50	90	6
58.3	70	5
66.7	51	4
75	67	5
83.3	25	2
91.7	14	1
100	19	1
<b>Total</b>	<b>1,413</b>	<b>0</b>

<b>HNSC</b>	<b>N</b>	<b>(%)</b>
0	676	49
6.7	196	14
13.3	122	9
20	68	5
26.7	62	5
33.3	119	9
40	39	3
46.7	23	2
53.3	23	2
60	17	1
66.7	14	1
73.3	8	1
80	15	1
86.7	5	0
93.3	2	0
100	2	0
<b>Total</b>	<b>1,391</b>	

<b>HNSE</b>	<b>N</b>	<b>(%)</b>
0	841	59
16.7	139	10
33.3	157	11
50	103	7
66.7	71	5
83.3	35	2
100	83	6
<b>Total</b>	<b>1,429</b>	

<b>HNSX</b>	<b>N</b>	<b>(%)</b>
0	561	45
16.7	71	6
33.3	220	18
50	54	4
66.7	154	12
83.3	31	3
100	165	13
<b>Total</b>	<b>1,256</b>	

<b>HNSP</b>	<b>N</b>	<b>(%)</b>
0	386	28
11.1	277	20
22.2	182	13
33.3	159	11
44.4	115	8
55.6	76	5
66.7	86	6
77.8	61	4
88.9	30	2
100	32	2
<b>Total</b>	<b>1,404</b>	

**Head and neck module: stage III-IV  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Pain in mouth	HNPA	626	43	461	32	228	16	130	9	1,445
2) Pain in jaw	HNPA	759	53	418	29	164	11	102	7	1,443
3) Soreness in mouth	HNPA	617	43	476	33	224	16	119	8	1,436
4) Painful throat	HNPA	489	34	525	37	264	18	161	11	1,439
5) Problems swallowing liquids	HNSW	701	49	418	29	201	14	126	9	1,446
6) Problems swallowing pureed food	HNSW	780	54	388	27	165	12	100	7	1,433
7) Problems swallowing solid food	HNSW	477	33	399	28	254	18	312	22	1,442
8) Choked when swallowing	HNSW	929	65	354	25	89	6	62	4	1,434
9) Problems with teeth	HNTE	737	53	320	23	174	13	166	12	1,397
10) Problems opening mouth wide	HNOM	857	60	319	22	147	10	118	8	1,441
11) Dry mouth	HNDR	644	45	418	29	212	15	167	12	1,441
12) Sticky saliva	HNSS	640	45	379	27	225	16	187	13	1,431
13) Sense of smell	HNSE	1,025	71	170	12	84	6	159	11	1,438
14) Sense of taste	HNSE	903	63	277	19	134	9	126	9	1,440
15) Coughed	HNCO	483	34	555	39	252	18	150	10	1,440
16) Been hoarse	HNSP	610	43	427	30	205	15	175	12	1,417
17) Felt ill	HNFI	806	56	415	29	136	9	84	6	1,441
18) Appearance bothered you	HNSC	935	65	332	23	121	8	53	4	1,441
19) Trouble eating	HNSO	559	39	427	30	254	18	200	14	1,440
20) Eating in front of family	HNSO	1,038	73	255	18	77	5	60	4	1,430
21) Eating in front of other people	HNSO	914	64	283	20	116	8	116	8	1,429
22) Trouble enjoying meals	HNSO	729	51	369	26	191	13	145	10	1,434
23) Trouble talking to people	HNSP	825	57	343	24	159	11	114	8	1,441
24) Trouble talking on telephone	HNSP	775	54	311	22	179	12	173	12	1,438
25) Social contact with family	HNSC	1,072	75	268	19	68	5	29	2	1,437
26) Social contact with friends	HNSC	1,030	72	289	20	82	6	40	3	1,441
27) Trouble going out in public	HNSC	1,037	72	267	19	87	6	53	4	1,444
28) Trouble with physical contact	HNSC	1,083	77	235	17	63	5	34	2	1,415
29) Less interest in sex	HNSX	595	46	298	23	206	16	189	15	1,288
30) Less sexual enjoyment	HNSX	627	50	256	20	178	14	198	16	1,259
				<b>No</b>	<b>Yes</b>	<b>Total</b>				
				N	N	N				
				(%)	(%)					
31) Used pain-killers	HNPBK	660	47	739	53	1,399				
32) Taken nutritional supplements	HNNU	1,043	73	385	27	1,428				
33) Used feeding tube	HNFE	1,168	82	261	18	1,429				
34) Lost weight	HNWL	820	59	576	41	1,396				
35) Gained weight	HNWG	1,018	74	355	26	1,373				



## Head and neck module:hypopharynx/larynx

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	5	1
v +3	150	34
v 2.0	0	0
v 3.0	281	64
Total	436	

#### Age

	N	(%)
<40	7	2
40-49	45	10
50-59	113	26
60-69	149	34
70-79	103	24
80+	19	4
Not known	0	0
Total	436	

#### Gender

	N	(%)
Male	387	89
Female	49	11
Not known	0	0
Total	436	

#### Stage

	N	(%)
Stage I-II	222	51
Stage III-IV	210	48
Recurrent/metastatic	0	0
Not known	4	1
Total	436	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	35.3	(21)	33.3	[25-50]
Swallowing	HNSW	36.7	(24.2)	33.3	[25-50]
Senses	HNSE	38.7	(33.7)	33.3	[0-66.7]
Speech	HNSP	50.0	(25.5)	44.4	[33.3-66.7]
Social eating	HNSO	32.4	(24.9)	33.3	[8.3-41.7]
Social contact	HNSC	28.3	(22.1)	33.3	[6.7-40]
Sexuality	HNSX	46.8	(35.2)	33.3	[33.3-66.7]
Teeth	HNTE	36.5	(31.4)	33.3	[0-66.7]
Opening mouth	HNOM	30.5	(28.6)	33.3	[0-33.3]
Dry mouth	HNDR	44.1	(33.5)	33.3	[33.3-66.7]
Sticky saliva	HNSS	45.0	(33.9)	33.3	[33.3-66.7]
Coughed	HNCO	54.8	(35.3)	66.7	[33.3-100]
Felt ill	HNFI	40.9	(31.3)	33.3	[33.3-66.7]
Pain killers	HNPk	71.5	(45.2)	100	[0-100]
Nutritional supp	HNNU	61.0	(48.8)	100	[0-100]
Feeding tube	HNFE	58.0	(49.4)	100	[0-100]
Weight loss	HNWL	67.1	(47)	100	[0-100]
Weight gain	HNWG	58.0	(49.4)	100	[0-100]

**Head and neck module:hypopharynx/larynx  
Constructed scales**

<b>HNPA</b>	<b>N</b>	<b>(%)</b>
0	33	8
8.3	32	8
16.7	31	8
25	28	7
33.3	146	35
41.7	38	9
50	41	10
58.3	17	4
66.7	18	4
75	13	3
83.3	11	3
91.7	4	1
100	2	1
<b>Total</b>	<b>414</b>	

<b>HNSO</b>	<b>N</b>	<b>(%)</b>
0	84	20
8.3	29	7
16.7	11	3
25	15	4
33.3	159	38
41.7	24	6
50	29	7
58.3	15	4
66.7	15	4
75	9	2
83.3	10	2
91.7	6	1
100	10	2
<b>Total</b>	<b>416</b>	

<b>HNSW</b>	<b>N</b>	<b>(%)</b>
0	64	15
8.3	16	4
16.7	18	4
25	13	3
33.3	136	33
41.7	44	11
50	41	10
58.3	23	6
66.7	23	6
75	12	3
83.3	12	3
91.7	3	1
100	10	2
<b>Total</b>	<b>415</b>	<b>0</b>

<b>HNSC</b>	<b>N</b>	<b>(%)</b>
0	101	25
6.7	18	4
13.3	20	5
20	12	3
26.7	3	1
33.3	138	34
40	35	9
46.7	29	7
53.3	13	3
60	8	2
66.7	11	3
73.3	9	2
80	5	1
86.7	5	1
93.3	1	0
100	0	0
<b>Total</b>	<b>408</b>	

<b>HNSE</b>	<b>N</b>	<b>(%)</b>
0	125	30
16.7	16	4
33.3	119	29
50	32	8
66.7	51	12
83.3	26	6
100	47	11
<b>Total</b>	<b>416</b>	

<b>HNSX</b>	<b>N</b>	<b>(%)</b>
0	87	23
16.7	5	1
33.3	121	32
50	16	4
66.7	66	17
83.3	14	4
100	75	20
<b>Total</b>	<b>384</b>	

<b>HNSP</b>	<b>N</b>	<b>(%)</b>
0	17	4
11.1	19	5
22.2	36	9
33.3	82	20
44.4	58	15
55.6	56	14
66.7	39	10
77.8	53	13
88.9	19	5
100	22	6
<b>Total</b>	<b>401</b>	

**Head and neck module:hypopharynx/larynx  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Pain in mouth	HNPA	110	26	233	56	50	12	25	6	418
2) Pain in jaw	HNPA	115	28	233	56	47	11	23	6	418
3) Soreness in mouth	HNPA	94	23	251	60	53	13	19	5	417
4) Painful throat	HNPA	57	14	220	53	85	20	56	13	418
5) Problems swallowing liquids	HNSW	85	20	243	58	52	12	39	9	419
6) Problems swallowing pureed food	HNSW	104	25	239	57	46	11	30	7	419
7) Problems swallowing solid food	HNSW	79	19	198	47	68	16	73	18	418
8) Choked when swallowing	HNSW	130	31	201	48	50	12	35	8	416
9) Problems with teeth	HNTE	116	28	193	47	56	14	50	12	415
10) Problems opening mouth wide	HNOM	140	34	207	50	38	9	33	8	418
11) Dry mouth	HNDR	95	23	162	39	90	22	70	17	417
12) Sticky saliva	HNSS	88	21	171	41	77	19	78	19	414
13) Sense of smell	HNSE	143	34	131	31	37	9	106	25	417
14) Sense of taste	HNSE	139	33	167	40	52	12	60	14	418
15) Coughed	HNSO	68	16	131	31	102	24	118	28	419
16) Been hoarse	HNSP	32	8	150	37	101	25	121	30	404
17) Felt ill	HNFI	91	22	199	48	72	17	57	14	419
18) Appearance bothered you	HNSC	139	33	200	48	51	12	27	7	417
19) Trouble eating	HNSO	100	24	205	49	53	13	60	14	418
20) Eating in front of family	HNSO	148	35	231	55	23	6	16	4	418
21) Eating in front of other people	HNSO	139	33	205	49	34	8	40	10	418
22) Trouble enjoying meals	HNSO	117	28	223	53	40	10	39	9	419
23) Trouble talking to people	HNSP	97	23	180	43	70	17	70	17	417
24) Trouble talking on telephone	HNSP	78	19	147	35	96	23	95	23	416
25) Social contact with family	HNSC	147	35	229	55	32	8	7	2	415
26) Social contact with friends	HNSC	141	34	213	51	51	12	12	3	417
27) Trouble going out in public	HNSC	140	33	197	47	51	12	31	7	419
28) Trouble with physical contact	HNSC	150	36	211	51	36	9	16	4	413
29) Less interest in sex	HNSX	91	23	137	35	79	20	86	22	393
30) Less sexual enjoyment	HNSX	92	24	132	34	72	19	89	23	385
		<b>No</b>		<b>Yes</b>		<b>Total</b>				
		N	(%)	N	(%)	N				
31) Used pain-killers	HNPk	100	29	251	72	351				
32) Taken nutritional supplements	HNNu	157	39	246	61	403				
33) Used feeding tube	HNFE	169	42	233	58	402				
34) Lost weight	HNWL	123	33	251	67	374				
35) Gained weight	HNWG	144	42	199	58	343				

## Head and neck module:oral cavity/oropharynx

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	14	5
v +3	244	90
v 2.0	0	0
v 3.0	14	5
Total	272	

#### Age

	N	(%)
<40	10	4
40-49	40	15
50-59	95	35
60-69	46	17
70-79	59	22
80+	21	8
Not known	1	0
Total	272	

#### Gender

	N	(%)
Male	182	67
Female	90	33
Not known	0	0
Total	272	

#### Stage

	N	(%)
Stage I-II	45	17
Stage III-IV	224	82
Recurrent/metastatic	3	1
Not known	0	0
Total	272	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Pain	HNPA	36.9	(25.5)	33.3	[16.7-58.3]
Swallowing	HNSW	20.5	(25.1)	8.3	[0-33.3]
Senses	HNSE	10.8	(20.6)	0	[0-16.7]
Speech	HNSP	13.9	(20.5)	0	[0-22.2]
Social eating	HNSO	18.0	(21)	8.3	[0-25]
Social contact	HNSC	7.6	(14.2)	0	[0-13.3]
Sexuality	HNSX	27.8	(36)	0	[0-50]
Teeth	HNTE	32.2	(35.6)	33.3	[0-66.7]
Opening mouth	HNOM	17.9	(30.8)	0	[0-33.3]
Dry mouth	HNDR	22.0	(29.2)	0	[0-33.3]
Sticky saliva	HNSS	21.2	(30.9)	0	[0-33.3]
Coughed	HNCO	19.6	(26.6)	0	[0-33.3]
Felt ill	HNFI	18.0	(26.6)	0	[0-33.3]
Pain killers	HNPCK	50.7	(50.1)	100	[0-100]
Nutritional supp	HNNU	14.9	(35.6)	0	[0-0]
Feeding tube	HNFE	4.0	(19.6)	0	[0-0]
Weight loss	HNWL	37.0	(48.4)	0	[0-100]
Weight gain	HNWG	9.1	(28.8)	0	[0-0]

**Head and neck module:oral cavity/oropharynx  
Constructed scales**

<b>HNSA</b>	N	(%)
0	25	10
8.3	13	5
16.7	39	16
25	39	16
33.3	30	12
41.7	13	5
50	26	10
58.3	18	7
66.7	17	7
75	11	4
83.3	9	4
91.7	4	2
100	5	2
Total	249	

<b>HNSO</b>	N	(%)
0	81	33
8.3	47	19
16.7	40	16
25	19	8
33.3	20	8
41.7	14	6
50	8	3
58.3	8	3
66.7	1	0
75	2	1
83.3	2	1
91.7	1	0
100	3	1
Total	246	

<b>HNSW</b>	N	(%)
0	106	43
8.3	26	11
16.7	21	9
25	22	9
33.3	12	5
41.7	15	6
50	13	5
58.3	8	3
66.7	6	2
75	13	5
83.3	3	1
91.7	1	0
100	1	0
Total	247	0

<b>HNSC</b>	N	(%)
0	153	64
6.7	26	11
13.3	22	9
20	11	5
26.7	12	5
33.3	5	2
40	3	1
46.7	3	1
53.3	1	0
60	2	1
66.7	1	0
73.3	0	0
80	2	1
86.7	0	0
93.3	0	0
100	0	0
Total	241	

<b>HNSE</b>	N	(%)
0	178	72
16.7	22	9
33.3	25	10
50	14	6
66.7	5	2
83.3	2	1
100	3	1
Total	249	

<b>HNSX</b>	N	(%)
0	99	52
16.7	17	9
33.3	23	12
50	6	3
66.7	21	11
83.3	1	1
100	25	13
Total	192	

<b>HNSP</b>	N	(%)
0	132	53
11.1	41	16
22.2	34	14
33.3	11	4
44.4	12	5
55.6	7	3
66.7	8	3
77.8	3	1
88.9	0	0
100	2	1
Total	250	

**Head and neck module:oral cavity/oropharynx  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Pain in mouth	HNPA	55	22	92	37	65	26	38	15	250
2) Pain in jaw	HNPA	119	48	66	26	40	16	25	10	250
3) Soreness in mouth	HNPA	46	18	101	40	64	26	39	16	250
4) Painful throat	HNPA	122	49	62	25	48	19	17	7	249
5) Problems swallowing liquids	HNSW	147	59	52	21	32	13	19	8	250
6) Problems swallowing pureed food	HNSW	157	63	49	20	25	10	17	7	248
7) Problems swallowing solid food	HNSW	123	50	45	18	37	15	43	17	248
8) Choked when swallowing	HNSW	214	86	26	10	7	3	2	1	249
9) Problems with teeth	HNTE	113	46	56	23	45	18	30	12	244
10) Problems opening mouth wide	HNOM	173	70	35	14	24	10	17	7	249
11) Dry mouth	HNDR	141	57	63	25	34	14	11	4	249
12) Sticky saliva	HNSS	153	61	51	20	30	12	16	6	250
13) Sense of smell	HNSE	214	86	20	8	11	4	5	2	250
14) Sense of taste	HNSE	181	73	40	16	19	8	9	4	249
15) Coughed	HNSO	143	57	76	30	22	9	9	4	250
16) Been hoarse	HNSP	203	81	31	12	12	5	4	2	250
17) Felt ill	HNFI	154	62	66	26	21	8	9	4	250
18) Appearance bothered you	HNSC	208	84	24	10	9	4	8	3	249
19) Trouble eating	HNSO	91	37	84	34	50	20	24	10	249
20) Eating in front of family	HNSO	218	89	16	7	8	3	4	2	246
21) Eating in front of other people	HNSO	193	78	30	12	16	7	8	3	247
22) Trouble enjoying meals	HNSO	150	61	49	20	37	15	12	5	248
23) Trouble talking to people	HNSP	176	70	45	18	19	8	10	4	250
24) Trouble talking on telephone	HNSP	169	68	44	18	23	9	14	6	250
25) Social contact with family	HNSC	206	83	29	12	9	4	5	2	249
26) Social contact with friends	HNSC	208	84	29	12	7	3	5	2	249
27) Trouble going out in public	HNSC	209	84	24	10	11	4	5	2	249
28) Trouble with physical contact	HNSC	217	89	14	6	7	3	5	2	243
29) Less interest in sex	HNSX	108	53	34	17	32	16	29	14	203
30) Less sexual enjoyment	HNSX	116	60	25	13	24	13	27	14	192
		<b>No</b>		<b>Yes</b>		<b>Total</b>				
		N	(%)	N	(%)	N				N
31) Used pain-killers	HNPB	113	49	116	51	229				229
32) Taken nutritional supplements	HNNU	212	85	37	15	249				249
33) Used feeding tube	HNFE	240	96	10	4	250				250
34) Lost weight	HNWL	153	63	90	37	243				243
35) Gained weight	HNWG	221	91	22	9	243				243

## Lung module: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	1,125	34
v +3	38	1
v 2.0	836	25
v 3.0	1,333	40
Total	3,332	

#### Primary disease site

	N	(%)
Lung: small cell	658	20
Lung: non-small cell	1,262	38
Mesothelioma	236	7
Lung: not known	1,176	35
Total	3,332	

#### Age

	N	(%)
<40	85	3
40-49	416	13
50-59	971	29
60-69	1,108	33
70-79	596	18
80+	60	2
Not known	96	3
Total	3,332	

#### Gender

	N	(%)
Male	1,925	58
Female	830	25
Not known	577	17
Total	3,332	

#### Stage

	N	(%)
Stage I-II	538	16
Stage III-IV	1,313	39
Recurrent/metastatic	307	9
Not known	1,174	35
Total	3,332	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	29.5	(24.6)	22.2	[11.1-44.4]
Coughing	LCCO	37.4	(27)	33.3	[33.3-66.7]
Haemoptysis	LCHA	5.7	(15.4)	0	[0-0]
Sore mouth	LCSM	5.3	(15.8)	0	[0-0]
Dysphagia	LCDS	7.7	(19)	0	[0-0]
Periph neuropathy	LCPN	11.3	(22.9)	0	[0-0]
Alopecia	LCPR	14.9	(32.6)	0	[0-0]
Pain in chest	LCPC	19.7	(26.4)	0	[0-33.3]
Pain in arm	LCPA	19.0	(27.9)	0	[0-33.3]
Pain other	LCPO	20.5	(29)	0	[0-33.3]

**Lung module: all stages  
Constructed scales**

LCDY	N	(%)
0	492	19
11.1	385	15
22.2	534	21
33.3	428	17
44.4	222	9
55.6	195	8
66.7	145	6
77.8	94	4
88.9	46	2
100	40	2
Total	2,581	

**Lung module: all stages  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	570	21	1,396	52	558	21	170	6	2,694
2) Cough blood	LCHA	2,317	86	311	12	59	2	12	0	2,699
3) Short of breath when rest	LCDY	1,840	69	625	23	164	6	51	2	2,680
4) Short of breath when walk	LCDY	936	35	1,100	41	445	17	191	7	2,672
5) Short of breath when climb stairs	LCDY	576	22	1,032	39	631	24	383	15	2,622
6) Sore mouth or tongue	LCSM	2,371	88	251	9	59	2	21	1	2,702
7) Trouble swallowing	LCDS	2,231	83	338	13	90	3	36	1	2,695
8) Tingling hands or feet	LCPN	2,047	76	450	17	129	5	68	3	2,694
9) Had hair loss	LCHR	2,137	80	152	6	93	4	284	11	2,666
10) Pain in chest	LCPC	1,513	57	823	31	236	9	93	4	2,665
11) Pain in arm or shoulder	LCPA	1,634	61	660	25	252	10	119	5	2,665
12) Pain in other parts of body	LCPO	1,498	60	564	23	321	13	109	4	2,492
13) Did pain medicine help	-	272	23	274	23	394	34	234	20	1,174





## Lung module: males

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	807	42
v +3	30	2
v 2.0	241	13
v 3.0	847	44
Total	1,925	

#### Primary disease site

	N	(%)
Lung: small cell	407	21
Lung: non-small cell	514	27
Mesothelioma	183	10
Lung: not known	821	43
Total	1,925	

### Age

	N	(%)
<40	36	2
40-49	188	10
50-59	548	29
60-69	692	36
70-79	416	22
80+	41	2
Not known	4	0
Total	1,925	

### Stage

	N	(%)
Stage I-II	385	20
Stage III-IV	580	30
Recurrent/metastatic	197	10
Not known	763	40
Total	1,925	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	29.4	(24.5)	22.2	[11.1-44.4]
Coughing	LCCO	37.6	(26.5)	33.3	[33.3-66.7]
Haemoptysis	LCHA	6.5	(15.8)	0	[0-0]
Sore mouth	LCSM	4.9	(15)	0	[0-0]
Dysphagia	LCDS	7.0	(18.2)	0	[0-0]
Periph neuropathy	LCPN	11.6	(22.9)	0	[0-16.7]
Alopecia	LCPR	14.7	(32.3)	0	[0-0]
Pain in chest	LCPC	19.6	(26)	0	[0-33.3]
Pain in arm	LCPA	16.4	(25.9)	0	[0-33.3]
Pain other	LCPO	17.2	(26.4)	0	[0-33.3]

**Lung module: males  
Constructed scales**

LCDY	N	(%)
0	282	20
11.1	214	15
22.2	286	20
33.3	241	17
44.4	128	9
55.6	112	8
66.7	82	6
77.8	48	3
88.9	30	2
100	18	1
Total	1,441	

**Lung module: males  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	296	20	813	54	301	20	94	6	1,504
2) Cough blood	LCHA	1,259	84	202	13	37	3	5	0	1,503
3) Short of breath when rest	LCDY	1,022	68	352	24	95	6	25	2	1,494
4) Short of breath when walk	LCDY	526	35	605	41	256	17	99	7	1,486
5) Short of breath when climb stairs	LCDY	334	23	554	38	369	25	208	14	1,465
6) Sore mouth or tongue	LCSM	1,331	89	133	9	28	2	10	1	1,502
7) Trouble swallowing	LCDS	1,266	84	174	12	44	3	18	1	1,502
8) Tingling hands or feet	LCPN	1,125	75	263	18	76	5	36	2	1,500
9) Had hair loss	LCHR	1,190	80	90	6	49	3	155	10	1,484
10) Pain in chest	LCPC	834	56	477	32	126	9	48	3	1,485
11) Pain in arm or shoulder	LCPA	971	65	348	23	119	8	48	3	1,486
12) Pain in other parts of body	LCPO	909	65	314	22	147	10	40	3	1,410
13) Did pain medicine help	-	160	29	104	19	175	32	109	20	548



## Lung module: females

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	298	36
v +3	8	1
v 2.0	136	16
v 3.0	388	47
Total	830	

#### Primary disease site

	N	(%)
Lung: small cell	236	28
Lung: non small cell	201	24
Mesothelioma	51	6
Lung: not known	342	41
Total	830	

#### Age

	N	(%)
<40	21	3
40-49	124	15
50-59	254	31
60-69	276	33
70-79	135	16
80+	19	2
Not known	1	0
Total	830	

#### Stage

	N	(%)
Stage I-II	149	18
Stage III-IV	187	23
Recurrent/metastatic	98	12
Not known	396	48
Total	830	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	30.0	(24.6)	22.2	[11.1-44.4]
Coughing	LCCO	36.2	(28.5)	33.3	[0-66.7]
Haemoptysis	LCHA	4.2	(13.9)	0	[0-0]
Sore mouth	LCSM	6.4	(17.7)	0	[0-0]
Dysphagia	LCDS	10.5	(22)	0	[0-0]
Periph neuropathy	LCPN	12.8	(25.4)	0	[0-33.3]
Alopecia	LCPR	22.5	(38.5)	0	[0-33.3]
Pain in chest	LCPC	18.7	(27.2)	0	[0-33.3]
Pain in arm	LCPA	19.2	(27.1)	0	[0-33.3]
Pain other	LCPO	21.1	(28.8)	0	[0-33.3]

**Lung module: females  
Constructed scales**

LCDY	N	(%)
0	98	16
11.1	107	17
22.2	144	23
33.3	95	15
44.4	46	7
55.6	49	8
66.7	30	5
77.8	28	5
88.9	12	2
100	10	2
Total	619	

**Lung module: females  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	163	25	308	48	127	20	46	7	644
2) Cough blood	LCHA	581	90	54	8	6	1	5	1	646
3) Short of breath when rest	LCDY	455	71	131	21	42	7	12	2	640
4) Short of breath when walk	LCDY	220	34	259	40	106	17	58	9	643
5) Short of breath when climb stairs	LCDY	116	19	270	43	143	23	99	16	628
6) Sore mouth or tongue	LCSM	557	86	67	10	17	3	8	1	649
7) Trouble swallowing	LCDS	497	77	104	16	28	4	14	2	643
8) Tingling hands or feet	LCPN	483	75	104	16	33	5	26	4	646
9) Had hair loss	LCHR	450	71	44	7	31	5	107	17	632
10) Pain in chest	LCPC	383	61	170	27	54	9	26	4	633
11) Pain in arm or shoulder	LCPA	375	59	171	27	62	10	23	4	631
12) Pain in other parts of body	LCPO	348	59	136	23	86	15	22	4	592
13) Did pain medicine help	-	66	24	63	23	88	32	56	21	273



## Lung module: <50

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	105	21
v +3	3	1
v 2.0	188	38
v 3.0	205	41
Total	501	

#### Primary disease site

	N	(%)
Lung: small cell	84	17
Lung: non small cell	200	40
Mesothelioma	46	9
Lung: not known	171	34
Total	501	

#### Age

	N	(%)
<40	85	17
40-49	416	83
50-59	0	0
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	501	

#### Gender

	N	(%)
Male	224	45
Female	145	29
Not known	132	26
Total	501	

#### Stage

	N	(%)
Stage I-II	65	13
Stage III-IV	176	35
Recurrent/metastatic	44	9
Not known	216	43
Total	501	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	28.7	(24.4)	22.2	[11.1-44.4]
Coughing	LCCO	35.9	(28.2)	33.3	[33.3-66.7]
Haemoptysis	LCHA	4.3	(13.7)	0	[0-0]
Sore mouth	LCSM	5.1	(16.6)	0	[0-0]
Dysphagia	LCDS	8.1	(19)	0	[0-0]
Periph neuropathy	LCPN	12.6	(23.2)	0	[0-33.3]
Alopecia	LCPR	20.9	(36)	0	[0-33.3]
Pain in chest	LCPC	22.3	(26.3)	33.3	[0-33.3]
Pain in arm	LCPA	21.8	(28.6)	0	[0-33.3]
Pain other	LCPO	22.2	(30)	0	[0-33.3]



**Lung module: <50  
Constructed scales**

<b>LCDY</b>	<b>N</b>	<b>(%)</b>
0	91	24
11.1	44	12
22.2	72	19
33.3	63	17
44.4	26	7
55.6	37	10
66.7	30	8
77.8	11	3
88.9	3	1
100	4	1
<b>Total</b>	<b>381</b>	

**Lung module: <50  
Single Items**

		<b>Not at all</b>		<b>A little</b>		<b>Quite a bit</b>		<b>Very much</b>		<b>Total</b>
		<b>N</b>	<b>(%)</b>	<b>N</b>	<b>(%)</b>	<b>N</b>	<b>(%)</b>	<b>N</b>	<b>(%)</b>	<b>N</b>
1) How much did you cough	<b>LCCO</b>	98	25	195	50	72	18	28	7	393
2) Cough blood	<b>LCHA</b>	352	89	35	9	5	1	2	1	394
3) Short of breath when rest	<b>LCDY</b>	264	67	103	26	22	6	5	1	394
4) Short of breath when walk	<b>LCDY</b>	151	39	154	39	71	18	16	4	392
5) Short of breath when climb stairs	<b>LCDY</b>	100	26	132	34	98	25	56	15	386
6) Sore mouth or tongue	<b>LCSM</b>	353	89	30	8	8	2	5	1	396
7) Trouble swallowing	<b>LCDS</b>	324	82	49	12	19	5	3	1	395
8) Tingling hands or feet	<b>LCPN</b>	288	73	73	18	28	7	7	2	396
9) Had hair loss	<b>LCHR</b>	277	71	34	9	29	7	51	13	391
10) Pain in chest	<b>LCPC</b>	197	50	145	37	40	10	13	3	395
11) Pain in arm or shoulder	<b>LCPA</b>	217	56	108	28	48	12	17	4	390
12) Pain in other parts of body	<b>LCPO</b>	208	58	81	23	54	15	17	5	360
13) Did pain medicine help	-	51	23	67	30	61	28	41	19	220



## Lung module: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	280	29
v +3	5	1
v 2.0	259	27
v 3.0	427	44
Total	971	

#### Primary disease site

	N	(%)
Lung: small cell	227	23
Lung: non small cell	340	35
Mesothelioma	92	9
Lung: not known	312	32
Total	971	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	971	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	971	

#### Gender

	N	(%)
Male	548	56
Female	254	26
Not known	169	17
Total	971	

#### Stage

	N	(%)
Stage I-II	130	13
Stage III-IV	362	37
Recurrent/metastatic	76	8
Not known	403	42
Total	971	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	27.2	(24.2)	22.2	[11.1-33.3]
Coughing	LCCO	35.1	(26.8)	33.3	[33.3-33.3]
Haemoptysis	LCHA	4.5	(13.3)	0	[0-0]
Sore mouth	LCSM	4.2	(13.3)	0	[0-0]
Dysphagia	LCDS	7.1	(18.5)	0	[0-0]
Periph neuropathy	LCPN	12.3	(24.9)	0	[0-0]
Alopecia	LCPR	17.9	(35.6)	0	[0-0]
Pain in chest	LCPC	19.7	(26.6)	0	[0-33.3]
Pain in arm	LCPA	19.1	(28.5)	0	[0-33.3]
Pain other	LCPO	22.3	(30.5)	0	[0-33.3]

**Lung module: 50-59**  
**Constructed scales**

LCDY	N	(%)
0	169	22
11.1	125	16
22.2	172	22
33.3	123	16
44.4	61	8
55.6	44	6
66.7	38	5
77.8	23	3
88.9	13	2
100	13	2
Total	781	

**Lung module: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	195	24	409	51	152	19	43	5	799
2) Cough blood	LCHA	708	89	74	9	17	2	0	0	799
3) Short of breath when rest	LCDY	583	73	163	20	39	5	14	2	799
4) Short of breath when walk	LCDY	316	40	322	41	106	13	51	6	795
5) Short of breath when climb stairs	LCDY	187	24	324	41	178	23	101	13	790
6) Sore mouth or tongue	LCSM	718	90	70	9	11	1	3	0	802
7) Trouble swallowing	LCDS	674	84	92	12	23	3	11	1	800
8) Tingling hands or feet	LCPN	603	76	127	16	39	5	30	4	799
9) Had hair loss	LCHR	608	77	43	6	27	3	108	14	786
10) Pain in chest	LCPC	448	57	248	31	63	8	31	4	790
11) Pain in arm or shoulder	LCPA	493	62	188	24	74	9	40	5	795
12) Pain in other parts of body	LCPO	438	59	156	21	115	15	38	5	747
13) Did pain medicine help	-	88	23	80	21	138	36	78	20	384



## Lung module: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	430	39
v +3	19	2
v 2.0	245	22
v 3.0	414	37
Total	1,108	

#### Primary disease site

	N	(%)
Lung: small cell	238	21
Lung: non small cell	380	34
Mesothelioma	79	7
Lung: not known	411	37
Total	1,108	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	1,108	100
70-79	0	0
80+	0	0
Not known	0	0
Total	1,108	

#### Gender

	N	(%)
Male	692	63
Female	276	25
Not known	140	13
Total	1,108	

#### Stage

	N	(%)
Stage I-II	183	17
Stage III-IV	418	38
Recurrent/metastatic	110	10
Not known	397	36
Total	1,108	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	30.3	(24.8)	22.2	[11.1-44.4]
Coughing	LCCO	39.8	(27)	33.3	[33.3-66.7]
Haemoptysis	LCHA	6.3	(16.5)	0	[0-0]
Sore mouth	LCSM	6.3	(16.9)	0	[0-0]
Dysphagia	LCDS	7.9	(18.8)	0	[0-0]
Periph neuropathy	LCPN	11.5	(22.9)	0	[0-0]
Alopecia	LCPR	14.2	(32.2)	0	[0-0]
Pain in chest	LCPC	18.9	(25.8)	0	[0-33.3]
Pain in arm	LCPA	18.7	(27.1)	0	[0-33.3]
Pain other	LCPO	20.5	(28.7)	0	[0-33.3]

**Lung module: 60-69  
Constructed scales**

LCDY	N	(%)
0	148	18
11.1	135	16
22.2	162	19
33.3	139	17
44.4	80	10
55.6	54	7
66.7	51	6
77.8	39	5
88.9	19	2
100	9	1
Total	836	

**Lung module: 60-69  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	157	18	462	52	203	23	63	7	885
2) Cough blood	LCHA	753	85	104	12	23	3	6	1	886
3) Short of breath when rest	LCDY	591	68	203	23	65	7	16	2	875
4) Short of breath when walk	LCDY	296	34	355	41	154	18	70	8	875
5) Short of breath when climb stairs	LCDY	180	21	334	39	203	24	134	16	851
6) Sore mouth or tongue	LCSM	755	85	100	11	22	3	8	1	885
7) Trouble swallowing	LCDS	724	82	120	14	30	3	10	1	884
8) Tingling hands or feet	LCPN	664	75	152	17	43	5	22	3	881
9) Had hair loss	LCHR	712	81	49	6	22	3	93	11	876
10) Pain in chest	LCPC	507	58	258	30	81	9	24	3	870
11) Pain in arm or shoulder	LCPA	531	61	228	26	82	9	33	4	874
12) Pain in other parts of body	LCPO	483	60	190	23	105	13	33	4	811
13) Did pain medicine help	-	80	23	84	24	111	31	79	22	354





## Lung module: $\geq 70$

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	308	47
v +3	11	2
v 2.0	140	21
v 3.0	197	30
Total	656	

#### Primary disease site

	N	(%)
Lung: small cell	109	17
Lung: non small cell	252	38
Mesothelioma	19	3
Lung: not known	276	42
Total	656	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	596	91
80+	60	9
Not known	0	0
Total	656	

#### Gender

	N	(%)
Male	457	70
Female	154	24
Not known	45	7
Total	656	

#### Stage

	N	(%)
Stage I-II	154	24
Stage III-IV	267	41
Recurrent/metastatic	77	12
Not known	158	24
Total	656	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	32.2	(24.9)	33.3	[11.1-44.4]
Coughing	LCCO	37.5	(26.4)	33.3	[33.3-66.7]
Haemoptysis	LCHA	7.4	(17.1)	0	[0-0]
Sore mouth	LCSM	5.5	(16.4)	0	[0-0]
Dysphagia	LCDS	8.1	(20)	0	[0-0]
Periph neuropathy	LCPN	8.9	(20)	0	[0-0]
Alopecia	LCPR	9.6	(26.3)	0	[0-0]
Pain in chest	LCPC	17.6	(26.7)	0	[0-33.3]
Pain in arm	LCPA	15.9	(26.9)	0	[0-33.3]
Pain other	LCPO	14.8	(25.4)	0	[0-33.3]

**Lung module:  $\geq 70$   
Constructed scales**

LCDY	N	(%)
0	71	15
11.1	72	15
22.2	101	21
33.3	87	18
44.4	46	9
55.6	50	10
66.7	22	5
77.8	18	4
88.9	9	2
100	13	3
Total	489	

**Lung module:  $\geq 70$   
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	103	20	283	54	104	20	32	6	522
2) Cough blood	LCHA	426	81	83	16	11	2	4	1	524
3) Short of breath when rest	LCDY	339	66	130	25	33	6	15	3	517
4) Short of breath when walk	LCDY	149	29	221	43	97	19	47	9	514
5) Short of breath when climb stairs	LCDY	95	19	195	39	129	26	81	16	500
6) Sore mouth or tongue	LCSM	459	88	45	9	15	3	4	1	523
7) Trouble swallowing	LCDS	431	83	64	12	16	3	10	2	521
8) Tingling hands or feet	LCPN	416	80	81	16	16	3	9	2	522
9) Had hair loss	LCHR	445	86	26	5	15	3	31	6	517
10) Pain in chest	LCPC	324	63	130	25	41	8	20	4	515
11) Pain in arm or shoulder	LCPA	348	68	106	21	36	7	22	4	512
12) Pain in other parts of body	LCPO	332	69	103	21	32	7	16	3	483
13) Did pain medicine help	-	47	31	32	21	50	33	22	15	151



## Lung module: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	242	45
v +3	2	0
v 2.0	249	46
v 3.0	45	8
Total	538	

#### Primary disease site

	N	(%)
Lung: small cell	4	1
Lung: non small cell	17	3
Lung: not known	517	96
Total	538	

#### Age

	N	(%)
<40	13	2
40-49	52	10
50-59	130	24
60-69	183	34
70-79	140	26
80+	14	3
Not known	6	1
Total	538	

#### Gender

	N	(%)
Male	385	72
Female	149	28
Not known	4	1
Total	538	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	33.2	(27.9)	27.8	[11.1-55.6]
Coughing	LCCO	44.3	(30.8)	33.3	[33.3-66.7]
Haemoptysis	LCHA	6.4	(17.4)	0	[0-0]
Sore mouth	LCSM	6.1	(18.9)	0	[0-0]
Dysphagia	LCDS	8.7	(21.7)	0	[0-0]
Periph neuropathy	LCPN	11.2	(23.2)	0	[0-0]
Alopecia	LCPR	8.8	(25.1)	0	[0-0]
Pain in chest	LCPC	22.7	(30.7)	0	[0-33.3]
Pain in arm	LCPA	20.0	(29.8)	0	[0-33.3]
Pain other	LCPO	17.9	(29.3)	0	[0-33.3]

**Lung module: stage I-II  
Constructed scales**

LCDY	N	(%)
0	89	20
11.1	55	13
22.2	75	17
33.3	59	14
44.4	45	10
55.6	37	8
66.7	31	7
77.8	18	4
88.9	13	3
100	16	4
Total	438	

**Lung module: stage I-II  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	88	19	190	41	126	27	57	12	461
2) Cough blood	LCHA	398	86	50	11	12	3	5	1	465
3) Short of breath when rest	LCDY	305	67	87	19	45	10	21	5	458
4) Short of breath when walk	LCDY	175	38	134	29	98	21	50	11	457
5) Short of breath when climb stairs	LCDY	101	22	123	27	127	28	101	22	452
6) Sore mouth or tongue	LCSM	412	88	33	7	13	3	9	2	467
7) Trouble swallowing	LCDS	383	82	55	12	14	3	13	3	465
8) Tingling hands or feet	LCPN	356	77	68	15	27	6	11	2	462
9) Had hair loss	LCHR	398	87	22	5	13	3	24	5	457
10) Pain in chest	LCPC	251	57	106	24	55	13	28	6	440
11) Pain in arm or shoulder	LCPA	276	62	92	21	51	12	24	5	443
12) Pain in other parts of body	LCPO	283	68	66	16	49	12	20	5	418
13) Did pain medicine help	-	41	19	39	18	70	33	65	30	215



## Lung module: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	498	38
v +3	0	0
v 2.0	472	36
v 3.0	343	26
Total	1,313	

#### Primary disease site

	N	(%)
Lung: small cell	1	0
Lung: non small cell	1,046	80
Lung: not known	266	20
Total	1,313	

#### Age

	N	(%)
<40	34	3
40-49	142	11
50-59	362	28
60-69	418	32
70-79	238	18
80+	29	2
Not known	90	7
Total	1,313	

#### Gender

	N	(%)
Male	580	44
Female	187	14
Not known	546	42
Total	1,313	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	31.5	(24.6)	22.2	[11.1-44.4]
Coughing	LCCO	38.4	(26.6)	33.3	[33.3-66.7]
Haemoptysis	LCHA	7.7	(17)	0	[0-0]
Sore mouth	LCSM	5.1	(14.9)	0	[0-0]
Dysphagia	LCDS	6.8	(17.8)	0	[0-0]
Periph neuropathy	LCPN	8.9	(19.8)	0	[0-0]
Alopecia	LCPR	5.2	(19.1)	0	[0-0]
Pain in chest	LCPC	20.8	(26.6)	0	[0-33.3]
Pain in arm	LCPA	22.4	(30.1)	0	[0-33.3]
Pain other	LCPO	23.8	(30.9)	0	[0-33.3]

**Lung module: stage III-IV  
Constructed scales**

LCDY	N	(%)
0	178	17
11.1	137	13
22.2	220	21
33.3	191	18
44.4	103	10
55.6	84	8
66.7	70	7
77.8	45	4
88.9	18	2
100	17	2
Total	1,063	

**Lung module: stage III-IV  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	212	19	593	53	242	22	70	6	1,117
2) Cough blood	LCHA	903	81	179	16	36	3	3	0	1,121
3) Short of breath when rest	LCDY	729	65	302	27	62	6	21	2	1,114
4) Short of breath when walk	LCDY	325	29	501	45	196	18	86	8	1,108
5) Short of breath when climb stairs	LCDY	219	20	420	39	266	25	171	16	1,076
6) Sore mouth or tongue	LCSM	984	88	110	10	24	2	5	0	1,123
7) Trouble swallowing	LCDS	947	85	128	11	33	3	12	1	1,120
8) Tingling hands or feet	LCPN	890	80	172	15	40	4	16	1	1,118
9) Had hair loss	LCHR	1,025	92	41	4	23	2	29	3	1,118
10) Pain in chest	LCPC	604	54	369	33	102	9	41	4	1,116
11) Pain in arm or shoulder	LCPA	629	57	292	26	124	11	69	6	1,114
12) Pain in other parts of body	LCPO	562	55	244	24	150	15	61	6	1,017
13) Did pain medicine help	-	53	12	130	29	175	39	95	21	453





## Lung module: recurrent/metastatic

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	116	38
v +3	5	2
v 2.0	89	29
v 3.0	97	32
Total	307	

#### Primary disease site

	N	(%)
Lung: small cell	115	37
Lung: non small cell	11	4
Mesothelioma	6	2
Lung: not known	175	57
Total	307	

### Age

	N	(%)
<40	4	1
40-49	40	13
50-59	76	25
60-69	110	36
70-79	68	22
80+	9	3
Not known	0	0
Total	307	

### Gender

	N	(%)
Male	197	64
Female	98	32
Not known	12	4
Total	307	

### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	38.3	(25)	33.3	[22.2-55.6]
Coughing	LCCO	36.3	(23.9)	33.3	[33.3-33.3]
Haemoptysis	LCHA	7.4	(17.7)	0	[0-0]
Sore mouth	LCSM	4.8	(13.4)	0	[0-0]
Dysphagia	LCDS	7.4	(15.3)	0	[0-0]
Periph neuropathy	LCPN	9.0	(19.6)	0	[0-0]
Alopecia	LCPR	2.7	(12.8)	0	[0-0]
Pain in chest	LCPC	25.6	(24.9)	33.3	[0-33.3]
Pain in arm	LCPA	20.5	(28.7)	0	[0-33.3]
Pain other	LCPO	25.4	(29.4)	33.3	[0-33.3]

**Lung module: recurrent/metastatic  
Constructed scales**

LCDY	N	(%)
0	8	8
11.1	15	14
22.2	18	17
33.3	20	19
44.4	10	9
55.6	15	14
66.7	8	8
77.8	7	7
88.9	3	3
100	2	2
Total	106	

**Lung module: recurrent/metastatic  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	19	17	69	62	19	17	5	5	112
2) Cough blood	LCHA	92	82	16	14	3	3	1	1	112
3) Short of breath when rest	LCDY	55	50	46	41	8	7	2	2	111
4) Short of breath when walk	LCDY	22	20	51	46	23	21	15	14	111
5) Short of breath when climb stairs	LCDY	12	11	42	40	32	30	20	19	106
6) Sore mouth or tongue	LCSM	96	87	12	11	2	2	0	0	110
7) Trouble swallowing	LCDS	89	80	21	19	2	2	0	0	112
8) Tingling hands or feet	LCPN	87	78	20	18	2	2	2	2	111
9) Had hair loss	LCHR	105	95	4	4	1	1	1	1	111
10) Pain in chest	LCPC	44	39	53	47	12	11	3	3	112
11) Pain in arm or shoulder	LCPA	66	59	28	25	13	12	5	5	112
12) Pain in other parts of body	LCPO	53	49	34	31	17	16	5	5	109
13) Did pain medicine help	-	No data available								



## Lung module: small cell lung cancer

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	211	32
v +3	0	0
v 2.0	8	1
v 3.0	439	67
Total	658	

#### Age

	N	(%)
<40	5	1
40-49	79	12
50-59	227	35
60-69	238	36
70-79	105	16
80+	4	1
Not known	0	0
Total	658	

#### Gender

	N	(%)
Male	407	62
Female	236	36
Not known	15	2
Total	658	

#### Stage

	N	(%)
Stage I-II	4	1
Stage III-IV	1	0
Recurrent/metastatic	115	18
Not known	538	82
Total	658	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	25.8	(22.4)	22.2	[11.1-33.3]
Coughing	LCCO	34.2	(23.9)	33.3	[33.3-33.3]
Haemoptysis	LCHA	3.1	(12)	0	[0-0]
Sore mouth	LCSM	5.2	(15.6)	0	[0-0]
Dysphagia	LCDS	9.8	(20.4)	0	[0-0]
Periph neuropathy	LCPN	16.9	(28.4)	0	[0-33.3]
Alopecia	LCPR	36.6	(46)	0	[0-100]
Pain in chest	LCPC	16.0	(22.9)	0	[0-33.3]
Pain in arm	LCPA	12.7	(23.3)	0	[0-33.3]
Pain other	LCPO	17.8	(27)	0	[0-33.3]

**Lung module: small cell lung cancer  
Constructed scales**

LCDY	N	(%)
0	124	20
11.1	120	19
22.2	148	24
33.3	95	15
44.4	39	6
55.6	44	7
66.7	26	4
77.8	16	3
88.9	6	1
100	6	1
Total	624	

**Lung module: small cell lung cancer  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) How much did you cough	LCCO	135	21	377	59	107	17	22	3	641
2) Cough blood	LCHA	591	92	41	6	5	1	3	0	640
3) Short of breath when rest	LCDY	477	75	127	20	25	4	7	1	636
4) Short of breath when walk	LCDY	255	40	261	41	90	14	33	5	639
5) Short of breath when climb stairs	LCDY	142	23	294	47	134	21	61	10	631
6) Sore mouth or tongue	LCSM	560	88	61	10	10	2	6	1	637
7) Trouble swallowing	LCDS	493	77	111	17	23	4	10	2	637
8) Tingling hands or feet	LCPN	431	68	127	20	44	7	36	6	638
9) Had hair loss	LCHR	363	59	31	5	27	4	198	32	619
10) Pain in chest	LCPC	390	61	199	31	35	6	12	2	636
11) Pain in arm or shoulder	LCPA	459	72	127	20	35	6	15	2	636
12) Pain in other parts of body	LCPO	390	64	138	23	65	11	20	3	613
13) Did pain medicine help	-	24	17	36	26	51	36	30	21	141



## Lung module: non-small cell lung cancer

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	556	44
v +3	0	0
v 2.0	516	41
v 3.0	190	15
Total	1,262	

#### Age

	N	(%)
<40	37	3
40-49	163	13
50-59	340	27
60-69	380	30
70-79	225	18
80+	27	2
Not known	90	7
Total	1,262	

#### Gender

	N	(%)
Male	514	41
Female	201	16
Not known	547	43
Total	1,262	

#### Stage

	N	(%)
Stage I-II	17	1
Stage III-IV	1,046	83
Recurrent/metastatic	11	1
Not known	188	15
Total	1,262	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Dyspnoea	LCDY	29.9	(24.2)	22.2	[11.1-44.4]
Coughing	LCCO	38.4	(26.6)	33.3	[33.3-66.7]
Haemoptysis	LCHA	7.6	(16.7)	0	[0-0]
Sore mouth	LCSM	5.2	(15.1)	0	[0-0]
Dysphagia	LCDS	6.5	(17.4)	0	[0-0]
Periph neuropathy	LCPN	9.0	(19.8)	0	[0-0]
Alopecia	LCPR	7.3	(22.9)	0	[0-0]
Pain in chest	LCPC	19.5	(25.6)	0	[0-33.3]
Pain in arm	LCPA	21.4	(29.4)	0	[0-33.3]
Pain other	LCPO	23.1	(30.3)	0	[0-33.3]



**Lung module: non-small cell lung cancer  
Constructed scales**

<b>LCDY</b>	<b>N</b>	<b>(%)</b>
0	202	18
11.1	155	14
22.2	235	21
33.3	191	17
44.4	95	9
55.6	87	8
66.7	65	6
77.8	46	4
88.9	14	1
100	16	1
Total	1,106	

**Lung module: non-small cell lung cancer  
Single Items**

		<b>Not at all</b>		<b>A little</b>		<b>Quite a bit</b>		<b>Very much</b>		<b>Total</b>
		<b>N</b>	<b>(%)</b>	<b>N</b>	<b>(%)</b>	<b>N</b>	<b>(%)</b>	<b>N</b>	<b>(%)</b>	<b>N</b>
1) How much did you cough	<b>LCCO</b>	220	19	620	53	249	21	74	6	1,163
2) Cough blood	<b>LCHA</b>	941	81	185	16	37	3	2	0	1,165
3) Short of breath when rest	<b>LCDY</b>	779	67	303	26	58	5	19	2	1,159
4) Short of breath when walk	<b>LCDY</b>	368	32	512	45	189	16	81	7	1,150
5) Short of breath when climb stairs	<b>LCDY</b>	240	21	463	41	258	23	161	14	1,122
6) Sore mouth or tongue	<b>LCSM</b>	1,024	88	114	10	27	2	5	0	1,170
7) Trouble swallowing	<b>LCDS</b>	996	86	120	10	38	3	10	1	1,164
8) Tingling hands or feet	<b>LCPN</b>	924	79	182	16	43	4	16	1	1,165
9) Had hair loss	<b>LCHR</b>	1,038	89	45	4	32	3	48	4	1,163
10) Pain in chest	<b>LCPC</b>	648	56	381	33	98	8	34	3	1,161
11) Pain in arm or shoulder	<b>LCPA</b>	666	58	305	26	122	11	65	6	1,158
12) Pain in other parts of body	<b>LCPO</b>	595	56	252	24	160	15	55	5	1,062
13) Did pain medicine help	-	125	24	132	25	182	34	90	17	529



## Oesophageal module: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	56	5
v +3	0	0
v 2.0	71	7
v 3.0	904	88
Total	1,031	

#### Age

	N	(%)
<40	9	1
40-49	101	10
50-59	237	23
60-69	346	34
70-79	270	26
80+	68	7
Not known	0	0
Total	1,031	

#### Gender

	N	(%)
Male	772	75
Female	248	24
Not known	11	1
Total	1,031	

#### Stage

	N	(%)
Stage I-II	118	11
Stage III-IV	47	5
Recurrent/metastatic	347	34
Not known	519	50
Total	1,031	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Swallow	OESW	41.7	(28.4)	44.4	[22.2-66.7]
Eating	OEEA	42.6	(28.7)	41.7	[16.7-66.7]
Reflux	OERX	17.4	(24.8)	0	[0-33.3]
Pain	OEPA	26.5	(24.4)	22.2	[11.1-44.4]
Saliva	OESV	23.1	(32.6)	0	[0-33.3]
Choking	OECH	18.3	(28.6)	0	[0-33.3]
Dry mouth	OEDM	27.6	(34)	0	[0-33.3]
Taste	OETA	30.9	(36.5)	0	[0-66.7]
Cough	OECO	20.1	(29.3)	0	[0-33.3]
Talking	OESP	12.1	(25.1)	0	[0-0]

**Oesophageal module: all stages**  
**Constructed scales**

<b>OESW</b>	N	(%)
0	84	15
11.1	46	8
22.2	54	10
33.3	82	15
44.4	79	14
55.6	71	13
66.7	60	11
77.8	39	7
88.9	23	4
100	25	4
Total	563	

<b>OEEA</b>	N	(%)
0	58	11
8.3	45	8
16.7	40	7
25	52	10
33.3	59	11
41.7	47	9
50	53	10
58.3	39	7
66.7	44	8
75	42	8
83.3	19	4
91.7	24	4
100	21	4
Total	543	

<b>OERX</b>	N	(%)
0	301	54
16.7	107	19
33.3	69	12
50	38	7
66.7	23	4
83.3	12	2
100	13	2
Total	563	

<b>OEPA</b>	N	(%)
0	138	25
11.1	93	17
22.2	94	17
33.3	79	14
44.4	55	10
55.6	34	6
66.7	26	5
77.8	22	4
88.9	5	1
100	7	1
Total	553	

**Oesophageal module: all stages**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Problems eating solid foods	OESW	263	47	119	21	96	17	88	16	566
2) Problems eating soft foods	OESW	93	17	106	19	162	29	203	36	564
3) Problems drinking liquids	OESW	37	7	47	8	140	25	342	60	566
4) Trouble swallowing saliva	OESV	332	59	114	20	66	12	47	8	559
5) Choked when swallowing	OECH	362	65	114	20	58	10	26	5	560
6) Trouble enjoying meals	OEEA	167	30	117	21	120	22	154	28	558
7) Felt full too quickly	OEEA	209	38	131	24	128	23	85	15	553
8) Trouble eating	OEEA	118	21	119	21	144	26	179	32	560
9) Eating in front of people	OEEA	332	60	74	13	58	10	93	17	557
10) Dry mouth	OEDM	292	52	134	24	81	14	57	10	564
11) Sense of taste	OETA	283	51	109	20	94	17	74	13	560
12) Trouble with coughing	OECO	341	61	136	24	54	10	32	6	563
13) Trouble with talking	OESP	432	77	83	15	26	5	23	4	564
14) Acid indigestion or heartburn	OERX	376	66	114	20	44	8	32	6	566
15) Acid or bile in mouth	OERX	381	68	106	19	43	8	33	6	563
16) Pain when eat	OEPA	243	44	154	28	94	17	68	12	559
17) Pain in chest	OEPA	262	47	170	30	84	15	48	9	564
18) Pain in stomach	OEPA	354	63	132	23	55	10	23	4	564

## Oesophageal module: males

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	51	7
v +3	0	0
v 2.0	58	8
v 3.0	663	86
Total	772	

#### Age

	N	(%)
<40	8	1
40-49	79	10
50-59	182	24
60-69	280	36
70-79	178	23
80+	45	6
Not known	0	0
Total	772	

#### Stage

	N	(%)
Stage I-II	78	10
Stage III-IV	32	4
Recurrent/metastatic	268	35
Not known	394	51
Total	772	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Swallow	OESW	40.8	(28.3)	44.4	[22.2-55.6]
Eating	OEEA	41.2	(28.7)	41.7	[16.7-66.7]
Reflux	OERX	17.2	(24.8)	0	[0-33.3]
Pain	OEPA	25.7	(23.6)	22.2	[11.1-38.9]
Saliva	OESV	23.7	(33.2)	0	[0-33.3]
Choking	OECH	18.3	(28.2)	0	[0-33.3]
Dry mouth	OEDM	25.3	(32.7)	0	[0-33.3]
Taste	OETA	31.9	(36.3)	33.3	[0-66.7]
Cough	OECO	19.7	(28.7)	0	[0-33.3]
Talking	OESP	11.6	(24.8)	0	[0-0]

**Oesophageal module: males**  
**Constructed scales**

<b>OESW</b>	N	(%)
0	68	16
11.1	34	8
22.2	44	10
33.3	64	15
44.4	65	15
55.6	58	13
66.7	39	9
77.8	27	6
88.9	15	3
100	21	5
Total	435	

<b>OEEA</b>	N	(%)
0	50	12
8.3	35	8
16.7	32	8
25	40	10
33.3	48	12
41.7	36	9
50	42	10
58.3	31	7
66.7	27	6
75	32	8
83.3	11	3
91.7	20	5
100	15	4
Total	419	

<b>OERX</b>	N	(%)
0	231	53
16.7	90	21
33.3	50	12
50	28	6
66.7	15	3
83.3	10	2
100	11	3
Total	435	

<b>OEPA</b>	N	(%)
0	105	25
11.1	77	18
22.2	73	17
33.3	66	15
44.4	41	10
55.6	26	6
66.7	18	4
77.8	13	3
88.9	4	1
100	5	1
Total	428	

**Oesophageal module: males  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Problems eating solid foods	OESW	187	43	101	23	80	18	70	16	438
2) Problems eating soft foods	OESW	66	15	75	17	138	32	156	36	435
3) Problems drinking liquids	OESW	31	7	31	7	116	27	259	59	437
4) Trouble swallowing saliva	OESV	254	59	86	20	52	12	39	9	431
5) Choked when swallowing	OECH	276	64	92	21	44	10	19	4	431
6) Trouble enjoying meals	OEEA	136	32	95	22	91	21	108	25	430
7) Felt full too quickly	OEEA	164	38	99	23	102	24	64	15	429
8) Trouble eating	OEEA	96	22	92	21	115	27	128	30	431
9) Eating in front of people	OEEA	260	61	63	15	38	9	68	16	429
10) Dry mouth	OEDM	237	55	103	24	58	13	37	9	435
11) Sense of taste	OETA	211	49	82	19	84	20	54	13	431
12) Trouble with coughing	OECO	264	61	106	24	42	10	22	5	434
13) Trouble with talking	OESP	337	78	61	14	20	5	17	4	435
14) Acid indigestion or heartburn	OERX	289	66	92	21	34	8	22	5	437
15) Acid or bile in mouth	OERX	295	68	82	19	32	7	26	6	435
16) Pain when eat	OEPA	192	44	123	28	72	17	46	11	433
17) Pain in chest	OEPA	208	48	140	32	60	14	28	6	436
18) Pain in stomach	OEPA	261	60	110	25	45	10	19	4	435



## Oesophageal module: females

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	5	2
v +3	0	0
v 2.0	12	5
v 3.0	231	93
Total	248	

#### Age

	N	(%)
<40	1	0
40-49	21	9
50-59	53	21
60-69	61	25
70-79	90	36
80+	22	9
Not known	0	0
Total	248	

#### Stage

	N	(%)
Stage I-II	39	16
Stage III-IV	15	6
Recurrent/metastatic	76	31
Not known	118	48
Total	248	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Swallow	OESW	44.7	(28.6)	44.4	[22.2-66.7]
Eating	OEEA	49.0	(28.3)	50	[25-66.7]
Reflux	OERX	17.2	(24.6)	0	[0-33.3]
Pain	OEPA	29.7	(27)	22.2	[0-44.4]
Saliva	OESV	21.3	(30.9)	0	[0-33.3]
Choking	OECH	18.5	(30.3)	0	[0-33.3]
Dry mouth	OEDM	35.9	(37.1)	33.3	[0-66.7]
Taste	OETA	27.7	(36.9)	0	[0-33.3]
Cough	OECO	21.6	(32.1)	0	[0-33.3]
Talking	OESP	12.6	(25.7)	0	[0-0]

**Oesophageal module: females  
Constructed scales**

<b>OESW</b>	<b>N</b>	<b>(%)</b>
0	15	13
11.1	11	9
22.2	9	8
33.3	16	14
44.4	13	11
55.6	13	11
66.7	20	17
77.8	10	9
88.9	8	7
100	3	3
Total	118	

<b>OEEA</b>	<b>N</b>	<b>(%)</b>
0	6	5
8.3	9	8
16.7	8	7
25	10	9
33.3	10	9
41.7	9	8
50	11	10
58.3	8	7
66.7	16	14
75	10	9
83.3	8	7
91.7	4	4
100	6	5
Total	115	

<b>OERX</b>	<b>N</b>	<b>(%)</b>
0	66	56
16.7	17	14
33.3	16	14
50	9	8
66.7	6	5
83.3	2	2
100	2	2
Total	118	

<b>OEPA</b>	<b>N</b>	<b>(%)</b>
0	30	26
11.1	15	13
22.2	20	17
33.3	11	10
44.4	13	11
55.6	8	7
66.7	8	7
77.8	8	7
88.9	1	1
100	2	2
Total	116	

**Oesophageal module: females  
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Problems eating solid foods	OESW	71	60	15	13	15	13	17	14	118
2) Problems eating soft foods	OESW	26	22	28	24	23	19	42	35	119
3) Problems drinking liquids	OESW	4	3	14	12	24	20	77	65	119
4) Trouble swallowing saliva	OESV	72	61	26	22	13	11	8	7	119
5) Choked when swallowing	OECH	80	67	19	16	13	11	7	6	119
6) Trouble enjoying meals	OEEA	26	22	20	17	29	24	44	37	119
7) Felt full too quickly	OEEA	40	35	31	27	23	20	21	18	115
8) Trouble eating	OEEA	18	15	24	20	28	24	49	41	119
9) Eating in front of people	OEEA	65	55	11	9	19	16	23	20	118
10) Dry mouth	OEDM	50	42	29	24	21	18	19	16	119
11) Sense of taste	OETA	66	56	25	21	10	8	18	15	119
12) Trouble with coughing	OECO	73	61	25	21	11	9	10	8	119
13) Trouble with talking	OESP	90	76	18	15	6	5	5	4	119
14) Acid indigestion or heartburn	OERX	82	69	19	16	9	8	9	8	119
15) Acid or bile in mouth	OERX	82	70	21	18	8	7	7	6	118
16) Pain when eat	OEPA	45	39	30	26	21	18	21	18	117
17) Pain in chest	OEPA	50	42	27	23	23	20	18	15	118
18) Pain in stomach	OEPA	86	72	19	16	10	8	4	3	119

## Oesophageal module: 50-59

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	19	8
v +3	0	0
v 2.0	20	8
v 3.0	198	84
Total	237	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	237	100
60-69	0	0
70-79	0	0
80+	0	0
Not known	0	0
Total	237	

#### Gender

	N	(%)
Male	182	77
Female	53	22
Not known	2	1
Total	237	

#### Stage

	N	(%)
Stage I-II	37	16
Stage III-IV	6	3
Recurrent/metastatic	75	32
Not known	119	50
Total	237	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Swallow	OESW	39.3	(28.8)	33.3	[11.1-55.6]
Eating	OEEA	40.8	(29.7)	41.7	[16.7-66.7]
Reflux	OERX	17.2	(25.5)	0	[0-33.3]
Pain	OEPA	24.9	(22.6)	22.2	[0-33.3]
Saliva	OESV	23.2	(34.9)	0	[0-33.3]
Choking	OECH	16.9	(27.4)	0	[0-33.3]
Dry mouth	OEDM	23.3	(31.6)	0	[0-33.3]
Taste	OETA	34.6	(37)	33.3	[0-66.7]
Cough	OECO	18.3	(26.3)	0	[0-33.3]
Talking	OESP	15.4	(26.8)	0	[0-33.3]

**Oesophageal module: 50-59**  
**Constructed scales**

<b>OESW</b>	N	(%)
0	24	19
11.1	9	7
22.2	10	8
33.3	21	17
44.4	20	16
55.6	17	13
66.7	8	6
77.8	6	5
88.9	6	5
100	6	5
Total	127	

<b>OEEA</b>	N	(%)
0	17	14
8.3	9	7
16.7	11	9
25	8	7
33.3	14	12
41.7	16	13
50	8	7
58.3	6	5
66.7	8	7
75	7	6
83.3	5	4
91.7	9	7
100	3	3
Total	121	

<b>OERX</b>	N	(%)
0	73	57
16.7	22	17
33.3	12	9
50	10	8
66.7	5	4
83.3	5	4
100	2	2
Total	129	

<b>OEPA</b>	N	(%)
0	34	27
11.1	16	13
22.2	25	20
33.3	23	18
44.4	14	11
55.6	6	5
66.7	2	2
77.8	5	4
88.9	1	1
100	1	1
Total	127	

**Oesophageal module: 50-59**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Problems eating solid foods	OESW	59	46	25	20	20	16	24	19	128
2) Problems eating soft foods	OESW	20	16	16	13	40	31	52	41	128
3) Problems drinking liquids	OESW	9	7	8	6	32	25	80	62	129
4) Trouble swallowing saliva	OESV	82	64	16	13	17	13	13	10	128
5) Choked when swallowing	OECH	85	66	26	20	12	9	5	4	128
6) Trouble enjoying meals	OEEA	39	31	31	24	24	19	33	26	127
7) Felt full too quickly	OEEA	49	40	30	24	29	23	16	13	124
8) Trouble eating	OEEA	32	26	27	22	30	24	36	29	125
9) Eating in front of people	OEEA	76	61	12	10	14	11	23	18	125
10) Dry mouth	OEDM	72	56	35	27	11	9	11	9	129
11) Sense of taste	OETA	57	45	28	22	24	19	19	15	128
12) Trouble with coughing	OECO	78	61	35	27	12	9	4	3	129
13) Trouble with talking	OESP	89	70	24	19	10	8	5	4	128
14) Acid indigestion or heartburn	OERX	86	67	24	19	10	8	9	7	129
15) Acid or bile in mouth	OERX	92	71	19	15	11	9	7	5	129
16) Pain when eat	OEPA	57	45	33	26	24	19	14	11	128
17) Pain in chest	OEPA	63	49	43	34	15	12	7	6	128
18) Pain in stomach	OEPA	82	64	32	25	8	6	7	5	129

## Oesophageal module: 60-69

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	16	5
v +3	0	0
v 2.0	32	9
v 3.0	298	86
Total	346	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	346	100
70-79	0	0
80+	0	0
Not known	0	0
Total	346	

#### Gender

	N	(%)
Male	280	81
Female	61	18
Not known	5	1
Total	346	

#### Stage

	N	(%)
Stage I-II	42	12
Stage III-IV	21	6
Recurrent/metastatic	106	31
Not known	177	51
Total	346	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Swallow	OESW	40.0	(29.8)	33.3	[11.1-66.7]
Eating	OEEA	42.2	(29)	41.7	[16.7-66.7]
Reflux	OERX	18.0	(24.9)	16.7	[0-33.3]
Pain	OEPA	27.2	(24.8)	22.2	[11.1-44.4]
Saliva	OESV	22.7	(31.5)	0	[0-33.3]
Choking	OECH	18.2	(28.3)	0	[0-33.3]
Dry mouth	OEDM	27.1	(34)	0	[0-33.3]
Taste	OETA	29.9	(36.3)	0	[0-66.7]
Cough	OECO	18.5	(27.9)	0	[0-33.3]
Talking	OESP	12.9	(27.6)	0	[0-0]

**Oesophageal module: 60-69**  
**Constructed scales**

<b>OESW</b>	N	(%)
0	37	19
11.1	19	10
22.2	17	9
33.3	26	13
44.4	20	10
55.6	24	12
66.7	26	13
77.8	10	5
88.9	9	5
100	9	5
Total	197	

<b>OEEA</b>	N	(%)
0	21	11
8.3	18	9
16.7	12	6
25	16	8
33.3	28	15
41.7	12	6
50	18	9
58.3	16	8
66.7	11	6
75	17	9
83.3	7	4
91.7	6	3
100	9	5
Total	191	

<b>OERX</b>	N	(%)
0	97	50
16.7	44	23
33.3	27	14
50	11	6
66.7	6	3
83.3	4	2
100	6	3
Total	195	

<b>OEPA</b>	N	(%)
0	48	25
11.1	34	17
22.2	29	15
33.3	32	16
44.4	13	7
55.6	14	7
66.7	13	7
77.8	9	5
88.9	1	1
100	2	1
Total	195	



**Oesophageal module: 60-69**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Problems eating solid foods	OESW	84	42	40	20	36	18	38	19	198
2) Problems eating soft foods	OESW	31	16	42	21	46	23	78	40	197
3) Problems drinking liquids	OESW	13	7	17	9	46	23	122	62	198
4) Trouble swallowing saliva	OESV	113	57	50	25	18	9	16	8	197
5) Choked when swallowing	OECH	126	64	42	21	19	10	9	5	196
6) Trouble enjoying meals	OEEA	66	34	38	20	33	17	57	29	194
7) Felt full too quickly	OEEA	70	36	49	25	47	24	28	14	194
8) Trouble eating	OEEA	43	22	45	23	48	24	61	31	197
9) Eating in front of people	OEEA	115	59	33	17	13	7	34	17	195
10) Dry mouth	OEDM	103	52	49	25	24	12	21	11	197
11) Sense of taste	OETA	100	52	38	20	30	16	25	13	193
12) Trouble with coughing	OECO	123	63	45	23	20	10	8	4	196
13) Trouble with talking	OESP	152	77	27	14	5	3	13	7	197
14) Acid indigestion or heartburn	OERX	130	66	43	22	13	7	11	6	197
15) Acid or bile in mouth	OERX	125	64	46	24	9	5	15	8	195
16) Pain when eat	OEPA	87	44	57	29	30	15	22	11	196
17) Pain in chest	OEPA	89	45	58	29	34	17	18	9	199
18) Pain in stomach	OEPA	119	60	45	23	25	13	8	4	197

## Oesophageal module: $\geq 70$

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	8	2
v +3	0	0
v 2.0	15	4
v 3.0	315	93
Total	338	

#### Age

	N	(%)
<40	0	0
40-49	0	0
50-59	0	0
60-69	0	0
70-79	270	80
80+	68	20
Not known	0	0
Total	338	

#### Gender

	N	(%)
Male	223	66
Female	112	33
Not known	3	1
Total	338	

#### Stage

	N	(%)
Stage I-II	23	7
Stage III-IV	13	4
Recurrent/metastatic	138	41
Not known	164	49
Total	338	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Swallow	OESW	46.0	(26.4)	44.4	[33.3-66.7]
Eating	OEEA	43.7	(28.3)	41.7	[25-66.7]
Reflux	OERX	16.4	(24.4)	0	[0-33.3]
Pain	OEPA	23.5	(24.3)	22.2	[0-33.3]
Saliva	OESV	25.4	(33.5)	0	[0-33.3]
Choking	OECH	20.1	(29.9)	0	[0-33.3]
Dry mouth	OEDM	33.2	(36.2)	33.3	[0-66.7]
Taste	OETA	27.5	(35.2)	0	[0-66.7]
Cough	OECO	25.3	(32.7)	0	[0-33.3]
Talking	OESP	9.9	(21.2)	0	[0-0]

**Oesophageal module:  $\geq 70$   
Constructed scales**

<b>OESW</b>	N	(%)
0	16	9
11.1	14	8
22.2	16	9
33.3	28	15
44.4	29	16
55.6	26	14
66.7	22	12
77.8	20	11
88.9	8	4
100	6	3
Total	185	

<b>OEEA</b>	N	(%)
0	16	9
8.3	14	8
16.7	12	7
25	25	14
33.3	11	6
41.7	14	8
50	19	11
58.3	14	8
66.7	19	11
75	13	7
83.3	6	3
91.7	7	4
100	7	4
Total	177	

<b>OERX</b>	N	(%)
0	106	58
16.7	27	15
33.3	24	13
50	13	7
66.7	7	4
83.3	3	2
100	4	2
Total	184	

<b>OEPA</b>	N	(%)
0	50	28
11.1	38	22
22.2	31	18
33.3	16	9
44.4	18	10
55.6	7	4
66.7	7	4
77.8	5	3
88.9	2	1
100	3	2
Total	177	

**Oesophageal module:  $\geq 70$   
Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Problems eating solid foods	OESW	99	54	35	19	32	17	19	10	185
2) Problems eating soft foods	OESW	34	18	41	22	59	32	51	28	185
3) Problems drinking liquids	OESW	11	6	20	11	51	28	103	56	185
4) Trouble swallowing saliva	OESV	102	57	34	19	29	16	15	8	180
5) Choked when swallowing	OECH	114	63	35	19	24	13	9	5	182
6) Trouble enjoying meals	OEEA	47	26	35	19	51	28	49	27	182
7) Felt full too quickly	OEEA	72	40	36	20	40	22	33	18	181
8) Trouble eating	OEEA	34	19	36	20	49	27	64	35	183
9) Eating in front of people	OEEA	111	61	20	11	24	13	27	15	182
10) Dry mouth	OEDM	85	46	37	20	38	21	23	13	183
11) Sense of taste	OETA	100	54	37	20	26	14	21	11	184
12) Trouble with coughing	OECO	98	54	48	26	20	11	17	9	183
13) Trouble with talking	OESP	145	78	28	15	9	5	3	2	185
14) Acid indigestion or heartburn	OERX	128	69	34	18	15	8	8	4	185
15) Acid or bile in mouth	OERX	128	70	28	15	19	10	9	5	184
16) Pain when eat	OEPA	85	47	49	27	27	15	19	11	180
17) Pain in chest	OEPA	95	52	49	27	21	12	17	9	182
18) Pain in stomach	OEPA	124	67	43	23	11	6	6	3	184

## Ovarian module: all stages

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	10	1
v +3	64	7
v 2.0	109	12
v 3.0	734	80
Total	917	

#### Age

	N	(%)
<40	44	5
40-49	136	15
50-59	255	28
60-69	317	35
70-79	156	17
80+	8	1
Not known	1	0
Total	917	

#### Stage

	N	(%)
Stage I-II	214	23
Stage III-IV	662	72
Recurrent/metastatic	18	2
Not known	23	3
Total	917	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Abdominal/GI	OVAG	21.9	(22.1)	16.7	[5.6-33.3]
Peripheral neuropathy	OVPN	17.1	(27.2)	0	[0-33.3]
Hormonal	OVHO	25.8	(30.3)	16.7	[0-33.3]
Body image	OVBI	22.2	(27.4)	16.7	[0-33.3]
Attitude to disease/treatment	OVAT	42.3	(30.6)	44.4	[22.2-66.7]
Chemotherapy side effects	OVCH	19.5	(20.5)	13.3	[0-26.7]
Other single items	OVOT	28.5	(23.7)	25	[8.3-41.7]

**Ovarian module: all stages**  
**Constructed scales**

<b>OVAG</b>	N	(%)
0	53	20
5.6	34	13
11.1	33	13
16.7	36	14
22.2	16	6
27.8	18	7
33.3	12	5
38.9	12	5
44.4	8	3
50	7	3
55.6	8	3
61.1	6	2
66.7	7	3
72.2	2	1
77.8	1	0
83.3	4	2
88.9	1	0
94.4	0	0
100	2	1

Total 260

<b>OVPN</b>	N	(%)
0	159	61
16.7	30	12
33.3	32	12
50	12	5
66.7	13	5
83.3	4	2
100	11	4

Total 261

<b>OVHO</b>	N	(%)
0	111	42
16.7	46	18
33.3	41	16
50	21	8
66.7	21	8
83.3	6	2
100	17	7

Total 263

<b>OVBI</b>	N	(%)
0	126	48
16.7	38	14
33.3	40	15
50	26	10
66.7	18	7
83.3	8	3
100	7	3

Total 263

<b>OVAT</b>	N	(%)
0	40	16
11.1	23	9
22.2	28	11
33.3	36	14
44.4	30	12
55.6	20	8
66.7	29	11
77.8	19	8
88.9	13	5
100	17	7

Total 255

<b>OVCH</b>	N	(%)
0	68	26
6.7	34	13
13.3	40	16
20	31	12
26.7	29	11
33.3	10	4
40	14	5
46.7	7	3
53.3	9	4
60	6	2
66.7	1	0
73.3	2	1
80	3	1
86.7	1	0
93.3	2	1
100	1	0

Total 258

Ovarian module: all stages  
Single Items

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Abdominal pain	OVAG	152	57	77	29	27	10	9	3	265
2) Bloating feeling	OVAG	137	52	76	29	35	13	15	6	263
3) Clothes feel too tight	OVAG	167	63	64	24	16	6	17	6	264
4) Change in bowel habit	OVAG	153	58	59	22	32	12	20	8	264
5) Passing wind	OVAG	130	49	71	27	38	14	25	10	264
6) Full up too quickly	OVAG	177	67	44	17	32	12	11	4	264
7) Indigestion or heartburn	OVOT	180	68	53	20	20	8	12	5	265
8) Lost hair	OVOT	215	83	32	12	7	3	6	2	260
9) Upset by hair loss	OVOT	<i>Insufficient data available</i>								
10) Food and drink taste different	OVOT	220	85	29	11	6	2	4	2	259
11) Tingling hands or feet	OVPN	177	68	47	18	26	10	12	5	262
12) Numbness in fingers or toes	OVPN	184	70	41	16	21	8	18	7	264
13) Weak arms or legs	OVCH	159	61	63	24	20	8	19	7	261
14) Pain in muscles or joints	OVCH	138	52	71	27	32	12	24	9	265
15) Problems with hearing	OVCH	197	74	46	17	15	6	7	3	265
16) Urinate frequently	OVCH	151	57	46	17	56	21	11	4	264
17) Skin problems	OVCH	183	70	44	17	21	8	15	6	263
18) Hot flushes	OVHO	137	52	60	23	42	16	24	9	263
19) Night sweats	OVHO	144	54	69	26	32	12	20	8	265
20) Physically less attractive	OVBI	174	66	45	17	29	11	15	6	263
21) Dissatisfied with body	OVBI	147	56	54	21	38	14	24	9	263
22) Disease a burden	OVAT	61	24	86	33	64	25	49	19	260
23) Treatment a burden	OVAT	109	42	64	25	54	21	30	12	257
24) Worried about health	OVAT	70	27	79	30	48	18	66	25	263
25) Interested in sex	-	164	64	54	21	29	11	8	3	255
26) Sexually active	-	154	61	66	26	26	10	6	2	252
27) Sex enjoyable	-	18	18	24	24	46	46	12	12	100
28) Dry vagina	-	<i>Insufficient data available</i>								

## Ovarian module: stage I-II

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	9	4
v +3	3	1
v 2.0	23	11
v 3.0	179	84
Total	214	

#### Age

	N	(%)
<40	25	12
40-49	37	17
50-59	64	30
60-69	57	27
70-79	29	14
80+	1	1
Not known	1	1
Total	214	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Abdominal/GI	OVAG	17.9	(20.9)	11.1	[0-22.2]
Peripheral neuropathy	OVPN	15.5	(26.8)	0	[0-16.7]
Hormonal	OVHO	30.8	(33.4)	16.7	[0-50]
Body image	OVBI	20.4	(26.8)	0	[0-33.3]
Attitude to disease/treatment	OVAT	36.6	(29.7)	33.3	[11.1-66.7]
Chemotherapy side effects	OVCH	19.5	(21.2)	13.3	[0-26.7]
Other single items	OVOT	28.7	(26.3)	25	[12.5-41.7]



**Ovarian module: stage I-II  
Constructed scales**

<b>OVAG</b>	N	(%)
0	32	26
5.6	19	16
11.1	16	13
16.7	15	12
22.2	10	8
27.8	6	5
33.3	5	4
38.9	1	1
44.4	5	4
50	1	1
55.6	4	3
61.1	1	1
66.7	2	2
72.2	1	1
77.8	0	0
83.3	1	1
88.9	1	1
94.4	0	0
100	1	1
Total	121	

<b>OVPN</b>	N	(%)
0	79	63
16.7	19	15
33.3	9	7
50	6	5
66.7	4	3
83.3	3	2
100	5	4
Total	125	

<b>OVHO</b>	N	(%)
0	48	39
16.7	18	15
33.3	19	15
50	11	9
66.7	12	10
83.3	4	3
100	12	10
Total	124	

<b>OVBI</b>	N	(%)
0	66	53
16.7	13	11
33.3	18	15
50	14	11
66.7	6	5
83.3	5	4
100	2	2
Total	124	

<b>OVAT</b>	N	(%)
0	24	20
11.1	13	11
22.2	22	18
33.3	12	10
44.4	11	9
55.6	10	8
66.7	13	11
77.8	10	8
88.9	2	2
100	6	5
Total	123	

<b>OVCH</b>	N	(%)
0	34	28
6.7	19	15
13.3	13	11
20	17	14
26.7	14	11
33.3	2	2
40	8	7
46.7	5	4
53.3	5	4
60	1	1
66.7	0	0
73.3	0	0
80	2	2
86.7	1	1
93.3	2	2
100	0	0
Total	123	

Ovarian module: stage I-II  
Single Items

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Abdominal pain	OVAG	74	59	36	29	14	11	1	1	125
2) Bloating feeling	OVAG	73	59	30	24	14	11	6	5	123
3) Clothes feel too tight	OVAG	86	69	24	19	6	5	8	7	124
4) Change in bowel habit	OVAG	84	68	26	21	6	5	8	7	124
5) Passing wind	OVAG	71	57	33	26	12	10	9	7	125
6) Full up too quickly	OVAG	90	73	21	17	11	9	2	2	124
7) Indigestion or heartburn	OVOT	79	63	34	27	8	6	4	3	125
8) Lost hair	OVOT	103	84	14	12	2	2	3	3	122
9) Upset by hair loss	OVOT	<i>Insufficient data available</i>								
10) Food and drink taste different	OVOT	108	89	10	8	0	0	3	3	121
11) Tingling hands or feet	OVPN	90	72	18	14	11	9	6	5	125
12) Numbness in fingers or toes	OVPN	91	73	19	15	6	5	9	7	125
13) Weak arms or legs	OVCH	79	64	27	22	8	7	10	8	124
14) Pain in muscles or joints	OVCH	61	49	32	26	19	15	13	10	125
15) Problems with hearing	OVCH	95	76	20	16	6	5	4	3	125
16) Urinate frequently	OVCH	75	60	23	18	24	19	3	2	125
17) Skin problems	OVCH	88	71	18	15	10	8	8	7	124
18) Hot flushes	OVHO	57	46	28	23	21	17	18	15	124
19) Night sweats	OVHO	61	49	35	28	16	13	13	10	125
20) Physically less attractive	OVBI	85	69	21	17	12	10	6	5	124
21) Dissatisfied with body	OVBI	76	61	16	13	23	19	9	7	124
22) Disease a burden	OVAT	41	33	41	33	26	21	15	12	123
23) Treatment a burden	OVAT	64	52	28	23	19	15	13	11	124
24) Worried about health	OVAT	35	28	40	32	21	17	28	23	124
25) Interested in sex	-	65	54	32	27	19	16	4	3	120
26) Sexually active	-	60	50	39	33	17	14	3	3	119
27) Sex enjoyable	-	<i>Insufficient data available</i>								
28) Dry vagina	-	<i>Insufficient data available</i>								

## Ovarian module: stage III-IV

### Characteristics of the sample

#### Version of the QLQ-C30

	N	(%)
v 1.0	0	0
v +3	61	9
v 2.0	79	12
v 3.0	522	79
Total	662	

#### Age

	N	(%)
<40	19	3
40-49	92	14
50-59	181	27
60-69	249	38
70-79	114	17
80+	7	1
Not known	0	0
Total	662	

#### Constructed scales

		Mean	(SD)	Median	[IQR]
Abdominal/GI	OVAG	26.7	(23.4)	16.7	[5.6-38.9]
Peripheral neuropathy	OVPN	18.7	(28.8)	0	[0-33.3]
Hormonal	OVHO	21.2	(26.6)	16.7	[0-33.3]
Body image	OVBI	23.9	(27.9)	16.7	[0-33.3]
Attitude to disease/treatment	OVAT	49.8	(30.6)	44.4	[33.3-77.8]
Chemotherapy side effects	OVCH	20.2	(20.6)	13.3	[6.7-26.7]
Other single items	OVOT	28.8	(22.9)	25	[8.3-41.7]

**Ovarian module: stage III-IV  
Constructed scales**

<b>OVAG</b>	N	(%)
0	19	16
5.6	11	9
11.1	12	10
16.7	18	15
22.2	5	4
27.8	10	9
33.3	7	6
38.9	8	7
44.4	3	3
50	6	5
55.6	4	3
61.1	5	4
66.7	5	4
72.2	0	0
77.8	1	1
83.3	3	3
88.9	0	0
94.4	0	0
100	1	1
Total	118	

<b>OVPN</b>	N	(%)
0	71	62
16.7	6	5
33.3	18	16
50	6	5
66.7	7	6
83.3	1	1
100	6	5
Total	115	

<b>OVHO</b>	N	(%)
0	55	47
16.7	21	18
33.3	20	17
50	9	8
66.7	7	6
83.3	2	2
100	4	3
Total	118	

<b>OVBI</b>	N	(%)
0	50	42
16.7	23	20
33.3	17	14
50	11	9
66.7	11	9
83.3	1	1
100	5	4
Total	118	

<b>OVAT</b>	N	(%)
0	12	11
11.1	8	7
22.2	5	5
33.3	18	16
44.4	16	14
55.6	9	8
66.7	14	13
77.8	9	8
88.9	10	9
100	10	9
Total	111	

<b>OVCH</b>	N	(%)
0	27	24
6.7	12	11
13.3	24	21
20	13	11
26.7	14	12
33.3	5	4
40	4	4
46.7	2	2
53.3	3	3
60	5	4
66.7	1	1
73.3	2	2
80	1	1
86.7	0	0
93.3	0	0
100	1	1
Total	114	


**Ovarian module: stage III-IV**  
**Single Items**

		Not at all		A little		Quite a bit		Very much		Total
		N	(%)	N	(%)	N	(%)	N	(%)	N
1) Abdominal pain	OVAG	61	51	37	31	13	11	8	7	119
2) Bloating feeling	OVAG	55	46	36	30	20	17	8	7	119
3) Clothes feel too tight	OVAG	69	58	33	28	8	7	9	8	119
4) Change in bowel habit	OVAG	56	47	28	24	24	20	11	9	119
5) Passing wind	OVAG	51	43	31	26	23	20	13	11	118
6) Full up too quickly	OVAG	70	59	21	18	20	17	8	7	119
7) Indigestion or heartburn	OVOT	82	69	18	15	11	9	8	7	119
8) Lost hair	OVOT	94	80	16	14	5	4	3	3	118
9) Upset by hair loss	OVOT	<i>Insufficient data available</i>								
10) Food and drink taste different	OVOT	94	80	16	14	6	5	1	1	117
11) Tingling hands or feet	OVPN	75	65	24	21	11	10	6	5	116
12) Numbness in fingers or toes	OVPN	80	68	16	14	13	11	9	8	118
13) Weak arms or legs	OVCH	68	59	29	25	12	10	7	6	116
14) Pain in muscles or joints	OVCH	65	55	34	29	11	9	9	8	119
15) Problems with hearing	OVCH	85	71	23	19	8	7	3	3	119
16) Urinate frequently	OVCH	65	55	17	14	29	25	7	6	118
17) Skin problems	OVCH	77	65	23	20	11	9	7	6	118
18) Hot flushes	OVHO	67	57	27	23	19	16	5	4	118
19) Night sweats	OVHO	72	61	28	24	14	12	5	4	119
20) Physically less attractive	OVBI	76	64	19	16	15	13	8	7	118
21) Dissatisfied with body	OVBI	60	51	33	28	12	10	13	11	118
22) Disease a burden	OVAT	15	13	38	33	33	28	30	26	116
23) Treatment a burden	OVAT	34	30	30	27	33	30	15	13	112
24) Worried about health	OVAT	28	24	31	26	24	20	35	30	118
25) Interested in sex	-	85	73	18	16	9	8	4	3	116
26) Sexually active	-	80	70	23	20	8	7	3	3	114
27) Sex enjoyable	-	<i>Insufficient data available</i>								
28) Dry vagina	-	<i>Insufficient data available</i>								


*EORTC QLQ-C30*

*Graphs*


## Global health status/QoL (QL)




## Physical functioning (PF)



## Role functioning (RF)




## Emotional functioning (EF)







## Cognitive functioning (CF)




## Social functioning (SF)




## Fatigue (FA)




## Nausea and vomiting (NV)




## Pain (PA)




## Dyspnoea (DY)




## Insomnia (SL)




## Appetite loss (AP)




## Constipation (CO)



## Diarrhoea (DI)



## Financial difficulties (FI)



*EORTC QLQ-C30*

*Correlation Matrices*

**Correlations**  
**General population**

	QL	PF	RF	EF	CF	SF	FA	NV	PA	DY	SL	AP	CO	DI	FI
<b>QL</b>	1.00														
<b>PF</b>	0.54	1.00													
<b>RF</b>	0.59	0.67	1.00												
<b>EF</b>	0.54	0.38	0.46	1.00											
<b>CF</b>	0.46	0.44	0.49	0.54	1.00										
<b>SF</b>	0.57	0.57	0.68	0.54	0.52	1.00									
<b>FA</b>	-0.59	-0.63	-0.66	-0.60	-0.56	-0.60	1.00								
<b>NV</b>	-0.28	-0.23	-0.29	-0.32	-0.29	-0.33	0.40	1.00							
<b>PA</b>	-0.59	-0.60	-0.68	-0.49	-0.45	-0.60	0.66	0.32	1.00						
<b>DY</b>	-0.40	-0.49	-0.43	-0.31	-0.37	-0.40	0.50	0.24	0.39	1.00					
<b>SL</b>	-0.44	-0.39	-0.43	-0.49	-0.44	-0.41	0.56	0.27	0.47	0.33	1.00				
<b>AP</b>	-0.35	-0.30	-0.37	-0.38	-0.36	-0.37	0.48	0.47	0.36	0.30	0.37	1.00			
<b>CO</b>	-0.21	-0.24	-0.24	-0.22	-0.29	-0.25	0.29	0.22	0.24	0.21	0.22	0.23	1.00		
<b>DI</b>	-0.21	-0.16	-0.22	-0.23	-0.24	-0.25	0.31	0.34	0.22	0.20	0.21	0.27	0.12	1.00	
<b>FI</b>	-0.41	-0.45	-0.47	-0.38	-0.38	-0.56	0.42	0.22	0.46	0.31	0.32	0.28	0.20	0.20	1.00



**Correlations  
Stage I-II**

	QL	PF	RF	EF	CF	SF	FA	NV	PA	DY	SL	AP	CO	DI	FI
<b>QL</b>	1.00														
<b>PF</b>	0.51	1.00													
<b>RF</b>	0.52	0.63	1.00												
<b>EF</b>	0.49	0.33	0.39	1.00											
<b>CF</b>	0.42	0.43	0.41	0.49	1.00										
<b>SF</b>	0.49	0.45	0.54	0.51	0.46	1.00									
<b>FA</b>	-0.60	-0.65	-0.66	-0.53	-0.51	-0.54	1.00								
<b>NV</b>	-0.35	-0.35	-0.40	-0.29	-0.29	-0.31	0.46	1.00							
<b>PA</b>	-0.50	-0.56	-0.52	-0.40	-0.41	-0.48	0.62	0.37	1.00						
<b>DY</b>	-0.35	-0.48	-0.40	-0.29	-0.29	-0.31	0.52	0.26	0.31	1.00					
<b>SL</b>	-0.36	-0.33	-0.34	-0.44	-0.37	-0.33	0.46	0.26	0.38	0.24	1.00				
<b>AP</b>	-0.40	-0.37	-0.44	-0.36	-0.32	-0.34	0.53	0.50	0.43	0.26	0.34	1.00			
<b>CO</b>	-0.25	-0.27	-0.22	-0.17	-0.23	-0.18	0.32	0.27	0.32	0.16	0.23	0.28	1.00		
<b>DI</b>	-0.20	-0.14	-0.21	-0.19	-0.19	-0.22	0.27	0.25	0.22	0.16	0.17	0.21	0.06	1.00	
<b>FI</b>	-0.30	-0.35	-0.30	-0.31	-0.26	-0.37	0.30	0.20	0.29	0.19	0.19	0.24	0.16	0.11	1.00

**Correlations  
Stage III-IV**

	QL	PF	RF	EF	CF	SF	FA	NV	PA	DY	SL	AP	CO	DI	FI
<b>QL</b>	1.00														
<b>PF</b>	0.55	1.00													
<b>RF</b>	0.55	0.75	1.00												
<b>EF</b>	0.45	0.27	0.33	1.00											
<b>CF</b>	0.40	0.44	0.38	0.44	1.00										
<b>SF</b>	0.53	0.54	0.59	0.43	0.41	1.00									
<b>FA</b>	-0.63	-0.71	-0.69	-0.47	-0.50	-0.56	1.00								
<b>NV</b>	-0.35	-0.34	-0.37	-0.26	-0.33	-0.31	0.44	1.00							
<b>PA</b>	-0.55	-0.61	-0.62	-0.38	-0.38	-0.48	0.62	0.37	1.00						
<b>DY</b>	-0.36	-0.41	-0.39	-0.25	-0.28	-0.29	0.48	0.22	0.28	1.00					
<b>SL</b>	-0.35	-0.24	-0.31	-0.41	-0.30	-0.30	0.42	0.21	0.36	0.25	1.00				
<b>AP</b>	-0.44	-0.43	-0.46	-0.32	-0.34	-0.36	0.56	0.51	0.41	0.29	0.30	1.00			
<b>CO</b>	-0.30	-0.33	-0.32	-0.21	-0.30	-0.27	0.36	0.29	0.36	0.18	0.20	0.31	1.00		
<b>DI</b>	-0.19	-0.14	-0.16	-0.15	-0.15	-0.18	0.21	0.22	0.16	0.12	0.13	0.19	0.07	1.00	
<b>FI</b>	-0.28	-0.14	-0.21	-0.27	-0.20	-0.30	0.23	0.15	0.23	0.13	0.19	0.16	0.11	0.06	1.00

**Correlations  
Recurrent/metastatic**

	QL	PF	RF	EF	CF	SF	FA	NV	PA	DY	SL	AP	CO	DI	FI
<b>QL</b>	1.00														
<b>PF</b>	0.54	1.00													
<b>RF</b>	0.63	0.59	1.00												
<b>EF</b>	0.51	0.34	0.40	1.00											
<b>CF</b>	0.46	0.42	0.43	0.49	1.00										
<b>SF</b>	0.57	0.47	0.63	0.46	0.47	1.00									
<b>FA</b>	-0.69	-0.65	-0.72	-0.47	-0.50	-0.60	1.00								
<b>NV</b>	-0.42	-0.33	-0.39	-0.30	-0.33	-0.36	0.49	1.00							
<b>PA</b>	-0.56	-0.52	-0.56	-0.42	-0.39	-0.50	0.62	0.38	1.00						
<b>DY</b>	-0.41	-0.39	-0.43	-0.25	-0.28	-0.34	0.48	0.27	0.31	1.00					
<b>SL</b>	-0.38	-0.30	-0.35	-0.43	-0.34	-0.31	0.42	0.27	0.39	0.23	1.00				
<b>AP</b>	-0.52	-0.38	-0.49	-0.33	-0.36	-0.43	0.59	0.52	0.43	0.30	0.31	1.00			
<b>CO</b>	-0.35	-0.29	-0.33	-0.23	-0.27	-0.29	0.39	0.33	0.39	0.22	0.23	0.36	1.00		
<b>DI</b>	-0.18	-0.11	-0.20	-0.13	-0.17	-0.19	0.22	0.24	0.13	0.16	0.12	0.17	0.01	1.00	
<b>FI</b>	-0.27	-0.26	-0.23	-0.31	-0.24	-0.32	0.26	0.16	0.26	0.15	0.19	0.14	0.14	0.08	1.00